[{"patientId": "6c7004d6-b1a3-f74f-e86a-ba1cf9983953", "eligibleTrials": [{"trialId": "NCT03668327", "trialName": "Preterm Birth Cohort Study in Guangzhou", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, 18.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple birth", "Patient has no overlapping conditions/medications with exclusion criterion: Stillbirth", "Patient has no overlapping conditions/medications with exclusion criterion: With major congenital abnormalities"]}, {"trialId": "NCT02665676", "trialName": "Embryonal Tumors of Infancy & Childhood: South Egypt Cancer Institute Experience", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, 18.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose age more than 18 years."]}, {"trialId": "NCT04216927", "trialName": "NO During CPB in Neonates to Reduce Risk of AKI", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (1.0, 31.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure to obtain informed consent from parent/guardian", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical signs of preoperative persistent elevated pulmonary vascular resistance,", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Episode of cardiac arrest within 1 week before surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Recent treatment with steroids and/or a condition that may require treatment with steroids (excluding steroid administration specifically for CPB),", "Patient has no overlapping conditions/medications with exclusion criterion: Use of inhaled NO (iNO) immediately prior to surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Structural renal abnormalities by ultrasound,", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative AKI,", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other investigational drugs,", "Patient has no overlapping conditions/medications with exclusion criterion: Weight less than \\<2 kg,", "Patient has no overlapping conditions/medications with exclusion criterion: Gestational age \\<36 weeks,", "Patient has no overlapping conditions/medications with exclusion criterion: Major extracardiac congenital anomalies,", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English speakers."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT06072976", "trialName": "The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (0.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Infant has already been on feeds", "Patient has no overlapping conditions/medications with exclusion criterion: Infants \\<34 weeks gestation", "Patient has no overlapping conditions/medications with exclusion criterion: Parents with contraindications to providing milk (i.e. drug use-cocaine, fentanyl, meth BUT oxy/suboxone/marijuana OK)", "Patient has no overlapping conditions/medications with exclusion criterion: Complicated gastroschisis", "Patient has no overlapping conditions/medications with exclusion criterion: Short gut syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Additional congenital anomalies that affect ability to tolerate milk (i.e. cyanotic congenital heart disease BUT kidney disease ok)"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT04504227", "trialName": "Effect of Thickened Feeds on Swallow Physiology in Children With Dysphagia", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, 21.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any pre-existing medical diagnoses that exclude brief resolved unexplained event diagnosis including seizure disorders and cyanotic congenital heart disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any nasal/pharyngeal/esophageal anomalies that might affect safe placement of the pharyngeal motility catheter", "Patient has no overlapping conditions/medications with exclusion criterion: Children fed exclusively by enteral tube", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to rice cereal or Gelmix thickener, which will be used to adjust liquid viscosity"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT04987476", "trialName": "Rhabdoid Tumors Cellular Architecture by Single-cell Analyses (InnovRT-2)", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (Not Specified, 17.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (1) matches Expected Range (1.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}]}, {"patientId": "6f3fc86a-e316-f704-12de-d2a994a8f852", "eligibleTrials": [{"trialId": "NCT03668327", "trialName": "Preterm Birth Cohort Study in Guangzhou", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, 18.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple birth", "Patient has no overlapping conditions/medications with exclusion criterion: Stillbirth", "Patient has no overlapping conditions/medications with exclusion criterion: With major congenital abnormalities"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (15.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT02665676", "trialName": "Embryonal Tumors of Infancy & Childhood: South Egypt Cancer Institute Experience", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, 18.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose age more than 18 years."]}, {"trialId": "NCT04216927", "trialName": "NO During CPB in Neonates to Reduce Risk of AKI", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (1.0, 31.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure to obtain informed consent from parent/guardian", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical signs of preoperative persistent elevated pulmonary vascular resistance,", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Episode of cardiac arrest within 1 week before surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Recent treatment with steroids and/or a condition that may require treatment with steroids (excluding steroid administration specifically for CPB),", "Patient has no overlapping conditions/medications with exclusion criterion: Use of inhaled NO (iNO) immediately prior to surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Structural renal abnormalities by ultrasound,", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative AKI,", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other investigational drugs,", "Patient has no overlapping conditions/medications with exclusion criterion: Weight less than \\<2 kg,", "Patient has no overlapping conditions/medications with exclusion criterion: Gestational age \\<36 weeks,", "Patient has no overlapping conditions/medications with exclusion criterion: Major extracardiac congenital anomalies,", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English speakers."]}, {"trialId": "NCT05780827", "trialName": "Analysis of Clinical Data of Patients With Temporomandibular Joint Disorder", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (12.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have received orthodontic treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of maxillofacial trauma", "Patient has no overlapping conditions/medications with exclusion criterion: Maternity", "Patient has no overlapping conditions/medications with exclusion criterion: Those who take any medicine for a long time", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases such as tumors, endocrine diseases, psychosocial diseases and immune diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Other persons who are unable to cooperate with the project by themselves, such as action barriers.\n\nControl group\n\nInclusion Criteria:\n\nSuffer from symptoms and signs of oral and maxillofacial dysfunction"]}, {"trialId": "NCT05706376", "trialName": "An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (13.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Families with individuals with significant mental or physical impairments precluding their ability to participate in groups"]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT06281327", "trialName": "Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (6.0, 18.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who are known to be allergic to avatrombopag or any of its excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who had used rituximab within the last 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who underwent splenectomy within the last 3 months；", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements；", "Patient has no overlapping conditions/medications with exclusion criterion: Any medical history or condition that the investigator deems unsuitable for participation in the study."]}, {"trialId": "NCT03150576", "trialName": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (16.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: T0 tumour in absence of axillary node \\>10mm.", "Patient has no overlapping conditions/medications with exclusion criterion: TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with myelodysplastic syndrome/acute myeloid leukaemia.", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of distant metastasis apparent prior to randomisation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled seizures.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breast feeding women.", "Patient has no overlapping conditions/medications with exclusion criterion: Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:\n\nEvidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.", "Patient has no overlapping conditions/medications with exclusion criterion: ECG with mean resting QTc \\>470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).", "Patient has no overlapping conditions/medications with exclusion criterion: Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable)."]}, {"trialId": "NCT04853576", "trialName": "A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (12.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Available 10/10 HLA-matched related donor", "Patient has no overlapping conditions/medications with exclusion criterion: Prior HSCT or contraindications to autologous HSCT", "Patient has no overlapping conditions/medications with exclusion criterion: Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to receive red blood cell (RBC) transfusion for any reason", "Patient has no overlapping conditions/medications with exclusion criterion: Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine", "Patient has no overlapping conditions/medications with exclusion criterion: Any history of severe cerebral vasculopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate end organ function", "Patient has no overlapping conditions/medications with exclusion criterion: Advanced liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior or current malignancy or immunodeficiency disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Immediate family member with a known or suspected Familial Cancer Syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined inclusion/exclusion criteria may apply"]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT06072976", "trialName": "The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (0.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Infant has already been on feeds", "Patient has no overlapping conditions/medications with exclusion criterion: Infants \\<34 weeks gestation", "Patient has no overlapping conditions/medications with exclusion criterion: Parents with contraindications to providing milk (i.e. drug use-cocaine, fentanyl, meth BUT oxy/suboxone/marijuana OK)", "Patient has no overlapping conditions/medications with exclusion criterion: Complicated gastroschisis", "Patient has no overlapping conditions/medications with exclusion criterion: Short gut syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Additional congenital anomalies that affect ability to tolerate milk (i.e. cyanotic congenital heart disease BUT kidney disease ok)"]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (4.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (13.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT04504227", "trialName": "Effect of Thickened Feeds on Swallow Physiology in Children With Dysphagia", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, 21.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any pre-existing medical diagnoses that exclude brief resolved unexplained event diagnosis including seizure disorders and cyanotic congenital heart disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any nasal/pharyngeal/esophageal anomalies that might affect safe placement of the pharyngeal motility catheter", "Patient has no overlapping conditions/medications with exclusion criterion: Children fed exclusively by enteral tube", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to rice cereal or Gelmix thickener, which will be used to adjust liquid viscosity"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT06049927", "trialName": "A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (6.0, 35.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from seasonal influenza in the past 6 moths;", "Patient has no overlapping conditions/medications with exclusion criterion: Axillary temperature \\>37.0°C;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma;", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;", "Patient has no overlapping conditions/medications with exclusion criterion: Severe chronic diseases(Such as down syndrome, diabetes, sickle cell anaemia or neurological disorders);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease (such as systemic lupus erythematosus) or immunodeficiency / immunosuppression (such as HIV, after organ transplantation)", "Patient has no overlapping conditions/medications with exclusion criterion: Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;", "Patient has no overlapping conditions/medications with exclusion criterion: Continuous use of corticosteroids or other immunosuppressive agents for ≥ 14 days within the past 6 months (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) and cytotoxic therapy in the past 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Acute diseases or acute exacerbation of chronic diseases in the past 3 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of blood products within in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of other investigational drugs in the past 30 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of attenuated live vaccines in the past 14 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of inactivated or subunit vaccines in the past 7 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other clinical trials before enrollment and in the follow-up period, or plans to participate in other clinical trials during the clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial"]}, {"trialId": "NCT03990727", "trialName": "Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (2.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: 1) Not willing to visit every year."]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT04987476", "trialName": "Rhabdoid Tumors Cellular Architecture by Single-cell Analyses (InnovRT-2)", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (Not Specified, 17.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (17) matches Expected Range (1.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}]}, {"patientId": "754934c2-e3b5-9771-9a73-547045f0504a", "eligibleTrials": [{"trialId": "NCT06286527", "trialName": "Quality of Sexual Life of PrEP Users", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unwilling to participate"]}, {"trialId": "NCT04484727", "trialName": "\"Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs\"", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients under 18 years", "Patient has no overlapping conditions/medications with exclusion criterion: ASA 4 and above", "Patient has no overlapping conditions/medications with exclusion criterion: severe COPD/emphysema/heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: PEEP\\>16 and/or FiO2 \\>80%", "Patient has no overlapping conditions/medications with exclusion criterion: elevated intracranial pressure", "Patient has no overlapping conditions/medications with exclusion criterion: defect coagulation", "Patient has no overlapping conditions/medications with exclusion criterion: non-treated known or suspected pneumothorax"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (15.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT05690776", "trialName": "PMCF Study on the Safety, Performance and Clinical Benefits Data of the Quattro X Broadband", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of infection;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient or immature bone;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient blood supply or previous infections which may hinder the healing process;", "Patient has no overlapping conditions/medications with exclusion criterion: Foreign body sensitivity;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant);", "Patient has no overlapping conditions/medications with exclusion criterion: The subject is unwilling or unable to give consent or to comply with the follow-up program;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject meets any contraindications of the appropriate Instruction for Use."]}, {"trialId": "NCT06100276", "trialName": "Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.", "Patient has no overlapping conditions/medications with exclusion criterion: Pathogenic repeat expansion in the C9orf72 gene", "Patient has no overlapping conditions/medications with exclusion criterion: Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications."]}, {"trialId": "NCT04666727", "trialName": "Role of Diet on the Microbiome of the Digestive System", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (45.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: • Current smokers (nicotine abuse only)\n\n  * Positive family history of colon cancer or colon cancer related syndromes\n  * Recent use of antibiotics in 1 month\n  * History of inflammatory bowel disease, and/or radiation enteritis or colitis\n  * Pregnant and breastfeeding women\n  * Women of child-bearing potential who have positive urine or serum pregnancy test\n  * Heavy drinker (defined as more than 14 drinks per week)\n  * Currently using anti-flatulence medications, probiotics and/or fiber supplements\n  * Major dietary restrictions and/or following a special diet\n  * Patient with positive fecal test/symptoms"]}, {"trialId": "NCT06507527", "trialName": "Frailty in Outpatient Digestive Endoscopy", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (70.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age below 70 years", "Patient has no overlapping conditions/medications with exclusion criterion: Non-ambulatory endoscopies", "Patient has no overlapping conditions/medications with exclusion criterion: Assessment of test contraindications by the endoscopist", "Patient has no overlapping conditions/medications with exclusion criterion: Non-acceptance to enter the study"]}, {"trialId": "NCT05731427", "trialName": "Research on the Mechanism Affecting Progression of Bronchiectasis", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04820127", "trialName": "Personalized Management of Psycho-behavioral Symptoms in Alzheimer's Disease: Impact on Health Resources Use", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (60.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: For the patient:", "Patient has no overlapping conditions/medications with exclusion criterion: Agitation symptoms attributable either to other concomitant prescriptions, or to other psychiatric or evolving somatic diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient living in a residential care facility or having an institutionalization project within 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with clinically significant or unstable disease that could affect he/her ability to come for the study visit or complete the evaluations planned as per protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant participation to any other interventional research study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under legal protection.\n\nFor the caregiver:", "Patient has no overlapping conditions/medications with exclusion criterion: Caregiver under legal protection.", "Patient has no overlapping conditions/medications with exclusion criterion: Limited internet access or caregiver feeling unable to use it"]}, {"trialId": "NCT05004727", "trialName": "Multi-Center PAMPA Study", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;", "Patient has no overlapping conditions/medications with exclusion criterion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);", "Patient has no overlapping conditions/medications with exclusion criterion: RA seropositivity (mid-high RF/ACPA titers);", "Patient has no overlapping conditions/medications with exclusion criterion: Current active malignancy;", "Patient has no overlapping conditions/medications with exclusion criterion: History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to the study agent."]}, {"trialId": "NCT06001827", "trialName": "SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Planned index procedure to revise or repair an existing fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Target artery inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Target vein inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound", "Patient has no overlapping conditions/medications with exclusion criterion: Known central venous stenosis of at least 50% on the side of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a stent or a stent graft within the access circuit", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected active infection at the time of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Congestive heart failure NYHA class 4", "Patient has no overlapping conditions/medications with exclusion criterion: Prior steal on the side of surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Life expectancy less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo kidney transplant surgery within 6 months of enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo home hemodialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Unwillingness or inability to give consent and/or comply with the study follow up schedule", "Patient has no overlapping conditions/medications with exclusion criterion: Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study."]}, {"trialId": "NCT05814627", "trialName": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to any janus kinase (JAK) inhibitor.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD)."]}, {"trialId": "NCT05286827", "trialName": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05840276", "trialName": "Cryoneurolysis Prior to Total Knee Arthroplasty", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications against ibuprofen or paracetamol, for example previous gastric ulcer, or known renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\< 100 bil/l); or against treatment with morphine", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuropathic pain", "Patient has no overlapping conditions/medications with exclusion criterion: Previous recipient of cryoneurolysis for the knee", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with daily use of high dose opioid (\\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled serious disease (cancer, diabetes, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disease associated with reactions to cold, such as cryoglobulinemia, cold urticarial and Reynaud's syndrome."]}, {"trialId": "NCT05809427", "trialName": "High Frequency Intraoral Ultrasound Probe for Early Diagnosis of Periodontal Diseases", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04886427", "trialName": "Implementation of a Multidimensional Quality Model", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Do not understand Dutch"]}, {"trialId": "NCT06265727", "trialName": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active of uncontrolled CNS metastases", "Patient has no overlapping conditions/medications with exclusion criterion: History of solid tumors other than the diseases under study", "Patient has no overlapping conditions/medications with exclusion criterion: History of and/or current cardiovascular events or conditions in the previous 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing \\>/= Grade 2 neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Hemoglobin A1C (HbA1C) \\>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active ocular disease at baseline", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic severe liver disease or live cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study", "Patient has no overlapping conditions/medications with exclusion criterion: Other significant cormorbidities."]}, {"trialId": "NCT06527027", "trialName": "LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,", "Patient has no overlapping conditions/medications with exclusion criterion: inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant."]}, {"trialId": "NCT05133076", "trialName": "Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: E1. Involvement in any investigational drug or device study within 30 days prior to this study,\n\nE2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in the study),\n\nE3. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation upon investigator judgment,\n\nE4. Surgery planned within the whole study period,\n\nE5. Evidence of active medical diseases affecting bowel transit,\n\nE6. Antibiotic treatment intake within the last month prior the study start (V0),\n\nE7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are permitted,\n\nE8. Any history of drug addiction in the past five years,\n\nE9. Pregnant or lactating women or intending to become pregnant,\n\nE10. Unwilling to maintain food habits and current physical activity for the whole study duration,\n\nE11. With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,\n\nE12. Having a lifestyle deemed incompatible with the study according to the investigator including drug and alcohol abuse,\n\nE13. Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n\nE14. Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,\n\nE15. Presenting a psychological or linguistic incapability to sign the informed consent,\n\nE16. Impossible to contact in case of emergency."]}, {"trialId": "NCT06504927", "trialName": "Biomarker Discovery in Lung Cancer - Malaysia", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (30.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is pregnant or lactating (self-declaration).", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is unwilling or unable to provide signed informed consent"]}, {"trialId": "NCT05377827", "trialName": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from study entry for any of the following:", "Patient has no overlapping conditions/medications with exclusion criterion: Received systemic anticancer therapy (including investigational therapy) or radiotherapy \\< 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:\n\n  * \\< 100 days post alloHCT\n  * \\< 6 weeks from prior donor leukocyte infusion\n  * Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.\n  * \\< 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with any anti-CD7 directed therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to one or more of the study agents.", "Patient has no overlapping conditions/medications with exclusion criterion: Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Confirmed HIV infection.", "Patient has no overlapping conditions/medications with exclusion criterion: History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic, uncontrolled hypotension."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT06552676", "trialName": "riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure of the percutaneous tracheostomy technique or recourse to surgical tracheostomy"]}, {"trialId": "NCT01521676", "trialName": "Predictive Clinical and Biological Parameters in Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: emergency"]}, {"trialId": "NCT04030676", "trialName": "QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Wardship patient and curatorial patient", "Patient has no overlapping conditions/medications with exclusion criterion: Patient unable to understand or sign the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Colectomy total or partial"]}, {"trialId": "NCT04560127", "trialName": "Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Any active autoimmune disease or history of autoimmune disease and expected recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis); subjects with skin diseases that does no need systemic treatment, for example, leukoderma, psoriasis, alopecia, those with controlled type I diabetes by insulin or those with asthma that has been completely resolved in childhood and with no need of any intervention can be enrolled; while subjects with asthma who need bronchodilator for medical intervention cannot be enrolled.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of strong CYP3A4/CYP2C19 inducers, including rifampicin (and its analogues) and St. John's Wort, or strong CYP3A4/CYP2C19 inhibitors within two weeks prior to signing informed consent form.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with other immune checkpoint inhibitors (include PD-1 antibody or other immunotherapy against PD-1/PD-L1).", "Patient has no overlapping conditions/medications with exclusion criterion: Known history of serious allergy to any monoclonal antibody or Apatinib.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwilling to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current presence of metastasis to central nervous system.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia or complications of severe pneumonia; oral or intravenous therapeutic antibiotics within two weeks prior to the start of study treatment (for example, subjects who are given with preventive antibiotics for prevention of urinary tract infection or exacerbation of chronic obstructive pulmonary disease are eligible for participation in the study).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women.", "Patient has no overlapping conditions/medications with exclusion criterion: Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators, such as alcoholism, drug abuse, other serious diseases (including mental disorders) requiring concomitant therapy, with serious laboratory examination abnormality, with family or social factors, that may affect subject's safety."]}, {"trialId": "NCT05078476", "trialName": "Rehabilitation of Finger Flexor Tendon Injuries", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\< 18 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients", "Patient has no overlapping conditions/medications with exclusion criterion: Replantation of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Primary tendon reconstructions"]}, {"trialId": "NCT06087627", "trialName": "A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have been treated for more than 7 days with dupilumab", "Patient has no overlapping conditions/medications with exclusion criterion: Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."]}, {"trialId": "NCT01341327", "trialName": "Observational Study for Left Main Disease Treatment", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Protected left main stenosis"]}, {"trialId": "NCT06337227", "trialName": "Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients for whom biological material cannot be recovered for study purposes;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who refuse to participate in the study"]}, {"trialId": "NCT06312176", "trialName": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Has breast cancer amenable to treatment with curative intent", "Patient has no overlapping conditions/medications with exclusion criterion: Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune disease that has required systemic treatment in the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy"]}, {"trialId": "NCT02907827", "trialName": "Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\\< 6weken)", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia", "Patient has no overlapping conditions/medications with exclusion criterion: Metallic devices implanted such as hip prostheses, since this can alter the imaging quality"]}, {"trialId": "NCT06291727", "trialName": "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients scheduled for bilateral TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Revision TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)", "Patient has no overlapping conditions/medications with exclusion criterion: Workers' Compensation patient", "Patient has no overlapping conditions/medications with exclusion criterion: Type I Diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Type II Diabetes requiring insulin medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-operative narcotics use with the exception of tramadol.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal insufficiency (GFR \\< 60) that may impact post-operative protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive deficiencies that prevent the patient from providing their own informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Language barrier preventing completion of study forms in English"]}, {"trialId": "NCT05650827", "trialName": "Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\< 18", "Patient has no overlapping conditions/medications with exclusion criterion: Living outside the greater Copenhagen area", "Patient has no overlapping conditions/medications with exclusion criterion: Any other malignancy requiring active treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Not eligible for chemotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Performance status \\> 2", "Patient has no overlapping conditions/medications with exclusion criterion: Not able to swallow liquids", "Patient has no overlapping conditions/medications with exclusion criterion: Parenteral nutrition or enteral nutrition via feeding tube", "Patient has no overlapping conditions/medications with exclusion criterion: Physical or mental disabilities that prohibit execution of test or training procedures", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to understand the Danish language"]}, {"trialId": "NCT06319027", "trialName": "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06146127", "trialName": "Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unequivocal histological features"]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT05752227", "trialName": "Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pure pleural lesions.", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical instability to reach the final diagnosis.", "Patient has no overlapping conditions/medications with exclusion criterion: Inaccessibility by ultrasound."]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (4.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05364827", "trialName": "CT Coronary Angiography Prior to CTO PCI", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: CTO with J-CTO score\\<2", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate/degraded CTCA images", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant/lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe contrast allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to provide written informed consent"]}, {"trialId": "NCT05038527", "trialName": "ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: ASA ≥ 4", "Patient has no overlapping conditions/medications with exclusion criterion: Formally diagnosed with a disease affecting the bone metabolism or wound healing (severe osteoporosis, osteomalacia, Pagets disease, hyperparathyreoidism etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disseminated cancer diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to any of the i-FACTOR Peptide Enhanced Bone Graft ingredients", "Patient has no overlapping conditions/medications with exclusion criterion: Smoking, extensive alcohol use or abuse of hallucinating drugs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver or kidney disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or breastfeeding patients", "Patient has no overlapping conditions/medications with exclusion criterion: Patients estimated not to be able to understand the information sheet or patients, who do not consent to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe psychiatric diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Ongoing infections"]}, {"trialId": "NCT06040827", "trialName": "A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06144476", "trialName": "Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.", "Patient has no overlapping conditions/medications with exclusion criterion: Surgery within the preceding 6 weeks", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection", "Patient has no overlapping conditions/medications with exclusion criterion: Alcohol or recreational drug abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency requiring treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to read or write English", "Patient has no overlapping conditions/medications with exclusion criterion: Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study"]}, {"trialId": "NCT03317327", "trialName": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB and stage I prostate cancer considered not necessary to treat", "Patient has no overlapping conditions/medications with exclusion criterion: Disease suitable for curative salvage surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 4 weeks prior to first administration of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant cardiac, pulmonary or other medical illness that would limit activity or survival", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to any of the components of the investigational product", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who test positive for hepatitis B, C or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of immunosuppressive therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease that has required systemic therapy within the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: Any reason why, in the opinion of the investigator, the patient should not participate"]}, {"trialId": "NCT04257227", "trialName": "Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Documented brain lesions", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to remain still while sitting up (45 degrees) for the duration of therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold"]}, {"trialId": "NCT05601427", "trialName": "Intra-Operative Adductor Canal Blocks", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or refusal to sign informed consent form", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.", "Patient has no overlapping conditions/medications with exclusion criterion: Non-osteoarthritis primary diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to analgesic medications", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal and/or regional anaesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Any use of opioid pain medication within four weeks of the index procedure(13)", "Patient has no overlapping conditions/medications with exclusion criterion: Pain catastrophizing scale score ≥16 (8, 9, 14)", "Patient has no overlapping conditions/medications with exclusion criterion: History of cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: History renal insufficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History or sensory and/or motor neuropathy to the ipsilateral limb", "Patient has no overlapping conditions/medications with exclusion criterion: Simultaneous, bilateral TKA", "Patient has no overlapping conditions/medications with exclusion criterion: Non-TKA prosthesis", "Patient has no overlapping conditions/medications with exclusion criterion: Scheduled for non-SDD TKA.", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative varus/valgus of \\>10 degrees.", "Patient has no overlapping conditions/medications with exclusion criterion: Planned General Anaesthetic", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Intrathecal Morphine"]}, {"trialId": "NCT03072927", "trialName": "MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (13.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT03916627", "trialName": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with metastatic disease for whom the intent of surgery would not be curative", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 1 year", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (16.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT04519476", "trialName": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n  1. Has received selinexor or another XPO1 inhibitor previously.\n  2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \\>5 years previously and without evidence of recurrence will be allowed.\n  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \\[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\\], primary amyloidosis, etc.) that is likely to interfere with study procedures.\n  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.\n  6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.\n  7. Concurrent use of other anti-cancer agents or treatments.\n  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\n  9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin\n  10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n  11. Pregnant or breastfeeding females.\n  12. BSA \\<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.\n  13. Life expectancy of less than 3 months.\n  14. Major surgery within 4 weeks prior to C1D1.\n  15. Active, unstable cardiovascular function, as indicated by the presence of:\n\n  1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.\n\n  18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.\n\n  19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).\n\n  20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n\n  21. Contraindication to any of the required concomitant drugs or supportive treatments.\n\n  22. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT06508827", "trialName": "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemoglobinopathies", "Patient has no overlapping conditions/medications with exclusion criterion: Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemochromatosis", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating female adults", "Patient has no overlapping conditions/medications with exclusion criterion: Active infections which in research teams' opinion increases risk for toxicities", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures."]}, {"trialId": "NCT05422027", "trialName": "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who meet any of the following criteria will not be enrolled:\n\n  1. Plasma cell leukemia.\n  2. Documented active amyloidosis.\n  3. Involvement of the central nervous system(CNS) by Multiple myeloma.\n  4. Prior exposure to a SINE compound, including ATG-010.\n  5. Currently, whether or not the patient is on medication, \\> Grade 2 peripheral neuropathy or ≥ Grade ≥ 2 painful neuropathy at baseline.\n  6. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and Selinexor (ATG-010) .\n  7. Active, unstable cardiovascular function, as indicated by the presence of:\n\n     1. Symptomatic ischemia, or\n     2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or\n     3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\<40%, or\n     4. Myocardial infarction within 6 months prior to C1D1.\n  8. Known positive serology for HIV or HIV seropositivity.\n  9. Known active hepatitis A, B, or C infection; eg. positive for HCV RNA or HBV-DNA.\n  10. Women who are pregnant or nursing.\n  11. Life expectancy of less than 6 months.\n  12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.\n  13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n  14. Contraindication to any of the required concomitant drugs or supportive treatments.\n  15. Has any concurrent diseases or complications that is likely to interfere with the study procedures.\n  16. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT05284227", "trialName": "Artificial Intelligence-augmented Perioperative Clinical Decision Support", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT05057676", "trialName": "Autoimmune Intervention Mastery Course Study", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05525676", "trialName": "Relationship Checkups to Reduce Veteran Suicide Risk", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports severe intimate partner violence in the last year.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports experiencing suicidal intent requiring hospitalization.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER experiences past-month psychosis or mania.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years."]}, {"trialId": "NCT05780476", "trialName": "A Novel VIRTUAL Reality Intervention for CAREgivers of People With Dementia (VirtualCare)", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving daily assistance for more than 10 hours from formal CGs;", "Patient has no overlapping conditions/medications with exclusion criterion: Being formal CGs (i.e., nurse or another paid figure);", "Patient has no overlapping conditions/medications with exclusion criterion: Being informal CGs of i) persons with moderate-to-severe AD, or ii) persons with non-AD diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Not having or being able to use a device connected to internet (e.g., smartphones or PC).", "Patient has no overlapping conditions/medications with exclusion criterion: Having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs.", "Patient has no overlapping conditions/medications with exclusion criterion: Only a family member for person with dementia is accepted.\n\nExclusion Criteria for experimental group (Psychoeducation + VR):", "Patient has no overlapping conditions/medications with exclusion criterion: Medical history of epilepsy.\n\nExclusion Criteria for subsample of caregivers assess with MRI:", "Patient has no overlapping conditions/medications with exclusion criterion: Metal implants, artificial prostheses, pace-makers, prosthetic heart valves;", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy."]}, {"trialId": "NCT05266976", "trialName": "Mode of Exercise and Bone Biomarkers in Older Veterans", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (60.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired renal function, defined as an eGRF of \\<60 mL/min/1.73m2", "Patient has no overlapping conditions/medications with exclusion criterion: Hepatobiliary disease, defined as liver function tests (AST, ALT) \\>1.5 times the upper limit of normal", "Patient has no overlapping conditions/medications with exclusion criterion: Thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH) \\<0.5 or \\>5.0 mU/L", "Patient has no overlapping conditions/medications with exclusion criterion: Serum Ca \\<8.5 or \\>10.3 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Serum 25(OH)D \\<20 ng/mL", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled hypertension, defined as resting systolic blood pressure (BP) \\>150 mmHg or diastolic BP \\>90 mmHg;", "Patient has no overlapping conditions/medications with exclusion criterion: History of type 1 or type 2 diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Cardiovascular disease, defined as subjective or objective indicators of ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the graded exercise test (GXT). Volunteers who have a positive GXT can be re-considered after follow-up evaluation, which must include diagnostic testing (e.g., stress echocardiogram or thallium stress test) with interpretation by a cardiologist", "Patient has no overlapping conditions/medications with exclusion criterion: Anemia, defined as a serum hemoglobin \\<12.1 g/dL for women and \\<14.3 g/dL for men", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture in the past 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Current diagnosis or symptoms of COVID-19\n\nIn the event of abnormal BP, live function, TSH, 25(OH)D, or hemoglobin values, volunteers can be reassessed, including after appropriate follow-up evaluation and treatment by a primary care provider. Those who have experienced symptoms of COVID-19 or have been formally diagnosed will be allowed to participate once symptoms have resolved and they are approved to return to exercise by their primary care provider."]}, {"trialId": "NCT06550427", "trialName": "Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT04802876", "trialName": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior systemic anti-cancer therapy, including investigational agents within 2 weeks. Medical Monitor could consider shorter interval for kinase inhibitors or other short half-life drugs prior to allocation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants with ≤Grade 2 neuropathy may be eligible.\n\n   Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study treatment.\n\n   Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose of the previous investigational agent.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with thymoma are not eligible. Patients with active CNS metastases and/or carcinomatous meningitis are not eligible. Subjects with up to three cerebral metastases are eligible, if all lesions are stable and have been definitively treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any of its excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior allogeneic stem cell transplantation or organ transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history of interstitial lung disease, (non-infectious) pneumonitis that required steroids or has current pneumonitis, uncontrolled lung including pulmonary fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Human Immunodeficiency Virus (HIV).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of active TBC (Bacillus Tuberculosis).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of trial treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with spartalizumab or tislelizumab. Highly effective contraception methods include:\n\n    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n    4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.\n\n    Notes:\n    * Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.\n    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.", "Patient has no overlapping conditions/medications with exclusion criterion: Sexually active males, unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with spartalizumab or tislelizumab should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen."]}, {"trialId": "NCT04816227", "trialName": "Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusing to participate in the study", "Patient has no overlapping conditions/medications with exclusion criterion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research", "Patient has no overlapping conditions/medications with exclusion criterion: Being pregnant or breastfeeding"]}, {"trialId": "NCT04167527", "trialName": "Endovascular Therapy for Low NIHSS Ischemic Strokes", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: NIHSS ≥6", "Patient has no overlapping conditions/medications with exclusion criterion: Any sign of intracranial hemorrhage on baseline CT/MR (SDH/SAH/ICH)", "Patient has no overlapping conditions/medications with exclusion criterion: Any imaging findings suggestive of futile recanalization in the judgment of the local investigator", "Patient has no overlapping conditions/medications with exclusion criterion: High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD", "Patient has no overlapping conditions/medications with exclusion criterion: Premorbid disability (mRS ≥3)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to randomize within 8 hours of last known well", "Patient has no overlapping conditions/medications with exclusion criterion: Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS", "Patient has no overlapping conditions/medications with exclusion criterion: Baseline blood glucose of \\<50 mg/dL (2.78 mmol) or \\>400 mg/dL (22.20 mmol)", "Patient has no overlapping conditions/medications with exclusion criterion: Known coagulation disorders as defined as platelet count \\<100,000/uL", "Patient has no overlapping conditions/medications with exclusion criterion: Known renal failure as defined as serum creatinine levels \\> 3.0 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Presumed septic embolus or suspicion of bacterial endocarditis", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another investigational treatment study in the previous 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Intubation and mechanical ventilation prior to study enrollment is medically indicated", "Patient has no overlapping conditions/medications with exclusion criterion: History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Site investigator does not have equipoise towards the ideal treatment concept (thrombectomy vs. best medical management)", "Patient has no overlapping conditions/medications with exclusion criterion: Known pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Prisoner or incarceration", "Patient has no overlapping conditions/medications with exclusion criterion: Known acute symptomatic COVID-19 infection"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (16.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT06218576", "trialName": "Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: age \\< 18 years"]}, {"trialId": "NCT03050476", "trialName": "Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (21.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Already on renal replacement therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic kidney disease defined as estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m2 \\[ CKD stage \\> 3 \\]", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Concurrent enrollment in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with ongoing infections or current use of steroids", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with high-risk emergency surgery or with follow-up procedures already planned at admission (like e.g. TEVAR)"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT05887076", "trialName": "Postoperative Delirium After Kidney Transplantation", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete data records of the parameters to be determined", "Patient has no overlapping conditions/medications with exclusion criterion: Underage Patients"]}, {"trialId": "NCT05272176", "trialName": "Veterans Coordinated Community Care (3C) Study", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired decision-making capacity", "Patient has no overlapping conditions/medications with exclusion criterion: Limited or no English language proficiency", "Patient has no overlapping conditions/medications with exclusion criterion: Terminal illness"]}, {"trialId": "NCT05968976", "trialName": "Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Legally incompetent adults;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous tremor-neurosurgery (e.g., DBS, thalamotomy);", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;", "Patient has no overlapping conditions/medications with exclusion criterion: Psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Current depression;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent."]}, {"trialId": "NCT06182527", "trialName": "Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: diabetes mellitus", "Patient has no overlapping conditions/medications with exclusion criterion: use of medication interfering with glucose metabolism (steroid, antidiabetic medications)", "Patient has no overlapping conditions/medications with exclusion criterion: surgery of upper GI-tract", "Patient has no overlapping conditions/medications with exclusion criterion: known plaster allergies", "Patient has no overlapping conditions/medications with exclusion criterion: any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion"]}, {"trialId": "NCT05505227", "trialName": "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: currently prescribing buprenorphine at full capacity"]}, {"trialId": "NCT05782127", "trialName": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous diagnosis of:\n\n   * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)\n   * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: History of active malignancy within the past year prior to screening, with the exception of:\n\n   * Adequately treated carcinoma in situ of the uterine cervix\n   * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n   * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.\n\n   Patients with ongoing horomonotherapy could be included.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.", "Patient has no overlapping conditions/medications with exclusion criterion: Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.", "Patient has no overlapping conditions/medications with exclusion criterion: Received live attenuated vaccines prior to initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions that could interfere with drug absorption including short gut syndrome, dysphagia, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mmHg or diastolic BP \\> 100 mmHg) or has not been stable for at least 1 month prior to treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:\n\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Unstable angina or angina requiring surgical or medical intervention\n    * Significant cardiac arrhythmia\n    * And/or myocardial infarction", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is a pregnant or lactating female.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has known or suspected to have hypersensitivity to any of the components of the assigned study treatments.", "Patient has no overlapping conditions/medications with exclusion criterion: Positive test result(s) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B surface \\[HBs\\] antibody positive and anti-hepatitis B core \\[HBc\\] antibody negative) may participate.", "Patient has no overlapping conditions/medications with exclusion criterion: Absence of social security affiliation."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT05537376", "trialName": "A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Veteran"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT05189327", "trialName": "Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient takes part in an interventional clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is unable to follow the schedule of the visits;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that the PI believes would prevent a study participant from participating in the study."]}, {"trialId": "NCT06176027", "trialName": "Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women"]}, {"trialId": "NCT06627127", "trialName": "A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects meeting any of the following criteria will be excluded from participation in this study:", "Patient has no overlapping conditions/medications with exclusion criterion: Major anatomical or functional abnormalities that would impair the ability of the electrode arrays to be positioned.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant comorbidities that contraindicate surgery or general anesthesia/DISE", "Patient has no overlapping conditions/medications with exclusion criterion: Significant tongue weakness", "Patient has no overlapping conditions/medications with exclusion criterion: Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia/DISE in the judgment of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior surgery or treatments that could compromise the placement and effectiveness of the electrode array systems:\n\n  * Airway cancer surgery or radiation,\n  * Mandible or maxilla surgery in the previous 3 years (not counting dental treatments),", "Patient has no overlapping conditions/medications with exclusion criterion: Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),", "Patient has no overlapping conditions/medications with exclusion criterion: Prior hypoglossal nerve stimulation device implantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently pregnant, or breastfeeding during the study period"]}, {"trialId": "NCT05555576", "trialName": "Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Opioid use 1 month prior to the ED visit;", "Patient has no overlapping conditions/medications with exclusion criterion: Already taking vitamin C supplement;", "Patient has no overlapping conditions/medications with exclusion criterion: Active cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for chronic pain;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for opioid use disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to fill out diary or unavailable for follow-up;", "Patient has no overlapping conditions/medications with exclusion criterion: Any allergy, intolerance or sensitivity to milk (lactose) or morphine", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with cyclosporin or coumadin", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)"]}, {"trialId": "NCT04557527", "trialName": "Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to hyaluronate or. HEALON5® PRO OVD", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\nStudy eye:", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of proliferative vitreoretinopathy (PVR) or any tractional RD", "Patient has no overlapping conditions/medications with exclusion criterion: Previous vitreoretinal surgery, open-globe injury or endophthalmitis", "Patient has no overlapping conditions/medications with exclusion criterion: Aphakia", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current congenital cataract", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current suprachoroidal haemorrhage", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment", "Patient has no overlapping conditions/medications with exclusion criterion: Current intraocular inflammation other than mild cellular activity thought to be secondary to RD", "Patient has no overlapping conditions/medications with exclusion criterion: Current ocular or periocular infection other than blepharitis"]}, {"trialId": "NCT05628376", "trialName": "TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:", "Patient has no overlapping conditions/medications with exclusion criterion: Positive margins, incomplete resection or insufficient nodal sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B/C:", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)"]}, {"trialId": "NCT04620876", "trialName": "Bimodal and Coaxial High Resolution Ophtalmic Imaging", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (1.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04838327", "trialName": "Rare Subtypes of Gastrointestinal Cancers", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions precluding translational blood sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Another concomitant cancer"]}, {"trialId": "NCT03344276", "trialName": "Assessing Neurocognition After Cerebrovascular Intervention", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: patients \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: patients with without compatibility for MRI", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring carotid stenting for reasons not related to long-standing stenosis", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study."]}, {"trialId": "NCT04695327", "trialName": "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled cardiac or vascular diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hepatic dysfunction, hepatitis or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: History of coagulation disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant, breastfeeding or intend to become pregnant.", "Patient has no overlapping conditions/medications with exclusion criterion: Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.", "Patient has no overlapping conditions/medications with exclusion criterion: Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol)."]}, {"trialId": "NCT06339827", "trialName": "ASk Questions in GYnecologic Oncology (ASQ-GYO)", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment discussion with a Gynecologic Oncologist"]}, {"trialId": "NCT03921827", "trialName": "External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (21.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with atrial fibrillation/ arrhythmias.", "Patient has no overlapping conditions/medications with exclusion criterion: Within 2 weeks of cardiac catheterization or arterial puncture at femoral puncture site.", "Patient has no overlapping conditions/medications with exclusion criterion: Decompensated heart failure , usually class 3 or 4", "Patient has no overlapping conditions/medications with exclusion criterion: LV EF \\<30%", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe AR", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent and uncontrolled hypertension (BP persistently \\>160/100 mmHg)", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding diathesis", "Patient has no overlapping conditions/medications with exclusion criterion: Active thrombophlebitis/ venous disease of lower limbs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe lower extremity vaso-occlusive disease", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a documented aortic aneurysm/ dissection requiring surgical repair", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy"]}, {"trialId": "NCT05312827", "trialName": "Training Intervention and Program of Support (TIPS): Fostering Family-centred Telehealth in Pediatric Rehabilitation", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03529227", "trialName": "Gazyva Infusion Reaction Investigation", "eligibilityCriteriaMet": ["Patient Age (100) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: The refusal of the patient to participate in the observational study and the withdrawal of informed consent that allow processing of personal data and data that refer to patient confidentiality."]}]}, {"patientId": "75c8628d-bace-81e5-fa6a-77717a1ab484", "eligibleTrials": [{"trialId": "NCT06286527", "trialName": "Quality of Sexual Life of PrEP Users", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unwilling to participate"]}, {"trialId": "NCT04484727", "trialName": "\"Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs\"", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients under 18 years", "Patient has no overlapping conditions/medications with exclusion criterion: ASA 4 and above", "Patient has no overlapping conditions/medications with exclusion criterion: severe COPD/emphysema/heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: PEEP\\>16 and/or FiO2 \\>80%", "Patient has no overlapping conditions/medications with exclusion criterion: elevated intracranial pressure", "Patient has no overlapping conditions/medications with exclusion criterion: defect coagulation", "Patient has no overlapping conditions/medications with exclusion criterion: non-treated known or suspected pneumothorax"]}, {"trialId": "NCT03869476", "trialName": "Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 99.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a diagnosis of secondary myelofibrosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman;", "Patient has no overlapping conditions/medications with exclusion criterion: Person prived of liberty by judicial or administrative decision;", "Patient has no overlapping conditions/medications with exclusion criterion: Person subject to a legal protection measure;"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (15.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT05690776", "trialName": "PMCF Study on the Safety, Performance and Clinical Benefits Data of the Quattro X Broadband", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of infection;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient or immature bone;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient blood supply or previous infections which may hinder the healing process;", "Patient has no overlapping conditions/medications with exclusion criterion: Foreign body sensitivity;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant);", "Patient has no overlapping conditions/medications with exclusion criterion: The subject is unwilling or unable to give consent or to comply with the follow-up program;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject meets any contraindications of the appropriate Instruction for Use."]}, {"trialId": "NCT06100276", "trialName": "Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.", "Patient has no overlapping conditions/medications with exclusion criterion: Pathogenic repeat expansion in the C9orf72 gene", "Patient has no overlapping conditions/medications with exclusion criterion: Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications."]}, {"trialId": "NCT06027827", "trialName": "Impact of Lateral Bone Grafting With Intraoperative Fusion in ACDF on Clinical Outcomes", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 60.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Drug or alcohol abusers; those with abnormal liver or kidney function unsuitable for surgery; those with cardiac insufficiency unsuitable for surgery; those with severe metabolic and endocrine diseases unsuitable for surgery; those with severe lung disorders such as asthma and abnormal lung function unsuitable for surgery; pregnant and breastfeeding women as well as those who are planning to become pregnant in the near future; those who have participated in other clinical trials within 3 months; and those who are not suitable for participation in the experiment in the opinion of the investigator."]}, {"trialId": "NCT06597227", "trialName": "Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  <!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL/min;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects."]}, {"trialId": "NCT04216927", "trialName": "NO During CPB in Neonates to Reduce Risk of AKI", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (1.0, 31.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure to obtain informed consent from parent/guardian", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical signs of preoperative persistent elevated pulmonary vascular resistance,", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Episode of cardiac arrest within 1 week before surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Recent treatment with steroids and/or a condition that may require treatment with steroids (excluding steroid administration specifically for CPB),", "Patient has no overlapping conditions/medications with exclusion criterion: Use of inhaled NO (iNO) immediately prior to surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Structural renal abnormalities by ultrasound,", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative AKI,", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other investigational drugs,", "Patient has no overlapping conditions/medications with exclusion criterion: Weight less than \\<2 kg,", "Patient has no overlapping conditions/medications with exclusion criterion: Gestational age \\<36 weeks,", "Patient has no overlapping conditions/medications with exclusion criterion: Major extracardiac congenital anomalies,", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English speakers."]}, {"trialId": "NCT05731427", "trialName": "Research on the Mechanism Affecting Progression of Bronchiectasis", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05666076", "trialName": "Peng Block or Suprascapular Nerve Block for Postoperative Analgesia in Shoulder Artroscopy ?", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with deformity and pathology in the shoulder region", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with known local anesthetic allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with BMI\\>35", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with alcohol and substance addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with opioid addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who cannot perceive and evaluate pain, such as psychiatric illness, mental retardation"]}, {"trialId": "NCT06525376", "trialName": "Validity and Reliability of Smartphone Inclinometer Application for Measurement of Cervical Range of Motion", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 30.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe spinal pathology.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy and lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Any musculoskeletal diseases that affect the cervical spine.", "Patient has no overlapping conditions/medications with exclusion criterion: Any neurological diseases that affect the cervical spine.", "Patient has no overlapping conditions/medications with exclusion criterion: History of trauma in the cervical spine.", "Patient has no overlapping conditions/medications with exclusion criterion: Signs of cervical radiculopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Signs of cervical myelopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Signs of serious pathology.", "Patient has no overlapping conditions/medications with exclusion criterion: subjects have a pacemaker or any other medical equipment that the magnet might have compromised."]}, {"trialId": "NCT05398627", "trialName": "Neurofeedback for Borderline Personality Disorder", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Current moderate or severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild alcohol or substance use would also interfere with the effects of the intervention.", "Patient has no overlapping conditions/medications with exclusion criterion: have a history of traumatic brain injury", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)", "Patient has no overlapping conditions/medications with exclusion criterion: are currently pregnant or breast feeding", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete questionnaires written in English", "Patient has no overlapping conditions/medications with exclusion criterion: current (within 3 weeks of testing) use of any antipsychotics, benzodiazepines, beta-blockers, or other medications (except SSRI antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. Inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population", "Patient has no overlapping conditions/medications with exclusion criterion: have a DSM-5 diagnosis of psychotic or organic mental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: have any eye problems or difficulties in corrected vision.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious suidicial ideation"]}, {"trialId": "NCT05626127", "trialName": "MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Accompanied with other primary malignant tumors;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies;", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete imaging or medical history data."]}, {"trialId": "NCT05780827", "trialName": "Analysis of Clinical Data of Patients With Temporomandibular Joint Disorder", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (12.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have received orthodontic treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of maxillofacial trauma", "Patient has no overlapping conditions/medications with exclusion criterion: Maternity", "Patient has no overlapping conditions/medications with exclusion criterion: Those who take any medicine for a long time", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases such as tumors, endocrine diseases, psychosocial diseases and immune diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Other persons who are unable to cooperate with the project by themselves, such as action barriers.\n\nControl group\n\nInclusion Criteria:\n\nSuffer from symptoms and signs of oral and maxillofacial dysfunction"]}, {"trialId": "NCT06191627", "trialName": "Patient Experience and Quality of Patch Testing on the Legs vs Back", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 89.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is 17 or younger", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or breastfeeding", "Patient has no overlapping conditions/medications with exclusion criterion: Specialized patch testing with low number of patches (less than 90)", "Patient has no overlapping conditions/medications with exclusion criterion: Rash that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Large tattoos that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Limited space on thighs or back due to body habitus", "Patient has no overlapping conditions/medications with exclusion criterion: Patient has specific needs necessitating use of the thighs or back (event, breastfeeding, etc.)"]}, {"trialId": "NCT05890027", "trialName": "Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who refuse to consent.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.", "Patient has no overlapping conditions/medications with exclusion criterion: Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors"]}, {"trialId": "NCT05004727", "trialName": "Multi-Center PAMPA Study", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;", "Patient has no overlapping conditions/medications with exclusion criterion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);", "Patient has no overlapping conditions/medications with exclusion criterion: RA seropositivity (mid-high RF/ACPA titers);", "Patient has no overlapping conditions/medications with exclusion criterion: Current active malignancy;", "Patient has no overlapping conditions/medications with exclusion criterion: History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to the study agent."]}, {"trialId": "NCT06001827", "trialName": "SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Planned index procedure to revise or repair an existing fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Target artery inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Target vein inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound", "Patient has no overlapping conditions/medications with exclusion criterion: Known central venous stenosis of at least 50% on the side of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a stent or a stent graft within the access circuit", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected active infection at the time of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Congestive heart failure NYHA class 4", "Patient has no overlapping conditions/medications with exclusion criterion: Prior steal on the side of surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Life expectancy less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo kidney transplant surgery within 6 months of enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo home hemodialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Unwillingness or inability to give consent and/or comply with the study follow up schedule", "Patient has no overlapping conditions/medications with exclusion criterion: Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study."]}, {"trialId": "NCT03947827", "trialName": "Minocycline as Adjunctive Treatment for Treatment Resistant Depression", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 substance use disorder within past 3 months, moderate or severe, based on SCID-5", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant major unstable medical illness", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or intent to become pregnant during study period", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of psychotic disorder, bipolar disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) within last year", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of borderline personality disorder (BPD)", "Patient has no overlapping conditions/medications with exclusion criterion: Possible or probable dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or current intolerance or contraindication to tetracyclines", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal readings in hematology, liver, or renal function tests", "Patient has no overlapping conditions/medications with exclusion criterion: Have Myasthenia Gravis", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant treatment with anticoagulants, diuretics, retinoids, ergot alkaloids, antacids containing aluminium/calcium/magnesium, bismuth and zinc salts, or quinapril"]}, {"trialId": "NCT03015727", "trialName": "Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: WHO type I squamous cell carcinoma or adenocarcinoma", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>65 or \\<18", "Patient has no overlapping conditions/medications with exclusion criterion: With a history of renal disease", "Patient has no overlapping conditions/medications with exclusion criterion: Prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Peripheral neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Emotional disturbance"]}, {"trialId": "NCT05814627", "trialName": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to any janus kinase (JAK) inhibitor.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD)."]}, {"trialId": "NCT05286827", "trialName": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05840276", "trialName": "Cryoneurolysis Prior to Total Knee Arthroplasty", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications against ibuprofen or paracetamol, for example previous gastric ulcer, or known renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\< 100 bil/l); or against treatment with morphine", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuropathic pain", "Patient has no overlapping conditions/medications with exclusion criterion: Previous recipient of cryoneurolysis for the knee", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with daily use of high dose opioid (\\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled serious disease (cancer, diabetes, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disease associated with reactions to cold, such as cryoglobulinemia, cold urticarial and Reynaud's syndrome."]}, {"trialId": "NCT06111027", "trialName": "Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Regular intake of benzodiazepines", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive impairment: score \\< 27 on Mini-mental state examination", "Patient has no overlapping conditions/medications with exclusion criterion: Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis"]}, {"trialId": "NCT05706376", "trialName": "An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (13.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Families with individuals with significant mental or physical impairments precluding their ability to participate in groups"]}, {"trialId": "NCT05809427", "trialName": "High Frequency Intraoral Ultrasound Probe for Early Diagnosis of Periodontal Diseases", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03460327", "trialName": "Bariatric Surgery and Pharmacokinetics of Candesartan", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Having previously undergone resections in the GI-tract"]}, {"trialId": "NCT04886427", "trialName": "Implementation of a Multidimensional Quality Model", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Do not understand Dutch"]}, {"trialId": "NCT06265727", "trialName": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active of uncontrolled CNS metastases", "Patient has no overlapping conditions/medications with exclusion criterion: History of solid tumors other than the diseases under study", "Patient has no overlapping conditions/medications with exclusion criterion: History of and/or current cardiovascular events or conditions in the previous 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing \\>/= Grade 2 neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Hemoglobin A1C (HbA1C) \\>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active ocular disease at baseline", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic severe liver disease or live cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study", "Patient has no overlapping conditions/medications with exclusion criterion: Other significant cormorbidities."]}, {"trialId": "NCT06527027", "trialName": "LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,", "Patient has no overlapping conditions/medications with exclusion criterion: inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant."]}, {"trialId": "NCT05133076", "trialName": "Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: E1. Involvement in any investigational drug or device study within 30 days prior to this study,\n\nE2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in the study),\n\nE3. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation upon investigator judgment,\n\nE4. Surgery planned within the whole study period,\n\nE5. Evidence of active medical diseases affecting bowel transit,\n\nE6. Antibiotic treatment intake within the last month prior the study start (V0),\n\nE7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are permitted,\n\nE8. Any history of drug addiction in the past five years,\n\nE9. Pregnant or lactating women or intending to become pregnant,\n\nE10. Unwilling to maintain food habits and current physical activity for the whole study duration,\n\nE11. With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,\n\nE12. Having a lifestyle deemed incompatible with the study according to the investigator including drug and alcohol abuse,\n\nE13. Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n\nE14. Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,\n\nE15. Presenting a psychological or linguistic incapability to sign the informed consent,\n\nE16. Impossible to contact in case of emergency."]}, {"trialId": "NCT05555927", "trialName": "Adjunctive Duration-doubled tDCS for the Treatment of Depressive Patients With Suicidal Ideation", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Assessed through applying the Mini-International Neuropsychiatric Interview (MINI)15 by professional psychiatrists that diagnosed any other current or past psychiatric axis-I disorders (except MDD in the patients);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver and kidney diseases, active endocrine diseases or clinical symptoms. Severe cardiovascular disease, respiratory system disease, haematologic diseases and cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal laboratory examination that may influence the health of participants;", "Patient has no overlapping conditions/medications with exclusion criterion: A history of any aignificant medical illness such as neurological disorders (such as cerebral trauma, seizure disorder, etc);", "Patient has no overlapping conditions/medications with exclusion criterion: Known current psychosis as determined by the DSM-5 or a history of a non-mood psychotic disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol and drug abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal scalp such as open wounds;", "Patient has no overlapping conditions/medications with exclusion criterion: HAMD-17 item 3 (suicide) score=4;", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving modified electroconvulsive therapy (MECT) or repetitive transcranial magnetic stimulation (rTMS) in the past 1 month;", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial concurrently or no more than 1 month prior to randomisation."]}, {"trialId": "NCT04998227", "trialName": "Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (20.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: cardiogenic shock, pregnancy, end-stage renal disease"]}, {"trialId": "NCT05377827", "trialName": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from study entry for any of the following:", "Patient has no overlapping conditions/medications with exclusion criterion: Received systemic anticancer therapy (including investigational therapy) or radiotherapy \\< 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:\n\n  * \\< 100 days post alloHCT\n  * \\< 6 weeks from prior donor leukocyte infusion\n  * Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.\n  * \\< 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with any anti-CD7 directed therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to one or more of the study agents.", "Patient has no overlapping conditions/medications with exclusion criterion: Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Confirmed HIV infection.", "Patient has no overlapping conditions/medications with exclusion criterion: History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic, uncontrolled hypotension."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT03150576", "trialName": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (16.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: T0 tumour in absence of axillary node \\>10mm.", "Patient has no overlapping conditions/medications with exclusion criterion: TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with myelodysplastic syndrome/acute myeloid leukaemia.", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of distant metastasis apparent prior to randomisation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled seizures.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breast feeding women.", "Patient has no overlapping conditions/medications with exclusion criterion: Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:\n\nEvidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.", "Patient has no overlapping conditions/medications with exclusion criterion: ECG with mean resting QTc \\>470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).", "Patient has no overlapping conditions/medications with exclusion criterion: Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable)."]}, {"trialId": "NCT06356376", "trialName": "The Effects of Pain and Pain Relief on Peripheral Nerve Excitability", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain conditions", "Patient has no overlapping conditions/medications with exclusion criterion: Neurological or Psychiatric disease", "Patient has no overlapping conditions/medications with exclusion criterion: Other major diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Pain medication within the last 24 hours"]}, {"trialId": "NCT05248776", "trialName": "Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a c-peptide value less than 0.5 nmol/l.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic, or non-peripheral vascular surgery within 6 months prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cardiac arrhythmia, systolic dysfunction, congestive heart failure, angina, myocardial ischemia or infarction, or stroke within 1 year prior to the study, or the presence of an abnormal ECG that, in the investigator's opinion, is clinically significant.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of drug abuse or a history of alcohol abuse within 2 years prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to basal cell or stage I squamous cell carcinoma of the skin.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase level above normal range for the testing laboratory, active liver disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a total bilirubin greater or equal 2 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is/ was lifetime on any insulin treatment or takes other diabetes treatment (except metformin).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of proteinuria ≥300 mg/day on a 12- or 24-hour urine collection within last year or an albumin/creatinine ratio greater or equal 300 μg/mg.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of any clinically significant retinopathy, which is defined as more than moderate nonproliferative diabetic retinopathy, any stage of proliferative diabetic retinopathy or any history of laser-treated retinopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has clinically significant peripheral or autonomic neuropathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of ulcerative colitis or Crohn's disease, or has undergone gastric resection.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of a psychiatric disorder that, in Principal Investigator opinion, will affect the subject ability to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of angioedema.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an acute, clinically significant illness within 30 days prior to the study or any other condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is not able to comply with the study scheduled visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is participating in another investigational study or has taken any investigational drug within 90 days prior to the study."]}, {"trialId": "NCT03269227", "trialName": "Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 85.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous thorax radiotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Chemotherapy is allowed but completed 3 weeks before RT starts", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial with any investigational agents within 30 days prior to study screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with M1 have to be excluded to this study", "Patient has no overlapping conditions/medications with exclusion criterion: FEV1 \\< 50", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>85 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Respiratory needing oxygen therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial pneumopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active pneumonitis", "Patient has no overlapping conditions/medications with exclusion criterion: Fissural disease", "Patient has no overlapping conditions/medications with exclusion criterion: Contralateral mediastinum involvement (N3) and M1", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."]}, {"trialId": "NCT06552676", "trialName": "riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure of the percutaneous tracheostomy technique or recourse to surgical tracheostomy"]}, {"trialId": "NCT01521676", "trialName": "Predictive Clinical and Biological Parameters in Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: emergency"]}, {"trialId": "NCT04030676", "trialName": "QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Wardship patient and curatorial patient", "Patient has no overlapping conditions/medications with exclusion criterion: Patient unable to understand or sign the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Colectomy total or partial"]}, {"trialId": "NCT04560127", "trialName": "Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Any active autoimmune disease or history of autoimmune disease and expected recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis); subjects with skin diseases that does no need systemic treatment, for example, leukoderma, psoriasis, alopecia, those with controlled type I diabetes by insulin or those with asthma that has been completely resolved in childhood and with no need of any intervention can be enrolled; while subjects with asthma who need bronchodilator for medical intervention cannot be enrolled.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of strong CYP3A4/CYP2C19 inducers, including rifampicin (and its analogues) and St. John's Wort, or strong CYP3A4/CYP2C19 inhibitors within two weeks prior to signing informed consent form.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with other immune checkpoint inhibitors (include PD-1 antibody or other immunotherapy against PD-1/PD-L1).", "Patient has no overlapping conditions/medications with exclusion criterion: Known history of serious allergy to any monoclonal antibody or Apatinib.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwilling to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current presence of metastasis to central nervous system.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia or complications of severe pneumonia; oral or intravenous therapeutic antibiotics within two weeks prior to the start of study treatment (for example, subjects who are given with preventive antibiotics for prevention of urinary tract infection or exacerbation of chronic obstructive pulmonary disease are eligible for participation in the study).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women.", "Patient has no overlapping conditions/medications with exclusion criterion: Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators, such as alcoholism, drug abuse, other serious diseases (including mental disorders) requiring concomitant therapy, with serious laboratory examination abnormality, with family or social factors, that may affect subject's safety."]}, {"trialId": "NCT05078476", "trialName": "Rehabilitation of Finger Flexor Tendon Injuries", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\< 18 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients", "Patient has no overlapping conditions/medications with exclusion criterion: Replantation of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Primary tendon reconstructions"]}, {"trialId": "NCT06087627", "trialName": "A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have been treated for more than 7 days with dupilumab", "Patient has no overlapping conditions/medications with exclusion criterion: Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."]}, {"trialId": "NCT04853576", "trialName": "A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (12.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Available 10/10 HLA-matched related donor", "Patient has no overlapping conditions/medications with exclusion criterion: Prior HSCT or contraindications to autologous HSCT", "Patient has no overlapping conditions/medications with exclusion criterion: Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to receive red blood cell (RBC) transfusion for any reason", "Patient has no overlapping conditions/medications with exclusion criterion: Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine", "Patient has no overlapping conditions/medications with exclusion criterion: Any history of severe cerebral vasculopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate end organ function", "Patient has no overlapping conditions/medications with exclusion criterion: Advanced liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior or current malignancy or immunodeficiency disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Immediate family member with a known or suspected Familial Cancer Syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined inclusion/exclusion criteria may apply"]}, {"trialId": "NCT01341327", "trialName": "Observational Study for Left Main Disease Treatment", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Protected left main stenosis"]}, {"trialId": "NCT06337227", "trialName": "Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients for whom biological material cannot be recovered for study purposes;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who refuse to participate in the study"]}, {"trialId": "NCT06312176", "trialName": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Has breast cancer amenable to treatment with curative intent", "Patient has no overlapping conditions/medications with exclusion criterion: Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune disease that has required systemic treatment in the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy"]}, {"trialId": "NCT06061627", "trialName": "A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Valvular heart disease that requires or has undergone surgical intervention", "Patient has no overlapping conditions/medications with exclusion criterion: After mechanical tricuspid valve replacement", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or permanent atrial fibrillation or atrial flutter", "Patient has no overlapping conditions/medications with exclusion criterion: Second or third degree atrioventricular block", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of acute myocardial infarction within 3 months prior to enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Patient's expected survival time is less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or planned to conceive", "Patient has no overlapping conditions/medications with exclusion criterion: Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with simple and persistent left superior vena cava", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with existing pacemaker implantation"]}, {"trialId": "NCT02907827", "trialName": "Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\\< 6weken)", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia", "Patient has no overlapping conditions/medications with exclusion criterion: Metallic devices implanted such as hip prostheses, since this can alter the imaging quality"]}, {"trialId": "NCT06291727", "trialName": "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients scheduled for bilateral TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Revision TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)", "Patient has no overlapping conditions/medications with exclusion criterion: Workers' Compensation patient", "Patient has no overlapping conditions/medications with exclusion criterion: Type I Diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Type II Diabetes requiring insulin medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-operative narcotics use with the exception of tramadol.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal insufficiency (GFR \\< 60) that may impact post-operative protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive deficiencies that prevent the patient from providing their own informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Language barrier preventing completion of study forms in English"]}, {"trialId": "NCT05650827", "trialName": "Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\< 18", "Patient has no overlapping conditions/medications with exclusion criterion: Living outside the greater Copenhagen area", "Patient has no overlapping conditions/medications with exclusion criterion: Any other malignancy requiring active treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Not eligible for chemotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Performance status \\> 2", "Patient has no overlapping conditions/medications with exclusion criterion: Not able to swallow liquids", "Patient has no overlapping conditions/medications with exclusion criterion: Parenteral nutrition or enteral nutrition via feeding tube", "Patient has no overlapping conditions/medications with exclusion criterion: Physical or mental disabilities that prohibit execution of test or training procedures", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to understand the Danish language"]}, {"trialId": "NCT06319027", "trialName": "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05536427", "trialName": "Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with immunodeficiency or a history of autoimmune disorders (e.g., rheumatoid arthropathy, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe concurrent medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, serious infection and infectious disease, active peptic ulcer, presence of active hemorrhage, and severe organ failure;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Grade III or IV cardiac failure defined by the New York Heart Association (NYHA), epileptic seizure, and mechanical or paralytic ileus within 6 months prior to the first administration of the investigational drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received chemotherapy and hormonal therapy within 28 days prior to signing the informed consent forms, or are currently taking other investigational drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with lymphoma, leukemia, myelodysplastic syndrome (MDS), or myelosuppression;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with allergy or a history of hypersensitivity to human blood albumin, or a history of allergy or hypersensitivity to any investigational drug or its excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with chronic diseases requiring immunotherapy or hormonal therapy; and subjects currently receiving corticosteroids for other diseases (except those using topical or inhaled steroids);", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with mental or neurological disorders that are not easily controlled;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects infected with human immunodeficiency virus (commonly known as AIDS) or treponema pallidum (commonly known as syphilis);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of other malignant tumors within the last 5 years;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with prior allogeneic stem cell transplantation or solid organ transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of drug or alcohol abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with any irAE of ≥ Grade 3 following prior immunotherapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who, in the judgment of the investigator, are not suitable to participate in this clinical study (e.g., with poor compliance)."]}, {"trialId": "NCT06093776", "trialName": "Rib Fracture Cryoanalgesia", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age Pregnant Incarcerated Confounding injuries or significant pain attributed to secondary injury Patients with any of the following: cryoglobulinemia; paroxysmal cold hemoglobinuria; cold urticarial; Raynaud's disease; open and/or infected wounds at or near the treatment site"]}, {"trialId": "NCT06146127", "trialName": "Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unequivocal histological features"]}, {"trialId": "NCT06330727", "trialName": "Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 59.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with diagnosis of diabetes, or taking anti-diabetic medication;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy, planned pregnancy, or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease)."]}, {"trialId": "NCT04855227", "trialName": "A Prospective Evaluation of Pain After Non-complex Ventral Hernia Repair", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is contraindicated for general anesthesia or surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a ventral hernia that will require retromuscular mesh placement or employ a technique, including (but not limited to) external oblique release, Rives- Stoppa, eTEP Rives-Stoppa, transversus abdominis release, other component separation techniques (i.e. anterior component separation) or eTEP transversus abdominis release.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a recurrent hernia.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will have an emergent hernia repair.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of chronic pain and/or taking daily pain medications for \\>6 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of substance abuse (excluding marijuana) and/or current (within 30 days) narcotic use.", "Patient has no overlapping conditions/medications with exclusion criterion: Current marijuana use that the subject is unwilling to discontinue within the 14 days prior to surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of MRSA infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with HbA1c level \\> 8.5%.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Exparel during the surgical procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will undergo a concomitant hernia repair or any other concomitant procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Current nicotine use (including vaping) within the past 30 days.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a known bleeding or clotting disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or suspected pregnancy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject belonging to other vulnerable population, e.g, prisoner or ward of the state.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is currently participating in another interventional or investigational research study."]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT06072976", "trialName": "The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (0.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Infant has already been on feeds", "Patient has no overlapping conditions/medications with exclusion criterion: Infants \\<34 weeks gestation", "Patient has no overlapping conditions/medications with exclusion criterion: Parents with contraindications to providing milk (i.e. drug use-cocaine, fentanyl, meth BUT oxy/suboxone/marijuana OK)", "Patient has no overlapping conditions/medications with exclusion criterion: Complicated gastroschisis", "Patient has no overlapping conditions/medications with exclusion criterion: Short gut syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Additional congenital anomalies that affect ability to tolerate milk (i.e. cyanotic congenital heart disease BUT kidney disease ok)"]}, {"trialId": "NCT05752227", "trialName": "Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pure pleural lesions.", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical instability to reach the final diagnosis.", "Patient has no overlapping conditions/medications with exclusion criterion: Inaccessibility by ultrasound."]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (4.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05364827", "trialName": "CT Coronary Angiography Prior to CTO PCI", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: CTO with J-CTO score\\<2", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate/degraded CTCA images", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant/lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe contrast allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to provide written informed consent"]}, {"trialId": "NCT05038527", "trialName": "ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: ASA ≥ 4", "Patient has no overlapping conditions/medications with exclusion criterion: Formally diagnosed with a disease affecting the bone metabolism or wound healing (severe osteoporosis, osteomalacia, Pagets disease, hyperparathyreoidism etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disseminated cancer diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to any of the i-FACTOR Peptide Enhanced Bone Graft ingredients", "Patient has no overlapping conditions/medications with exclusion criterion: Smoking, extensive alcohol use or abuse of hallucinating drugs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver or kidney disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or breastfeeding patients", "Patient has no overlapping conditions/medications with exclusion criterion: Patients estimated not to be able to understand the information sheet or patients, who do not consent to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe psychiatric diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Ongoing infections"]}, {"trialId": "NCT06200376", "trialName": "A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating, or plan to pregnant or give birth during the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;", "Patient has no overlapping conditions/medications with exclusion criterion: History of splenectomy or organ transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;", "Patient has no overlapping conditions/medications with exclusion criterion: Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of high risk cardiovascular disease, including but not limited to:\n\n    * Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);\n    * Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;\n    * Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;\n    * Rating of heart function as defined by the New York Heart Association (NYHA) standards\\>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;\n    * Left ventricular ejection fraction (LVEF) \\< the center lower limit. If no lower limit existed, LVEF\\<50%;\n    * Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);", "Patient has no overlapping conditions/medications with exclusion criterion: History of another malignant tumor, except the following:\n\n    * Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;\n    * Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;\n    * Adequately treated carcinoma in situ without evidence of disease;", "Patient has no overlapping conditions/medications with exclusion criterion: Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Unexplained \\>38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment"]}, {"trialId": "NCT06040827", "trialName": "A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06144476", "trialName": "Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.", "Patient has no overlapping conditions/medications with exclusion criterion: Surgery within the preceding 6 weeks", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection", "Patient has no overlapping conditions/medications with exclusion criterion: Alcohol or recreational drug abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency requiring treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to read or write English", "Patient has no overlapping conditions/medications with exclusion criterion: Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study"]}, {"trialId": "NCT03317327", "trialName": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB and stage I prostate cancer considered not necessary to treat", "Patient has no overlapping conditions/medications with exclusion criterion: Disease suitable for curative salvage surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 4 weeks prior to first administration of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant cardiac, pulmonary or other medical illness that would limit activity or survival", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to any of the components of the investigational product", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who test positive for hepatitis B, C or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of immunosuppressive therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease that has required systemic therapy within the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: Any reason why, in the opinion of the investigator, the patient should not participate"]}, {"trialId": "NCT04257227", "trialName": "Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Documented brain lesions", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to remain still while sitting up (45 degrees) for the duration of therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold"]}, {"trialId": "NCT05601427", "trialName": "Intra-Operative Adductor Canal Blocks", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or refusal to sign informed consent form", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.", "Patient has no overlapping conditions/medications with exclusion criterion: Non-osteoarthritis primary diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to analgesic medications", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal and/or regional anaesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Any use of opioid pain medication within four weeks of the index procedure(13)", "Patient has no overlapping conditions/medications with exclusion criterion: Pain catastrophizing scale score ≥16 (8, 9, 14)", "Patient has no overlapping conditions/medications with exclusion criterion: History of cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: History renal insufficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History or sensory and/or motor neuropathy to the ipsilateral limb", "Patient has no overlapping conditions/medications with exclusion criterion: Simultaneous, bilateral TKA", "Patient has no overlapping conditions/medications with exclusion criterion: Non-TKA prosthesis", "Patient has no overlapping conditions/medications with exclusion criterion: Scheduled for non-SDD TKA.", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative varus/valgus of \\>10 degrees.", "Patient has no overlapping conditions/medications with exclusion criterion: Planned General Anaesthetic", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Intrathecal Morphine"]}, {"trialId": "NCT03072927", "trialName": "MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (13.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT06585527", "trialName": "Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with encephalitis disease, multiple sclerosis, or other CNS (Central Nervous System) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of organ transplantation or waiting for organ transplantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled infectious diseases or other serious diseases, such as HIV positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with any unstable systemic illness (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris beginning within the last 3 months, congestive heart failure, myocardial infarction occurring within 12 months before enrollment, severe arrhythmia requiring medical treatment, liver or kidney failure, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with systemic autoimmune diseases or immunodeficiency diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe allergic constitution.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases requiring long-term treatment with immune agents or glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with mental disorders."]}, {"trialId": "NCT05956327", "trialName": "Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Lack of reliability and sanity (examined by an independent psychiatrist)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive urine drug screen for illicit drugs (except benzodiazepines)", "Patient has no overlapping conditions/medications with exclusion criterion: Acute suicide risk", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant psychiatric axis-I disorders according to the diagnostic testing procedure (Mini International Neuropsychiatric Interview, MINI)", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant neurological or other disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation"]}, {"trialId": "NCT03916627", "trialName": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with metastatic disease for whom the intent of surgery would not be curative", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 1 year", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply"]}, {"trialId": "NCT04504227", "trialName": "Effect of Thickened Feeds on Swallow Physiology in Children With Dysphagia", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (Not Specified, 21.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any pre-existing medical diagnoses that exclude brief resolved unexplained event diagnosis including seizure disorders and cyanotic congenital heart disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any nasal/pharyngeal/esophageal anomalies that might affect safe placement of the pharyngeal motility catheter", "Patient has no overlapping conditions/medications with exclusion criterion: Children fed exclusively by enteral tube", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to rice cereal or Gelmix thickener, which will be used to adjust liquid viscosity"]}, {"trialId": "NCT03712527", "trialName": "Intra-discal Injection of PRP for Low Back Pain", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 60.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: - Patient with Modic 1 discopathy in different vertebral levels", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a Modic I signal abnormality related to a static spinal disorder (such as previous vertebral fractures, or isthmic lysis, or spondyloarthritis)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a history of lumbar spine surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with suspected spondylodiscitis or other infection", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under anticoagulant or antiaggregant therapy, or with a coagulation disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with allergy to iodine or to any of the components of Xylocaine", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to MRI: Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with anatomical difficulty of access to the injection area (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with an uncontrolled severe disease (i.e. heart, pulmonary, gastro-intestinal, neurologic, endocrine, auto-immune affections) limiting the patient's safety (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with previous malignancy less than 5 years (except for non-melanoma skin cancer)", "Patient has no overlapping conditions/medications with exclusion criterion: Prior to the screening visit:", "Patient has no overlapping conditions/medications with exclusion criterion: a current and recent use of morphine (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: a systemic or local corticosteroid therapy (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: Porphyria", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with sphincter disorders indicating a cauda equina syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Psychotic state not controlled by a treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (βHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age", "Patient has no overlapping conditions/medications with exclusion criterion: Vulnerable persons protected by law", "Patient has no overlapping conditions/medications with exclusion criterion: Persons under guardianship", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who are in a dependency or employment with the sponsor or the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Subject unable to read or/and write"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT04519476", "trialName": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n  1. Has received selinexor or another XPO1 inhibitor previously.\n  2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \\>5 years previously and without evidence of recurrence will be allowed.\n  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \\[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\\], primary amyloidosis, etc.) that is likely to interfere with study procedures.\n  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.\n  6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.\n  7. Concurrent use of other anti-cancer agents or treatments.\n  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\n  9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin\n  10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n  11. Pregnant or breastfeeding females.\n  12. BSA \\<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.\n  13. Life expectancy of less than 3 months.\n  14. Major surgery within 4 weeks prior to C1D1.\n  15. Active, unstable cardiovascular function, as indicated by the presence of:\n\n  1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.\n\n  18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.\n\n  19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).\n\n  20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n\n  21. Contraindication to any of the required concomitant drugs or supportive treatments.\n\n  22. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT06508827", "trialName": "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemoglobinopathies", "Patient has no overlapping conditions/medications with exclusion criterion: Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemochromatosis", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating female adults", "Patient has no overlapping conditions/medications with exclusion criterion: Active infections which in research teams' opinion increases risk for toxicities", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures."]}, {"trialId": "NCT05900427", "trialName": "Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Ages: \\<18 and \\>90", "Patient has no overlapping conditions/medications with exclusion criterion: Weight \\< 60 kg", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple surgeries during one hospital stay", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or any contraindication to local anesthetics used in trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindicated for use of liposomal bupivacaine", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver/kidney disease", "Patient has no overlapping conditions/medications with exclusion criterion: Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who received another local anesthetic block prior to the interscalene block.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to consent in English"]}, {"trialId": "NCT05422027", "trialName": "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who meet any of the following criteria will not be enrolled:\n\n  1. Plasma cell leukemia.\n  2. Documented active amyloidosis.\n  3. Involvement of the central nervous system(CNS) by Multiple myeloma.\n  4. Prior exposure to a SINE compound, including ATG-010.\n  5. Currently, whether or not the patient is on medication, \\> Grade 2 peripheral neuropathy or ≥ Grade ≥ 2 painful neuropathy at baseline.\n  6. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and Selinexor (ATG-010) .\n  7. Active, unstable cardiovascular function, as indicated by the presence of:\n\n     1. Symptomatic ischemia, or\n     2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or\n     3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\<40%, or\n     4. Myocardial infarction within 6 months prior to C1D1.\n  8. Known positive serology for HIV or HIV seropositivity.\n  9. Known active hepatitis A, B, or C infection; eg. positive for HCV RNA or HBV-DNA.\n  10. Women who are pregnant or nursing.\n  11. Life expectancy of less than 6 months.\n  12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.\n  13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n  14. Contraindication to any of the required concomitant drugs or supportive treatments.\n  15. Has any concurrent diseases or complications that is likely to interfere with the study procedures.\n  16. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT05284227", "trialName": "Artificial Intelligence-augmented Perioperative Clinical Decision Support", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT06049927", "trialName": "A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (6.0, 35.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from seasonal influenza in the past 6 moths;", "Patient has no overlapping conditions/medications with exclusion criterion: Axillary temperature \\>37.0°C;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma;", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;", "Patient has no overlapping conditions/medications with exclusion criterion: Severe chronic diseases(Such as down syndrome, diabetes, sickle cell anaemia or neurological disorders);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease (such as systemic lupus erythematosus) or immunodeficiency / immunosuppression (such as HIV, after organ transplantation)", "Patient has no overlapping conditions/medications with exclusion criterion: Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;", "Patient has no overlapping conditions/medications with exclusion criterion: Continuous use of corticosteroids or other immunosuppressive agents for ≥ 14 days within the past 6 months (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) and cytotoxic therapy in the past 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Acute diseases or acute exacerbation of chronic diseases in the past 3 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of blood products within in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of other investigational drugs in the past 30 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of attenuated live vaccines in the past 14 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of inactivated or subunit vaccines in the past 7 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other clinical trials before enrollment and in the follow-up period, or plans to participate in other clinical trials during the clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial"]}, {"trialId": "NCT05057676", "trialName": "Autoimmune Intervention Mastery Course Study", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04772027", "trialName": "Motor Parameters in Patients With Limb Girdle Muscular Dystrophy", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: § For all:", "Patient has no overlapping conditions/medications with exclusion criterion: Without associated neuromuscular disorders such as respiratory or muscular-squeletic diseases, apart from the consequences of dystrophy;", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to the tests;", "Patient has no overlapping conditions/medications with exclusion criterion: Noncontrol cardiac rhythm disorders;", "Patient has no overlapping conditions/medications with exclusion criterion: Lying down position intolerance due to severe respiratory troubles;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman."]}, {"trialId": "NCT05159427", "trialName": "Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to independently provide an informed consent for themselves or mentally incapacitated.", "Patient has no overlapping conditions/medications with exclusion criterion: Physical disability (including blindness or deafness) that requires special arrangements.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant clinical illness, including cardiovascular disease, neurological disease, organ failure, or malignancy in the opinion of the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Any surgical procedure within 3 weeks prior to screening", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of severe seasonal allergies or severe allergic diseases including drug allergies, food allergies and allergy against the SmartPill® device", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to any of the study drugs or the products' excipients", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Sulfonamide derivatives", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Lidocaine", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of XIFAXAN", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to acrylate or methacrylate, commonly used components of medical adhesives", "Patient has no overlapping conditions/medications with exclusion criterion: Any other factor, condition, or disease, including, but not limited to, cardiovascular, respiratory, hematological, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the patient, alter drug absorption and pharmacokinetics or impact the validity of the study results.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Type 1 Diabetes Mellitus (DM), diabetic ketoacidosis, with or without coma", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Glucose 6-phosphate dehydrogenase (G6PD) deficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of drug addiction or alcohol abuse within the past 12 months.", "Patient has no overlapping conditions/medications with exclusion criterion: History of significant psychiatric or neurological illness, including seizure disorders.", "Patient has no overlapping conditions/medications with exclusion criterion: Any medical or surgical conditions which might significantly interfere with the functions of gastrointestinal tract (e.g., gastric/intestinal bypass surgeries, fistulas, strictures, stenosis, or physiological/mechanical obstruction of the G.I tract, gastric bezoars, irritable bowel disease, crohn's disease, diverticulosis, or chronic narcotic use).", "Patient has no overlapping conditions/medications with exclusion criterion: History of dysphagia to liquids, food, or pills", "Patient has no overlapping conditions/medications with exclusion criterion: History of abdominal radiation therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating females", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal lab values during screening in the opinion of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of alcohol and/or nicotine containing products 48 hours prior to dosing visits, and throughout PK sampling visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any medications and/or supplements, prescriptions or over the counter 1 week prior to beginning the study, and throughout the study except for birth control with approved methods of contraception when used consistently and correctly (Implants (i.e. Implanon, Nexplanon), Injectables (i.e. Depo-Provera), Combined, Oral Contraceptives, Intrauterine Devices (IUD's) (i.e. Mirena, ParaGard), and Sexual Abstinence are accepted).", "Patient has no overlapping conditions/medications with exclusion criterion: Use of aspirin or any blood thinner medications.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteers unwilling or unable to take the proposed drugs or undergo G.I intubation", "Patient has no overlapping conditions/medications with exclusion criterion: Enrollment in a clinical trial in the past 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Current enrollment in a clinical trial with another study drug, vaccine or medical device", "Patient has no overlapping conditions/medications with exclusion criterion: Fasting blood glucose level \\< 80 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwillingness to fast for 19 hours.", "Patient has no overlapping conditions/medications with exclusion criterion: Blood donations in the past 8 weeks except for apheresis.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer shows a positive result of COVID-19 Antigen Rapid test in dosing visits", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having any of the following symptoms:\n\n    * Fever (over 100.4 oF or 38 oC) or feeling feverish\n    * New cough\n    * New shortness of breath", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having two of any of these symptoms:\n\n    * Chills\n    * Muscle aches\n    * New URI symptom(s) (runny nose, nasal congestion, and/or sore throat)\n    * New loss of sense of smell or sense of taste\n    * New headache", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has been in close contact in the last 14 days with someone recently diagnosed with COVID-19", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has returned from international travel within the past 10 days"]}, {"trialId": "NCT05525676", "trialName": "Relationship Checkups to Reduce Veteran Suicide Risk", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports severe intimate partner violence in the last year.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports experiencing suicidal intent requiring hospitalization.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER experiences past-month psychosis or mania.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years."]}, {"trialId": "NCT05763576", "trialName": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Healthy volunteers:", "Patient has no overlapping conditions/medications with exclusion criterion: History of any clinically significant disease", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant disease that could interfere with treatment or conduct of study", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)\n\nCHB participants:", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of liver cirrhosis or decompensated liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: History or suspicion of hepatocellular carcinoma (HCC)", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study."]}, {"trialId": "NCT05780476", "trialName": "A Novel VIRTUAL Reality Intervention for CAREgivers of People With Dementia (VirtualCare)", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving daily assistance for more than 10 hours from formal CGs;", "Patient has no overlapping conditions/medications with exclusion criterion: Being formal CGs (i.e., nurse or another paid figure);", "Patient has no overlapping conditions/medications with exclusion criterion: Being informal CGs of i) persons with moderate-to-severe AD, or ii) persons with non-AD diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Not having or being able to use a device connected to internet (e.g., smartphones or PC).", "Patient has no overlapping conditions/medications with exclusion criterion: Having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs.", "Patient has no overlapping conditions/medications with exclusion criterion: Only a family member for person with dementia is accepted.\n\nExclusion Criteria for experimental group (Psychoeducation + VR):", "Patient has no overlapping conditions/medications with exclusion criterion: Medical history of epilepsy.\n\nExclusion Criteria for subsample of caregivers assess with MRI:", "Patient has no overlapping conditions/medications with exclusion criterion: Metal implants, artificial prostheses, pace-makers, prosthetic heart valves;", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy."]}, {"trialId": "NCT03990727", "trialName": "Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (2.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: 1) Not willing to visit every year."]}, {"trialId": "NCT05721027", "trialName": "Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Not available for follow-up", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergic to or intolerant of investigational medications", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic steroid use", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney disease (GFR \\<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x the upper limit of normal)"]}, {"trialId": "NCT06550427", "trialName": "Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT04802876", "trialName": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior systemic anti-cancer therapy, including investigational agents within 2 weeks. Medical Monitor could consider shorter interval for kinase inhibitors or other short half-life drugs prior to allocation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants with ≤Grade 2 neuropathy may be eligible.\n\n   Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study treatment.\n\n   Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose of the previous investigational agent.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with thymoma are not eligible. Patients with active CNS metastases and/or carcinomatous meningitis are not eligible. Subjects with up to three cerebral metastases are eligible, if all lesions are stable and have been definitively treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any of its excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior allogeneic stem cell transplantation or organ transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history of interstitial lung disease, (non-infectious) pneumonitis that required steroids or has current pneumonitis, uncontrolled lung including pulmonary fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Human Immunodeficiency Virus (HIV).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of active TBC (Bacillus Tuberculosis).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of trial treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with spartalizumab or tislelizumab. Highly effective contraception methods include:\n\n    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n    4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.\n\n    Notes:\n    * Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.\n    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.", "Patient has no overlapping conditions/medications with exclusion criterion: Sexually active males, unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with spartalizumab or tislelizumab should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen."]}, {"trialId": "NCT04816227", "trialName": "Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusing to participate in the study", "Patient has no overlapping conditions/medications with exclusion criterion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research", "Patient has no overlapping conditions/medications with exclusion criterion: Being pregnant or breastfeeding"]}, {"trialId": "NCT06187727", "trialName": "Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Mechanical complications;", "Patient has no overlapping conditions/medications with exclusion criterion: Cardiogenic shock;", "Patient has no overlapping conditions/medications with exclusion criterion: Experienced myocardial infarction within 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Aortic dissection;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included", "Patient has no overlapping conditions/medications with exclusion criterion: Urinary system infection"]}, {"trialId": "NCT04167527", "trialName": "Endovascular Therapy for Low NIHSS Ischemic Strokes", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: NIHSS ≥6", "Patient has no overlapping conditions/medications with exclusion criterion: Any sign of intracranial hemorrhage on baseline CT/MR (SDH/SAH/ICH)", "Patient has no overlapping conditions/medications with exclusion criterion: Any imaging findings suggestive of futile recanalization in the judgment of the local investigator", "Patient has no overlapping conditions/medications with exclusion criterion: High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD", "Patient has no overlapping conditions/medications with exclusion criterion: Premorbid disability (mRS ≥3)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to randomize within 8 hours of last known well", "Patient has no overlapping conditions/medications with exclusion criterion: Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS", "Patient has no overlapping conditions/medications with exclusion criterion: Baseline blood glucose of \\<50 mg/dL (2.78 mmol) or \\>400 mg/dL (22.20 mmol)", "Patient has no overlapping conditions/medications with exclusion criterion: Known coagulation disorders as defined as platelet count \\<100,000/uL", "Patient has no overlapping conditions/medications with exclusion criterion: Known renal failure as defined as serum creatinine levels \\> 3.0 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Presumed septic embolus or suspicion of bacterial endocarditis", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another investigational treatment study in the previous 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Intubation and mechanical ventilation prior to study enrollment is medically indicated", "Patient has no overlapping conditions/medications with exclusion criterion: History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Site investigator does not have equipoise towards the ideal treatment concept (thrombectomy vs. best medical management)", "Patient has no overlapping conditions/medications with exclusion criterion: Known pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Prisoner or incarceration", "Patient has no overlapping conditions/medications with exclusion criterion: Known acute symptomatic COVID-19 infection"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT06218576", "trialName": "Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: age \\< 18 years"]}, {"trialId": "NCT03050476", "trialName": "Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (21.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Already on renal replacement therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic kidney disease defined as estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m2 \\[ CKD stage \\> 3 \\]", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Concurrent enrollment in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with ongoing infections or current use of steroids", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with high-risk emergency surgery or with follow-up procedures already planned at admission (like e.g. TEVAR)"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT05500027", "trialName": "sCD8, as a Novel Biomarker for Pancreatic Cancer", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 85.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusal to participate", "Patient has no overlapping conditions/medications with exclusion criterion: Age less than 18-year old and over 85-year old"]}, {"trialId": "NCT05755776", "trialName": "The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Men and women of childbearing potential who are unwilling to use an \"effective\" method of contraception as defined in the protocol during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have received a solid organ or bone marrow transplant", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or existing clinical liver failure (Child-Pugh score ≥ grade B)."]}, {"trialId": "NCT05887076", "trialName": "Postoperative Delirium After Kidney Transplantation", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete data records of the parameters to be determined", "Patient has no overlapping conditions/medications with exclusion criterion: Underage Patients"]}, {"trialId": "NCT05272176", "trialName": "Veterans Coordinated Community Care (3C) Study", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired decision-making capacity", "Patient has no overlapping conditions/medications with exclusion criterion: Limited or no English language proficiency", "Patient has no overlapping conditions/medications with exclusion criterion: Terminal illness"]}, {"trialId": "NCT05968976", "trialName": "Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Legally incompetent adults;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous tremor-neurosurgery (e.g., DBS, thalamotomy);", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;", "Patient has no overlapping conditions/medications with exclusion criterion: Psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Current depression;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent."]}, {"trialId": "NCT06182527", "trialName": "Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: diabetes mellitus", "Patient has no overlapping conditions/medications with exclusion criterion: use of medication interfering with glucose metabolism (steroid, antidiabetic medications)", "Patient has no overlapping conditions/medications with exclusion criterion: surgery of upper GI-tract", "Patient has no overlapping conditions/medications with exclusion criterion: known plaster allergies", "Patient has no overlapping conditions/medications with exclusion criterion: any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion"]}, {"trialId": "NCT06222827", "trialName": "Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, any major comorbidities (diabetes mellitus, cancer, severe autoimmune diseases, chronic renal failure, articular diseases that restricts exercise or participation in study assessments in the physician's opinion...), a history of relevant drug or food allergies; history of cardiovascular, respiratory, central nervous system disease; neuromuscular diseases except FSHD (e.g., myopathy, neuropathy, neuromuscular junction disorders)", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who are on drug(s) or supplements that may affect muscle function, as determined by the treating physician must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Orthopedic conditions, such as unresolved fracture or arthrosis, interfering or precluding testing of muscle function", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to muscle MRI as per clinic standard practice", "Patient has no overlapping conditions/medications with exclusion criterion: Articular contracture limiting movements, scapular fixation or other surgeries, preceding or planned", "Patient has no overlapping conditions/medications with exclusion criterion: Any known hypersensitivity to satralizumab or any of its components and/or history of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of latent or active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection for at least 4 weeks prior to enrollment), active opportunistic or life-threatening infections", "Patient has no overlapping conditions/medications with exclusion criterion: History of diverticulitis or concurrent severe GI disorders (such as symptomatic diverticulosis) that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation. Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit (Visit 1, week 0)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody.", "Patient has no overlapping conditions/medications with exclusion criterion: Acute or chronic history of liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal laboratory results with: White blood cells (WBC) \\< 3.0x 10\\^9/L ; Absolute Neutrophils Counts (ANC)\\< 2.0x 10\\^9/L ; Platelet count \\< 10x10\\^4/µl ; Absolute lymphocyte count (ALC) \\< 0.8x 10\\^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 times the upper limit of normal (ULN)", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment (defined as a glomerular filtration rate of \\<30mL/min/1.73m²)", "Patient has no overlapping conditions/medications with exclusion criterion: Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation", "Patient has no overlapping conditions/medications with exclusion criterion: For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier \\[patient or partner\\] in conjunction with a spermicidal product, contraceptive pill, patch, injectable, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of another investigational product within 6 months or 5 half-lives (whichever is longer), or currently participating in a prospective study with an investigational product, whether it concerns an experimental drug or a medical device. Note: concurrent participation in natural history studies (non-drug, non-device studies) is not allowed during the course of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior treatment with any agent targeting the IL-6 inhibition pathway (e.g. tocilizumab, sarilumab), alemtuzumab treatment, total body irradiation, or bone marrow transplantation; treatment in the past 24 weeks with an anti-B-lymphocyte antigen CD20 (e.g. rituximab, ocrelizumab), eculizumab, anti-B-lymphocyte stimulator, or any other multiple sclerosis disease-modifying treatment; treatment in the past 2 years with an anti-T-cell surface glycoprotein CD4, cladribine, cyclophosphamide, or mitoxantrone; or treatment with any other investigational drug within 3 months prior to baseline. See section 4.4.4 for details on the vaccination and immunization.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject, or close relative of the subject, is the investigator or a coinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code."]}, {"trialId": "NCT05505227", "trialName": "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: currently prescribing buprenorphine at full capacity"]}, {"trialId": "NCT05782127", "trialName": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous diagnosis of:\n\n   * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)\n   * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: History of active malignancy within the past year prior to screening, with the exception of:\n\n   * Adequately treated carcinoma in situ of the uterine cervix\n   * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n   * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.\n\n   Patients with ongoing horomonotherapy could be included.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.", "Patient has no overlapping conditions/medications with exclusion criterion: Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.", "Patient has no overlapping conditions/medications with exclusion criterion: Received live attenuated vaccines prior to initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions that could interfere with drug absorption including short gut syndrome, dysphagia, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mmHg or diastolic BP \\> 100 mmHg) or has not been stable for at least 1 month prior to treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:\n\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Unstable angina or angina requiring surgical or medical intervention\n    * Significant cardiac arrhythmia\n    * And/or myocardial infarction", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is a pregnant or lactating female.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has known or suspected to have hypersensitivity to any of the components of the assigned study treatments.", "Patient has no overlapping conditions/medications with exclusion criterion: Positive test result(s) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B surface \\[HBs\\] antibody positive and anti-hepatitis B core \\[HBc\\] antibody negative) may participate.", "Patient has no overlapping conditions/medications with exclusion criterion: Absence of social security affiliation."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT06524427", "trialName": "Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with the previous history of other malignancies;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with secondary primary cancer when enrolled;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as pure ground glass opacity (GGO) before surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as mixed GGO whose solid part \\<= 50% and Maximum diameter of tumor \\<= 2cm;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with small cell lung cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with prior unilateral open thoracic surgical procedures;", "Patient has no overlapping conditions/medications with exclusion criterion: Woman who is pregnant or breastfeeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with an active bacterial or fungal infection that is difficult to control;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with serious psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months."]}, {"trialId": "NCT05537376", "trialName": "A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Veteran"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT05189327", "trialName": "Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient takes part in an interventional clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is unable to follow the schedule of the visits;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that the PI believes would prevent a study participant from participating in the study."]}, {"trialId": "NCT06447727", "trialName": "Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: After liver metastasis was diagnosed, the liver underwent external radiation therapy and transhepatic arterial chemoembolization", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with extrahepatic metastases", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe arrhythmia or heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: Other researchers considered it inappropriate to participate in this study"]}, {"trialId": "NCT06176027", "trialName": "Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women"]}, {"trialId": "NCT05775627", "trialName": "Sleep and Metabolism", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dietary restrictions\n\n   Participants must not have dietary restrictions that could systematically bias their macronutrient intake. The following will exclude participants from enrolling in the study based on their diet:\n   * Participants who choose not to or cannot consume dairy products (milk, yogurt, cheese, ice cream)", "Patient has no overlapping conditions/medications with exclusion criterion: Body Composition\n\n   A body mass index (BMI) of 18.5\\< \\[BMI\\] \\< 25 kg/m2 and a waist circumference \\<94/80cm.", "Patient has no overlapping conditions/medications with exclusion criterion: Psychiatric/psychological suitability\n\n   Each participant will undergo a structured interview (Mini International Neuropsychiatric Interview) with a qualified OHSU physician. This physician will supervise the administration and scoring of a Beck Depression Inventory II (BDI-II) questionnaire for each potential participant. The following will exclude individuals from participating based on their psychiatric or psychological evaluation:\n   * Individuals with evidence of psychopathology on the BDI-II, or in a structured clinical interview with the physician\n   * A history of severe psychiatric illnesses\n   * Alcoholism\n   * Drug dependency\n   * Major depression\n   * Manic depressive illness\n   * Schizophrenic disorders\n   * Panic disorder\n   * Generalized anxiety disorder\n   * Post-traumatic stress disorder\n   * Agoraphobia\n   * Claustrophobia\n   * Paranoid personality disorder\n   * Schizoid personality disorder\n   * Schizotypal personality disorder\n   * Borderline personality disorder\n   * Antisocial personality disorder.\n   * History of using antidepressant medication\n   * History of using neuroleptic medication\n   * History of using tranquilizers", "Patient has no overlapping conditions/medications with exclusion criterion: Drug/alcohol use\n\n   Volunteers must be drug-free (including caffeine, nicotine, alcohol and herbal medications) for the entire duration of the outpatient and in-laboratory study period, with no history of drug or alcohol dependency. All participants must be:\n   * Current non-smokers, and are required to have a history of less than 5 'pack years' of smoking", "Patient has no overlapping conditions/medications with exclusion criterion: Medication/drug use\n\n   Volunteers must not be taking any prescribed medications or over the counter medications, with an exception for birth control.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior shift work\n\n   For stability of endogenous circadian rhythmicity, volunteers must have no history of the following 1 year prior to the study:\n   * Working irregular day and night hours\n   * Regular night work\n   * Rotating shift work f\n   * Not have traveled more than 1 time zone during 3 months prior to the study", "Patient has no overlapping conditions/medications with exclusion criterion: Chronobiologic and sleep disorders\n\n   * Hypernychthemeral sleep/wake cycle\n   * Delayed sleep phase syndrome (wake time \\> 2 hours later than desired or habitually after 10:00 AM)\n   * Advanced sleep phase syndrome (wake time \\> 2 h earlier than desired or habitually before 5:00 AM)\n   * Narcolepsy\n   * Sleep apnea (apnea index \\>15)\n   * Insomnia (sleep complaint by history or polygraphically recorded sleep efficiency \\< 80%)\n   * Hypersomnia\n   * Periodic Limb Movement (PLMS) (PLMS index \\>15)\n   * Nocturnal Paroxysmal Dystonia\n   * REM-sleep behavior disorder\n   * Nocturnal Enuresis; (self-report and first night in the laboratory)\n   * Obstructive sleep apnea (apnea/hypopnea index \\>5/h as determined by at-home monitoring)\n   * The investigators will also exclude individuals with extreme chronotype using the Horne-Ostberg Morningness/Eveningness questionnaire (i.e., the Owl/Lark Questionnaire)", "Patient has no overlapping conditions/medications with exclusion criterion: Diseases of the Cardiovascular System\n\n   * Hypertension (systolic blood pressure \\> 140 or diastolic blood pressure \\> 90)\n   * Heart failure\n   * Cardiomyopathy\n   * Cor pulmonale\n   * Ischemic heart disease\n   * Valvular heart disease\n   * History of heart transplantation\n   * Cardiac tumors\n   * Pericardial disease", "Patient has no overlapping conditions/medications with exclusion criterion: Metabolic Syndrome\n\n   Following American Heart Association cutoffs, participants who have, in addition to abdominal fat (obese exclusion criteria), two or more of these factors will be excluded from the study:\n   * HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women\n   * Systolic blood pressure \\>135 mmHg or diastolic blood pressure \\>85 mmHg\n   * Fasting blood glucose ≥ 100 mg/dL\n   * Triglycerides ≥ 150 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-Diabetes/Diabetes\n\n    For participants who have a fasting blood glucose level of ≥ 100 mg/dL the investigators will measure hemoglobin A1c to exclude for diabetes (HbA1c\\>5.7%).", "Patient has no overlapping conditions/medications with exclusion criterion: Hypertension\n\n    An upper cut off of 140/90 mmHg during an office blood pressure measure will be used as an exclusion criterion. After 5 minutes of rest in a seated position, blood pressure will be measured 3 times, taken 1 minute apart. The average will be used to confirm eligibility criteria. Current or history of beta blocker use will also be exclusionary.", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Respiratory System\n\n    * Asthma\n    * Cystic fibroses\n    * Chronic bronchitis\n    * Emphysema\n    * Airway obstruction\n    * Interstitial lung diseases\n    * Pulmonary hypertension\n    * Lung neoplasms\n    * ARDS", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Kidney and Urinary Tract\n\n    * Acute or chronic renal failure\n    * History of renal transplantation\n    * Tubulointerstitial diseases of the kidney\n    * Urinary tract obstruction\n    * Tumors of the urinary tract", "Patient has no overlapping conditions/medications with exclusion criterion: Infectious Diseases\n\n    * Infective endocarditis\n    * HIV infection\n    * Sexually transmitted diseases \\[e.g., syphilis (including congenital syphilis and its sequelae), gonorrhea\\],\n    * Urinary tract infection\n    * Osteomyelitis\n    * Brucellosis\n    * Toxoplasmosis,\n    * Tuberculosis\n    * Leptospirosis\n    * Lyme disease\n    * Mononucleosis\n    * Hepatitis\n    * Parasitic infections such as malaria, toxoplasmosis, giardiasis, schistosomiasis, leishmaniasis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Gastrointestinal System\n\n    * Esophagitis\n    * Peptic ulcer and gastritis\n    * Neoplasms of the esophagus, stomach or bowel\n    * Disorders of absorption\n    * Inflammatory bowel disease\n    * Diseases of the small and large intestine\n    * Acute appendicitis\n    * Cirrhosis or neoplasms of the liver\n    * History of liver transplantation\n    * Diseases of the gallbladder and bile ducts\n    * Pancreatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Immune System, Connective Tissue and Joints\n\n    * AIDS\n    * Systemic lupus erythematosus\n    * Rheumatoid arthritis\n    * Scleroderma\n    * Ankylosing spondylitis\n    * Vasculitis\n    * Sarcoidosis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Hematopoietic System\n\n    * Anemia\n    * Leukemia\n    * Myeloproliferative diseases\n    * History of bone marrow transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Neoplastic Diseases\n\n    * Lymphoma\n    * Carcinoma\n    * Melanoma\n    * Any other neoplastic diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Endocrine and Metabolic Diseases\n\n    * Thyroid disease\n    * Addison's Disease\n    * Cushing's Syndrome\n    * Aldosteronism\n    * Hypoaldosteronism\n    * Pheochromocytoma\n    * Disorders of sexual differentiation that require hormone supplementation that may alter body weight\n    * Disorders of neuroendocrine regulation\n    * Diseases of the anterior pituitary and hypothalamus\n    * Hemochromatosis porphyria\n    * Wilson's Disease\n    * Glycogen storage diseases\n    * Diseases of the parathyroid gland\n    * Metabolic bone disease\n    * Disorders of phosphorus or magnesium metabolism\n    * Paget's Disease", "Patient has no overlapping conditions/medications with exclusion criterion: Neurologic Disorders\n\n    * Epilepsy and disorders of consciousness\n    * Dementia\n    * Amnesic disorders\n    * Neoplastic diseases of the central nervous system\n    * Demyelinating diseases\n    * Parkinson's Disease\n    * Muscular dystrophy\n    * Myasthenia gravis\n    * Periodic paralysis\n    * Dermatomyositis\n    * Polymyositis\n    * Infections of the nervous system\n    * Stroke\n    * History of transient ischemic attacks\n    * Hydrocephalus\n    * Tumors of the pituitary gland\n    * Pinealoma\n    * Intervertebral disc disease\n    * Ataxia\n    * Gilles de la Tourette Syndrome\n    * Huntington's Disease\n    * Tardive dyskinesia\n    * History of recurrent migraine headaches\n    * Neuromuscular disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects must not be currently participating in another research study that would influence their safe participation in our study. Subjects must not be participating in a research study in which they do the following:\n\n    * Ingest experimental medication\n    * Give blood samples"]}, {"trialId": "NCT04280627", "trialName": "Changes in the Microbiome Associated With Transplantation", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Outside of stated age range.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to give informed consent"]}, {"trialId": "NCT06627127", "trialName": "A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects meeting any of the following criteria will be excluded from participation in this study:", "Patient has no overlapping conditions/medications with exclusion criterion: Major anatomical or functional abnormalities that would impair the ability of the electrode arrays to be positioned.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant comorbidities that contraindicate surgery or general anesthesia/DISE", "Patient has no overlapping conditions/medications with exclusion criterion: Significant tongue weakness", "Patient has no overlapping conditions/medications with exclusion criterion: Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia/DISE in the judgment of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior surgery or treatments that could compromise the placement and effectiveness of the electrode array systems:\n\n  * Airway cancer surgery or radiation,\n  * Mandible or maxilla surgery in the previous 3 years (not counting dental treatments),", "Patient has no overlapping conditions/medications with exclusion criterion: Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),", "Patient has no overlapping conditions/medications with exclusion criterion: Prior hypoglossal nerve stimulation device implantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently pregnant, or breastfeeding during the study period"]}, {"trialId": "NCT06441227", "trialName": "Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who suffer from any serious clinical diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease or medical history that can interfere with the test results or any significant laboratory abnormality that is judged by researchers to be of clinical significance.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of malignant tumors.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have taken any prescription drugs, over-the-counter drugs and Chinese herbs within 14 days before taking the study drug, or within 5 half-life of the drug at the time of screening; those who plan to take non-study drugs during the trial period.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have participated in the clinical trial of any drug or medical device within 3 months before screening, or have not been within 5 half-life of the drug before screening (when both standards are met, the standard shall be based on the long-term standard).", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects received siRNA in the past 12 months, or antisense oligonucleotide drugs in the past six months.", "Patient has no overlapping conditions/medications with exclusion criterion: The abnormal upper limit of hypersensitive C-reactive protein during the screening period is \\>1.5 times the normal upper limit, or the normal upper limit of prothrombin time/international standard ratio (PT/INR), activated partial thrombin time (aPTT) \\> 1.25 times normal upper limit.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening for infectious diseases during the screening period (including hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, syphilis spirochete antibody).", "Patient has no overlapping conditions/medications with exclusion criterion: 12-lead electrocardiogram abnormal and clinical significance, or electrocardiogram QT interval (QTcF) male \\> 450 ms, female \\> 470 ms.", "Patient has no overlapping conditions/medications with exclusion criterion: The total amount of blood donated or blood loss ≥ 200 mL within 1 month before administration, or the total amount of blood donation or blood loss ≥ 400 mL within 3 months before administration, or received blood transfusion within 8 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have a serious infection, serious trauma or major surgery within 3 months before administration; those who plan to undergo surgery within two weeks during and after the end of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Suspected people with a history of allergy to research drugs or any ingredients in research drugs, allergies or previous history of serious drug allergies.", "Patient has no overlapping conditions/medications with exclusion criterion: People who have had blood collection difficulties or cannot tolerate venous punctures in the past, such as needle fainting and blood fainting.", "Patient has no overlapping conditions/medications with exclusion criterion: Glomerular filtration rate (eGFR) is lower than GFR 60 mL/min/1.73 m2.", "Patient has no overlapping conditions/medications with exclusion criterion: Smoke an average of ≥ 5 cigarettes per day in the first three months of administration; the average daily intake of alcohol in the first month before administration exceeded 15 grams.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening and visiting drug screening test is positive or alcohol breath test is positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Other circumstances in which the researcher believes that the subject is not suitable to participate in this experiment."]}, {"trialId": "NCT05763927", "trialName": "Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have previously received immune checkpoint inhibitors;", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reactions to PD-1 monoclonal antibody active ingredients, TKI inhibitor-related ingredients or any excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with organ bleeding or bleeding tendency, except for rectal primary tumor bleeding (need investigator to assess the risk of bleeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: years or at the same time have a history of other malignant tumors, but cured skin basal cell carcinoma and cervical carcinoma in situ and thyroid;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled epilepsy, central nervous system disease or mental disorders, the investigator judged that their clinical severity may hinder the signing of informed consent or affect the patient 's compliance with oral drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically serious (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalent daily) or other immunosuppressive agents (including organ transplant recipients) within 2 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other interventional drug clinical trials within 4 weeks before the first dose;", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery or severe trauma within 4 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Serious infection (CTCAE greater than grade 2) within 4 weeks before the first dose of study drug,Such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging suggests active pulmonary inflammation, symptoms and signs of infection within 2 weeks before the first dose of study drug, or the need for oral or intravenous antibiotics (excluding prophylactic antibiotics);", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes); autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone, using stable doses of insulin type 1 diabetes can be included; but excluding vitiligo or recovered childhood asthma/allergy, without any intervention in adults;", "Patient has no overlapping conditions/medications with exclusion criterion: History of immunodeficiency, including positive HIV test, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Active pulmonary tuberculosis infection found by medical history or CT examination, Or patients with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or patients with a history of active pulmonary tuberculosis infection but without regular treatment 1 year before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with active hepatitis (HBV DNA ≥ 2000 IU/ml or 10000 copies/ml), hepatitis C (hepatitis C antibody positive,HCV-RNA was above the lower limit of detection of the assay);", "Patient has no overlapping conditions/medications with exclusion criterion: Had a known history of psychotropic drug abuse, alcoholism, or drug use;", "Patient has no overlapping conditions/medications with exclusion criterion: Had a history, illness, treatment, or laboratory abnormality that could interfere with the results of the trial, prevent the subject from participating throughout the study, or the investigator considered participation to be in the subject 's best interest."]}, {"trialId": "NCT05555576", "trialName": "Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Opioid use 1 month prior to the ED visit;", "Patient has no overlapping conditions/medications with exclusion criterion: Already taking vitamin C supplement;", "Patient has no overlapping conditions/medications with exclusion criterion: Active cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for chronic pain;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for opioid use disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to fill out diary or unavailable for follow-up;", "Patient has no overlapping conditions/medications with exclusion criterion: Any allergy, intolerance or sensitivity to milk (lactose) or morphine", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with cyclosporin or coumadin", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)"]}, {"trialId": "NCT04557527", "trialName": "Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to hyaluronate or. HEALON5® PRO OVD", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\nStudy eye:", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of proliferative vitreoretinopathy (PVR) or any tractional RD", "Patient has no overlapping conditions/medications with exclusion criterion: Previous vitreoretinal surgery, open-globe injury or endophthalmitis", "Patient has no overlapping conditions/medications with exclusion criterion: Aphakia", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current congenital cataract", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current suprachoroidal haemorrhage", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment", "Patient has no overlapping conditions/medications with exclusion criterion: Current intraocular inflammation other than mild cellular activity thought to be secondary to RD", "Patient has no overlapping conditions/medications with exclusion criterion: Current ocular or periocular infection other than blepharitis"]}, {"trialId": "NCT05427227", "trialName": "Prospectively Predict the Efficacy and Explore the Mechanism of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous systemic therapy for metastatic GI cancer\n\n  * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.\n  * Allergic constitution or allergic history to protium biologic product or any investigating agents.\n  * Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.\n  * Pregnancy or lactation period\n  * Other previous malignancy within 5 year, except non-melanoma skin cancer\n  * Legal incapacity"]}, {"trialId": "NCT05628376", "trialName": "TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:", "Patient has no overlapping conditions/medications with exclusion criterion: Positive margins, incomplete resection or insufficient nodal sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B/C:", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)"]}, {"trialId": "NCT04620876", "trialName": "Bimodal and Coaxial High Resolution Ophtalmic Imaging", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (1.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05757076", "trialName": "Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of secondary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy status (verbal)"]}, {"trialId": "NCT04838327", "trialName": "Rare Subtypes of Gastrointestinal Cancers", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions precluding translational blood sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Another concomitant cancer"]}, {"trialId": "NCT03344276", "trialName": "Assessing Neurocognition After Cerebrovascular Intervention", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: patients \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: patients with without compatibility for MRI", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring carotid stenting for reasons not related to long-standing stenosis", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study."]}, {"trialId": "NCT06186427", "trialName": "A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who cannot tolerate puncture biopsy or surgical contraindications;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have undergone radiotherapy and chemotherapy in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Individuals who are allergic to multiple drugs or foods;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who refuse nuclear medicine examinations;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who do not agree to sign an informed consent form and are unable or willing to follow up."]}, {"trialId": "NCT04695327", "trialName": "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled cardiac or vascular diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hepatic dysfunction, hepatitis or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: History of coagulation disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant, breastfeeding or intend to become pregnant.", "Patient has no overlapping conditions/medications with exclusion criterion: Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.", "Patient has no overlapping conditions/medications with exclusion criterion: Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol)."]}, {"trialId": "NCT06339827", "trialName": "ASk Questions in GYnecologic Oncology (ASQ-GYO)", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment discussion with a Gynecologic Oncologist"]}, {"trialId": "NCT03921827", "trialName": "External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (21.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with atrial fibrillation/ arrhythmias.", "Patient has no overlapping conditions/medications with exclusion criterion: Within 2 weeks of cardiac catheterization or arterial puncture at femoral puncture site.", "Patient has no overlapping conditions/medications with exclusion criterion: Decompensated heart failure , usually class 3 or 4", "Patient has no overlapping conditions/medications with exclusion criterion: LV EF \\<30%", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe AR", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent and uncontrolled hypertension (BP persistently \\>160/100 mmHg)", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding diathesis", "Patient has no overlapping conditions/medications with exclusion criterion: Active thrombophlebitis/ venous disease of lower limbs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe lower extremity vaso-occlusive disease", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a documented aortic aneurysm/ dissection requiring surgical repair", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy"]}, {"trialId": "NCT05312827", "trialName": "Training Intervention and Program of Support (TIPS): Fostering Family-centred Telehealth in Pediatric Rehabilitation", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03529227", "trialName": "Gazyva Infusion Reaction Investigation", "eligibilityCriteriaMet": ["Patient Age (21) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: The refusal of the patient to participate in the observational study and the withdrawal of informed consent that allow processing of personal data and data that refer to patient confidentiality."]}]}, {"patientId": "76ce01ae-b5bb-6e8d-9d26-f900352ab25c", "eligibleTrials": [{"trialId": "NCT06286527", "trialName": "Quality of Sexual Life of PrEP Users", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unwilling to participate"]}, {"trialId": "NCT04484727", "trialName": "\"Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs\"", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients under 18 years", "Patient has no overlapping conditions/medications with exclusion criterion: ASA 4 and above", "Patient has no overlapping conditions/medications with exclusion criterion: severe COPD/emphysema/heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: PEEP\\>16 and/or FiO2 \\>80%", "Patient has no overlapping conditions/medications with exclusion criterion: elevated intracranial pressure", "Patient has no overlapping conditions/medications with exclusion criterion: defect coagulation", "Patient has no overlapping conditions/medications with exclusion criterion: non-treated known or suspected pneumothorax"]}, {"trialId": "NCT03869476", "trialName": "Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 99.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a diagnosis of secondary myelofibrosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman;", "Patient has no overlapping conditions/medications with exclusion criterion: Person prived of liberty by judicial or administrative decision;", "Patient has no overlapping conditions/medications with exclusion criterion: Person subject to a legal protection measure;"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (15.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT05690776", "trialName": "PMCF Study on the Safety, Performance and Clinical Benefits Data of the Quattro X Broadband", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of infection;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient or immature bone;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient blood supply or previous infections which may hinder the healing process;", "Patient has no overlapping conditions/medications with exclusion criterion: Foreign body sensitivity;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant);", "Patient has no overlapping conditions/medications with exclusion criterion: The subject is unwilling or unable to give consent or to comply with the follow-up program;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject meets any contraindications of the appropriate Instruction for Use."]}, {"trialId": "NCT06100276", "trialName": "Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.", "Patient has no overlapping conditions/medications with exclusion criterion: Pathogenic repeat expansion in the C9orf72 gene", "Patient has no overlapping conditions/medications with exclusion criterion: Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications."]}, {"trialId": "NCT04666727", "trialName": "Role of Diet on the Microbiome of the Digestive System", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (45.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: • Current smokers (nicotine abuse only)\n\n  * Positive family history of colon cancer or colon cancer related syndromes\n  * Recent use of antibiotics in 1 month\n  * History of inflammatory bowel disease, and/or radiation enteritis or colitis\n  * Pregnant and breastfeeding women\n  * Women of child-bearing potential who have positive urine or serum pregnancy test\n  * Heavy drinker (defined as more than 14 drinks per week)\n  * Currently using anti-flatulence medications, probiotics and/or fiber supplements\n  * Major dietary restrictions and/or following a special diet\n  * Patient with positive fecal test/symptoms"]}, {"trialId": "NCT06027827", "trialName": "Impact of Lateral Bone Grafting With Intraoperative Fusion in ACDF on Clinical Outcomes", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 60.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Drug or alcohol abusers; those with abnormal liver or kidney function unsuitable for surgery; those with cardiac insufficiency unsuitable for surgery; those with severe metabolic and endocrine diseases unsuitable for surgery; those with severe lung disorders such as asthma and abnormal lung function unsuitable for surgery; pregnant and breastfeeding women as well as those who are planning to become pregnant in the near future; those who have participated in other clinical trials within 3 months; and those who are not suitable for participation in the experiment in the opinion of the investigator."]}, {"trialId": "NCT06597227", "trialName": "Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  <!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL/min;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects."]}, {"trialId": "NCT05731427", "trialName": "Research on the Mechanism Affecting Progression of Bronchiectasis", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05666076", "trialName": "Peng Block or Suprascapular Nerve Block for Postoperative Analgesia in Shoulder Artroscopy ?", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with deformity and pathology in the shoulder region", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with known local anesthetic allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with BMI\\>35", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with alcohol and substance addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with opioid addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who cannot perceive and evaluate pain, such as psychiatric illness, mental retardation"]}, {"trialId": "NCT05626127", "trialName": "MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Accompanied with other primary malignant tumors;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies;", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete imaging or medical history data."]}, {"trialId": "NCT06191627", "trialName": "Patient Experience and Quality of Patch Testing on the Legs vs Back", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 89.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is 17 or younger", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or breastfeeding", "Patient has no overlapping conditions/medications with exclusion criterion: Specialized patch testing with low number of patches (less than 90)", "Patient has no overlapping conditions/medications with exclusion criterion: Rash that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Large tattoos that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Limited space on thighs or back due to body habitus", "Patient has no overlapping conditions/medications with exclusion criterion: Patient has specific needs necessitating use of the thighs or back (event, breastfeeding, etc.)"]}, {"trialId": "NCT05890027", "trialName": "Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who refuse to consent.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.", "Patient has no overlapping conditions/medications with exclusion criterion: Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors"]}, {"trialId": "NCT05004727", "trialName": "Multi-Center PAMPA Study", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;", "Patient has no overlapping conditions/medications with exclusion criterion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);", "Patient has no overlapping conditions/medications with exclusion criterion: RA seropositivity (mid-high RF/ACPA titers);", "Patient has no overlapping conditions/medications with exclusion criterion: Current active malignancy;", "Patient has no overlapping conditions/medications with exclusion criterion: History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to the study agent."]}, {"trialId": "NCT06001827", "trialName": "SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Planned index procedure to revise or repair an existing fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Target artery inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Target vein inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound", "Patient has no overlapping conditions/medications with exclusion criterion: Known central venous stenosis of at least 50% on the side of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a stent or a stent graft within the access circuit", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected active infection at the time of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Congestive heart failure NYHA class 4", "Patient has no overlapping conditions/medications with exclusion criterion: Prior steal on the side of surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Life expectancy less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo kidney transplant surgery within 6 months of enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo home hemodialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Unwillingness or inability to give consent and/or comply with the study follow up schedule", "Patient has no overlapping conditions/medications with exclusion criterion: Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study."]}, {"trialId": "NCT03947827", "trialName": "Minocycline as Adjunctive Treatment for Treatment Resistant Depression", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 substance use disorder within past 3 months, moderate or severe, based on SCID-5", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant major unstable medical illness", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or intent to become pregnant during study period", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of psychotic disorder, bipolar disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) within last year", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of borderline personality disorder (BPD)", "Patient has no overlapping conditions/medications with exclusion criterion: Possible or probable dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or current intolerance or contraindication to tetracyclines", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal readings in hematology, liver, or renal function tests", "Patient has no overlapping conditions/medications with exclusion criterion: Have Myasthenia Gravis", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant treatment with anticoagulants, diuretics, retinoids, ergot alkaloids, antacids containing aluminium/calcium/magnesium, bismuth and zinc salts, or quinapril"]}, {"trialId": "NCT03015727", "trialName": "Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: WHO type I squamous cell carcinoma or adenocarcinoma", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>65 or \\<18", "Patient has no overlapping conditions/medications with exclusion criterion: With a history of renal disease", "Patient has no overlapping conditions/medications with exclusion criterion: Prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Peripheral neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Emotional disturbance"]}, {"trialId": "NCT05814627", "trialName": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to any janus kinase (JAK) inhibitor.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD)."]}, {"trialId": "NCT05286827", "trialName": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05840276", "trialName": "Cryoneurolysis Prior to Total Knee Arthroplasty", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications against ibuprofen or paracetamol, for example previous gastric ulcer, or known renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\< 100 bil/l); or against treatment with morphine", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuropathic pain", "Patient has no overlapping conditions/medications with exclusion criterion: Previous recipient of cryoneurolysis for the knee", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with daily use of high dose opioid (\\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled serious disease (cancer, diabetes, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disease associated with reactions to cold, such as cryoglobulinemia, cold urticarial and Reynaud's syndrome."]}, {"trialId": "NCT06111027", "trialName": "Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Regular intake of benzodiazepines", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive impairment: score \\< 27 on Mini-mental state examination", "Patient has no overlapping conditions/medications with exclusion criterion: Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis"]}, {"trialId": "NCT05706376", "trialName": "An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (13.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Families with individuals with significant mental or physical impairments precluding their ability to participate in groups"]}, {"trialId": "NCT05809427", "trialName": "High Frequency Intraoral Ultrasound Probe for Early Diagnosis of Periodontal Diseases", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03460327", "trialName": "Bariatric Surgery and Pharmacokinetics of Candesartan", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Having previously undergone resections in the GI-tract"]}, {"trialId": "NCT04886427", "trialName": "Implementation of a Multidimensional Quality Model", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Do not understand Dutch"]}, {"trialId": "NCT06265727", "trialName": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active of uncontrolled CNS metastases", "Patient has no overlapping conditions/medications with exclusion criterion: History of solid tumors other than the diseases under study", "Patient has no overlapping conditions/medications with exclusion criterion: History of and/or current cardiovascular events or conditions in the previous 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing \\>/= Grade 2 neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Hemoglobin A1C (HbA1C) \\>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active ocular disease at baseline", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic severe liver disease or live cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study", "Patient has no overlapping conditions/medications with exclusion criterion: Other significant cormorbidities."]}, {"trialId": "NCT04448327", "trialName": "Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (50.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuroleptic use", "Patient has no overlapping conditions/medications with exclusion criterion: Any psychiatric disorder involving a history of psychosis (e.g. schizophrenia, bipolar I disorder)", "Patient has no overlapping conditions/medications with exclusion criterion: Active suicidal ideation with intent and/or plan or history of a suicide attempt within the last year", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe substance use disorder within the past 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of significant cardiovascular or cerebrovascular disease (e.g. congestive heart failure, stroke, cardiac conduction disorders, history of asystole or non-sustained ventricular tachycardia)", "Patient has no overlapping conditions/medications with exclusion criterion: Diseases affecting the CNS (e.g. MS, epilepsy, neurodegenerative diseases, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Traumatic brain injury with cognitive sequelae", "Patient has no overlapping conditions/medications with exclusion criterion: MRI or tVNS contraindications (e.g. claustrophobia, metallic implants or devices)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (uncommon, given the age of this cohort is 50+ years) due to unknown health risks for the fetus"]}, {"trialId": "NCT06527027", "trialName": "LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,", "Patient has no overlapping conditions/medications with exclusion criterion: inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant."]}, {"trialId": "NCT05133076", "trialName": "Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: E1. Involvement in any investigational drug or device study within 30 days prior to this study,\n\nE2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in the study),\n\nE3. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation upon investigator judgment,\n\nE4. Surgery planned within the whole study period,\n\nE5. Evidence of active medical diseases affecting bowel transit,\n\nE6. Antibiotic treatment intake within the last month prior the study start (V0),\n\nE7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are permitted,\n\nE8. Any history of drug addiction in the past five years,\n\nE9. Pregnant or lactating women or intending to become pregnant,\n\nE10. Unwilling to maintain food habits and current physical activity for the whole study duration,\n\nE11. With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,\n\nE12. Having a lifestyle deemed incompatible with the study according to the investigator including drug and alcohol abuse,\n\nE13. Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n\nE14. Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,\n\nE15. Presenting a psychological or linguistic incapability to sign the informed consent,\n\nE16. Impossible to contact in case of emergency."]}, {"trialId": "NCT06504927", "trialName": "Biomarker Discovery in Lung Cancer - Malaysia", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (30.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is pregnant or lactating (self-declaration).", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is unwilling or unable to provide signed informed consent"]}, {"trialId": "NCT04998227", "trialName": "Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (20.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: cardiogenic shock, pregnancy, end-stage renal disease"]}, {"trialId": "NCT05377827", "trialName": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from study entry for any of the following:", "Patient has no overlapping conditions/medications with exclusion criterion: Received systemic anticancer therapy (including investigational therapy) or radiotherapy \\< 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:\n\n  * \\< 100 days post alloHCT\n  * \\< 6 weeks from prior donor leukocyte infusion\n  * Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.\n  * \\< 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with any anti-CD7 directed therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to one or more of the study agents.", "Patient has no overlapping conditions/medications with exclusion criterion: Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Confirmed HIV infection.", "Patient has no overlapping conditions/medications with exclusion criterion: History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic, uncontrolled hypotension."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT03150576", "trialName": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (16.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: T0 tumour in absence of axillary node \\>10mm.", "Patient has no overlapping conditions/medications with exclusion criterion: TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with myelodysplastic syndrome/acute myeloid leukaemia.", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of distant metastasis apparent prior to randomisation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled seizures.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breast feeding women.", "Patient has no overlapping conditions/medications with exclusion criterion: Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:\n\nEvidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.", "Patient has no overlapping conditions/medications with exclusion criterion: ECG with mean resting QTc \\>470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).", "Patient has no overlapping conditions/medications with exclusion criterion: Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable)."]}, {"trialId": "NCT06356376", "trialName": "The Effects of Pain and Pain Relief on Peripheral Nerve Excitability", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain conditions", "Patient has no overlapping conditions/medications with exclusion criterion: Neurological or Psychiatric disease", "Patient has no overlapping conditions/medications with exclusion criterion: Other major diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Pain medication within the last 24 hours"]}, {"trialId": "NCT05248776", "trialName": "Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a c-peptide value less than 0.5 nmol/l.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic, or non-peripheral vascular surgery within 6 months prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cardiac arrhythmia, systolic dysfunction, congestive heart failure, angina, myocardial ischemia or infarction, or stroke within 1 year prior to the study, or the presence of an abnormal ECG that, in the investigator's opinion, is clinically significant.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of drug abuse or a history of alcohol abuse within 2 years prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to basal cell or stage I squamous cell carcinoma of the skin.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase level above normal range for the testing laboratory, active liver disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a total bilirubin greater or equal 2 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is/ was lifetime on any insulin treatment or takes other diabetes treatment (except metformin).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of proteinuria ≥300 mg/day on a 12- or 24-hour urine collection within last year or an albumin/creatinine ratio greater or equal 300 μg/mg.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of any clinically significant retinopathy, which is defined as more than moderate nonproliferative diabetic retinopathy, any stage of proliferative diabetic retinopathy or any history of laser-treated retinopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has clinically significant peripheral or autonomic neuropathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of ulcerative colitis or Crohn's disease, or has undergone gastric resection.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of a psychiatric disorder that, in Principal Investigator opinion, will affect the subject ability to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of angioedema.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an acute, clinically significant illness within 30 days prior to the study or any other condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is not able to comply with the study scheduled visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is participating in another investigational study or has taken any investigational drug within 90 days prior to the study."]}, {"trialId": "NCT03269227", "trialName": "Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous thorax radiotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Chemotherapy is allowed but completed 3 weeks before RT starts", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial with any investigational agents within 30 days prior to study screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with M1 have to be excluded to this study", "Patient has no overlapping conditions/medications with exclusion criterion: FEV1 \\< 50", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>85 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Respiratory needing oxygen therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial pneumopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active pneumonitis", "Patient has no overlapping conditions/medications with exclusion criterion: Fissural disease", "Patient has no overlapping conditions/medications with exclusion criterion: Contralateral mediastinum involvement (N3) and M1", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."]}, {"trialId": "NCT06552676", "trialName": "riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure of the percutaneous tracheostomy technique or recourse to surgical tracheostomy"]}, {"trialId": "NCT05309876", "trialName": "Secondary Prevention With the Lifestyle Tool", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (35.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: conditions or treatments that in the judgement of the Investigator could affect the study evaluation"]}, {"trialId": "NCT01521676", "trialName": "Predictive Clinical and Biological Parameters in Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: emergency"]}, {"trialId": "NCT04030676", "trialName": "QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Wardship patient and curatorial patient", "Patient has no overlapping conditions/medications with exclusion criterion: Patient unable to understand or sign the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Colectomy total or partial"]}, {"trialId": "NCT04560127", "trialName": "Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Any active autoimmune disease or history of autoimmune disease and expected recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis); subjects with skin diseases that does no need systemic treatment, for example, leukoderma, psoriasis, alopecia, those with controlled type I diabetes by insulin or those with asthma that has been completely resolved in childhood and with no need of any intervention can be enrolled; while subjects with asthma who need bronchodilator for medical intervention cannot be enrolled.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of strong CYP3A4/CYP2C19 inducers, including rifampicin (and its analogues) and St. John's Wort, or strong CYP3A4/CYP2C19 inhibitors within two weeks prior to signing informed consent form.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with other immune checkpoint inhibitors (include PD-1 antibody or other immunotherapy against PD-1/PD-L1).", "Patient has no overlapping conditions/medications with exclusion criterion: Known history of serious allergy to any monoclonal antibody or Apatinib.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwilling to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current presence of metastasis to central nervous system.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia or complications of severe pneumonia; oral or intravenous therapeutic antibiotics within two weeks prior to the start of study treatment (for example, subjects who are given with preventive antibiotics for prevention of urinary tract infection or exacerbation of chronic obstructive pulmonary disease are eligible for participation in the study).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women.", "Patient has no overlapping conditions/medications with exclusion criterion: Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators, such as alcoholism, drug abuse, other serious diseases (including mental disorders) requiring concomitant therapy, with serious laboratory examination abnormality, with family or social factors, that may affect subject's safety."]}, {"trialId": "NCT05078476", "trialName": "Rehabilitation of Finger Flexor Tendon Injuries", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\< 18 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients", "Patient has no overlapping conditions/medications with exclusion criterion: Replantation of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Primary tendon reconstructions"]}, {"trialId": "NCT06087627", "trialName": "A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have been treated for more than 7 days with dupilumab", "Patient has no overlapping conditions/medications with exclusion criterion: Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."]}, {"trialId": "NCT01341327", "trialName": "Observational Study for Left Main Disease Treatment", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Protected left main stenosis"]}, {"trialId": "NCT06337227", "trialName": "Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients for whom biological material cannot be recovered for study purposes;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who refuse to participate in the study"]}, {"trialId": "NCT06312176", "trialName": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Has breast cancer amenable to treatment with curative intent", "Patient has no overlapping conditions/medications with exclusion criterion: Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune disease that has required systemic treatment in the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy"]}, {"trialId": "NCT06061627", "trialName": "A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Valvular heart disease that requires or has undergone surgical intervention", "Patient has no overlapping conditions/medications with exclusion criterion: After mechanical tricuspid valve replacement", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or permanent atrial fibrillation or atrial flutter", "Patient has no overlapping conditions/medications with exclusion criterion: Second or third degree atrioventricular block", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of acute myocardial infarction within 3 months prior to enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Patient's expected survival time is less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or planned to conceive", "Patient has no overlapping conditions/medications with exclusion criterion: Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with simple and persistent left superior vena cava", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with existing pacemaker implantation"]}, {"trialId": "NCT02907827", "trialName": "Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\\< 6weken)", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia", "Patient has no overlapping conditions/medications with exclusion criterion: Metallic devices implanted such as hip prostheses, since this can alter the imaging quality"]}, {"trialId": "NCT06291727", "trialName": "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients scheduled for bilateral TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Revision TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)", "Patient has no overlapping conditions/medications with exclusion criterion: Workers' Compensation patient", "Patient has no overlapping conditions/medications with exclusion criterion: Type I Diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Type II Diabetes requiring insulin medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-operative narcotics use with the exception of tramadol.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal insufficiency (GFR \\< 60) that may impact post-operative protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive deficiencies that prevent the patient from providing their own informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Language barrier preventing completion of study forms in English"]}, {"trialId": "NCT05650827", "trialName": "Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\< 18", "Patient has no overlapping conditions/medications with exclusion criterion: Living outside the greater Copenhagen area", "Patient has no overlapping conditions/medications with exclusion criterion: Any other malignancy requiring active treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Not eligible for chemotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Performance status \\> 2", "Patient has no overlapping conditions/medications with exclusion criterion: Not able to swallow liquids", "Patient has no overlapping conditions/medications with exclusion criterion: Parenteral nutrition or enteral nutrition via feeding tube", "Patient has no overlapping conditions/medications with exclusion criterion: Physical or mental disabilities that prohibit execution of test or training procedures", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to understand the Danish language"]}, {"trialId": "NCT06319027", "trialName": "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05536427", "trialName": "Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with immunodeficiency or a history of autoimmune disorders (e.g., rheumatoid arthropathy, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe concurrent medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, serious infection and infectious disease, active peptic ulcer, presence of active hemorrhage, and severe organ failure;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Grade III or IV cardiac failure defined by the New York Heart Association (NYHA), epileptic seizure, and mechanical or paralytic ileus within 6 months prior to the first administration of the investigational drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received chemotherapy and hormonal therapy within 28 days prior to signing the informed consent forms, or are currently taking other investigational drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with lymphoma, leukemia, myelodysplastic syndrome (MDS), or myelosuppression;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with allergy or a history of hypersensitivity to human blood albumin, or a history of allergy or hypersensitivity to any investigational drug or its excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with chronic diseases requiring immunotherapy or hormonal therapy; and subjects currently receiving corticosteroids for other diseases (except those using topical or inhaled steroids);", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with mental or neurological disorders that are not easily controlled;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects infected with human immunodeficiency virus (commonly known as AIDS) or treponema pallidum (commonly known as syphilis);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of other malignant tumors within the last 5 years;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with prior allogeneic stem cell transplantation or solid organ transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of drug or alcohol abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with any irAE of ≥ Grade 3 following prior immunotherapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who, in the judgment of the investigator, are not suitable to participate in this clinical study (e.g., with poor compliance)."]}, {"trialId": "NCT06093776", "trialName": "Rib Fracture Cryoanalgesia", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age Pregnant Incarcerated Confounding injuries or significant pain attributed to secondary injury Patients with any of the following: cryoglobulinemia; paroxysmal cold hemoglobinuria; cold urticarial; Raynaud's disease; open and/or infected wounds at or near the treatment site"]}, {"trialId": "NCT06146127", "trialName": "Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unequivocal histological features"]}, {"trialId": "NCT06330727", "trialName": "Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 59.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with diagnosis of diabetes, or taking anti-diabetic medication;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy, planned pregnancy, or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease)."]}, {"trialId": "NCT04855227", "trialName": "A Prospective Evaluation of Pain After Non-complex Ventral Hernia Repair", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is contraindicated for general anesthesia or surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a ventral hernia that will require retromuscular mesh placement or employ a technique, including (but not limited to) external oblique release, Rives- Stoppa, eTEP Rives-Stoppa, transversus abdominis release, other component separation techniques (i.e. anterior component separation) or eTEP transversus abdominis release.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a recurrent hernia.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will have an emergent hernia repair.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of chronic pain and/or taking daily pain medications for \\>6 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of substance abuse (excluding marijuana) and/or current (within 30 days) narcotic use.", "Patient has no overlapping conditions/medications with exclusion criterion: Current marijuana use that the subject is unwilling to discontinue within the 14 days prior to surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of MRSA infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with HbA1c level \\> 8.5%.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Exparel during the surgical procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will undergo a concomitant hernia repair or any other concomitant procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Current nicotine use (including vaping) within the past 30 days.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a known bleeding or clotting disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or suspected pregnancy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject belonging to other vulnerable population, e.g, prisoner or ward of the state.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is currently participating in another interventional or investigational research study."]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT05752227", "trialName": "Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pure pleural lesions.", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical instability to reach the final diagnosis.", "Patient has no overlapping conditions/medications with exclusion criterion: Inaccessibility by ultrasound."]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (4.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05364827", "trialName": "CT Coronary Angiography Prior to CTO PCI", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: CTO with J-CTO score\\<2", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate/degraded CTCA images", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant/lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe contrast allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to provide written informed consent"]}, {"trialId": "NCT05038527", "trialName": "ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: ASA ≥ 4", "Patient has no overlapping conditions/medications with exclusion criterion: Formally diagnosed with a disease affecting the bone metabolism or wound healing (severe osteoporosis, osteomalacia, Pagets disease, hyperparathyreoidism etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disseminated cancer diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to any of the i-FACTOR Peptide Enhanced Bone Graft ingredients", "Patient has no overlapping conditions/medications with exclusion criterion: Smoking, extensive alcohol use or abuse of hallucinating drugs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver or kidney disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or breastfeeding patients", "Patient has no overlapping conditions/medications with exclusion criterion: Patients estimated not to be able to understand the information sheet or patients, who do not consent to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe psychiatric diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Ongoing infections"]}, {"trialId": "NCT06200376", "trialName": "A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating, or plan to pregnant or give birth during the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;", "Patient has no overlapping conditions/medications with exclusion criterion: History of splenectomy or organ transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;", "Patient has no overlapping conditions/medications with exclusion criterion: Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of high risk cardiovascular disease, including but not limited to:\n\n    * Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);\n    * Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;\n    * Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;\n    * Rating of heart function as defined by the New York Heart Association (NYHA) standards\\>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;\n    * Left ventricular ejection fraction (LVEF) \\< the center lower limit. If no lower limit existed, LVEF\\<50%;\n    * Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);", "Patient has no overlapping conditions/medications with exclusion criterion: History of another malignant tumor, except the following:\n\n    * Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;\n    * Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;\n    * Adequately treated carcinoma in situ without evidence of disease;", "Patient has no overlapping conditions/medications with exclusion criterion: Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Unexplained \\>38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment"]}, {"trialId": "NCT06040827", "trialName": "A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06144476", "trialName": "Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.", "Patient has no overlapping conditions/medications with exclusion criterion: Surgery within the preceding 6 weeks", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection", "Patient has no overlapping conditions/medications with exclusion criterion: Alcohol or recreational drug abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency requiring treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to read or write English", "Patient has no overlapping conditions/medications with exclusion criterion: Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study"]}, {"trialId": "NCT03317327", "trialName": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB and stage I prostate cancer considered not necessary to treat", "Patient has no overlapping conditions/medications with exclusion criterion: Disease suitable for curative salvage surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 4 weeks prior to first administration of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant cardiac, pulmonary or other medical illness that would limit activity or survival", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to any of the components of the investigational product", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who test positive for hepatitis B, C or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of immunosuppressive therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease that has required systemic therapy within the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: Any reason why, in the opinion of the investigator, the patient should not participate"]}, {"trialId": "NCT04257227", "trialName": "Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Documented brain lesions", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to remain still while sitting up (45 degrees) for the duration of therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold"]}, {"trialId": "NCT05601427", "trialName": "Intra-Operative Adductor Canal Blocks", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or refusal to sign informed consent form", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.", "Patient has no overlapping conditions/medications with exclusion criterion: Non-osteoarthritis primary diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to analgesic medications", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal and/or regional anaesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Any use of opioid pain medication within four weeks of the index procedure(13)", "Patient has no overlapping conditions/medications with exclusion criterion: Pain catastrophizing scale score ≥16 (8, 9, 14)", "Patient has no overlapping conditions/medications with exclusion criterion: History of cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: History renal insufficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History or sensory and/or motor neuropathy to the ipsilateral limb", "Patient has no overlapping conditions/medications with exclusion criterion: Simultaneous, bilateral TKA", "Patient has no overlapping conditions/medications with exclusion criterion: Non-TKA prosthesis", "Patient has no overlapping conditions/medications with exclusion criterion: Scheduled for non-SDD TKA.", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative varus/valgus of \\>10 degrees.", "Patient has no overlapping conditions/medications with exclusion criterion: Planned General Anaesthetic", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Intrathecal Morphine"]}, {"trialId": "NCT03072927", "trialName": "MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (13.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT06585527", "trialName": "Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with encephalitis disease, multiple sclerosis, or other CNS (Central Nervous System) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of organ transplantation or waiting for organ transplantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled infectious diseases or other serious diseases, such as HIV positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with any unstable systemic illness (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris beginning within the last 3 months, congestive heart failure, myocardial infarction occurring within 12 months before enrollment, severe arrhythmia requiring medical treatment, liver or kidney failure, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with systemic autoimmune diseases or immunodeficiency diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe allergic constitution.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases requiring long-term treatment with immune agents or glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with mental disorders."]}, {"trialId": "NCT05956327", "trialName": "Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Lack of reliability and sanity (examined by an independent psychiatrist)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive urine drug screen for illicit drugs (except benzodiazepines)", "Patient has no overlapping conditions/medications with exclusion criterion: Acute suicide risk", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant psychiatric axis-I disorders according to the diagnostic testing procedure (Mini International Neuropsychiatric Interview, MINI)", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant neurological or other disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation"]}, {"trialId": "NCT05649176", "trialName": "Lifestyle Intervention for Improving Insulin Resistance and Concern for Health", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (50.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a diagnosis of Type 2 diabetes received more than five years ago.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who have type 1 diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Participants being treated with prescription or over the counter medications that have a significant effect on insulin resistance, obesity, high density lipoprotein cholesterol, triglycerides, metabolic rate and those that significantly increase body weight.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are on concomitant therapy with glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with evidence and/or history (within the preceding 6 months) of significant gastrointestinal dysfunction.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants that have had a fluctuation in body weight \\>5% in the preceding 2 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other conditions that may impede testing of the study hypothesis."]}, {"trialId": "NCT03916627", "trialName": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with metastatic disease for whom the intent of surgery would not be curative", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 1 year", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply"]}, {"trialId": "NCT03712527", "trialName": "Intra-discal Injection of PRP for Low Back Pain", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 60.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: - Patient with Modic 1 discopathy in different vertebral levels", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a Modic I signal abnormality related to a static spinal disorder (such as previous vertebral fractures, or isthmic lysis, or spondyloarthritis)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a history of lumbar spine surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with suspected spondylodiscitis or other infection", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under anticoagulant or antiaggregant therapy, or with a coagulation disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with allergy to iodine or to any of the components of Xylocaine", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to MRI: Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with anatomical difficulty of access to the injection area (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with an uncontrolled severe disease (i.e. heart, pulmonary, gastro-intestinal, neurologic, endocrine, auto-immune affections) limiting the patient's safety (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with previous malignancy less than 5 years (except for non-melanoma skin cancer)", "Patient has no overlapping conditions/medications with exclusion criterion: Prior to the screening visit:", "Patient has no overlapping conditions/medications with exclusion criterion: a current and recent use of morphine (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: a systemic or local corticosteroid therapy (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: Porphyria", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with sphincter disorders indicating a cauda equina syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Psychotic state not controlled by a treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (βHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age", "Patient has no overlapping conditions/medications with exclusion criterion: Vulnerable persons protected by law", "Patient has no overlapping conditions/medications with exclusion criterion: Persons under guardianship", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who are in a dependency or employment with the sponsor or the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Subject unable to read or/and write"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (16.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT04519476", "trialName": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n  1. Has received selinexor or another XPO1 inhibitor previously.\n  2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \\>5 years previously and without evidence of recurrence will be allowed.\n  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \\[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\\], primary amyloidosis, etc.) that is likely to interfere with study procedures.\n  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.\n  6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.\n  7. Concurrent use of other anti-cancer agents or treatments.\n  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\n  9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin\n  10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n  11. Pregnant or breastfeeding females.\n  12. BSA \\<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.\n  13. Life expectancy of less than 3 months.\n  14. Major surgery within 4 weeks prior to C1D1.\n  15. Active, unstable cardiovascular function, as indicated by the presence of:\n\n  1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.\n\n  18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.\n\n  19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).\n\n  20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n\n  21. Contraindication to any of the required concomitant drugs or supportive treatments.\n\n  22. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT06508827", "trialName": "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemoglobinopathies", "Patient has no overlapping conditions/medications with exclusion criterion: Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemochromatosis", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating female adults", "Patient has no overlapping conditions/medications with exclusion criterion: Active infections which in research teams' opinion increases risk for toxicities", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures."]}, {"trialId": "NCT05900427", "trialName": "Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Ages: \\<18 and \\>90", "Patient has no overlapping conditions/medications with exclusion criterion: Weight \\< 60 kg", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple surgeries during one hospital stay", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or any contraindication to local anesthetics used in trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindicated for use of liposomal bupivacaine", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver/kidney disease", "Patient has no overlapping conditions/medications with exclusion criterion: Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who received another local anesthetic block prior to the interscalene block.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to consent in English"]}, {"trialId": "NCT05422027", "trialName": "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who meet any of the following criteria will not be enrolled:\n\n  1. Plasma cell leukemia.\n  2. Documented active amyloidosis.\n  3. Involvement of the central nervous system(CNS) by Multiple myeloma.\n  4. Prior exposure to a SINE compound, including ATG-010.\n  5. Currently, whether or not the patient is on medication, \\> Grade 2 peripheral neuropathy or ≥ Grade ≥ 2 painful neuropathy at baseline.\n  6. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and Selinexor (ATG-010) .\n  7. Active, unstable cardiovascular function, as indicated by the presence of:\n\n     1. Symptomatic ischemia, or\n     2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or\n     3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\<40%, or\n     4. Myocardial infarction within 6 months prior to C1D1.\n  8. Known positive serology for HIV or HIV seropositivity.\n  9. Known active hepatitis A, B, or C infection; eg. positive for HCV RNA or HBV-DNA.\n  10. Women who are pregnant or nursing.\n  11. Life expectancy of less than 6 months.\n  12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.\n  13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n  14. Contraindication to any of the required concomitant drugs or supportive treatments.\n  15. Has any concurrent diseases or complications that is likely to interfere with the study procedures.\n  16. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT05284227", "trialName": "Artificial Intelligence-augmented Perioperative Clinical Decision Support", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT05057676", "trialName": "Autoimmune Intervention Mastery Course Study", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04772027", "trialName": "Motor Parameters in Patients With Limb Girdle Muscular Dystrophy", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: § For all:", "Patient has no overlapping conditions/medications with exclusion criterion: Without associated neuromuscular disorders such as respiratory or muscular-squeletic diseases, apart from the consequences of dystrophy;", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to the tests;", "Patient has no overlapping conditions/medications with exclusion criterion: Noncontrol cardiac rhythm disorders;", "Patient has no overlapping conditions/medications with exclusion criterion: Lying down position intolerance due to severe respiratory troubles;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman."]}, {"trialId": "NCT05525676", "trialName": "Relationship Checkups to Reduce Veteran Suicide Risk", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports severe intimate partner violence in the last year.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports experiencing suicidal intent requiring hospitalization.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER experiences past-month psychosis or mania.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years."]}, {"trialId": "NCT05763576", "trialName": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Healthy volunteers:", "Patient has no overlapping conditions/medications with exclusion criterion: History of any clinically significant disease", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant disease that could interfere with treatment or conduct of study", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)\n\nCHB participants:", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of liver cirrhosis or decompensated liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: History or suspicion of hepatocellular carcinoma (HCC)", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study."]}, {"trialId": "NCT05695027", "trialName": "Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (40.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05780476", "trialName": "A Novel VIRTUAL Reality Intervention for CAREgivers of People With Dementia (VirtualCare)", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving daily assistance for more than 10 hours from formal CGs;", "Patient has no overlapping conditions/medications with exclusion criterion: Being formal CGs (i.e., nurse or another paid figure);", "Patient has no overlapping conditions/medications with exclusion criterion: Being informal CGs of i) persons with moderate-to-severe AD, or ii) persons with non-AD diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Not having or being able to use a device connected to internet (e.g., smartphones or PC).", "Patient has no overlapping conditions/medications with exclusion criterion: Having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs.", "Patient has no overlapping conditions/medications with exclusion criterion: Only a family member for person with dementia is accepted.\n\nExclusion Criteria for experimental group (Psychoeducation + VR):", "Patient has no overlapping conditions/medications with exclusion criterion: Medical history of epilepsy.\n\nExclusion Criteria for subsample of caregivers assess with MRI:", "Patient has no overlapping conditions/medications with exclusion criterion: Metal implants, artificial prostheses, pace-makers, prosthetic heart valves;", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy."]}, {"trialId": "NCT03990727", "trialName": "Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (2.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: 1) Not willing to visit every year."]}, {"trialId": "NCT05721027", "trialName": "Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Not available for follow-up", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergic to or intolerant of investigational medications", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic steroid use", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney disease (GFR \\<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x the upper limit of normal)"]}, {"trialId": "NCT06550427", "trialName": "Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT04802876", "trialName": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior systemic anti-cancer therapy, including investigational agents within 2 weeks. Medical Monitor could consider shorter interval for kinase inhibitors or other short half-life drugs prior to allocation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants with ≤Grade 2 neuropathy may be eligible.\n\n   Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study treatment.\n\n   Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose of the previous investigational agent.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with thymoma are not eligible. Patients with active CNS metastases and/or carcinomatous meningitis are not eligible. Subjects with up to three cerebral metastases are eligible, if all lesions are stable and have been definitively treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any of its excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior allogeneic stem cell transplantation or organ transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history of interstitial lung disease, (non-infectious) pneumonitis that required steroids or has current pneumonitis, uncontrolled lung including pulmonary fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Human Immunodeficiency Virus (HIV).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of active TBC (Bacillus Tuberculosis).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of trial treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with spartalizumab or tislelizumab. Highly effective contraception methods include:\n\n    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n    4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.\n\n    Notes:\n    * Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.\n    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.", "Patient has no overlapping conditions/medications with exclusion criterion: Sexually active males, unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with spartalizumab or tislelizumab should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen."]}, {"trialId": "NCT04816227", "trialName": "Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusing to participate in the study", "Patient has no overlapping conditions/medications with exclusion criterion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research", "Patient has no overlapping conditions/medications with exclusion criterion: Being pregnant or breastfeeding"]}, {"trialId": "NCT06187727", "trialName": "Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Mechanical complications;", "Patient has no overlapping conditions/medications with exclusion criterion: Cardiogenic shock;", "Patient has no overlapping conditions/medications with exclusion criterion: Experienced myocardial infarction within 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Aortic dissection;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included", "Patient has no overlapping conditions/medications with exclusion criterion: Urinary system infection"]}, {"trialId": "NCT04167527", "trialName": "Endovascular Therapy for Low NIHSS Ischemic Strokes", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: NIHSS ≥6", "Patient has no overlapping conditions/medications with exclusion criterion: Any sign of intracranial hemorrhage on baseline CT/MR (SDH/SAH/ICH)", "Patient has no overlapping conditions/medications with exclusion criterion: Any imaging findings suggestive of futile recanalization in the judgment of the local investigator", "Patient has no overlapping conditions/medications with exclusion criterion: High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD", "Patient has no overlapping conditions/medications with exclusion criterion: Premorbid disability (mRS ≥3)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to randomize within 8 hours of last known well", "Patient has no overlapping conditions/medications with exclusion criterion: Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS", "Patient has no overlapping conditions/medications with exclusion criterion: Baseline blood glucose of \\<50 mg/dL (2.78 mmol) or \\>400 mg/dL (22.20 mmol)", "Patient has no overlapping conditions/medications with exclusion criterion: Known coagulation disorders as defined as platelet count \\<100,000/uL", "Patient has no overlapping conditions/medications with exclusion criterion: Known renal failure as defined as serum creatinine levels \\> 3.0 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Presumed septic embolus or suspicion of bacterial endocarditis", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another investigational treatment study in the previous 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Intubation and mechanical ventilation prior to study enrollment is medically indicated", "Patient has no overlapping conditions/medications with exclusion criterion: History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Site investigator does not have equipoise towards the ideal treatment concept (thrombectomy vs. best medical management)", "Patient has no overlapping conditions/medications with exclusion criterion: Known pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Prisoner or incarceration", "Patient has no overlapping conditions/medications with exclusion criterion: Known acute symptomatic COVID-19 infection"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (16.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT06218576", "trialName": "Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: age \\< 18 years"]}, {"trialId": "NCT03050476", "trialName": "Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (21.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Already on renal replacement therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic kidney disease defined as estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m2 \\[ CKD stage \\> 3 \\]", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Concurrent enrollment in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with ongoing infections or current use of steroids", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with high-risk emergency surgery or with follow-up procedures already planned at admission (like e.g. TEVAR)"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT05500027", "trialName": "sCD8, as a Novel Biomarker for Pancreatic Cancer", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusal to participate", "Patient has no overlapping conditions/medications with exclusion criterion: Age less than 18-year old and over 85-year old"]}, {"trialId": "NCT05755776", "trialName": "The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Men and women of childbearing potential who are unwilling to use an \"effective\" method of contraception as defined in the protocol during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have received a solid organ or bone marrow transplant", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or existing clinical liver failure (Child-Pugh score ≥ grade B)."]}, {"trialId": "NCT05887076", "trialName": "Postoperative Delirium After Kidney Transplantation", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete data records of the parameters to be determined", "Patient has no overlapping conditions/medications with exclusion criterion: Underage Patients"]}, {"trialId": "NCT05272176", "trialName": "Veterans Coordinated Community Care (3C) Study", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired decision-making capacity", "Patient has no overlapping conditions/medications with exclusion criterion: Limited or no English language proficiency", "Patient has no overlapping conditions/medications with exclusion criterion: Terminal illness"]}, {"trialId": "NCT05968976", "trialName": "Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Legally incompetent adults;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous tremor-neurosurgery (e.g., DBS, thalamotomy);", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;", "Patient has no overlapping conditions/medications with exclusion criterion: Psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Current depression;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent."]}, {"trialId": "NCT06182527", "trialName": "Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: diabetes mellitus", "Patient has no overlapping conditions/medications with exclusion criterion: use of medication interfering with glucose metabolism (steroid, antidiabetic medications)", "Patient has no overlapping conditions/medications with exclusion criterion: surgery of upper GI-tract", "Patient has no overlapping conditions/medications with exclusion criterion: known plaster allergies", "Patient has no overlapping conditions/medications with exclusion criterion: any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion"]}, {"trialId": "NCT06222827", "trialName": "Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, any major comorbidities (diabetes mellitus, cancer, severe autoimmune diseases, chronic renal failure, articular diseases that restricts exercise or participation in study assessments in the physician's opinion...), a history of relevant drug or food allergies; history of cardiovascular, respiratory, central nervous system disease; neuromuscular diseases except FSHD (e.g., myopathy, neuropathy, neuromuscular junction disorders)", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who are on drug(s) or supplements that may affect muscle function, as determined by the treating physician must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Orthopedic conditions, such as unresolved fracture or arthrosis, interfering or precluding testing of muscle function", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to muscle MRI as per clinic standard practice", "Patient has no overlapping conditions/medications with exclusion criterion: Articular contracture limiting movements, scapular fixation or other surgeries, preceding or planned", "Patient has no overlapping conditions/medications with exclusion criterion: Any known hypersensitivity to satralizumab or any of its components and/or history of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of latent or active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection for at least 4 weeks prior to enrollment), active opportunistic or life-threatening infections", "Patient has no overlapping conditions/medications with exclusion criterion: History of diverticulitis or concurrent severe GI disorders (such as symptomatic diverticulosis) that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation. Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit (Visit 1, week 0)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody.", "Patient has no overlapping conditions/medications with exclusion criterion: Acute or chronic history of liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal laboratory results with: White blood cells (WBC) \\< 3.0x 10\\^9/L ; Absolute Neutrophils Counts (ANC)\\< 2.0x 10\\^9/L ; Platelet count \\< 10x10\\^4/µl ; Absolute lymphocyte count (ALC) \\< 0.8x 10\\^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 times the upper limit of normal (ULN)", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment (defined as a glomerular filtration rate of \\<30mL/min/1.73m²)", "Patient has no overlapping conditions/medications with exclusion criterion: Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation", "Patient has no overlapping conditions/medications with exclusion criterion: For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier \\[patient or partner\\] in conjunction with a spermicidal product, contraceptive pill, patch, injectable, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of another investigational product within 6 months or 5 half-lives (whichever is longer), or currently participating in a prospective study with an investigational product, whether it concerns an experimental drug or a medical device. Note: concurrent participation in natural history studies (non-drug, non-device studies) is not allowed during the course of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior treatment with any agent targeting the IL-6 inhibition pathway (e.g. tocilizumab, sarilumab), alemtuzumab treatment, total body irradiation, or bone marrow transplantation; treatment in the past 24 weeks with an anti-B-lymphocyte antigen CD20 (e.g. rituximab, ocrelizumab), eculizumab, anti-B-lymphocyte stimulator, or any other multiple sclerosis disease-modifying treatment; treatment in the past 2 years with an anti-T-cell surface glycoprotein CD4, cladribine, cyclophosphamide, or mitoxantrone; or treatment with any other investigational drug within 3 months prior to baseline. See section 4.4.4 for details on the vaccination and immunization.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject, or close relative of the subject, is the investigator or a coinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code."]}, {"trialId": "NCT05505227", "trialName": "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: currently prescribing buprenorphine at full capacity"]}, {"trialId": "NCT05782127", "trialName": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous diagnosis of:\n\n   * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)\n   * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: History of active malignancy within the past year prior to screening, with the exception of:\n\n   * Adequately treated carcinoma in situ of the uterine cervix\n   * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n   * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.\n\n   Patients with ongoing horomonotherapy could be included.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.", "Patient has no overlapping conditions/medications with exclusion criterion: Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.", "Patient has no overlapping conditions/medications with exclusion criterion: Received live attenuated vaccines prior to initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions that could interfere with drug absorption including short gut syndrome, dysphagia, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mmHg or diastolic BP \\> 100 mmHg) or has not been stable for at least 1 month prior to treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:\n\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Unstable angina or angina requiring surgical or medical intervention\n    * Significant cardiac arrhythmia\n    * And/or myocardial infarction", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is a pregnant or lactating female.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has known or suspected to have hypersensitivity to any of the components of the assigned study treatments.", "Patient has no overlapping conditions/medications with exclusion criterion: Positive test result(s) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B surface \\[HBs\\] antibody positive and anti-hepatitis B core \\[HBc\\] antibody negative) may participate.", "Patient has no overlapping conditions/medications with exclusion criterion: Absence of social security affiliation."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT06524427", "trialName": "Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with the previous history of other malignancies;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with secondary primary cancer when enrolled;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as pure ground glass opacity (GGO) before surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as mixed GGO whose solid part \\<= 50% and Maximum diameter of tumor \\<= 2cm;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with small cell lung cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with prior unilateral open thoracic surgical procedures;", "Patient has no overlapping conditions/medications with exclusion criterion: Woman who is pregnant or breastfeeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with an active bacterial or fungal infection that is difficult to control;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with serious psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months."]}, {"trialId": "NCT05537376", "trialName": "A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Veteran"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT05189327", "trialName": "Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient takes part in an interventional clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is unable to follow the schedule of the visits;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that the PI believes would prevent a study participant from participating in the study."]}, {"trialId": "NCT06447727", "trialName": "Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: After liver metastasis was diagnosed, the liver underwent external radiation therapy and transhepatic arterial chemoembolization", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with extrahepatic metastases", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe arrhythmia or heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: Other researchers considered it inappropriate to participate in this study"]}, {"trialId": "NCT06176027", "trialName": "Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women"]}, {"trialId": "NCT04280627", "trialName": "Changes in the Microbiome Associated With Transplantation", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Outside of stated age range.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to give informed consent"]}, {"trialId": "NCT03969927", "trialName": "User-friendliness of a Portable Driving Simulator", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (25.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of traumatic brain injury or any other neurological condition apart from stroke, PD, and MS."]}, {"trialId": "NCT06627127", "trialName": "A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects meeting any of the following criteria will be excluded from participation in this study:", "Patient has no overlapping conditions/medications with exclusion criterion: Major anatomical or functional abnormalities that would impair the ability of the electrode arrays to be positioned.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant comorbidities that contraindicate surgery or general anesthesia/DISE", "Patient has no overlapping conditions/medications with exclusion criterion: Significant tongue weakness", "Patient has no overlapping conditions/medications with exclusion criterion: Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia/DISE in the judgment of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior surgery or treatments that could compromise the placement and effectiveness of the electrode array systems:\n\n  * Airway cancer surgery or radiation,\n  * Mandible or maxilla surgery in the previous 3 years (not counting dental treatments),", "Patient has no overlapping conditions/medications with exclusion criterion: Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),", "Patient has no overlapping conditions/medications with exclusion criterion: Prior hypoglossal nerve stimulation device implantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently pregnant, or breastfeeding during the study period"]}, {"trialId": "NCT05763927", "trialName": "Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have previously received immune checkpoint inhibitors;", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reactions to PD-1 monoclonal antibody active ingredients, TKI inhibitor-related ingredients or any excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with organ bleeding or bleeding tendency, except for rectal primary tumor bleeding (need investigator to assess the risk of bleeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: years or at the same time have a history of other malignant tumors, but cured skin basal cell carcinoma and cervical carcinoma in situ and thyroid;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled epilepsy, central nervous system disease or mental disorders, the investigator judged that their clinical severity may hinder the signing of informed consent or affect the patient 's compliance with oral drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically serious (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalent daily) or other immunosuppressive agents (including organ transplant recipients) within 2 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other interventional drug clinical trials within 4 weeks before the first dose;", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery or severe trauma within 4 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Serious infection (CTCAE greater than grade 2) within 4 weeks before the first dose of study drug,Such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging suggests active pulmonary inflammation, symptoms and signs of infection within 2 weeks before the first dose of study drug, or the need for oral or intravenous antibiotics (excluding prophylactic antibiotics);", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes); autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone, using stable doses of insulin type 1 diabetes can be included; but excluding vitiligo or recovered childhood asthma/allergy, without any intervention in adults;", "Patient has no overlapping conditions/medications with exclusion criterion: History of immunodeficiency, including positive HIV test, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Active pulmonary tuberculosis infection found by medical history or CT examination, Or patients with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or patients with a history of active pulmonary tuberculosis infection but without regular treatment 1 year before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with active hepatitis (HBV DNA ≥ 2000 IU/ml or 10000 copies/ml), hepatitis C (hepatitis C antibody positive,HCV-RNA was above the lower limit of detection of the assay);", "Patient has no overlapping conditions/medications with exclusion criterion: Had a known history of psychotropic drug abuse, alcoholism, or drug use;", "Patient has no overlapping conditions/medications with exclusion criterion: Had a history, illness, treatment, or laboratory abnormality that could interfere with the results of the trial, prevent the subject from participating throughout the study, or the investigator considered participation to be in the subject 's best interest."]}, {"trialId": "NCT05318976", "trialName": "A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (50.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from the study if 1 or more of the following criteria are applicable:", "Patient has no overlapping conditions/medications with exclusion criterion: Have any contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in-skull and cardiac devices other than those approved as safe for use in MRI scanners);", "Patient has no overlapping conditions/medications with exclusion criterion: Receives considerable help to carry out basic ADL living either in the home or as a resident in a nursing home or similar facility;", "Patient has no overlapping conditions/medications with exclusion criterion: Lifetime history of a major psychiatric disorder including schizophrenia and bipolar disorder. Major depressive disorder that has resulted in 2 or more hospitalizations in a lifetime. Major depressive episode during the past 5 years that is judged by the clinical team unlikely to have been part of Alzheimer's prodrome. History of suicidality.", "Patient has no overlapping conditions/medications with exclusion criterion: History of substance abuse within 12 months; use of cannabis or cannabis products within 6 months of consent;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another clinical trial where patients receive treatment with an investigational drug or treatment device or have had previous treatment with any investigational medicinal product within 60 days or 5 half-lives (whichever is longer) prior to study drug treatment;", "Patient has no overlapping conditions/medications with exclusion criterion: A prior organ or stem cell transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Seated blood pressure of ≥ 165/105 mmHg at Screening."]}, {"trialId": "NCT05264727", "trialName": "Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (25.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05555576", "trialName": "Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Opioid use 1 month prior to the ED visit;", "Patient has no overlapping conditions/medications with exclusion criterion: Already taking vitamin C supplement;", "Patient has no overlapping conditions/medications with exclusion criterion: Active cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for chronic pain;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for opioid use disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to fill out diary or unavailable for follow-up;", "Patient has no overlapping conditions/medications with exclusion criterion: Any allergy, intolerance or sensitivity to milk (lactose) or morphine", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with cyclosporin or coumadin", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)"]}, {"trialId": "NCT04557527", "trialName": "Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to hyaluronate or. HEALON5® PRO OVD", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\nStudy eye:", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of proliferative vitreoretinopathy (PVR) or any tractional RD", "Patient has no overlapping conditions/medications with exclusion criterion: Previous vitreoretinal surgery, open-globe injury or endophthalmitis", "Patient has no overlapping conditions/medications with exclusion criterion: Aphakia", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current congenital cataract", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current suprachoroidal haemorrhage", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment", "Patient has no overlapping conditions/medications with exclusion criterion: Current intraocular inflammation other than mild cellular activity thought to be secondary to RD", "Patient has no overlapping conditions/medications with exclusion criterion: Current ocular or periocular infection other than blepharitis"]}, {"trialId": "NCT05427227", "trialName": "Prospectively Predict the Efficacy and Explore the Mechanism of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous systemic therapy for metastatic GI cancer\n\n  * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.\n  * Allergic constitution or allergic history to protium biologic product or any investigating agents.\n  * Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.\n  * Pregnancy or lactation period\n  * Other previous malignancy within 5 year, except non-melanoma skin cancer\n  * Legal incapacity"]}, {"trialId": "NCT05628376", "trialName": "TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:", "Patient has no overlapping conditions/medications with exclusion criterion: Positive margins, incomplete resection or insufficient nodal sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B/C:", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)"]}, {"trialId": "NCT04620876", "trialName": "Bimodal and Coaxial High Resolution Ophtalmic Imaging", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (1.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05757076", "trialName": "Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of secondary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy status (verbal)"]}, {"trialId": "NCT04838327", "trialName": "Rare Subtypes of Gastrointestinal Cancers", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions precluding translational blood sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Another concomitant cancer"]}, {"trialId": "NCT03344276", "trialName": "Assessing Neurocognition After Cerebrovascular Intervention", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: patients \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: patients with without compatibility for MRI", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring carotid stenting for reasons not related to long-standing stenosis", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study."]}, {"trialId": "NCT06186427", "trialName": "A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who cannot tolerate puncture biopsy or surgical contraindications;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have undergone radiotherapy and chemotherapy in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Individuals who are allergic to multiple drugs or foods;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who refuse nuclear medicine examinations;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who do not agree to sign an informed consent form and are unable or willing to follow up."]}, {"trialId": "NCT04695327", "trialName": "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled cardiac or vascular diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hepatic dysfunction, hepatitis or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: History of coagulation disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant, breastfeeding or intend to become pregnant.", "Patient has no overlapping conditions/medications with exclusion criterion: Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.", "Patient has no overlapping conditions/medications with exclusion criterion: Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol)."]}, {"trialId": "NCT06339827", "trialName": "ASk Questions in GYnecologic Oncology (ASQ-GYO)", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment discussion with a Gynecologic Oncologist"]}, {"trialId": "NCT03921827", "trialName": "External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (21.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with atrial fibrillation/ arrhythmias.", "Patient has no overlapping conditions/medications with exclusion criterion: Within 2 weeks of cardiac catheterization or arterial puncture at femoral puncture site.", "Patient has no overlapping conditions/medications with exclusion criterion: Decompensated heart failure , usually class 3 or 4", "Patient has no overlapping conditions/medications with exclusion criterion: LV EF \\<30%", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe AR", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent and uncontrolled hypertension (BP persistently \\>160/100 mmHg)", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding diathesis", "Patient has no overlapping conditions/medications with exclusion criterion: Active thrombophlebitis/ venous disease of lower limbs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe lower extremity vaso-occlusive disease", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a documented aortic aneurysm/ dissection requiring surgical repair", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy"]}, {"trialId": "NCT05312827", "trialName": "Training Intervention and Program of Support (TIPS): Fostering Family-centred Telehealth in Pediatric Rehabilitation", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03529227", "trialName": "Gazyva Infusion Reaction Investigation", "eligibilityCriteriaMet": ["Patient Age (57) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: The refusal of the patient to participate in the observational study and the withdrawal of informed consent that allow processing of personal data and data that refer to patient confidentiality."]}]}, {"patientId": "7935fd9e-34bb-b8ba-c8bb-a613a89351cf", "eligibleTrials": [{"trialId": "NCT06286527", "trialName": "Quality of Sexual Life of PrEP Users", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unwilling to participate"]}, {"trialId": "NCT04484727", "trialName": "\"Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs\"", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients under 18 years", "Patient has no overlapping conditions/medications with exclusion criterion: ASA 4 and above", "Patient has no overlapping conditions/medications with exclusion criterion: severe COPD/emphysema/heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: PEEP\\>16 and/or FiO2 \\>80%", "Patient has no overlapping conditions/medications with exclusion criterion: elevated intracranial pressure", "Patient has no overlapping conditions/medications with exclusion criterion: defect coagulation", "Patient has no overlapping conditions/medications with exclusion criterion: non-treated known or suspected pneumothorax"]}, {"trialId": "NCT03869476", "trialName": "Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 99.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a diagnosis of secondary myelofibrosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman;", "Patient has no overlapping conditions/medications with exclusion criterion: Person prived of liberty by judicial or administrative decision;", "Patient has no overlapping conditions/medications with exclusion criterion: Person subject to a legal protection measure;"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (15.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT05690776", "trialName": "PMCF Study on the Safety, Performance and Clinical Benefits Data of the Quattro X Broadband", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of infection;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient or immature bone;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient blood supply or previous infections which may hinder the healing process;", "Patient has no overlapping conditions/medications with exclusion criterion: Foreign body sensitivity;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant);", "Patient has no overlapping conditions/medications with exclusion criterion: The subject is unwilling or unable to give consent or to comply with the follow-up program;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject meets any contraindications of the appropriate Instruction for Use."]}, {"trialId": "NCT06100276", "trialName": "Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.", "Patient has no overlapping conditions/medications with exclusion criterion: Pathogenic repeat expansion in the C9orf72 gene", "Patient has no overlapping conditions/medications with exclusion criterion: Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications."]}, {"trialId": "NCT06027827", "trialName": "Impact of Lateral Bone Grafting With Intraoperative Fusion in ACDF on Clinical Outcomes", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 60.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Drug or alcohol abusers; those with abnormal liver or kidney function unsuitable for surgery; those with cardiac insufficiency unsuitable for surgery; those with severe metabolic and endocrine diseases unsuitable for surgery; those with severe lung disorders such as asthma and abnormal lung function unsuitable for surgery; pregnant and breastfeeding women as well as those who are planning to become pregnant in the near future; those who have participated in other clinical trials within 3 months; and those who are not suitable for participation in the experiment in the opinion of the investigator."]}, {"trialId": "NCT06597227", "trialName": "Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  <!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL/min;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects."]}, {"trialId": "NCT04216927", "trialName": "NO During CPB in Neonates to Reduce Risk of AKI", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (1.0, 31.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure to obtain informed consent from parent/guardian", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical signs of preoperative persistent elevated pulmonary vascular resistance,", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Episode of cardiac arrest within 1 week before surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Recent treatment with steroids and/or a condition that may require treatment with steroids (excluding steroid administration specifically for CPB),", "Patient has no overlapping conditions/medications with exclusion criterion: Use of inhaled NO (iNO) immediately prior to surgery,", "Patient has no overlapping conditions/medications with exclusion criterion: Structural renal abnormalities by ultrasound,", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative AKI,", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other investigational drugs,", "Patient has no overlapping conditions/medications with exclusion criterion: Weight less than \\<2 kg,", "Patient has no overlapping conditions/medications with exclusion criterion: Gestational age \\<36 weeks,", "Patient has no overlapping conditions/medications with exclusion criterion: Major extracardiac congenital anomalies,", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English speakers."]}, {"trialId": "NCT05731427", "trialName": "Research on the Mechanism Affecting Progression of Bronchiectasis", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05666076", "trialName": "Peng Block or Suprascapular Nerve Block for Postoperative Analgesia in Shoulder Artroscopy ?", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with deformity and pathology in the shoulder region", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with known local anesthetic allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with BMI\\>35", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with alcohol and substance addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with opioid addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who cannot perceive and evaluate pain, such as psychiatric illness, mental retardation"]}, {"trialId": "NCT06525376", "trialName": "Validity and Reliability of Smartphone Inclinometer Application for Measurement of Cervical Range of Motion", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 30.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe spinal pathology.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy and lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Any musculoskeletal diseases that affect the cervical spine.", "Patient has no overlapping conditions/medications with exclusion criterion: Any neurological diseases that affect the cervical spine.", "Patient has no overlapping conditions/medications with exclusion criterion: History of trauma in the cervical spine.", "Patient has no overlapping conditions/medications with exclusion criterion: Signs of cervical radiculopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Signs of cervical myelopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Signs of serious pathology.", "Patient has no overlapping conditions/medications with exclusion criterion: subjects have a pacemaker or any other medical equipment that the magnet might have compromised."]}, {"trialId": "NCT05398627", "trialName": "Neurofeedback for Borderline Personality Disorder", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 55.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Current moderate or severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild alcohol or substance use would also interfere with the effects of the intervention.", "Patient has no overlapping conditions/medications with exclusion criterion: have a history of traumatic brain injury", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)", "Patient has no overlapping conditions/medications with exclusion criterion: are currently pregnant or breast feeding", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete questionnaires written in English", "Patient has no overlapping conditions/medications with exclusion criterion: current (within 3 weeks of testing) use of any antipsychotics, benzodiazepines, beta-blockers, or other medications (except SSRI antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. Inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population", "Patient has no overlapping conditions/medications with exclusion criterion: have a DSM-5 diagnosis of psychotic or organic mental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: have any eye problems or difficulties in corrected vision.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious suidicial ideation"]}, {"trialId": "NCT05626127", "trialName": "MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Accompanied with other primary malignant tumors;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies;", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete imaging or medical history data."]}, {"trialId": "NCT05780827", "trialName": "Analysis of Clinical Data of Patients With Temporomandibular Joint Disorder", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (12.0, 40.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have received orthodontic treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of maxillofacial trauma", "Patient has no overlapping conditions/medications with exclusion criterion: Maternity", "Patient has no overlapping conditions/medications with exclusion criterion: Those who take any medicine for a long time", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases such as tumors, endocrine diseases, psychosocial diseases and immune diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Other persons who are unable to cooperate with the project by themselves, such as action barriers.\n\nControl group\n\nInclusion Criteria:\n\nSuffer from symptoms and signs of oral and maxillofacial dysfunction"]}, {"trialId": "NCT06191627", "trialName": "Patient Experience and Quality of Patch Testing on the Legs vs Back", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 89.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is 17 or younger", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or breastfeeding", "Patient has no overlapping conditions/medications with exclusion criterion: Specialized patch testing with low number of patches (less than 90)", "Patient has no overlapping conditions/medications with exclusion criterion: Rash that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Large tattoos that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Limited space on thighs or back due to body habitus", "Patient has no overlapping conditions/medications with exclusion criterion: Patient has specific needs necessitating use of the thighs or back (event, breastfeeding, etc.)"]}, {"trialId": "NCT05890027", "trialName": "Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who refuse to consent.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.", "Patient has no overlapping conditions/medications with exclusion criterion: Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors"]}, {"trialId": "NCT05004727", "trialName": "Multi-Center PAMPA Study", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;", "Patient has no overlapping conditions/medications with exclusion criterion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);", "Patient has no overlapping conditions/medications with exclusion criterion: RA seropositivity (mid-high RF/ACPA titers);", "Patient has no overlapping conditions/medications with exclusion criterion: Current active malignancy;", "Patient has no overlapping conditions/medications with exclusion criterion: History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to the study agent."]}, {"trialId": "NCT06001827", "trialName": "SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Planned index procedure to revise or repair an existing fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Target artery inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Target vein inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound", "Patient has no overlapping conditions/medications with exclusion criterion: Known central venous stenosis of at least 50% on the side of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a stent or a stent graft within the access circuit", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected active infection at the time of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Congestive heart failure NYHA class 4", "Patient has no overlapping conditions/medications with exclusion criterion: Prior steal on the side of surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Life expectancy less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo kidney transplant surgery within 6 months of enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo home hemodialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Unwillingness or inability to give consent and/or comply with the study follow up schedule", "Patient has no overlapping conditions/medications with exclusion criterion: Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study."]}, {"trialId": "NCT03947827", "trialName": "Minocycline as Adjunctive Treatment for Treatment Resistant Depression", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 substance use disorder within past 3 months, moderate or severe, based on SCID-5", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant major unstable medical illness", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or intent to become pregnant during study period", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of psychotic disorder, bipolar disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) within last year", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of borderline personality disorder (BPD)", "Patient has no overlapping conditions/medications with exclusion criterion: Possible or probable dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or current intolerance or contraindication to tetracyclines", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal readings in hematology, liver, or renal function tests", "Patient has no overlapping conditions/medications with exclusion criterion: Have Myasthenia Gravis", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant treatment with anticoagulants, diuretics, retinoids, ergot alkaloids, antacids containing aluminium/calcium/magnesium, bismuth and zinc salts, or quinapril"]}, {"trialId": "NCT03015727", "trialName": "Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: WHO type I squamous cell carcinoma or adenocarcinoma", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>65 or \\<18", "Patient has no overlapping conditions/medications with exclusion criterion: With a history of renal disease", "Patient has no overlapping conditions/medications with exclusion criterion: Prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Peripheral neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Emotional disturbance"]}, {"trialId": "NCT05814627", "trialName": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to any janus kinase (JAK) inhibitor.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD)."]}, {"trialId": "NCT05286827", "trialName": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05840276", "trialName": "Cryoneurolysis Prior to Total Knee Arthroplasty", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications against ibuprofen or paracetamol, for example previous gastric ulcer, or known renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\< 100 bil/l); or against treatment with morphine", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuropathic pain", "Patient has no overlapping conditions/medications with exclusion criterion: Previous recipient of cryoneurolysis for the knee", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with daily use of high dose opioid (\\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled serious disease (cancer, diabetes, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disease associated with reactions to cold, such as cryoglobulinemia, cold urticarial and Reynaud's syndrome."]}, {"trialId": "NCT06111027", "trialName": "Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Regular intake of benzodiazepines", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive impairment: score \\< 27 on Mini-mental state examination", "Patient has no overlapping conditions/medications with exclusion criterion: Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis"]}, {"trialId": "NCT05706376", "trialName": "An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (13.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Families with individuals with significant mental or physical impairments precluding their ability to participate in groups"]}, {"trialId": "NCT05809427", "trialName": "High Frequency Intraoral Ultrasound Probe for Early Diagnosis of Periodontal Diseases", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03460327", "trialName": "Bariatric Surgery and Pharmacokinetics of Candesartan", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Having previously undergone resections in the GI-tract"]}, {"trialId": "NCT04886427", "trialName": "Implementation of a Multidimensional Quality Model", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Do not understand Dutch"]}, {"trialId": "NCT06265727", "trialName": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active of uncontrolled CNS metastases", "Patient has no overlapping conditions/medications with exclusion criterion: History of solid tumors other than the diseases under study", "Patient has no overlapping conditions/medications with exclusion criterion: History of and/or current cardiovascular events or conditions in the previous 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing \\>/= Grade 2 neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Hemoglobin A1C (HbA1C) \\>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active ocular disease at baseline", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic severe liver disease or live cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study", "Patient has no overlapping conditions/medications with exclusion criterion: Other significant cormorbidities."]}, {"trialId": "NCT06527027", "trialName": "LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,", "Patient has no overlapping conditions/medications with exclusion criterion: inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant."]}, {"trialId": "NCT05133076", "trialName": "Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: E1. Involvement in any investigational drug or device study within 30 days prior to this study,\n\nE2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in the study),\n\nE3. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation upon investigator judgment,\n\nE4. Surgery planned within the whole study period,\n\nE5. Evidence of active medical diseases affecting bowel transit,\n\nE6. Antibiotic treatment intake within the last month prior the study start (V0),\n\nE7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are permitted,\n\nE8. Any history of drug addiction in the past five years,\n\nE9. Pregnant or lactating women or intending to become pregnant,\n\nE10. Unwilling to maintain food habits and current physical activity for the whole study duration,\n\nE11. With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,\n\nE12. Having a lifestyle deemed incompatible with the study according to the investigator including drug and alcohol abuse,\n\nE13. Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n\nE14. Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,\n\nE15. Presenting a psychological or linguistic incapability to sign the informed consent,\n\nE16. Impossible to contact in case of emergency."]}, {"trialId": "NCT05555927", "trialName": "Adjunctive Duration-doubled tDCS for the Treatment of Depressive Patients With Suicidal Ideation", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 50.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Assessed through applying the Mini-International Neuropsychiatric Interview (MINI)15 by professional psychiatrists that diagnosed any other current or past psychiatric axis-I disorders (except MDD in the patients);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver and kidney diseases, active endocrine diseases or clinical symptoms. Severe cardiovascular disease, respiratory system disease, haematologic diseases and cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal laboratory examination that may influence the health of participants;", "Patient has no overlapping conditions/medications with exclusion criterion: A history of any aignificant medical illness such as neurological disorders (such as cerebral trauma, seizure disorder, etc);", "Patient has no overlapping conditions/medications with exclusion criterion: Known current psychosis as determined by the DSM-5 or a history of a non-mood psychotic disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol and drug abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal scalp such as open wounds;", "Patient has no overlapping conditions/medications with exclusion criterion: HAMD-17 item 3 (suicide) score=4;", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving modified electroconvulsive therapy (MECT) or repetitive transcranial magnetic stimulation (rTMS) in the past 1 month;", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial concurrently or no more than 1 month prior to randomisation."]}, {"trialId": "NCT04998227", "trialName": "Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (20.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: cardiogenic shock, pregnancy, end-stage renal disease"]}, {"trialId": "NCT05377827", "trialName": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from study entry for any of the following:", "Patient has no overlapping conditions/medications with exclusion criterion: Received systemic anticancer therapy (including investigational therapy) or radiotherapy \\< 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:\n\n  * \\< 100 days post alloHCT\n  * \\< 6 weeks from prior donor leukocyte infusion\n  * Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.\n  * \\< 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with any anti-CD7 directed therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to one or more of the study agents.", "Patient has no overlapping conditions/medications with exclusion criterion: Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Confirmed HIV infection.", "Patient has no overlapping conditions/medications with exclusion criterion: History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic, uncontrolled hypotension."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT03150576", "trialName": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (16.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: T0 tumour in absence of axillary node \\>10mm.", "Patient has no overlapping conditions/medications with exclusion criterion: TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with myelodysplastic syndrome/acute myeloid leukaemia.", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of distant metastasis apparent prior to randomisation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled seizures.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breast feeding women.", "Patient has no overlapping conditions/medications with exclusion criterion: Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:\n\nEvidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.", "Patient has no overlapping conditions/medications with exclusion criterion: ECG with mean resting QTc \\>470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).", "Patient has no overlapping conditions/medications with exclusion criterion: Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable)."]}, {"trialId": "NCT06356376", "trialName": "The Effects of Pain and Pain Relief on Peripheral Nerve Excitability", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain conditions", "Patient has no overlapping conditions/medications with exclusion criterion: Neurological or Psychiatric disease", "Patient has no overlapping conditions/medications with exclusion criterion: Other major diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Pain medication within the last 24 hours"]}, {"trialId": "NCT05248776", "trialName": "Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a c-peptide value less than 0.5 nmol/l.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic, or non-peripheral vascular surgery within 6 months prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cardiac arrhythmia, systolic dysfunction, congestive heart failure, angina, myocardial ischemia or infarction, or stroke within 1 year prior to the study, or the presence of an abnormal ECG that, in the investigator's opinion, is clinically significant.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of drug abuse or a history of alcohol abuse within 2 years prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to basal cell or stage I squamous cell carcinoma of the skin.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase level above normal range for the testing laboratory, active liver disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a total bilirubin greater or equal 2 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is/ was lifetime on any insulin treatment or takes other diabetes treatment (except metformin).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of proteinuria ≥300 mg/day on a 12- or 24-hour urine collection within last year or an albumin/creatinine ratio greater or equal 300 μg/mg.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of any clinically significant retinopathy, which is defined as more than moderate nonproliferative diabetic retinopathy, any stage of proliferative diabetic retinopathy or any history of laser-treated retinopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has clinically significant peripheral or autonomic neuropathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of ulcerative colitis or Crohn's disease, or has undergone gastric resection.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of a psychiatric disorder that, in Principal Investigator opinion, will affect the subject ability to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of angioedema.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an acute, clinically significant illness within 30 days prior to the study or any other condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is not able to comply with the study scheduled visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is participating in another investigational study or has taken any investigational drug within 90 days prior to the study."]}, {"trialId": "NCT03269227", "trialName": "Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous thorax radiotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Chemotherapy is allowed but completed 3 weeks before RT starts", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial with any investigational agents within 30 days prior to study screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with M1 have to be excluded to this study", "Patient has no overlapping conditions/medications with exclusion criterion: FEV1 \\< 50", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>85 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Respiratory needing oxygen therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial pneumopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active pneumonitis", "Patient has no overlapping conditions/medications with exclusion criterion: Fissural disease", "Patient has no overlapping conditions/medications with exclusion criterion: Contralateral mediastinum involvement (N3) and M1", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."]}, {"trialId": "NCT06552676", "trialName": "riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure of the percutaneous tracheostomy technique or recourse to surgical tracheostomy"]}, {"trialId": "NCT01521676", "trialName": "Predictive Clinical and Biological Parameters in Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: emergency"]}, {"trialId": "NCT04030676", "trialName": "QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Wardship patient and curatorial patient", "Patient has no overlapping conditions/medications with exclusion criterion: Patient unable to understand or sign the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Colectomy total or partial"]}, {"trialId": "NCT04560127", "trialName": "Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Any active autoimmune disease or history of autoimmune disease and expected recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis); subjects with skin diseases that does no need systemic treatment, for example, leukoderma, psoriasis, alopecia, those with controlled type I diabetes by insulin or those with asthma that has been completely resolved in childhood and with no need of any intervention can be enrolled; while subjects with asthma who need bronchodilator for medical intervention cannot be enrolled.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of strong CYP3A4/CYP2C19 inducers, including rifampicin (and its analogues) and St. John's Wort, or strong CYP3A4/CYP2C19 inhibitors within two weeks prior to signing informed consent form.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with other immune checkpoint inhibitors (include PD-1 antibody or other immunotherapy against PD-1/PD-L1).", "Patient has no overlapping conditions/medications with exclusion criterion: Known history of serious allergy to any monoclonal antibody or Apatinib.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwilling to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current presence of metastasis to central nervous system.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia or complications of severe pneumonia; oral or intravenous therapeutic antibiotics within two weeks prior to the start of study treatment (for example, subjects who are given with preventive antibiotics for prevention of urinary tract infection or exacerbation of chronic obstructive pulmonary disease are eligible for participation in the study).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women.", "Patient has no overlapping conditions/medications with exclusion criterion: Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators, such as alcoholism, drug abuse, other serious diseases (including mental disorders) requiring concomitant therapy, with serious laboratory examination abnormality, with family or social factors, that may affect subject's safety."]}, {"trialId": "NCT05078476", "trialName": "Rehabilitation of Finger Flexor Tendon Injuries", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\< 18 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients", "Patient has no overlapping conditions/medications with exclusion criterion: Replantation of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Primary tendon reconstructions"]}, {"trialId": "NCT06087627", "trialName": "A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have been treated for more than 7 days with dupilumab", "Patient has no overlapping conditions/medications with exclusion criterion: Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."]}, {"trialId": "NCT04853576", "trialName": "A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (12.0, 50.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Available 10/10 HLA-matched related donor", "Patient has no overlapping conditions/medications with exclusion criterion: Prior HSCT or contraindications to autologous HSCT", "Patient has no overlapping conditions/medications with exclusion criterion: Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to receive red blood cell (RBC) transfusion for any reason", "Patient has no overlapping conditions/medications with exclusion criterion: Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine", "Patient has no overlapping conditions/medications with exclusion criterion: Any history of severe cerebral vasculopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate end organ function", "Patient has no overlapping conditions/medications with exclusion criterion: Advanced liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior or current malignancy or immunodeficiency disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Immediate family member with a known or suspected Familial Cancer Syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined inclusion/exclusion criteria may apply"]}, {"trialId": "NCT01341327", "trialName": "Observational Study for Left Main Disease Treatment", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Protected left main stenosis"]}, {"trialId": "NCT06337227", "trialName": "Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients for whom biological material cannot be recovered for study purposes;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who refuse to participate in the study"]}, {"trialId": "NCT06312176", "trialName": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Has breast cancer amenable to treatment with curative intent", "Patient has no overlapping conditions/medications with exclusion criterion: Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune disease that has required systemic treatment in the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy"]}, {"trialId": "NCT06061627", "trialName": "A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Valvular heart disease that requires or has undergone surgical intervention", "Patient has no overlapping conditions/medications with exclusion criterion: After mechanical tricuspid valve replacement", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or permanent atrial fibrillation or atrial flutter", "Patient has no overlapping conditions/medications with exclusion criterion: Second or third degree atrioventricular block", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of acute myocardial infarction within 3 months prior to enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Patient's expected survival time is less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or planned to conceive", "Patient has no overlapping conditions/medications with exclusion criterion: Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with simple and persistent left superior vena cava", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with existing pacemaker implantation"]}, {"trialId": "NCT02907827", "trialName": "Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\\< 6weken)", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia", "Patient has no overlapping conditions/medications with exclusion criterion: Metallic devices implanted such as hip prostheses, since this can alter the imaging quality"]}, {"trialId": "NCT06291727", "trialName": "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients scheduled for bilateral TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Revision TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)", "Patient has no overlapping conditions/medications with exclusion criterion: Workers' Compensation patient", "Patient has no overlapping conditions/medications with exclusion criterion: Type I Diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Type II Diabetes requiring insulin medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-operative narcotics use with the exception of tramadol.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal insufficiency (GFR \\< 60) that may impact post-operative protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive deficiencies that prevent the patient from providing their own informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Language barrier preventing completion of study forms in English"]}, {"trialId": "NCT05650827", "trialName": "Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\< 18", "Patient has no overlapping conditions/medications with exclusion criterion: Living outside the greater Copenhagen area", "Patient has no overlapping conditions/medications with exclusion criterion: Any other malignancy requiring active treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Not eligible for chemotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Performance status \\> 2", "Patient has no overlapping conditions/medications with exclusion criterion: Not able to swallow liquids", "Patient has no overlapping conditions/medications with exclusion criterion: Parenteral nutrition or enteral nutrition via feeding tube", "Patient has no overlapping conditions/medications with exclusion criterion: Physical or mental disabilities that prohibit execution of test or training procedures", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to understand the Danish language"]}, {"trialId": "NCT06319027", "trialName": "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05536427", "trialName": "Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with immunodeficiency or a history of autoimmune disorders (e.g., rheumatoid arthropathy, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe concurrent medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, serious infection and infectious disease, active peptic ulcer, presence of active hemorrhage, and severe organ failure;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Grade III or IV cardiac failure defined by the New York Heart Association (NYHA), epileptic seizure, and mechanical or paralytic ileus within 6 months prior to the first administration of the investigational drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received chemotherapy and hormonal therapy within 28 days prior to signing the informed consent forms, or are currently taking other investigational drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with lymphoma, leukemia, myelodysplastic syndrome (MDS), or myelosuppression;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with allergy or a history of hypersensitivity to human blood albumin, or a history of allergy or hypersensitivity to any investigational drug or its excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with chronic diseases requiring immunotherapy or hormonal therapy; and subjects currently receiving corticosteroids for other diseases (except those using topical or inhaled steroids);", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with mental or neurological disorders that are not easily controlled;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects infected with human immunodeficiency virus (commonly known as AIDS) or treponema pallidum (commonly known as syphilis);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of other malignant tumors within the last 5 years;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with prior allogeneic stem cell transplantation or solid organ transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of drug or alcohol abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with any irAE of ≥ Grade 3 following prior immunotherapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who, in the judgment of the investigator, are not suitable to participate in this clinical study (e.g., with poor compliance)."]}, {"trialId": "NCT06093776", "trialName": "Rib Fracture Cryoanalgesia", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age Pregnant Incarcerated Confounding injuries or significant pain attributed to secondary injury Patients with any of the following: cryoglobulinemia; paroxysmal cold hemoglobinuria; cold urticarial; Raynaud's disease; open and/or infected wounds at or near the treatment site"]}, {"trialId": "NCT06146127", "trialName": "Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unequivocal histological features"]}, {"trialId": "NCT06330727", "trialName": "Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 59.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with diagnosis of diabetes, or taking anti-diabetic medication;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy, planned pregnancy, or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease)."]}, {"trialId": "NCT04855227", "trialName": "A Prospective Evaluation of Pain After Non-complex Ventral Hernia Repair", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is contraindicated for general anesthesia or surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a ventral hernia that will require retromuscular mesh placement or employ a technique, including (but not limited to) external oblique release, Rives- Stoppa, eTEP Rives-Stoppa, transversus abdominis release, other component separation techniques (i.e. anterior component separation) or eTEP transversus abdominis release.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a recurrent hernia.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will have an emergent hernia repair.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of chronic pain and/or taking daily pain medications for \\>6 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of substance abuse (excluding marijuana) and/or current (within 30 days) narcotic use.", "Patient has no overlapping conditions/medications with exclusion criterion: Current marijuana use that the subject is unwilling to discontinue within the 14 days prior to surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of MRSA infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with HbA1c level \\> 8.5%.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Exparel during the surgical procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will undergo a concomitant hernia repair or any other concomitant procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Current nicotine use (including vaping) within the past 30 days.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a known bleeding or clotting disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or suspected pregnancy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject belonging to other vulnerable population, e.g, prisoner or ward of the state.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is currently participating in another interventional or investigational research study."]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT06072976", "trialName": "The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (0.0, 55.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Infant has already been on feeds", "Patient has no overlapping conditions/medications with exclusion criterion: Infants \\<34 weeks gestation", "Patient has no overlapping conditions/medications with exclusion criterion: Parents with contraindications to providing milk (i.e. drug use-cocaine, fentanyl, meth BUT oxy/suboxone/marijuana OK)", "Patient has no overlapping conditions/medications with exclusion criterion: Complicated gastroschisis", "Patient has no overlapping conditions/medications with exclusion criterion: Short gut syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Additional congenital anomalies that affect ability to tolerate milk (i.e. cyanotic congenital heart disease BUT kidney disease ok)"]}, {"trialId": "NCT05752227", "trialName": "Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pure pleural lesions.", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical instability to reach the final diagnosis.", "Patient has no overlapping conditions/medications with exclusion criterion: Inaccessibility by ultrasound."]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (4.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05364827", "trialName": "CT Coronary Angiography Prior to CTO PCI", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: CTO with J-CTO score\\<2", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate/degraded CTCA images", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant/lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe contrast allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to provide written informed consent"]}, {"trialId": "NCT05038527", "trialName": "ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: ASA ≥ 4", "Patient has no overlapping conditions/medications with exclusion criterion: Formally diagnosed with a disease affecting the bone metabolism or wound healing (severe osteoporosis, osteomalacia, Pagets disease, hyperparathyreoidism etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disseminated cancer diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to any of the i-FACTOR Peptide Enhanced Bone Graft ingredients", "Patient has no overlapping conditions/medications with exclusion criterion: Smoking, extensive alcohol use or abuse of hallucinating drugs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver or kidney disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or breastfeeding patients", "Patient has no overlapping conditions/medications with exclusion criterion: Patients estimated not to be able to understand the information sheet or patients, who do not consent to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe psychiatric diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Ongoing infections"]}, {"trialId": "NCT06200376", "trialName": "A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating, or plan to pregnant or give birth during the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;", "Patient has no overlapping conditions/medications with exclusion criterion: History of splenectomy or organ transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;", "Patient has no overlapping conditions/medications with exclusion criterion: Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of high risk cardiovascular disease, including but not limited to:\n\n    * Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);\n    * Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;\n    * Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;\n    * Rating of heart function as defined by the New York Heart Association (NYHA) standards\\>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;\n    * Left ventricular ejection fraction (LVEF) \\< the center lower limit. If no lower limit existed, LVEF\\<50%;\n    * Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);", "Patient has no overlapping conditions/medications with exclusion criterion: History of another malignant tumor, except the following:\n\n    * Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;\n    * Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;\n    * Adequately treated carcinoma in situ without evidence of disease;", "Patient has no overlapping conditions/medications with exclusion criterion: Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Unexplained \\>38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment"]}, {"trialId": "NCT06040827", "trialName": "A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06144476", "trialName": "Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.", "Patient has no overlapping conditions/medications with exclusion criterion: Surgery within the preceding 6 weeks", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection", "Patient has no overlapping conditions/medications with exclusion criterion: Alcohol or recreational drug abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency requiring treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to read or write English", "Patient has no overlapping conditions/medications with exclusion criterion: Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study"]}, {"trialId": "NCT03317327", "trialName": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB and stage I prostate cancer considered not necessary to treat", "Patient has no overlapping conditions/medications with exclusion criterion: Disease suitable for curative salvage surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 4 weeks prior to first administration of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant cardiac, pulmonary or other medical illness that would limit activity or survival", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to any of the components of the investigational product", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who test positive for hepatitis B, C or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of immunosuppressive therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease that has required systemic therapy within the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: Any reason why, in the opinion of the investigator, the patient should not participate"]}, {"trialId": "NCT04257227", "trialName": "Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Documented brain lesions", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to remain still while sitting up (45 degrees) for the duration of therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold"]}, {"trialId": "NCT05601427", "trialName": "Intra-Operative Adductor Canal Blocks", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or refusal to sign informed consent form", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.", "Patient has no overlapping conditions/medications with exclusion criterion: Non-osteoarthritis primary diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to analgesic medications", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal and/or regional anaesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Any use of opioid pain medication within four weeks of the index procedure(13)", "Patient has no overlapping conditions/medications with exclusion criterion: Pain catastrophizing scale score ≥16 (8, 9, 14)", "Patient has no overlapping conditions/medications with exclusion criterion: History of cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: History renal insufficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History or sensory and/or motor neuropathy to the ipsilateral limb", "Patient has no overlapping conditions/medications with exclusion criterion: Simultaneous, bilateral TKA", "Patient has no overlapping conditions/medications with exclusion criterion: Non-TKA prosthesis", "Patient has no overlapping conditions/medications with exclusion criterion: Scheduled for non-SDD TKA.", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative varus/valgus of \\>10 degrees.", "Patient has no overlapping conditions/medications with exclusion criterion: Planned General Anaesthetic", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Intrathecal Morphine"]}, {"trialId": "NCT03072927", "trialName": "MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (13.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT06585527", "trialName": "Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with encephalitis disease, multiple sclerosis, or other CNS (Central Nervous System) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of organ transplantation or waiting for organ transplantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled infectious diseases or other serious diseases, such as HIV positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with any unstable systemic illness (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris beginning within the last 3 months, congestive heart failure, myocardial infarction occurring within 12 months before enrollment, severe arrhythmia requiring medical treatment, liver or kidney failure, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with systemic autoimmune diseases or immunodeficiency diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe allergic constitution.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases requiring long-term treatment with immune agents or glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with mental disorders."]}, {"trialId": "NCT05956327", "trialName": "Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Lack of reliability and sanity (examined by an independent psychiatrist)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive urine drug screen for illicit drugs (except benzodiazepines)", "Patient has no overlapping conditions/medications with exclusion criterion: Acute suicide risk", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant psychiatric axis-I disorders according to the diagnostic testing procedure (Mini International Neuropsychiatric Interview, MINI)", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant neurological or other disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation"]}, {"trialId": "NCT03916627", "trialName": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with metastatic disease for whom the intent of surgery would not be curative", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 1 year", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply"]}, {"trialId": "NCT03712527", "trialName": "Intra-discal Injection of PRP for Low Back Pain", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 60.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: - Patient with Modic 1 discopathy in different vertebral levels", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a Modic I signal abnormality related to a static spinal disorder (such as previous vertebral fractures, or isthmic lysis, or spondyloarthritis)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a history of lumbar spine surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with suspected spondylodiscitis or other infection", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under anticoagulant or antiaggregant therapy, or with a coagulation disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with allergy to iodine or to any of the components of Xylocaine", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to MRI: Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with anatomical difficulty of access to the injection area (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with an uncontrolled severe disease (i.e. heart, pulmonary, gastro-intestinal, neurologic, endocrine, auto-immune affections) limiting the patient's safety (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with previous malignancy less than 5 years (except for non-melanoma skin cancer)", "Patient has no overlapping conditions/medications with exclusion criterion: Prior to the screening visit:", "Patient has no overlapping conditions/medications with exclusion criterion: a current and recent use of morphine (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: a systemic or local corticosteroid therapy (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: Porphyria", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with sphincter disorders indicating a cauda equina syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Psychotic state not controlled by a treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (βHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age", "Patient has no overlapping conditions/medications with exclusion criterion: Vulnerable persons protected by law", "Patient has no overlapping conditions/medications with exclusion criterion: Persons under guardianship", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who are in a dependency or employment with the sponsor or the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Subject unable to read or/and write"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (16.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT04519476", "trialName": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n  1. Has received selinexor or another XPO1 inhibitor previously.\n  2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \\>5 years previously and without evidence of recurrence will be allowed.\n  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \\[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\\], primary amyloidosis, etc.) that is likely to interfere with study procedures.\n  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.\n  6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.\n  7. Concurrent use of other anti-cancer agents or treatments.\n  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\n  9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin\n  10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n  11. Pregnant or breastfeeding females.\n  12. BSA \\<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.\n  13. Life expectancy of less than 3 months.\n  14. Major surgery within 4 weeks prior to C1D1.\n  15. Active, unstable cardiovascular function, as indicated by the presence of:\n\n  1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.\n\n  18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.\n\n  19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).\n\n  20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n\n  21. Contraindication to any of the required concomitant drugs or supportive treatments.\n\n  22. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT06508827", "trialName": "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemoglobinopathies", "Patient has no overlapping conditions/medications with exclusion criterion: Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemochromatosis", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating female adults", "Patient has no overlapping conditions/medications with exclusion criterion: Active infections which in research teams' opinion increases risk for toxicities", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures."]}, {"trialId": "NCT05900427", "trialName": "Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Ages: \\<18 and \\>90", "Patient has no overlapping conditions/medications with exclusion criterion: Weight \\< 60 kg", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple surgeries during one hospital stay", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or any contraindication to local anesthetics used in trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindicated for use of liposomal bupivacaine", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver/kidney disease", "Patient has no overlapping conditions/medications with exclusion criterion: Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who received another local anesthetic block prior to the interscalene block.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to consent in English"]}, {"trialId": "NCT05422027", "trialName": "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who meet any of the following criteria will not be enrolled:\n\n  1. Plasma cell leukemia.\n  2. Documented active amyloidosis.\n  3. Involvement of the central nervous system(CNS) by Multiple myeloma.\n  4. Prior exposure to a SINE compound, including ATG-010.\n  5. Currently, whether or not the patient is on medication, \\> Grade 2 peripheral neuropathy or ≥ Grade ≥ 2 painful neuropathy at baseline.\n  6. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and Selinexor (ATG-010) .\n  7. Active, unstable cardiovascular function, as indicated by the presence of:\n\n     1. Symptomatic ischemia, or\n     2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or\n     3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\<40%, or\n     4. Myocardial infarction within 6 months prior to C1D1.\n  8. Known positive serology for HIV or HIV seropositivity.\n  9. Known active hepatitis A, B, or C infection; eg. positive for HCV RNA or HBV-DNA.\n  10. Women who are pregnant or nursing.\n  11. Life expectancy of less than 6 months.\n  12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.\n  13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n  14. Contraindication to any of the required concomitant drugs or supportive treatments.\n  15. Has any concurrent diseases or complications that is likely to interfere with the study procedures.\n  16. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT05284227", "trialName": "Artificial Intelligence-augmented Perioperative Clinical Decision Support", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT06049927", "trialName": "A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (6.0, 35.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from seasonal influenza in the past 6 moths;", "Patient has no overlapping conditions/medications with exclusion criterion: Axillary temperature \\>37.0°C;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma;", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;", "Patient has no overlapping conditions/medications with exclusion criterion: Severe chronic diseases(Such as down syndrome, diabetes, sickle cell anaemia or neurological disorders);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease (such as systemic lupus erythematosus) or immunodeficiency / immunosuppression (such as HIV, after organ transplantation)", "Patient has no overlapping conditions/medications with exclusion criterion: Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;", "Patient has no overlapping conditions/medications with exclusion criterion: Continuous use of corticosteroids or other immunosuppressive agents for ≥ 14 days within the past 6 months (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) and cytotoxic therapy in the past 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Acute diseases or acute exacerbation of chronic diseases in the past 3 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of blood products within in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of other investigational drugs in the past 30 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of attenuated live vaccines in the past 14 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of inactivated or subunit vaccines in the past 7 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other clinical trials before enrollment and in the follow-up period, or plans to participate in other clinical trials during the clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial"]}, {"trialId": "NCT05057676", "trialName": "Autoimmune Intervention Mastery Course Study", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04772027", "trialName": "Motor Parameters in Patients With Limb Girdle Muscular Dystrophy", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: § For all:", "Patient has no overlapping conditions/medications with exclusion criterion: Without associated neuromuscular disorders such as respiratory or muscular-squeletic diseases, apart from the consequences of dystrophy;", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to the tests;", "Patient has no overlapping conditions/medications with exclusion criterion: Noncontrol cardiac rhythm disorders;", "Patient has no overlapping conditions/medications with exclusion criterion: Lying down position intolerance due to severe respiratory troubles;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman."]}, {"trialId": "NCT05159427", "trialName": "Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 55.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to independently provide an informed consent for themselves or mentally incapacitated.", "Patient has no overlapping conditions/medications with exclusion criterion: Physical disability (including blindness or deafness) that requires special arrangements.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant clinical illness, including cardiovascular disease, neurological disease, organ failure, or malignancy in the opinion of the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Any surgical procedure within 3 weeks prior to screening", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of severe seasonal allergies or severe allergic diseases including drug allergies, food allergies and allergy against the SmartPill® device", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to any of the study drugs or the products' excipients", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Sulfonamide derivatives", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Lidocaine", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of XIFAXAN", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to acrylate or methacrylate, commonly used components of medical adhesives", "Patient has no overlapping conditions/medications with exclusion criterion: Any other factor, condition, or disease, including, but not limited to, cardiovascular, respiratory, hematological, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the patient, alter drug absorption and pharmacokinetics or impact the validity of the study results.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Type 1 Diabetes Mellitus (DM), diabetic ketoacidosis, with or without coma", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Glucose 6-phosphate dehydrogenase (G6PD) deficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of drug addiction or alcohol abuse within the past 12 months.", "Patient has no overlapping conditions/medications with exclusion criterion: History of significant psychiatric or neurological illness, including seizure disorders.", "Patient has no overlapping conditions/medications with exclusion criterion: Any medical or surgical conditions which might significantly interfere with the functions of gastrointestinal tract (e.g., gastric/intestinal bypass surgeries, fistulas, strictures, stenosis, or physiological/mechanical obstruction of the G.I tract, gastric bezoars, irritable bowel disease, crohn's disease, diverticulosis, or chronic narcotic use).", "Patient has no overlapping conditions/medications with exclusion criterion: History of dysphagia to liquids, food, or pills", "Patient has no overlapping conditions/medications with exclusion criterion: History of abdominal radiation therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating females", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal lab values during screening in the opinion of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of alcohol and/or nicotine containing products 48 hours prior to dosing visits, and throughout PK sampling visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any medications and/or supplements, prescriptions or over the counter 1 week prior to beginning the study, and throughout the study except for birth control with approved methods of contraception when used consistently and correctly (Implants (i.e. Implanon, Nexplanon), Injectables (i.e. Depo-Provera), Combined, Oral Contraceptives, Intrauterine Devices (IUD's) (i.e. Mirena, ParaGard), and Sexual Abstinence are accepted).", "Patient has no overlapping conditions/medications with exclusion criterion: Use of aspirin or any blood thinner medications.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteers unwilling or unable to take the proposed drugs or undergo G.I intubation", "Patient has no overlapping conditions/medications with exclusion criterion: Enrollment in a clinical trial in the past 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Current enrollment in a clinical trial with another study drug, vaccine or medical device", "Patient has no overlapping conditions/medications with exclusion criterion: Fasting blood glucose level \\< 80 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwillingness to fast for 19 hours.", "Patient has no overlapping conditions/medications with exclusion criterion: Blood donations in the past 8 weeks except for apheresis.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer shows a positive result of COVID-19 Antigen Rapid test in dosing visits", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having any of the following symptoms:\n\n    * Fever (over 100.4 oF or 38 oC) or feeling feverish\n    * New cough\n    * New shortness of breath", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having two of any of these symptoms:\n\n    * Chills\n    * Muscle aches\n    * New URI symptom(s) (runny nose, nasal congestion, and/or sore throat)\n    * New loss of sense of smell or sense of taste\n    * New headache", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has been in close contact in the last 14 days with someone recently diagnosed with COVID-19", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has returned from international travel within the past 10 days"]}, {"trialId": "NCT05525676", "trialName": "Relationship Checkups to Reduce Veteran Suicide Risk", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports severe intimate partner violence in the last year.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports experiencing suicidal intent requiring hospitalization.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER experiences past-month psychosis or mania.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years."]}, {"trialId": "NCT05763576", "trialName": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Healthy volunteers:", "Patient has no overlapping conditions/medications with exclusion criterion: History of any clinically significant disease", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant disease that could interfere with treatment or conduct of study", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)\n\nCHB participants:", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of liver cirrhosis or decompensated liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: History or suspicion of hepatocellular carcinoma (HCC)", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study."]}, {"trialId": "NCT05780476", "trialName": "A Novel VIRTUAL Reality Intervention for CAREgivers of People With Dementia (VirtualCare)", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving daily assistance for more than 10 hours from formal CGs;", "Patient has no overlapping conditions/medications with exclusion criterion: Being formal CGs (i.e., nurse or another paid figure);", "Patient has no overlapping conditions/medications with exclusion criterion: Being informal CGs of i) persons with moderate-to-severe AD, or ii) persons with non-AD diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Not having or being able to use a device connected to internet (e.g., smartphones or PC).", "Patient has no overlapping conditions/medications with exclusion criterion: Having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs.", "Patient has no overlapping conditions/medications with exclusion criterion: Only a family member for person with dementia is accepted.\n\nExclusion Criteria for experimental group (Psychoeducation + VR):", "Patient has no overlapping conditions/medications with exclusion criterion: Medical history of epilepsy.\n\nExclusion Criteria for subsample of caregivers assess with MRI:", "Patient has no overlapping conditions/medications with exclusion criterion: Metal implants, artificial prostheses, pace-makers, prosthetic heart valves;", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy."]}, {"trialId": "NCT03990727", "trialName": "Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (2.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: 1) Not willing to visit every year."]}, {"trialId": "NCT05721027", "trialName": "Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Not available for follow-up", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergic to or intolerant of investigational medications", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic steroid use", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney disease (GFR \\<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x the upper limit of normal)"]}, {"trialId": "NCT06550427", "trialName": "Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT04802876", "trialName": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior systemic anti-cancer therapy, including investigational agents within 2 weeks. Medical Monitor could consider shorter interval for kinase inhibitors or other short half-life drugs prior to allocation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants with ≤Grade 2 neuropathy may be eligible.\n\n   Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study treatment.\n\n   Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose of the previous investigational agent.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with thymoma are not eligible. Patients with active CNS metastases and/or carcinomatous meningitis are not eligible. Subjects with up to three cerebral metastases are eligible, if all lesions are stable and have been definitively treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any of its excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior allogeneic stem cell transplantation or organ transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history of interstitial lung disease, (non-infectious) pneumonitis that required steroids or has current pneumonitis, uncontrolled lung including pulmonary fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Human Immunodeficiency Virus (HIV).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of active TBC (Bacillus Tuberculosis).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of trial treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with spartalizumab or tislelizumab. Highly effective contraception methods include:\n\n    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n    4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.\n\n    Notes:\n    * Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.\n    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.", "Patient has no overlapping conditions/medications with exclusion criterion: Sexually active males, unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with spartalizumab or tislelizumab should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen."]}, {"trialId": "NCT04816227", "trialName": "Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusing to participate in the study", "Patient has no overlapping conditions/medications with exclusion criterion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research", "Patient has no overlapping conditions/medications with exclusion criterion: Being pregnant or breastfeeding"]}, {"trialId": "NCT06187727", "trialName": "Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Mechanical complications;", "Patient has no overlapping conditions/medications with exclusion criterion: Cardiogenic shock;", "Patient has no overlapping conditions/medications with exclusion criterion: Experienced myocardial infarction within 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Aortic dissection;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included", "Patient has no overlapping conditions/medications with exclusion criterion: Urinary system infection"]}, {"trialId": "NCT04167527", "trialName": "Endovascular Therapy for Low NIHSS Ischemic Strokes", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: NIHSS ≥6", "Patient has no overlapping conditions/medications with exclusion criterion: Any sign of intracranial hemorrhage on baseline CT/MR (SDH/SAH/ICH)", "Patient has no overlapping conditions/medications with exclusion criterion: Any imaging findings suggestive of futile recanalization in the judgment of the local investigator", "Patient has no overlapping conditions/medications with exclusion criterion: High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD", "Patient has no overlapping conditions/medications with exclusion criterion: Premorbid disability (mRS ≥3)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to randomize within 8 hours of last known well", "Patient has no overlapping conditions/medications with exclusion criterion: Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS", "Patient has no overlapping conditions/medications with exclusion criterion: Baseline blood glucose of \\<50 mg/dL (2.78 mmol) or \\>400 mg/dL (22.20 mmol)", "Patient has no overlapping conditions/medications with exclusion criterion: Known coagulation disorders as defined as platelet count \\<100,000/uL", "Patient has no overlapping conditions/medications with exclusion criterion: Known renal failure as defined as serum creatinine levels \\> 3.0 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Presumed septic embolus or suspicion of bacterial endocarditis", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another investigational treatment study in the previous 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Intubation and mechanical ventilation prior to study enrollment is medically indicated", "Patient has no overlapping conditions/medications with exclusion criterion: History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Site investigator does not have equipoise towards the ideal treatment concept (thrombectomy vs. best medical management)", "Patient has no overlapping conditions/medications with exclusion criterion: Known pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Prisoner or incarceration", "Patient has no overlapping conditions/medications with exclusion criterion: Known acute symptomatic COVID-19 infection"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (16.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT06218576", "trialName": "Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: age \\< 18 years"]}, {"trialId": "NCT03050476", "trialName": "Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (21.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Already on renal replacement therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic kidney disease defined as estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m2 \\[ CKD stage \\> 3 \\]", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Concurrent enrollment in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with ongoing infections or current use of steroids", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with high-risk emergency surgery or with follow-up procedures already planned at admission (like e.g. TEVAR)"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT05500027", "trialName": "sCD8, as a Novel Biomarker for Pancreatic Cancer", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusal to participate", "Patient has no overlapping conditions/medications with exclusion criterion: Age less than 18-year old and over 85-year old"]}, {"trialId": "NCT05755776", "trialName": "The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Men and women of childbearing potential who are unwilling to use an \"effective\" method of contraception as defined in the protocol during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have received a solid organ or bone marrow transplant", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or existing clinical liver failure (Child-Pugh score ≥ grade B)."]}, {"trialId": "NCT05887076", "trialName": "Postoperative Delirium After Kidney Transplantation", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete data records of the parameters to be determined", "Patient has no overlapping conditions/medications with exclusion criterion: Underage Patients"]}, {"trialId": "NCT05272176", "trialName": "Veterans Coordinated Community Care (3C) Study", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired decision-making capacity", "Patient has no overlapping conditions/medications with exclusion criterion: Limited or no English language proficiency", "Patient has no overlapping conditions/medications with exclusion criterion: Terminal illness"]}, {"trialId": "NCT05968976", "trialName": "Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Legally incompetent adults;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous tremor-neurosurgery (e.g., DBS, thalamotomy);", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;", "Patient has no overlapping conditions/medications with exclusion criterion: Psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Current depression;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent."]}, {"trialId": "NCT06182527", "trialName": "Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: diabetes mellitus", "Patient has no overlapping conditions/medications with exclusion criterion: use of medication interfering with glucose metabolism (steroid, antidiabetic medications)", "Patient has no overlapping conditions/medications with exclusion criterion: surgery of upper GI-tract", "Patient has no overlapping conditions/medications with exclusion criterion: known plaster allergies", "Patient has no overlapping conditions/medications with exclusion criterion: any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion"]}, {"trialId": "NCT06222827", "trialName": "Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, any major comorbidities (diabetes mellitus, cancer, severe autoimmune diseases, chronic renal failure, articular diseases that restricts exercise or participation in study assessments in the physician's opinion...), a history of relevant drug or food allergies; history of cardiovascular, respiratory, central nervous system disease; neuromuscular diseases except FSHD (e.g., myopathy, neuropathy, neuromuscular junction disorders)", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who are on drug(s) or supplements that may affect muscle function, as determined by the treating physician must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Orthopedic conditions, such as unresolved fracture or arthrosis, interfering or precluding testing of muscle function", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to muscle MRI as per clinic standard practice", "Patient has no overlapping conditions/medications with exclusion criterion: Articular contracture limiting movements, scapular fixation or other surgeries, preceding or planned", "Patient has no overlapping conditions/medications with exclusion criterion: Any known hypersensitivity to satralizumab or any of its components and/or history of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of latent or active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection for at least 4 weeks prior to enrollment), active opportunistic or life-threatening infections", "Patient has no overlapping conditions/medications with exclusion criterion: History of diverticulitis or concurrent severe GI disorders (such as symptomatic diverticulosis) that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation. Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit (Visit 1, week 0)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody.", "Patient has no overlapping conditions/medications with exclusion criterion: Acute or chronic history of liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal laboratory results with: White blood cells (WBC) \\< 3.0x 10\\^9/L ; Absolute Neutrophils Counts (ANC)\\< 2.0x 10\\^9/L ; Platelet count \\< 10x10\\^4/µl ; Absolute lymphocyte count (ALC) \\< 0.8x 10\\^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 times the upper limit of normal (ULN)", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment (defined as a glomerular filtration rate of \\<30mL/min/1.73m²)", "Patient has no overlapping conditions/medications with exclusion criterion: Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation", "Patient has no overlapping conditions/medications with exclusion criterion: For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier \\[patient or partner\\] in conjunction with a spermicidal product, contraceptive pill, patch, injectable, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of another investigational product within 6 months or 5 half-lives (whichever is longer), or currently participating in a prospective study with an investigational product, whether it concerns an experimental drug or a medical device. Note: concurrent participation in natural history studies (non-drug, non-device studies) is not allowed during the course of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior treatment with any agent targeting the IL-6 inhibition pathway (e.g. tocilizumab, sarilumab), alemtuzumab treatment, total body irradiation, or bone marrow transplantation; treatment in the past 24 weeks with an anti-B-lymphocyte antigen CD20 (e.g. rituximab, ocrelizumab), eculizumab, anti-B-lymphocyte stimulator, or any other multiple sclerosis disease-modifying treatment; treatment in the past 2 years with an anti-T-cell surface glycoprotein CD4, cladribine, cyclophosphamide, or mitoxantrone; or treatment with any other investigational drug within 3 months prior to baseline. See section 4.4.4 for details on the vaccination and immunization.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject, or close relative of the subject, is the investigator or a coinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code."]}, {"trialId": "NCT05505227", "trialName": "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: currently prescribing buprenorphine at full capacity"]}, {"trialId": "NCT05782127", "trialName": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous diagnosis of:\n\n   * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)\n   * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: History of active malignancy within the past year prior to screening, with the exception of:\n\n   * Adequately treated carcinoma in situ of the uterine cervix\n   * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n   * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.\n\n   Patients with ongoing horomonotherapy could be included.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.", "Patient has no overlapping conditions/medications with exclusion criterion: Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.", "Patient has no overlapping conditions/medications with exclusion criterion: Received live attenuated vaccines prior to initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions that could interfere with drug absorption including short gut syndrome, dysphagia, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mmHg or diastolic BP \\> 100 mmHg) or has not been stable for at least 1 month prior to treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:\n\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Unstable angina or angina requiring surgical or medical intervention\n    * Significant cardiac arrhythmia\n    * And/or myocardial infarction", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is a pregnant or lactating female.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has known or suspected to have hypersensitivity to any of the components of the assigned study treatments.", "Patient has no overlapping conditions/medications with exclusion criterion: Positive test result(s) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B surface \\[HBs\\] antibody positive and anti-hepatitis B core \\[HBc\\] antibody negative) may participate.", "Patient has no overlapping conditions/medications with exclusion criterion: Absence of social security affiliation."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT06524427", "trialName": "Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with the previous history of other malignancies;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with secondary primary cancer when enrolled;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as pure ground glass opacity (GGO) before surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as mixed GGO whose solid part \\<= 50% and Maximum diameter of tumor \\<= 2cm;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with small cell lung cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with prior unilateral open thoracic surgical procedures;", "Patient has no overlapping conditions/medications with exclusion criterion: Woman who is pregnant or breastfeeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with an active bacterial or fungal infection that is difficult to control;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with serious psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months."]}, {"trialId": "NCT05537376", "trialName": "A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Veteran"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT05189327", "trialName": "Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient takes part in an interventional clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is unable to follow the schedule of the visits;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that the PI believes would prevent a study participant from participating in the study."]}, {"trialId": "NCT06447727", "trialName": "Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: After liver metastasis was diagnosed, the liver underwent external radiation therapy and transhepatic arterial chemoembolization", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with extrahepatic metastases", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe arrhythmia or heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: Other researchers considered it inappropriate to participate in this study"]}, {"trialId": "NCT06176027", "trialName": "Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women"]}, {"trialId": "NCT05775627", "trialName": "Sleep and Metabolism", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 40.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dietary restrictions\n\n   Participants must not have dietary restrictions that could systematically bias their macronutrient intake. The following will exclude participants from enrolling in the study based on their diet:\n   * Participants who choose not to or cannot consume dairy products (milk, yogurt, cheese, ice cream)", "Patient has no overlapping conditions/medications with exclusion criterion: Body Composition\n\n   A body mass index (BMI) of 18.5\\< \\[BMI\\] \\< 25 kg/m2 and a waist circumference \\<94/80cm.", "Patient has no overlapping conditions/medications with exclusion criterion: Psychiatric/psychological suitability\n\n   Each participant will undergo a structured interview (Mini International Neuropsychiatric Interview) with a qualified OHSU physician. This physician will supervise the administration and scoring of a Beck Depression Inventory II (BDI-II) questionnaire for each potential participant. The following will exclude individuals from participating based on their psychiatric or psychological evaluation:\n   * Individuals with evidence of psychopathology on the BDI-II, or in a structured clinical interview with the physician\n   * A history of severe psychiatric illnesses\n   * Alcoholism\n   * Drug dependency\n   * Major depression\n   * Manic depressive illness\n   * Schizophrenic disorders\n   * Panic disorder\n   * Generalized anxiety disorder\n   * Post-traumatic stress disorder\n   * Agoraphobia\n   * Claustrophobia\n   * Paranoid personality disorder\n   * Schizoid personality disorder\n   * Schizotypal personality disorder\n   * Borderline personality disorder\n   * Antisocial personality disorder.\n   * History of using antidepressant medication\n   * History of using neuroleptic medication\n   * History of using tranquilizers", "Patient has no overlapping conditions/medications with exclusion criterion: Drug/alcohol use\n\n   Volunteers must be drug-free (including caffeine, nicotine, alcohol and herbal medications) for the entire duration of the outpatient and in-laboratory study period, with no history of drug or alcohol dependency. All participants must be:\n   * Current non-smokers, and are required to have a history of less than 5 'pack years' of smoking", "Patient has no overlapping conditions/medications with exclusion criterion: Medication/drug use\n\n   Volunteers must not be taking any prescribed medications or over the counter medications, with an exception for birth control.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior shift work\n\n   For stability of endogenous circadian rhythmicity, volunteers must have no history of the following 1 year prior to the study:\n   * Working irregular day and night hours\n   * Regular night work\n   * Rotating shift work f\n   * Not have traveled more than 1 time zone during 3 months prior to the study", "Patient has no overlapping conditions/medications with exclusion criterion: Chronobiologic and sleep disorders\n\n   * Hypernychthemeral sleep/wake cycle\n   * Delayed sleep phase syndrome (wake time \\> 2 hours later than desired or habitually after 10:00 AM)\n   * Advanced sleep phase syndrome (wake time \\> 2 h earlier than desired or habitually before 5:00 AM)\n   * Narcolepsy\n   * Sleep apnea (apnea index \\>15)\n   * Insomnia (sleep complaint by history or polygraphically recorded sleep efficiency \\< 80%)\n   * Hypersomnia\n   * Periodic Limb Movement (PLMS) (PLMS index \\>15)\n   * Nocturnal Paroxysmal Dystonia\n   * REM-sleep behavior disorder\n   * Nocturnal Enuresis; (self-report and first night in the laboratory)\n   * Obstructive sleep apnea (apnea/hypopnea index \\>5/h as determined by at-home monitoring)\n   * The investigators will also exclude individuals with extreme chronotype using the Horne-Ostberg Morningness/Eveningness questionnaire (i.e., the Owl/Lark Questionnaire)", "Patient has no overlapping conditions/medications with exclusion criterion: Diseases of the Cardiovascular System\n\n   * Hypertension (systolic blood pressure \\> 140 or diastolic blood pressure \\> 90)\n   * Heart failure\n   * Cardiomyopathy\n   * Cor pulmonale\n   * Ischemic heart disease\n   * Valvular heart disease\n   * History of heart transplantation\n   * Cardiac tumors\n   * Pericardial disease", "Patient has no overlapping conditions/medications with exclusion criterion: Metabolic Syndrome\n\n   Following American Heart Association cutoffs, participants who have, in addition to abdominal fat (obese exclusion criteria), two or more of these factors will be excluded from the study:\n   * HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women\n   * Systolic blood pressure \\>135 mmHg or diastolic blood pressure \\>85 mmHg\n   * Fasting blood glucose ≥ 100 mg/dL\n   * Triglycerides ≥ 150 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-Diabetes/Diabetes\n\n    For participants who have a fasting blood glucose level of ≥ 100 mg/dL the investigators will measure hemoglobin A1c to exclude for diabetes (HbA1c\\>5.7%).", "Patient has no overlapping conditions/medications with exclusion criterion: Hypertension\n\n    An upper cut off of 140/90 mmHg during an office blood pressure measure will be used as an exclusion criterion. After 5 minutes of rest in a seated position, blood pressure will be measured 3 times, taken 1 minute apart. The average will be used to confirm eligibility criteria. Current or history of beta blocker use will also be exclusionary.", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Respiratory System\n\n    * Asthma\n    * Cystic fibroses\n    * Chronic bronchitis\n    * Emphysema\n    * Airway obstruction\n    * Interstitial lung diseases\n    * Pulmonary hypertension\n    * Lung neoplasms\n    * ARDS", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Kidney and Urinary Tract\n\n    * Acute or chronic renal failure\n    * History of renal transplantation\n    * Tubulointerstitial diseases of the kidney\n    * Urinary tract obstruction\n    * Tumors of the urinary tract", "Patient has no overlapping conditions/medications with exclusion criterion: Infectious Diseases\n\n    * Infective endocarditis\n    * HIV infection\n    * Sexually transmitted diseases \\[e.g., syphilis (including congenital syphilis and its sequelae), gonorrhea\\],\n    * Urinary tract infection\n    * Osteomyelitis\n    * Brucellosis\n    * Toxoplasmosis,\n    * Tuberculosis\n    * Leptospirosis\n    * Lyme disease\n    * Mononucleosis\n    * Hepatitis\n    * Parasitic infections such as malaria, toxoplasmosis, giardiasis, schistosomiasis, leishmaniasis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Gastrointestinal System\n\n    * Esophagitis\n    * Peptic ulcer and gastritis\n    * Neoplasms of the esophagus, stomach or bowel\n    * Disorders of absorption\n    * Inflammatory bowel disease\n    * Diseases of the small and large intestine\n    * Acute appendicitis\n    * Cirrhosis or neoplasms of the liver\n    * History of liver transplantation\n    * Diseases of the gallbladder and bile ducts\n    * Pancreatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Immune System, Connective Tissue and Joints\n\n    * AIDS\n    * Systemic lupus erythematosus\n    * Rheumatoid arthritis\n    * Scleroderma\n    * Ankylosing spondylitis\n    * Vasculitis\n    * Sarcoidosis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Hematopoietic System\n\n    * Anemia\n    * Leukemia\n    * Myeloproliferative diseases\n    * History of bone marrow transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Neoplastic Diseases\n\n    * Lymphoma\n    * Carcinoma\n    * Melanoma\n    * Any other neoplastic diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Endocrine and Metabolic Diseases\n\n    * Thyroid disease\n    * Addison's Disease\n    * Cushing's Syndrome\n    * Aldosteronism\n    * Hypoaldosteronism\n    * Pheochromocytoma\n    * Disorders of sexual differentiation that require hormone supplementation that may alter body weight\n    * Disorders of neuroendocrine regulation\n    * Diseases of the anterior pituitary and hypothalamus\n    * Hemochromatosis porphyria\n    * Wilson's Disease\n    * Glycogen storage diseases\n    * Diseases of the parathyroid gland\n    * Metabolic bone disease\n    * Disorders of phosphorus or magnesium metabolism\n    * Paget's Disease", "Patient has no overlapping conditions/medications with exclusion criterion: Neurologic Disorders\n\n    * Epilepsy and disorders of consciousness\n    * Dementia\n    * Amnesic disorders\n    * Neoplastic diseases of the central nervous system\n    * Demyelinating diseases\n    * Parkinson's Disease\n    * Muscular dystrophy\n    * Myasthenia gravis\n    * Periodic paralysis\n    * Dermatomyositis\n    * Polymyositis\n    * Infections of the nervous system\n    * Stroke\n    * History of transient ischemic attacks\n    * Hydrocephalus\n    * Tumors of the pituitary gland\n    * Pinealoma\n    * Intervertebral disc disease\n    * Ataxia\n    * Gilles de la Tourette Syndrome\n    * Huntington's Disease\n    * Tardive dyskinesia\n    * History of recurrent migraine headaches\n    * Neuromuscular disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects must not be currently participating in another research study that would influence their safe participation in our study. Subjects must not be participating in a research study in which they do the following:\n\n    * Ingest experimental medication\n    * Give blood samples"]}, {"trialId": "NCT04280627", "trialName": "Changes in the Microbiome Associated With Transplantation", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Outside of stated age range.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to give informed consent"]}, {"trialId": "NCT03969927", "trialName": "User-friendliness of a Portable Driving Simulator", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (25.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of traumatic brain injury or any other neurological condition apart from stroke, PD, and MS."]}, {"trialId": "NCT06627127", "trialName": "A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects meeting any of the following criteria will be excluded from participation in this study:", "Patient has no overlapping conditions/medications with exclusion criterion: Major anatomical or functional abnormalities that would impair the ability of the electrode arrays to be positioned.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant comorbidities that contraindicate surgery or general anesthesia/DISE", "Patient has no overlapping conditions/medications with exclusion criterion: Significant tongue weakness", "Patient has no overlapping conditions/medications with exclusion criterion: Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia/DISE in the judgment of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior surgery or treatments that could compromise the placement and effectiveness of the electrode array systems:\n\n  * Airway cancer surgery or radiation,\n  * Mandible or maxilla surgery in the previous 3 years (not counting dental treatments),", "Patient has no overlapping conditions/medications with exclusion criterion: Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),", "Patient has no overlapping conditions/medications with exclusion criterion: Prior hypoglossal nerve stimulation device implantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently pregnant, or breastfeeding during the study period"]}, {"trialId": "NCT06441227", "trialName": "Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 55.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who suffer from any serious clinical diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease or medical history that can interfere with the test results or any significant laboratory abnormality that is judged by researchers to be of clinical significance.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of malignant tumors.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have taken any prescription drugs, over-the-counter drugs and Chinese herbs within 14 days before taking the study drug, or within 5 half-life of the drug at the time of screening; those who plan to take non-study drugs during the trial period.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have participated in the clinical trial of any drug or medical device within 3 months before screening, or have not been within 5 half-life of the drug before screening (when both standards are met, the standard shall be based on the long-term standard).", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects received siRNA in the past 12 months, or antisense oligonucleotide drugs in the past six months.", "Patient has no overlapping conditions/medications with exclusion criterion: The abnormal upper limit of hypersensitive C-reactive protein during the screening period is \\>1.5 times the normal upper limit, or the normal upper limit of prothrombin time/international standard ratio (PT/INR), activated partial thrombin time (aPTT) \\> 1.25 times normal upper limit.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening for infectious diseases during the screening period (including hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, syphilis spirochete antibody).", "Patient has no overlapping conditions/medications with exclusion criterion: 12-lead electrocardiogram abnormal and clinical significance, or electrocardiogram QT interval (QTcF) male \\> 450 ms, female \\> 470 ms.", "Patient has no overlapping conditions/medications with exclusion criterion: The total amount of blood donated or blood loss ≥ 200 mL within 1 month before administration, or the total amount of blood donation or blood loss ≥ 400 mL within 3 months before administration, or received blood transfusion within 8 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have a serious infection, serious trauma or major surgery within 3 months before administration; those who plan to undergo surgery within two weeks during and after the end of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Suspected people with a history of allergy to research drugs or any ingredients in research drugs, allergies or previous history of serious drug allergies.", "Patient has no overlapping conditions/medications with exclusion criterion: People who have had blood collection difficulties or cannot tolerate venous punctures in the past, such as needle fainting and blood fainting.", "Patient has no overlapping conditions/medications with exclusion criterion: Glomerular filtration rate (eGFR) is lower than GFR 60 mL/min/1.73 m2.", "Patient has no overlapping conditions/medications with exclusion criterion: Smoke an average of ≥ 5 cigarettes per day in the first three months of administration; the average daily intake of alcohol in the first month before administration exceeded 15 grams.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening and visiting drug screening test is positive or alcohol breath test is positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Other circumstances in which the researcher believes that the subject is not suitable to participate in this experiment."]}, {"trialId": "NCT05763927", "trialName": "Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have previously received immune checkpoint inhibitors;", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reactions to PD-1 monoclonal antibody active ingredients, TKI inhibitor-related ingredients or any excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with organ bleeding or bleeding tendency, except for rectal primary tumor bleeding (need investigator to assess the risk of bleeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: years or at the same time have a history of other malignant tumors, but cured skin basal cell carcinoma and cervical carcinoma in situ and thyroid;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled epilepsy, central nervous system disease or mental disorders, the investigator judged that their clinical severity may hinder the signing of informed consent or affect the patient 's compliance with oral drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically serious (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalent daily) or other immunosuppressive agents (including organ transplant recipients) within 2 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other interventional drug clinical trials within 4 weeks before the first dose;", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery or severe trauma within 4 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Serious infection (CTCAE greater than grade 2) within 4 weeks before the first dose of study drug,Such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging suggests active pulmonary inflammation, symptoms and signs of infection within 2 weeks before the first dose of study drug, or the need for oral or intravenous antibiotics (excluding prophylactic antibiotics);", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes); autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone, using stable doses of insulin type 1 diabetes can be included; but excluding vitiligo or recovered childhood asthma/allergy, without any intervention in adults;", "Patient has no overlapping conditions/medications with exclusion criterion: History of immunodeficiency, including positive HIV test, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Active pulmonary tuberculosis infection found by medical history or CT examination, Or patients with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or patients with a history of active pulmonary tuberculosis infection but without regular treatment 1 year before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with active hepatitis (HBV DNA ≥ 2000 IU/ml or 10000 copies/ml), hepatitis C (hepatitis C antibody positive,HCV-RNA was above the lower limit of detection of the assay);", "Patient has no overlapping conditions/medications with exclusion criterion: Had a known history of psychotropic drug abuse, alcoholism, or drug use;", "Patient has no overlapping conditions/medications with exclusion criterion: Had a history, illness, treatment, or laboratory abnormality that could interfere with the results of the trial, prevent the subject from participating throughout the study, or the investigator considered participation to be in the subject 's best interest."]}, {"trialId": "NCT05264727", "trialName": "Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (25.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05555576", "trialName": "Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Opioid use 1 month prior to the ED visit;", "Patient has no overlapping conditions/medications with exclusion criterion: Already taking vitamin C supplement;", "Patient has no overlapping conditions/medications with exclusion criterion: Active cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for chronic pain;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for opioid use disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to fill out diary or unavailable for follow-up;", "Patient has no overlapping conditions/medications with exclusion criterion: Any allergy, intolerance or sensitivity to milk (lactose) or morphine", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with cyclosporin or coumadin", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)"]}, {"trialId": "NCT04557527", "trialName": "Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to hyaluronate or. HEALON5® PRO OVD", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\nStudy eye:", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of proliferative vitreoretinopathy (PVR) or any tractional RD", "Patient has no overlapping conditions/medications with exclusion criterion: Previous vitreoretinal surgery, open-globe injury or endophthalmitis", "Patient has no overlapping conditions/medications with exclusion criterion: Aphakia", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current congenital cataract", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current suprachoroidal haemorrhage", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment", "Patient has no overlapping conditions/medications with exclusion criterion: Current intraocular inflammation other than mild cellular activity thought to be secondary to RD", "Patient has no overlapping conditions/medications with exclusion criterion: Current ocular or periocular infection other than blepharitis"]}, {"trialId": "NCT05427227", "trialName": "Prospectively Predict the Efficacy and Explore the Mechanism of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous systemic therapy for metastatic GI cancer\n\n  * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.\n  * Allergic constitution or allergic history to protium biologic product or any investigating agents.\n  * Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.\n  * Pregnancy or lactation period\n  * Other previous malignancy within 5 year, except non-melanoma skin cancer\n  * Legal incapacity"]}, {"trialId": "NCT05628376", "trialName": "TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:", "Patient has no overlapping conditions/medications with exclusion criterion: Positive margins, incomplete resection or insufficient nodal sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B/C:", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)"]}, {"trialId": "NCT04620876", "trialName": "Bimodal and Coaxial High Resolution Ophtalmic Imaging", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (1.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05757076", "trialName": "Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of secondary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy status (verbal)"]}, {"trialId": "NCT04838327", "trialName": "Rare Subtypes of Gastrointestinal Cancers", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions precluding translational blood sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Another concomitant cancer"]}, {"trialId": "NCT03344276", "trialName": "Assessing Neurocognition After Cerebrovascular Intervention", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: patients \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: patients with without compatibility for MRI", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring carotid stenting for reasons not related to long-standing stenosis", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study."]}, {"trialId": "NCT06186427", "trialName": "A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who cannot tolerate puncture biopsy or surgical contraindications;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have undergone radiotherapy and chemotherapy in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Individuals who are allergic to multiple drugs or foods;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who refuse nuclear medicine examinations;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who do not agree to sign an informed consent form and are unable or willing to follow up."]}, {"trialId": "NCT04695327", "trialName": "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled cardiac or vascular diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hepatic dysfunction, hepatitis or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: History of coagulation disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant, breastfeeding or intend to become pregnant.", "Patient has no overlapping conditions/medications with exclusion criterion: Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.", "Patient has no overlapping conditions/medications with exclusion criterion: Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol)."]}, {"trialId": "NCT06339827", "trialName": "ASk Questions in GYnecologic Oncology (ASQ-GYO)", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment discussion with a Gynecologic Oncologist"]}, {"trialId": "NCT03921827", "trialName": "External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (21.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with atrial fibrillation/ arrhythmias.", "Patient has no overlapping conditions/medications with exclusion criterion: Within 2 weeks of cardiac catheterization or arterial puncture at femoral puncture site.", "Patient has no overlapping conditions/medications with exclusion criterion: Decompensated heart failure , usually class 3 or 4", "Patient has no overlapping conditions/medications with exclusion criterion: LV EF \\<30%", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe AR", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent and uncontrolled hypertension (BP persistently \\>160/100 mmHg)", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding diathesis", "Patient has no overlapping conditions/medications with exclusion criterion: Active thrombophlebitis/ venous disease of lower limbs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe lower extremity vaso-occlusive disease", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a documented aortic aneurysm/ dissection requiring surgical repair", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy"]}, {"trialId": "NCT05312827", "trialName": "Training Intervention and Program of Support (TIPS): Fostering Family-centred Telehealth in Pediatric Rehabilitation", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03529227", "trialName": "Gazyva Infusion Reaction Investigation", "eligibilityCriteriaMet": ["Patient Age (29) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: The refusal of the patient to participate in the observational study and the withdrawal of informed consent that allow processing of personal data and data that refer to patient confidentiality."]}]}, {"patientId": "7a30894a-e796-7923-c099-0d9c275d49c1", "eligibleTrials": [{"trialId": "NCT06286527", "trialName": "Quality of Sexual Life of PrEP Users", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unwilling to participate"]}, {"trialId": "NCT04484727", "trialName": "\"Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs\"", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients under 18 years", "Patient has no overlapping conditions/medications with exclusion criterion: ASA 4 and above", "Patient has no overlapping conditions/medications with exclusion criterion: severe COPD/emphysema/heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: PEEP\\>16 and/or FiO2 \\>80%", "Patient has no overlapping conditions/medications with exclusion criterion: elevated intracranial pressure", "Patient has no overlapping conditions/medications with exclusion criterion: defect coagulation", "Patient has no overlapping conditions/medications with exclusion criterion: non-treated known or suspected pneumothorax"]}, {"trialId": "NCT03869476", "trialName": "Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 99.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a diagnosis of secondary myelofibrosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman;", "Patient has no overlapping conditions/medications with exclusion criterion: Person prived of liberty by judicial or administrative decision;", "Patient has no overlapping conditions/medications with exclusion criterion: Person subject to a legal protection measure;"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (15.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT05690776", "trialName": "PMCF Study on the Safety, Performance and Clinical Benefits Data of the Quattro X Broadband", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of infection;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient or immature bone;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient blood supply or previous infections which may hinder the healing process;", "Patient has no overlapping conditions/medications with exclusion criterion: Foreign body sensitivity;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant);", "Patient has no overlapping conditions/medications with exclusion criterion: The subject is unwilling or unable to give consent or to comply with the follow-up program;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject meets any contraindications of the appropriate Instruction for Use."]}, {"trialId": "NCT06100276", "trialName": "Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.", "Patient has no overlapping conditions/medications with exclusion criterion: Pathogenic repeat expansion in the C9orf72 gene", "Patient has no overlapping conditions/medications with exclusion criterion: Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications."]}, {"trialId": "NCT06027827", "trialName": "Impact of Lateral Bone Grafting With Intraoperative Fusion in ACDF on Clinical Outcomes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 60.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Drug or alcohol abusers; those with abnormal liver or kidney function unsuitable for surgery; those with cardiac insufficiency unsuitable for surgery; those with severe metabolic and endocrine diseases unsuitable for surgery; those with severe lung disorders such as asthma and abnormal lung function unsuitable for surgery; pregnant and breastfeeding women as well as those who are planning to become pregnant in the near future; those who have participated in other clinical trials within 3 months; and those who are not suitable for participation in the experiment in the opinion of the investigator."]}, {"trialId": "NCT06597227", "trialName": "Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  <!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL/min;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects."]}, {"trialId": "NCT05731427", "trialName": "Research on the Mechanism Affecting Progression of Bronchiectasis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05666076", "trialName": "Peng Block or Suprascapular Nerve Block for Postoperative Analgesia in Shoulder Artroscopy ?", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with deformity and pathology in the shoulder region", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with known local anesthetic allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with BMI\\>35", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with alcohol and substance addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with opioid addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who cannot perceive and evaluate pain, such as psychiatric illness, mental retardation"]}, {"trialId": "NCT05398627", "trialName": "Neurofeedback for Borderline Personality Disorder", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Current moderate or severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild alcohol or substance use would also interfere with the effects of the intervention.", "Patient has no overlapping conditions/medications with exclusion criterion: have a history of traumatic brain injury", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)", "Patient has no overlapping conditions/medications with exclusion criterion: are currently pregnant or breast feeding", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete questionnaires written in English", "Patient has no overlapping conditions/medications with exclusion criterion: current (within 3 weeks of testing) use of any antipsychotics, benzodiazepines, beta-blockers, or other medications (except SSRI antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. Inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population", "Patient has no overlapping conditions/medications with exclusion criterion: have a DSM-5 diagnosis of psychotic or organic mental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: have any eye problems or difficulties in corrected vision.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious suidicial ideation"]}, {"trialId": "NCT05626127", "trialName": "MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Accompanied with other primary malignant tumors;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies;", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete imaging or medical history data."]}, {"trialId": "NCT05780827", "trialName": "Analysis of Clinical Data of Patients With Temporomandibular Joint Disorder", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (12.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have received orthodontic treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of maxillofacial trauma", "Patient has no overlapping conditions/medications with exclusion criterion: Maternity", "Patient has no overlapping conditions/medications with exclusion criterion: Those who take any medicine for a long time", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases such as tumors, endocrine diseases, psychosocial diseases and immune diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Other persons who are unable to cooperate with the project by themselves, such as action barriers.\n\nControl group\n\nInclusion Criteria:\n\nSuffer from symptoms and signs of oral and maxillofacial dysfunction"]}, {"trialId": "NCT06191627", "trialName": "Patient Experience and Quality of Patch Testing on the Legs vs Back", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 89.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is 17 or younger", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or breastfeeding", "Patient has no overlapping conditions/medications with exclusion criterion: Specialized patch testing with low number of patches (less than 90)", "Patient has no overlapping conditions/medications with exclusion criterion: Rash that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Large tattoos that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Limited space on thighs or back due to body habitus", "Patient has no overlapping conditions/medications with exclusion criterion: Patient has specific needs necessitating use of the thighs or back (event, breastfeeding, etc.)"]}, {"trialId": "NCT05890027", "trialName": "Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who refuse to consent.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.", "Patient has no overlapping conditions/medications with exclusion criterion: Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors"]}, {"trialId": "NCT05004727", "trialName": "Multi-Center PAMPA Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;", "Patient has no overlapping conditions/medications with exclusion criterion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);", "Patient has no overlapping conditions/medications with exclusion criterion: RA seropositivity (mid-high RF/ACPA titers);", "Patient has no overlapping conditions/medications with exclusion criterion: Current active malignancy;", "Patient has no overlapping conditions/medications with exclusion criterion: History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to the study agent."]}, {"trialId": "NCT06001827", "trialName": "SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Planned index procedure to revise or repair an existing fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Target artery inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Target vein inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound", "Patient has no overlapping conditions/medications with exclusion criterion: Known central venous stenosis of at least 50% on the side of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a stent or a stent graft within the access circuit", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected active infection at the time of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Congestive heart failure NYHA class 4", "Patient has no overlapping conditions/medications with exclusion criterion: Prior steal on the side of surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Life expectancy less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo kidney transplant surgery within 6 months of enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo home hemodialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Unwillingness or inability to give consent and/or comply with the study follow up schedule", "Patient has no overlapping conditions/medications with exclusion criterion: Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study."]}, {"trialId": "NCT03947827", "trialName": "Minocycline as Adjunctive Treatment for Treatment Resistant Depression", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 substance use disorder within past 3 months, moderate or severe, based on SCID-5", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant major unstable medical illness", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or intent to become pregnant during study period", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of psychotic disorder, bipolar disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) within last year", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of borderline personality disorder (BPD)", "Patient has no overlapping conditions/medications with exclusion criterion: Possible or probable dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or current intolerance or contraindication to tetracyclines", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal readings in hematology, liver, or renal function tests", "Patient has no overlapping conditions/medications with exclusion criterion: Have Myasthenia Gravis", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant treatment with anticoagulants, diuretics, retinoids, ergot alkaloids, antacids containing aluminium/calcium/magnesium, bismuth and zinc salts, or quinapril"]}, {"trialId": "NCT03015727", "trialName": "Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: WHO type I squamous cell carcinoma or adenocarcinoma", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>65 or \\<18", "Patient has no overlapping conditions/medications with exclusion criterion: With a history of renal disease", "Patient has no overlapping conditions/medications with exclusion criterion: Prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Peripheral neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Emotional disturbance"]}, {"trialId": "NCT05814627", "trialName": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to any janus kinase (JAK) inhibitor.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD)."]}, {"trialId": "NCT05286827", "trialName": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05840276", "trialName": "Cryoneurolysis Prior to Total Knee Arthroplasty", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications against ibuprofen or paracetamol, for example previous gastric ulcer, or known renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\< 100 bil/l); or against treatment with morphine", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuropathic pain", "Patient has no overlapping conditions/medications with exclusion criterion: Previous recipient of cryoneurolysis for the knee", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with daily use of high dose opioid (\\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled serious disease (cancer, diabetes, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disease associated with reactions to cold, such as cryoglobulinemia, cold urticarial and Reynaud's syndrome."]}, {"trialId": "NCT06111027", "trialName": "Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Regular intake of benzodiazepines", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive impairment: score \\< 27 on Mini-mental state examination", "Patient has no overlapping conditions/medications with exclusion criterion: Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis"]}, {"trialId": "NCT05706376", "trialName": "An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (13.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Families with individuals with significant mental or physical impairments precluding their ability to participate in groups"]}, {"trialId": "NCT05809427", "trialName": "High Frequency Intraoral Ultrasound Probe for Early Diagnosis of Periodontal Diseases", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03460327", "trialName": "Bariatric Surgery and Pharmacokinetics of Candesartan", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Having previously undergone resections in the GI-tract"]}, {"trialId": "NCT04886427", "trialName": "Implementation of a Multidimensional Quality Model", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Do not understand Dutch"]}, {"trialId": "NCT06265727", "trialName": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active of uncontrolled CNS metastases", "Patient has no overlapping conditions/medications with exclusion criterion: History of solid tumors other than the diseases under study", "Patient has no overlapping conditions/medications with exclusion criterion: History of and/or current cardiovascular events or conditions in the previous 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing \\>/= Grade 2 neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Hemoglobin A1C (HbA1C) \\>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active ocular disease at baseline", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic severe liver disease or live cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study", "Patient has no overlapping conditions/medications with exclusion criterion: Other significant cormorbidities."]}, {"trialId": "NCT06527027", "trialName": "LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,", "Patient has no overlapping conditions/medications with exclusion criterion: inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant."]}, {"trialId": "NCT05133076", "trialName": "Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: E1. Involvement in any investigational drug or device study within 30 days prior to this study,\n\nE2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in the study),\n\nE3. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation upon investigator judgment,\n\nE4. Surgery planned within the whole study period,\n\nE5. Evidence of active medical diseases affecting bowel transit,\n\nE6. Antibiotic treatment intake within the last month prior the study start (V0),\n\nE7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are permitted,\n\nE8. Any history of drug addiction in the past five years,\n\nE9. Pregnant or lactating women or intending to become pregnant,\n\nE10. Unwilling to maintain food habits and current physical activity for the whole study duration,\n\nE11. With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,\n\nE12. Having a lifestyle deemed incompatible with the study according to the investigator including drug and alcohol abuse,\n\nE13. Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n\nE14. Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,\n\nE15. Presenting a psychological or linguistic incapability to sign the informed consent,\n\nE16. Impossible to contact in case of emergency."]}, {"trialId": "NCT05555927", "trialName": "Adjunctive Duration-doubled tDCS for the Treatment of Depressive Patients With Suicidal Ideation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Assessed through applying the Mini-International Neuropsychiatric Interview (MINI)15 by professional psychiatrists that diagnosed any other current or past psychiatric axis-I disorders (except MDD in the patients);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver and kidney diseases, active endocrine diseases or clinical symptoms. Severe cardiovascular disease, respiratory system disease, haematologic diseases and cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal laboratory examination that may influence the health of participants;", "Patient has no overlapping conditions/medications with exclusion criterion: A history of any aignificant medical illness such as neurological disorders (such as cerebral trauma, seizure disorder, etc);", "Patient has no overlapping conditions/medications with exclusion criterion: Known current psychosis as determined by the DSM-5 or a history of a non-mood psychotic disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol and drug abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal scalp such as open wounds;", "Patient has no overlapping conditions/medications with exclusion criterion: HAMD-17 item 3 (suicide) score=4;", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving modified electroconvulsive therapy (MECT) or repetitive transcranial magnetic stimulation (rTMS) in the past 1 month;", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial concurrently or no more than 1 month prior to randomisation."]}, {"trialId": "NCT06504927", "trialName": "Biomarker Discovery in Lung Cancer - Malaysia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (30.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is pregnant or lactating (self-declaration).", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is unwilling or unable to provide signed informed consent"]}, {"trialId": "NCT04998227", "trialName": "Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (20.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: cardiogenic shock, pregnancy, end-stage renal disease"]}, {"trialId": "NCT05377827", "trialName": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from study entry for any of the following:", "Patient has no overlapping conditions/medications with exclusion criterion: Received systemic anticancer therapy (including investigational therapy) or radiotherapy \\< 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:\n\n  * \\< 100 days post alloHCT\n  * \\< 6 weeks from prior donor leukocyte infusion\n  * Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.\n  * \\< 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with any anti-CD7 directed therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to one or more of the study agents.", "Patient has no overlapping conditions/medications with exclusion criterion: Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Confirmed HIV infection.", "Patient has no overlapping conditions/medications with exclusion criterion: History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic, uncontrolled hypotension."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT03150576", "trialName": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: T0 tumour in absence of axillary node \\>10mm.", "Patient has no overlapping conditions/medications with exclusion criterion: TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with myelodysplastic syndrome/acute myeloid leukaemia.", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of distant metastasis apparent prior to randomisation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled seizures.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breast feeding women.", "Patient has no overlapping conditions/medications with exclusion criterion: Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:\n\nEvidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.", "Patient has no overlapping conditions/medications with exclusion criterion: ECG with mean resting QTc \\>470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).", "Patient has no overlapping conditions/medications with exclusion criterion: Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable)."]}, {"trialId": "NCT06356376", "trialName": "The Effects of Pain and Pain Relief on Peripheral Nerve Excitability", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain conditions", "Patient has no overlapping conditions/medications with exclusion criterion: Neurological or Psychiatric disease", "Patient has no overlapping conditions/medications with exclusion criterion: Other major diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Pain medication within the last 24 hours"]}, {"trialId": "NCT05248776", "trialName": "Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a c-peptide value less than 0.5 nmol/l.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic, or non-peripheral vascular surgery within 6 months prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cardiac arrhythmia, systolic dysfunction, congestive heart failure, angina, myocardial ischemia or infarction, or stroke within 1 year prior to the study, or the presence of an abnormal ECG that, in the investigator's opinion, is clinically significant.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of drug abuse or a history of alcohol abuse within 2 years prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to basal cell or stage I squamous cell carcinoma of the skin.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase level above normal range for the testing laboratory, active liver disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a total bilirubin greater or equal 2 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is/ was lifetime on any insulin treatment or takes other diabetes treatment (except metformin).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of proteinuria ≥300 mg/day on a 12- or 24-hour urine collection within last year or an albumin/creatinine ratio greater or equal 300 μg/mg.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of any clinically significant retinopathy, which is defined as more than moderate nonproliferative diabetic retinopathy, any stage of proliferative diabetic retinopathy or any history of laser-treated retinopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has clinically significant peripheral or autonomic neuropathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of ulcerative colitis or Crohn's disease, or has undergone gastric resection.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of a psychiatric disorder that, in Principal Investigator opinion, will affect the subject ability to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of angioedema.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an acute, clinically significant illness within 30 days prior to the study or any other condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is not able to comply with the study scheduled visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is participating in another investigational study or has taken any investigational drug within 90 days prior to the study."]}, {"trialId": "NCT03269227", "trialName": "Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 85.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous thorax radiotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Chemotherapy is allowed but completed 3 weeks before RT starts", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial with any investigational agents within 30 days prior to study screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with M1 have to be excluded to this study", "Patient has no overlapping conditions/medications with exclusion criterion: FEV1 \\< 50", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>85 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Respiratory needing oxygen therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial pneumopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active pneumonitis", "Patient has no overlapping conditions/medications with exclusion criterion: Fissural disease", "Patient has no overlapping conditions/medications with exclusion criterion: Contralateral mediastinum involvement (N3) and M1", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."]}, {"trialId": "NCT06552676", "trialName": "riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure of the percutaneous tracheostomy technique or recourse to surgical tracheostomy"]}, {"trialId": "NCT01521676", "trialName": "Predictive Clinical and Biological Parameters in Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: emergency"]}, {"trialId": "NCT04030676", "trialName": "QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Wardship patient and curatorial patient", "Patient has no overlapping conditions/medications with exclusion criterion: Patient unable to understand or sign the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Colectomy total or partial"]}, {"trialId": "NCT04560127", "trialName": "Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Any active autoimmune disease or history of autoimmune disease and expected recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis); subjects with skin diseases that does no need systemic treatment, for example, leukoderma, psoriasis, alopecia, those with controlled type I diabetes by insulin or those with asthma that has been completely resolved in childhood and with no need of any intervention can be enrolled; while subjects with asthma who need bronchodilator for medical intervention cannot be enrolled.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of strong CYP3A4/CYP2C19 inducers, including rifampicin (and its analogues) and St. John's Wort, or strong CYP3A4/CYP2C19 inhibitors within two weeks prior to signing informed consent form.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with other immune checkpoint inhibitors (include PD-1 antibody or other immunotherapy against PD-1/PD-L1).", "Patient has no overlapping conditions/medications with exclusion criterion: Known history of serious allergy to any monoclonal antibody or Apatinib.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwilling to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current presence of metastasis to central nervous system.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia or complications of severe pneumonia; oral or intravenous therapeutic antibiotics within two weeks prior to the start of study treatment (for example, subjects who are given with preventive antibiotics for prevention of urinary tract infection or exacerbation of chronic obstructive pulmonary disease are eligible for participation in the study).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women.", "Patient has no overlapping conditions/medications with exclusion criterion: Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators, such as alcoholism, drug abuse, other serious diseases (including mental disorders) requiring concomitant therapy, with serious laboratory examination abnormality, with family or social factors, that may affect subject's safety."]}, {"trialId": "NCT05078476", "trialName": "Rehabilitation of Finger Flexor Tendon Injuries", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\< 18 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients", "Patient has no overlapping conditions/medications with exclusion criterion: Replantation of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Primary tendon reconstructions"]}, {"trialId": "NCT06087627", "trialName": "A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have been treated for more than 7 days with dupilumab", "Patient has no overlapping conditions/medications with exclusion criterion: Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."]}, {"trialId": "NCT04853576", "trialName": "A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (12.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Available 10/10 HLA-matched related donor", "Patient has no overlapping conditions/medications with exclusion criterion: Prior HSCT or contraindications to autologous HSCT", "Patient has no overlapping conditions/medications with exclusion criterion: Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to receive red blood cell (RBC) transfusion for any reason", "Patient has no overlapping conditions/medications with exclusion criterion: Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine", "Patient has no overlapping conditions/medications with exclusion criterion: Any history of severe cerebral vasculopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate end organ function", "Patient has no overlapping conditions/medications with exclusion criterion: Advanced liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior or current malignancy or immunodeficiency disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Immediate family member with a known or suspected Familial Cancer Syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined inclusion/exclusion criteria may apply"]}, {"trialId": "NCT01341327", "trialName": "Observational Study for Left Main Disease Treatment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Protected left main stenosis"]}, {"trialId": "NCT06337227", "trialName": "Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients for whom biological material cannot be recovered for study purposes;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who refuse to participate in the study"]}, {"trialId": "NCT06312176", "trialName": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Has breast cancer amenable to treatment with curative intent", "Patient has no overlapping conditions/medications with exclusion criterion: Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune disease that has required systemic treatment in the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy"]}, {"trialId": "NCT06061627", "trialName": "A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Valvular heart disease that requires or has undergone surgical intervention", "Patient has no overlapping conditions/medications with exclusion criterion: After mechanical tricuspid valve replacement", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or permanent atrial fibrillation or atrial flutter", "Patient has no overlapping conditions/medications with exclusion criterion: Second or third degree atrioventricular block", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of acute myocardial infarction within 3 months prior to enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Patient's expected survival time is less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or planned to conceive", "Patient has no overlapping conditions/medications with exclusion criterion: Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with simple and persistent left superior vena cava", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with existing pacemaker implantation"]}, {"trialId": "NCT02907827", "trialName": "Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\\< 6weken)", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia", "Patient has no overlapping conditions/medications with exclusion criterion: Metallic devices implanted such as hip prostheses, since this can alter the imaging quality"]}, {"trialId": "NCT06291727", "trialName": "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients scheduled for bilateral TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Revision TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)", "Patient has no overlapping conditions/medications with exclusion criterion: Workers' Compensation patient", "Patient has no overlapping conditions/medications with exclusion criterion: Type I Diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Type II Diabetes requiring insulin medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-operative narcotics use with the exception of tramadol.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal insufficiency (GFR \\< 60) that may impact post-operative protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive deficiencies that prevent the patient from providing their own informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Language barrier preventing completion of study forms in English"]}, {"trialId": "NCT05650827", "trialName": "Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\< 18", "Patient has no overlapping conditions/medications with exclusion criterion: Living outside the greater Copenhagen area", "Patient has no overlapping conditions/medications with exclusion criterion: Any other malignancy requiring active treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Not eligible for chemotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Performance status \\> 2", "Patient has no overlapping conditions/medications with exclusion criterion: Not able to swallow liquids", "Patient has no overlapping conditions/medications with exclusion criterion: Parenteral nutrition or enteral nutrition via feeding tube", "Patient has no overlapping conditions/medications with exclusion criterion: Physical or mental disabilities that prohibit execution of test or training procedures", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to understand the Danish language"]}, {"trialId": "NCT06319027", "trialName": "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05536427", "trialName": "Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with immunodeficiency or a history of autoimmune disorders (e.g., rheumatoid arthropathy, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe concurrent medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, serious infection and infectious disease, active peptic ulcer, presence of active hemorrhage, and severe organ failure;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Grade III or IV cardiac failure defined by the New York Heart Association (NYHA), epileptic seizure, and mechanical or paralytic ileus within 6 months prior to the first administration of the investigational drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received chemotherapy and hormonal therapy within 28 days prior to signing the informed consent forms, or are currently taking other investigational drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with lymphoma, leukemia, myelodysplastic syndrome (MDS), or myelosuppression;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with allergy or a history of hypersensitivity to human blood albumin, or a history of allergy or hypersensitivity to any investigational drug or its excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with chronic diseases requiring immunotherapy or hormonal therapy; and subjects currently receiving corticosteroids for other diseases (except those using topical or inhaled steroids);", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with mental or neurological disorders that are not easily controlled;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects infected with human immunodeficiency virus (commonly known as AIDS) or treponema pallidum (commonly known as syphilis);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of other malignant tumors within the last 5 years;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with prior allogeneic stem cell transplantation or solid organ transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of drug or alcohol abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with any irAE of ≥ Grade 3 following prior immunotherapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who, in the judgment of the investigator, are not suitable to participate in this clinical study (e.g., with poor compliance)."]}, {"trialId": "NCT06093776", "trialName": "Rib Fracture Cryoanalgesia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age Pregnant Incarcerated Confounding injuries or significant pain attributed to secondary injury Patients with any of the following: cryoglobulinemia; paroxysmal cold hemoglobinuria; cold urticarial; Raynaud's disease; open and/or infected wounds at or near the treatment site"]}, {"trialId": "NCT06146127", "trialName": "Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unequivocal histological features"]}, {"trialId": "NCT06330727", "trialName": "Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 59.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with diagnosis of diabetes, or taking anti-diabetic medication;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy, planned pregnancy, or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease)."]}, {"trialId": "NCT04855227", "trialName": "A Prospective Evaluation of Pain After Non-complex Ventral Hernia Repair", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is contraindicated for general anesthesia or surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a ventral hernia that will require retromuscular mesh placement or employ a technique, including (but not limited to) external oblique release, Rives- Stoppa, eTEP Rives-Stoppa, transversus abdominis release, other component separation techniques (i.e. anterior component separation) or eTEP transversus abdominis release.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a recurrent hernia.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will have an emergent hernia repair.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of chronic pain and/or taking daily pain medications for \\>6 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of substance abuse (excluding marijuana) and/or current (within 30 days) narcotic use.", "Patient has no overlapping conditions/medications with exclusion criterion: Current marijuana use that the subject is unwilling to discontinue within the 14 days prior to surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of MRSA infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with HbA1c level \\> 8.5%.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Exparel during the surgical procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will undergo a concomitant hernia repair or any other concomitant procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Current nicotine use (including vaping) within the past 30 days.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a known bleeding or clotting disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or suspected pregnancy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject belonging to other vulnerable population, e.g, prisoner or ward of the state.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is currently participating in another interventional or investigational research study."]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT06072976", "trialName": "The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (0.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Infant has already been on feeds", "Patient has no overlapping conditions/medications with exclusion criterion: Infants \\<34 weeks gestation", "Patient has no overlapping conditions/medications with exclusion criterion: Parents with contraindications to providing milk (i.e. drug use-cocaine, fentanyl, meth BUT oxy/suboxone/marijuana OK)", "Patient has no overlapping conditions/medications with exclusion criterion: Complicated gastroschisis", "Patient has no overlapping conditions/medications with exclusion criterion: Short gut syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Additional congenital anomalies that affect ability to tolerate milk (i.e. cyanotic congenital heart disease BUT kidney disease ok)"]}, {"trialId": "NCT05752227", "trialName": "Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pure pleural lesions.", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical instability to reach the final diagnosis.", "Patient has no overlapping conditions/medications with exclusion criterion: Inaccessibility by ultrasound."]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (4.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05364827", "trialName": "CT Coronary Angiography Prior to CTO PCI", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: CTO with J-CTO score\\<2", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate/degraded CTCA images", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant/lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe contrast allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to provide written informed consent"]}, {"trialId": "NCT05038527", "trialName": "ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: ASA ≥ 4", "Patient has no overlapping conditions/medications with exclusion criterion: Formally diagnosed with a disease affecting the bone metabolism or wound healing (severe osteoporosis, osteomalacia, Pagets disease, hyperparathyreoidism etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disseminated cancer diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to any of the i-FACTOR Peptide Enhanced Bone Graft ingredients", "Patient has no overlapping conditions/medications with exclusion criterion: Smoking, extensive alcohol use or abuse of hallucinating drugs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver or kidney disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or breastfeeding patients", "Patient has no overlapping conditions/medications with exclusion criterion: Patients estimated not to be able to understand the information sheet or patients, who do not consent to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe psychiatric diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Ongoing infections"]}, {"trialId": "NCT06200376", "trialName": "A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating, or plan to pregnant or give birth during the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;", "Patient has no overlapping conditions/medications with exclusion criterion: History of splenectomy or organ transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;", "Patient has no overlapping conditions/medications with exclusion criterion: Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of high risk cardiovascular disease, including but not limited to:\n\n    * Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);\n    * Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;\n    * Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;\n    * Rating of heart function as defined by the New York Heart Association (NYHA) standards\\>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;\n    * Left ventricular ejection fraction (LVEF) \\< the center lower limit. If no lower limit existed, LVEF\\<50%;\n    * Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);", "Patient has no overlapping conditions/medications with exclusion criterion: History of another malignant tumor, except the following:\n\n    * Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;\n    * Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;\n    * Adequately treated carcinoma in situ without evidence of disease;", "Patient has no overlapping conditions/medications with exclusion criterion: Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Unexplained \\>38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment"]}, {"trialId": "NCT06040827", "trialName": "A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06144476", "trialName": "Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.", "Patient has no overlapping conditions/medications with exclusion criterion: Surgery within the preceding 6 weeks", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection", "Patient has no overlapping conditions/medications with exclusion criterion: Alcohol or recreational drug abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency requiring treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to read or write English", "Patient has no overlapping conditions/medications with exclusion criterion: Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study"]}, {"trialId": "NCT03317327", "trialName": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB and stage I prostate cancer considered not necessary to treat", "Patient has no overlapping conditions/medications with exclusion criterion: Disease suitable for curative salvage surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 4 weeks prior to first administration of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant cardiac, pulmonary or other medical illness that would limit activity or survival", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to any of the components of the investigational product", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who test positive for hepatitis B, C or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of immunosuppressive therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease that has required systemic therapy within the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: Any reason why, in the opinion of the investigator, the patient should not participate"]}, {"trialId": "NCT04257227", "trialName": "Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Documented brain lesions", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to remain still while sitting up (45 degrees) for the duration of therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold"]}, {"trialId": "NCT05601427", "trialName": "Intra-Operative Adductor Canal Blocks", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or refusal to sign informed consent form", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.", "Patient has no overlapping conditions/medications with exclusion criterion: Non-osteoarthritis primary diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to analgesic medications", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal and/or regional anaesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Any use of opioid pain medication within four weeks of the index procedure(13)", "Patient has no overlapping conditions/medications with exclusion criterion: Pain catastrophizing scale score ≥16 (8, 9, 14)", "Patient has no overlapping conditions/medications with exclusion criterion: History of cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: History renal insufficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History or sensory and/or motor neuropathy to the ipsilateral limb", "Patient has no overlapping conditions/medications with exclusion criterion: Simultaneous, bilateral TKA", "Patient has no overlapping conditions/medications with exclusion criterion: Non-TKA prosthesis", "Patient has no overlapping conditions/medications with exclusion criterion: Scheduled for non-SDD TKA.", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative varus/valgus of \\>10 degrees.", "Patient has no overlapping conditions/medications with exclusion criterion: Planned General Anaesthetic", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Intrathecal Morphine"]}, {"trialId": "NCT03072927", "trialName": "MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (13.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT06585527", "trialName": "Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with encephalitis disease, multiple sclerosis, or other CNS (Central Nervous System) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of organ transplantation or waiting for organ transplantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled infectious diseases or other serious diseases, such as HIV positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with any unstable systemic illness (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris beginning within the last 3 months, congestive heart failure, myocardial infarction occurring within 12 months before enrollment, severe arrhythmia requiring medical treatment, liver or kidney failure, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with systemic autoimmune diseases or immunodeficiency diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe allergic constitution.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases requiring long-term treatment with immune agents or glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with mental disorders."]}, {"trialId": "NCT05956327", "trialName": "Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Lack of reliability and sanity (examined by an independent psychiatrist)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive urine drug screen for illicit drugs (except benzodiazepines)", "Patient has no overlapping conditions/medications with exclusion criterion: Acute suicide risk", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant psychiatric axis-I disorders according to the diagnostic testing procedure (Mini International Neuropsychiatric Interview, MINI)", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant neurological or other disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation"]}, {"trialId": "NCT03916627", "trialName": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with metastatic disease for whom the intent of surgery would not be curative", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 1 year", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply"]}, {"trialId": "NCT03712527", "trialName": "Intra-discal Injection of PRP for Low Back Pain", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 60.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: - Patient with Modic 1 discopathy in different vertebral levels", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a Modic I signal abnormality related to a static spinal disorder (such as previous vertebral fractures, or isthmic lysis, or spondyloarthritis)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a history of lumbar spine surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with suspected spondylodiscitis or other infection", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under anticoagulant or antiaggregant therapy, or with a coagulation disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with allergy to iodine or to any of the components of Xylocaine", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to MRI: Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with anatomical difficulty of access to the injection area (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with an uncontrolled severe disease (i.e. heart, pulmonary, gastro-intestinal, neurologic, endocrine, auto-immune affections) limiting the patient's safety (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with previous malignancy less than 5 years (except for non-melanoma skin cancer)", "Patient has no overlapping conditions/medications with exclusion criterion: Prior to the screening visit:", "Patient has no overlapping conditions/medications with exclusion criterion: a current and recent use of morphine (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: a systemic or local corticosteroid therapy (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: Porphyria", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with sphincter disorders indicating a cauda equina syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Psychotic state not controlled by a treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (βHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age", "Patient has no overlapping conditions/medications with exclusion criterion: Vulnerable persons protected by law", "Patient has no overlapping conditions/medications with exclusion criterion: Persons under guardianship", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who are in a dependency or employment with the sponsor or the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Subject unable to read or/and write"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT04519476", "trialName": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n  1. Has received selinexor or another XPO1 inhibitor previously.\n  2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \\>5 years previously and without evidence of recurrence will be allowed.\n  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \\[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\\], primary amyloidosis, etc.) that is likely to interfere with study procedures.\n  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.\n  6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.\n  7. Concurrent use of other anti-cancer agents or treatments.\n  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\n  9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin\n  10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n  11. Pregnant or breastfeeding females.\n  12. BSA \\<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.\n  13. Life expectancy of less than 3 months.\n  14. Major surgery within 4 weeks prior to C1D1.\n  15. Active, unstable cardiovascular function, as indicated by the presence of:\n\n  1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.\n\n  18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.\n\n  19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).\n\n  20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n\n  21. Contraindication to any of the required concomitant drugs or supportive treatments.\n\n  22. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT06508827", "trialName": "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemoglobinopathies", "Patient has no overlapping conditions/medications with exclusion criterion: Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemochromatosis", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating female adults", "Patient has no overlapping conditions/medications with exclusion criterion: Active infections which in research teams' opinion increases risk for toxicities", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures."]}, {"trialId": "NCT05900427", "trialName": "Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Ages: \\<18 and \\>90", "Patient has no overlapping conditions/medications with exclusion criterion: Weight \\< 60 kg", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple surgeries during one hospital stay", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or any contraindication to local anesthetics used in trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindicated for use of liposomal bupivacaine", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver/kidney disease", "Patient has no overlapping conditions/medications with exclusion criterion: Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who received another local anesthetic block prior to the interscalene block.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to consent in English"]}, {"trialId": "NCT05422027", "trialName": "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who meet any of the following criteria will not be enrolled:\n\n  1. Plasma cell leukemia.\n  2. Documented active amyloidosis.\n  3. Involvement of the central nervous system(CNS) by Multiple myeloma.\n  4. Prior exposure to a SINE compound, including ATG-010.\n  5. Currently, whether or not the patient is on medication, \\> Grade 2 peripheral neuropathy or ≥ Grade ≥ 2 painful neuropathy at baseline.\n  6. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and Selinexor (ATG-010) .\n  7. Active, unstable cardiovascular function, as indicated by the presence of:\n\n     1. Symptomatic ischemia, or\n     2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or\n     3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\<40%, or\n     4. Myocardial infarction within 6 months prior to C1D1.\n  8. Known positive serology for HIV or HIV seropositivity.\n  9. Known active hepatitis A, B, or C infection; eg. positive for HCV RNA or HBV-DNA.\n  10. Women who are pregnant or nursing.\n  11. Life expectancy of less than 6 months.\n  12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.\n  13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n  14. Contraindication to any of the required concomitant drugs or supportive treatments.\n  15. Has any concurrent diseases or complications that is likely to interfere with the study procedures.\n  16. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT05284227", "trialName": "Artificial Intelligence-augmented Perioperative Clinical Decision Support", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT06049927", "trialName": "A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (6.0, 35.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from seasonal influenza in the past 6 moths;", "Patient has no overlapping conditions/medications with exclusion criterion: Axillary temperature \\>37.0°C;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma;", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;", "Patient has no overlapping conditions/medications with exclusion criterion: Severe chronic diseases(Such as down syndrome, diabetes, sickle cell anaemia or neurological disorders);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease (such as systemic lupus erythematosus) or immunodeficiency / immunosuppression (such as HIV, after organ transplantation)", "Patient has no overlapping conditions/medications with exclusion criterion: Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;", "Patient has no overlapping conditions/medications with exclusion criterion: Continuous use of corticosteroids or other immunosuppressive agents for ≥ 14 days within the past 6 months (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) and cytotoxic therapy in the past 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Acute diseases or acute exacerbation of chronic diseases in the past 3 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of blood products within in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of other investigational drugs in the past 30 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of attenuated live vaccines in the past 14 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of inactivated or subunit vaccines in the past 7 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other clinical trials before enrollment and in the follow-up period, or plans to participate in other clinical trials during the clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial"]}, {"trialId": "NCT05057676", "trialName": "Autoimmune Intervention Mastery Course Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04772027", "trialName": "Motor Parameters in Patients With Limb Girdle Muscular Dystrophy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: § For all:", "Patient has no overlapping conditions/medications with exclusion criterion: Without associated neuromuscular disorders such as respiratory or muscular-squeletic diseases, apart from the consequences of dystrophy;", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to the tests;", "Patient has no overlapping conditions/medications with exclusion criterion: Noncontrol cardiac rhythm disorders;", "Patient has no overlapping conditions/medications with exclusion criterion: Lying down position intolerance due to severe respiratory troubles;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman."]}, {"trialId": "NCT05159427", "trialName": "Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to independently provide an informed consent for themselves or mentally incapacitated.", "Patient has no overlapping conditions/medications with exclusion criterion: Physical disability (including blindness or deafness) that requires special arrangements.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant clinical illness, including cardiovascular disease, neurological disease, organ failure, or malignancy in the opinion of the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Any surgical procedure within 3 weeks prior to screening", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of severe seasonal allergies or severe allergic diseases including drug allergies, food allergies and allergy against the SmartPill® device", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to any of the study drugs or the products' excipients", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Sulfonamide derivatives", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Lidocaine", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of XIFAXAN", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to acrylate or methacrylate, commonly used components of medical adhesives", "Patient has no overlapping conditions/medications with exclusion criterion: Any other factor, condition, or disease, including, but not limited to, cardiovascular, respiratory, hematological, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the patient, alter drug absorption and pharmacokinetics or impact the validity of the study results.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Type 1 Diabetes Mellitus (DM), diabetic ketoacidosis, with or without coma", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Glucose 6-phosphate dehydrogenase (G6PD) deficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of drug addiction or alcohol abuse within the past 12 months.", "Patient has no overlapping conditions/medications with exclusion criterion: History of significant psychiatric or neurological illness, including seizure disorders.", "Patient has no overlapping conditions/medications with exclusion criterion: Any medical or surgical conditions which might significantly interfere with the functions of gastrointestinal tract (e.g., gastric/intestinal bypass surgeries, fistulas, strictures, stenosis, or physiological/mechanical obstruction of the G.I tract, gastric bezoars, irritable bowel disease, crohn's disease, diverticulosis, or chronic narcotic use).", "Patient has no overlapping conditions/medications with exclusion criterion: History of dysphagia to liquids, food, or pills", "Patient has no overlapping conditions/medications with exclusion criterion: History of abdominal radiation therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating females", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal lab values during screening in the opinion of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of alcohol and/or nicotine containing products 48 hours prior to dosing visits, and throughout PK sampling visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any medications and/or supplements, prescriptions or over the counter 1 week prior to beginning the study, and throughout the study except for birth control with approved methods of contraception when used consistently and correctly (Implants (i.e. Implanon, Nexplanon), Injectables (i.e. Depo-Provera), Combined, Oral Contraceptives, Intrauterine Devices (IUD's) (i.e. Mirena, ParaGard), and Sexual Abstinence are accepted).", "Patient has no overlapping conditions/medications with exclusion criterion: Use of aspirin or any blood thinner medications.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteers unwilling or unable to take the proposed drugs or undergo G.I intubation", "Patient has no overlapping conditions/medications with exclusion criterion: Enrollment in a clinical trial in the past 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Current enrollment in a clinical trial with another study drug, vaccine or medical device", "Patient has no overlapping conditions/medications with exclusion criterion: Fasting blood glucose level \\< 80 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwillingness to fast for 19 hours.", "Patient has no overlapping conditions/medications with exclusion criterion: Blood donations in the past 8 weeks except for apheresis.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer shows a positive result of COVID-19 Antigen Rapid test in dosing visits", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having any of the following symptoms:\n\n    * Fever (over 100.4 oF or 38 oC) or feeling feverish\n    * New cough\n    * New shortness of breath", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having two of any of these symptoms:\n\n    * Chills\n    * Muscle aches\n    * New URI symptom(s) (runny nose, nasal congestion, and/or sore throat)\n    * New loss of sense of smell or sense of taste\n    * New headache", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has been in close contact in the last 14 days with someone recently diagnosed with COVID-19", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has returned from international travel within the past 10 days"]}, {"trialId": "NCT05525676", "trialName": "Relationship Checkups to Reduce Veteran Suicide Risk", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports severe intimate partner violence in the last year.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports experiencing suicidal intent requiring hospitalization.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER experiences past-month psychosis or mania.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years."]}, {"trialId": "NCT05763576", "trialName": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Healthy volunteers:", "Patient has no overlapping conditions/medications with exclusion criterion: History of any clinically significant disease", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant disease that could interfere with treatment or conduct of study", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)\n\nCHB participants:", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of liver cirrhosis or decompensated liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: History or suspicion of hepatocellular carcinoma (HCC)", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study."]}, {"trialId": "NCT05780476", "trialName": "A Novel VIRTUAL Reality Intervention for CAREgivers of People With Dementia (VirtualCare)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving daily assistance for more than 10 hours from formal CGs;", "Patient has no overlapping conditions/medications with exclusion criterion: Being formal CGs (i.e., nurse or another paid figure);", "Patient has no overlapping conditions/medications with exclusion criterion: Being informal CGs of i) persons with moderate-to-severe AD, or ii) persons with non-AD diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Not having or being able to use a device connected to internet (e.g., smartphones or PC).", "Patient has no overlapping conditions/medications with exclusion criterion: Having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs.", "Patient has no overlapping conditions/medications with exclusion criterion: Only a family member for person with dementia is accepted.\n\nExclusion Criteria for experimental group (Psychoeducation + VR):", "Patient has no overlapping conditions/medications with exclusion criterion: Medical history of epilepsy.\n\nExclusion Criteria for subsample of caregivers assess with MRI:", "Patient has no overlapping conditions/medications with exclusion criterion: Metal implants, artificial prostheses, pace-makers, prosthetic heart valves;", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy."]}, {"trialId": "NCT03990727", "trialName": "Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (2.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: 1) Not willing to visit every year."]}, {"trialId": "NCT05721027", "trialName": "Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Not available for follow-up", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergic to or intolerant of investigational medications", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic steroid use", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney disease (GFR \\<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x the upper limit of normal)"]}, {"trialId": "NCT06550427", "trialName": "Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT04802876", "trialName": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior systemic anti-cancer therapy, including investigational agents within 2 weeks. Medical Monitor could consider shorter interval for kinase inhibitors or other short half-life drugs prior to allocation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants with ≤Grade 2 neuropathy may be eligible.\n\n   Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study treatment.\n\n   Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose of the previous investigational agent.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with thymoma are not eligible. Patients with active CNS metastases and/or carcinomatous meningitis are not eligible. Subjects with up to three cerebral metastases are eligible, if all lesions are stable and have been definitively treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any of its excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior allogeneic stem cell transplantation or organ transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history of interstitial lung disease, (non-infectious) pneumonitis that required steroids or has current pneumonitis, uncontrolled lung including pulmonary fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Human Immunodeficiency Virus (HIV).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of active TBC (Bacillus Tuberculosis).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of trial treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with spartalizumab or tislelizumab. Highly effective contraception methods include:\n\n    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n    4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.\n\n    Notes:\n    * Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.\n    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.", "Patient has no overlapping conditions/medications with exclusion criterion: Sexually active males, unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with spartalizumab or tislelizumab should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen."]}, {"trialId": "NCT04816227", "trialName": "Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusing to participate in the study", "Patient has no overlapping conditions/medications with exclusion criterion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research", "Patient has no overlapping conditions/medications with exclusion criterion: Being pregnant or breastfeeding"]}, {"trialId": "NCT06187727", "trialName": "Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Mechanical complications;", "Patient has no overlapping conditions/medications with exclusion criterion: Cardiogenic shock;", "Patient has no overlapping conditions/medications with exclusion criterion: Experienced myocardial infarction within 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Aortic dissection;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included", "Patient has no overlapping conditions/medications with exclusion criterion: Urinary system infection"]}, {"trialId": "NCT04167527", "trialName": "Endovascular Therapy for Low NIHSS Ischemic Strokes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: NIHSS ≥6", "Patient has no overlapping conditions/medications with exclusion criterion: Any sign of intracranial hemorrhage on baseline CT/MR (SDH/SAH/ICH)", "Patient has no overlapping conditions/medications with exclusion criterion: Any imaging findings suggestive of futile recanalization in the judgment of the local investigator", "Patient has no overlapping conditions/medications with exclusion criterion: High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD", "Patient has no overlapping conditions/medications with exclusion criterion: Premorbid disability (mRS ≥3)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to randomize within 8 hours of last known well", "Patient has no overlapping conditions/medications with exclusion criterion: Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS", "Patient has no overlapping conditions/medications with exclusion criterion: Baseline blood glucose of \\<50 mg/dL (2.78 mmol) or \\>400 mg/dL (22.20 mmol)", "Patient has no overlapping conditions/medications with exclusion criterion: Known coagulation disorders as defined as platelet count \\<100,000/uL", "Patient has no overlapping conditions/medications with exclusion criterion: Known renal failure as defined as serum creatinine levels \\> 3.0 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Presumed septic embolus or suspicion of bacterial endocarditis", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another investigational treatment study in the previous 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Intubation and mechanical ventilation prior to study enrollment is medically indicated", "Patient has no overlapping conditions/medications with exclusion criterion: History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Site investigator does not have equipoise towards the ideal treatment concept (thrombectomy vs. best medical management)", "Patient has no overlapping conditions/medications with exclusion criterion: Known pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Prisoner or incarceration", "Patient has no overlapping conditions/medications with exclusion criterion: Known acute symptomatic COVID-19 infection"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT06218576", "trialName": "Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: age \\< 18 years"]}, {"trialId": "NCT03050476", "trialName": "Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (21.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Already on renal replacement therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic kidney disease defined as estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m2 \\[ CKD stage \\> 3 \\]", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Concurrent enrollment in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with ongoing infections or current use of steroids", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with high-risk emergency surgery or with follow-up procedures already planned at admission (like e.g. TEVAR)"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT05500027", "trialName": "sCD8, as a Novel Biomarker for Pancreatic Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 85.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusal to participate", "Patient has no overlapping conditions/medications with exclusion criterion: Age less than 18-year old and over 85-year old"]}, {"trialId": "NCT05755776", "trialName": "The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Men and women of childbearing potential who are unwilling to use an \"effective\" method of contraception as defined in the protocol during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have received a solid organ or bone marrow transplant", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or existing clinical liver failure (Child-Pugh score ≥ grade B)."]}, {"trialId": "NCT05887076", "trialName": "Postoperative Delirium After Kidney Transplantation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete data records of the parameters to be determined", "Patient has no overlapping conditions/medications with exclusion criterion: Underage Patients"]}, {"trialId": "NCT05272176", "trialName": "Veterans Coordinated Community Care (3C) Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired decision-making capacity", "Patient has no overlapping conditions/medications with exclusion criterion: Limited or no English language proficiency", "Patient has no overlapping conditions/medications with exclusion criterion: Terminal illness"]}, {"trialId": "NCT05968976", "trialName": "Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Legally incompetent adults;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous tremor-neurosurgery (e.g., DBS, thalamotomy);", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;", "Patient has no overlapping conditions/medications with exclusion criterion: Psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Current depression;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent."]}, {"trialId": "NCT06182527", "trialName": "Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: diabetes mellitus", "Patient has no overlapping conditions/medications with exclusion criterion: use of medication interfering with glucose metabolism (steroid, antidiabetic medications)", "Patient has no overlapping conditions/medications with exclusion criterion: surgery of upper GI-tract", "Patient has no overlapping conditions/medications with exclusion criterion: known plaster allergies", "Patient has no overlapping conditions/medications with exclusion criterion: any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion"]}, {"trialId": "NCT06222827", "trialName": "Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, any major comorbidities (diabetes mellitus, cancer, severe autoimmune diseases, chronic renal failure, articular diseases that restricts exercise or participation in study assessments in the physician's opinion...), a history of relevant drug or food allergies; history of cardiovascular, respiratory, central nervous system disease; neuromuscular diseases except FSHD (e.g., myopathy, neuropathy, neuromuscular junction disorders)", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who are on drug(s) or supplements that may affect muscle function, as determined by the treating physician must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Orthopedic conditions, such as unresolved fracture or arthrosis, interfering or precluding testing of muscle function", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to muscle MRI as per clinic standard practice", "Patient has no overlapping conditions/medications with exclusion criterion: Articular contracture limiting movements, scapular fixation or other surgeries, preceding or planned", "Patient has no overlapping conditions/medications with exclusion criterion: Any known hypersensitivity to satralizumab or any of its components and/or history of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of latent or active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection for at least 4 weeks prior to enrollment), active opportunistic or life-threatening infections", "Patient has no overlapping conditions/medications with exclusion criterion: History of diverticulitis or concurrent severe GI disorders (such as symptomatic diverticulosis) that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation. Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit (Visit 1, week 0)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody.", "Patient has no overlapping conditions/medications with exclusion criterion: Acute or chronic history of liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal laboratory results with: White blood cells (WBC) \\< 3.0x 10\\^9/L ; Absolute Neutrophils Counts (ANC)\\< 2.0x 10\\^9/L ; Platelet count \\< 10x10\\^4/µl ; Absolute lymphocyte count (ALC) \\< 0.8x 10\\^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 times the upper limit of normal (ULN)", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment (defined as a glomerular filtration rate of \\<30mL/min/1.73m²)", "Patient has no overlapping conditions/medications with exclusion criterion: Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation", "Patient has no overlapping conditions/medications with exclusion criterion: For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier \\[patient or partner\\] in conjunction with a spermicidal product, contraceptive pill, patch, injectable, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of another investigational product within 6 months or 5 half-lives (whichever is longer), or currently participating in a prospective study with an investigational product, whether it concerns an experimental drug or a medical device. Note: concurrent participation in natural history studies (non-drug, non-device studies) is not allowed during the course of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior treatment with any agent targeting the IL-6 inhibition pathway (e.g. tocilizumab, sarilumab), alemtuzumab treatment, total body irradiation, or bone marrow transplantation; treatment in the past 24 weeks with an anti-B-lymphocyte antigen CD20 (e.g. rituximab, ocrelizumab), eculizumab, anti-B-lymphocyte stimulator, or any other multiple sclerosis disease-modifying treatment; treatment in the past 2 years with an anti-T-cell surface glycoprotein CD4, cladribine, cyclophosphamide, or mitoxantrone; or treatment with any other investigational drug within 3 months prior to baseline. See section 4.4.4 for details on the vaccination and immunization.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject, or close relative of the subject, is the investigator or a coinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code."]}, {"trialId": "NCT05505227", "trialName": "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: currently prescribing buprenorphine at full capacity"]}, {"trialId": "NCT05782127", "trialName": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous diagnosis of:\n\n   * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)\n   * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: History of active malignancy within the past year prior to screening, with the exception of:\n\n   * Adequately treated carcinoma in situ of the uterine cervix\n   * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n   * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.\n\n   Patients with ongoing horomonotherapy could be included.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.", "Patient has no overlapping conditions/medications with exclusion criterion: Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.", "Patient has no overlapping conditions/medications with exclusion criterion: Received live attenuated vaccines prior to initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions that could interfere with drug absorption including short gut syndrome, dysphagia, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mmHg or diastolic BP \\> 100 mmHg) or has not been stable for at least 1 month prior to treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:\n\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Unstable angina or angina requiring surgical or medical intervention\n    * Significant cardiac arrhythmia\n    * And/or myocardial infarction", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is a pregnant or lactating female.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has known or suspected to have hypersensitivity to any of the components of the assigned study treatments.", "Patient has no overlapping conditions/medications with exclusion criterion: Positive test result(s) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B surface \\[HBs\\] antibody positive and anti-hepatitis B core \\[HBc\\] antibody negative) may participate.", "Patient has no overlapping conditions/medications with exclusion criterion: Absence of social security affiliation."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT06524427", "trialName": "Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with the previous history of other malignancies;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with secondary primary cancer when enrolled;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as pure ground glass opacity (GGO) before surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as mixed GGO whose solid part \\<= 50% and Maximum diameter of tumor \\<= 2cm;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with small cell lung cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with prior unilateral open thoracic surgical procedures;", "Patient has no overlapping conditions/medications with exclusion criterion: Woman who is pregnant or breastfeeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with an active bacterial or fungal infection that is difficult to control;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with serious psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months."]}, {"trialId": "NCT05537376", "trialName": "A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Veteran"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT05189327", "trialName": "Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient takes part in an interventional clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is unable to follow the schedule of the visits;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that the PI believes would prevent a study participant from participating in the study."]}, {"trialId": "NCT06447727", "trialName": "Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: After liver metastasis was diagnosed, the liver underwent external radiation therapy and transhepatic arterial chemoembolization", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with extrahepatic metastases", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe arrhythmia or heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: Other researchers considered it inappropriate to participate in this study"]}, {"trialId": "NCT06176027", "trialName": "Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women"]}, {"trialId": "NCT05775627", "trialName": "Sleep and Metabolism", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dietary restrictions\n\n   Participants must not have dietary restrictions that could systematically bias their macronutrient intake. The following will exclude participants from enrolling in the study based on their diet:\n   * Participants who choose not to or cannot consume dairy products (milk, yogurt, cheese, ice cream)", "Patient has no overlapping conditions/medications with exclusion criterion: Body Composition\n\n   A body mass index (BMI) of 18.5\\< \\[BMI\\] \\< 25 kg/m2 and a waist circumference \\<94/80cm.", "Patient has no overlapping conditions/medications with exclusion criterion: Psychiatric/psychological suitability\n\n   Each participant will undergo a structured interview (Mini International Neuropsychiatric Interview) with a qualified OHSU physician. This physician will supervise the administration and scoring of a Beck Depression Inventory II (BDI-II) questionnaire for each potential participant. The following will exclude individuals from participating based on their psychiatric or psychological evaluation:\n   * Individuals with evidence of psychopathology on the BDI-II, or in a structured clinical interview with the physician\n   * A history of severe psychiatric illnesses\n   * Alcoholism\n   * Drug dependency\n   * Major depression\n   * Manic depressive illness\n   * Schizophrenic disorders\n   * Panic disorder\n   * Generalized anxiety disorder\n   * Post-traumatic stress disorder\n   * Agoraphobia\n   * Claustrophobia\n   * Paranoid personality disorder\n   * Schizoid personality disorder\n   * Schizotypal personality disorder\n   * Borderline personality disorder\n   * Antisocial personality disorder.\n   * History of using antidepressant medication\n   * History of using neuroleptic medication\n   * History of using tranquilizers", "Patient has no overlapping conditions/medications with exclusion criterion: Drug/alcohol use\n\n   Volunteers must be drug-free (including caffeine, nicotine, alcohol and herbal medications) for the entire duration of the outpatient and in-laboratory study period, with no history of drug or alcohol dependency. All participants must be:\n   * Current non-smokers, and are required to have a history of less than 5 'pack years' of smoking", "Patient has no overlapping conditions/medications with exclusion criterion: Medication/drug use\n\n   Volunteers must not be taking any prescribed medications or over the counter medications, with an exception for birth control.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior shift work\n\n   For stability of endogenous circadian rhythmicity, volunteers must have no history of the following 1 year prior to the study:\n   * Working irregular day and night hours\n   * Regular night work\n   * Rotating shift work f\n   * Not have traveled more than 1 time zone during 3 months prior to the study", "Patient has no overlapping conditions/medications with exclusion criterion: Chronobiologic and sleep disorders\n\n   * Hypernychthemeral sleep/wake cycle\n   * Delayed sleep phase syndrome (wake time \\> 2 hours later than desired or habitually after 10:00 AM)\n   * Advanced sleep phase syndrome (wake time \\> 2 h earlier than desired or habitually before 5:00 AM)\n   * Narcolepsy\n   * Sleep apnea (apnea index \\>15)\n   * Insomnia (sleep complaint by history or polygraphically recorded sleep efficiency \\< 80%)\n   * Hypersomnia\n   * Periodic Limb Movement (PLMS) (PLMS index \\>15)\n   * Nocturnal Paroxysmal Dystonia\n   * REM-sleep behavior disorder\n   * Nocturnal Enuresis; (self-report and first night in the laboratory)\n   * Obstructive sleep apnea (apnea/hypopnea index \\>5/h as determined by at-home monitoring)\n   * The investigators will also exclude individuals with extreme chronotype using the Horne-Ostberg Morningness/Eveningness questionnaire (i.e., the Owl/Lark Questionnaire)", "Patient has no overlapping conditions/medications with exclusion criterion: Diseases of the Cardiovascular System\n\n   * Hypertension (systolic blood pressure \\> 140 or diastolic blood pressure \\> 90)\n   * Heart failure\n   * Cardiomyopathy\n   * Cor pulmonale\n   * Ischemic heart disease\n   * Valvular heart disease\n   * History of heart transplantation\n   * Cardiac tumors\n   * Pericardial disease", "Patient has no overlapping conditions/medications with exclusion criterion: Metabolic Syndrome\n\n   Following American Heart Association cutoffs, participants who have, in addition to abdominal fat (obese exclusion criteria), two or more of these factors will be excluded from the study:\n   * HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women\n   * Systolic blood pressure \\>135 mmHg or diastolic blood pressure \\>85 mmHg\n   * Fasting blood glucose ≥ 100 mg/dL\n   * Triglycerides ≥ 150 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-Diabetes/Diabetes\n\n    For participants who have a fasting blood glucose level of ≥ 100 mg/dL the investigators will measure hemoglobin A1c to exclude for diabetes (HbA1c\\>5.7%).", "Patient has no overlapping conditions/medications with exclusion criterion: Hypertension\n\n    An upper cut off of 140/90 mmHg during an office blood pressure measure will be used as an exclusion criterion. After 5 minutes of rest in a seated position, blood pressure will be measured 3 times, taken 1 minute apart. The average will be used to confirm eligibility criteria. Current or history of beta blocker use will also be exclusionary.", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Respiratory System\n\n    * Asthma\n    * Cystic fibroses\n    * Chronic bronchitis\n    * Emphysema\n    * Airway obstruction\n    * Interstitial lung diseases\n    * Pulmonary hypertension\n    * Lung neoplasms\n    * ARDS", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Kidney and Urinary Tract\n\n    * Acute or chronic renal failure\n    * History of renal transplantation\n    * Tubulointerstitial diseases of the kidney\n    * Urinary tract obstruction\n    * Tumors of the urinary tract", "Patient has no overlapping conditions/medications with exclusion criterion: Infectious Diseases\n\n    * Infective endocarditis\n    * HIV infection\n    * Sexually transmitted diseases \\[e.g., syphilis (including congenital syphilis and its sequelae), gonorrhea\\],\n    * Urinary tract infection\n    * Osteomyelitis\n    * Brucellosis\n    * Toxoplasmosis,\n    * Tuberculosis\n    * Leptospirosis\n    * Lyme disease\n    * Mononucleosis\n    * Hepatitis\n    * Parasitic infections such as malaria, toxoplasmosis, giardiasis, schistosomiasis, leishmaniasis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Gastrointestinal System\n\n    * Esophagitis\n    * Peptic ulcer and gastritis\n    * Neoplasms of the esophagus, stomach or bowel\n    * Disorders of absorption\n    * Inflammatory bowel disease\n    * Diseases of the small and large intestine\n    * Acute appendicitis\n    * Cirrhosis or neoplasms of the liver\n    * History of liver transplantation\n    * Diseases of the gallbladder and bile ducts\n    * Pancreatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Immune System, Connective Tissue and Joints\n\n    * AIDS\n    * Systemic lupus erythematosus\n    * Rheumatoid arthritis\n    * Scleroderma\n    * Ankylosing spondylitis\n    * Vasculitis\n    * Sarcoidosis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Hematopoietic System\n\n    * Anemia\n    * Leukemia\n    * Myeloproliferative diseases\n    * History of bone marrow transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Neoplastic Diseases\n\n    * Lymphoma\n    * Carcinoma\n    * Melanoma\n    * Any other neoplastic diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Endocrine and Metabolic Diseases\n\n    * Thyroid disease\n    * Addison's Disease\n    * Cushing's Syndrome\n    * Aldosteronism\n    * Hypoaldosteronism\n    * Pheochromocytoma\n    * Disorders of sexual differentiation that require hormone supplementation that may alter body weight\n    * Disorders of neuroendocrine regulation\n    * Diseases of the anterior pituitary and hypothalamus\n    * Hemochromatosis porphyria\n    * Wilson's Disease\n    * Glycogen storage diseases\n    * Diseases of the parathyroid gland\n    * Metabolic bone disease\n    * Disorders of phosphorus or magnesium metabolism\n    * Paget's Disease", "Patient has no overlapping conditions/medications with exclusion criterion: Neurologic Disorders\n\n    * Epilepsy and disorders of consciousness\n    * Dementia\n    * Amnesic disorders\n    * Neoplastic diseases of the central nervous system\n    * Demyelinating diseases\n    * Parkinson's Disease\n    * Muscular dystrophy\n    * Myasthenia gravis\n    * Periodic paralysis\n    * Dermatomyositis\n    * Polymyositis\n    * Infections of the nervous system\n    * Stroke\n    * History of transient ischemic attacks\n    * Hydrocephalus\n    * Tumors of the pituitary gland\n    * Pinealoma\n    * Intervertebral disc disease\n    * Ataxia\n    * Gilles de la Tourette Syndrome\n    * Huntington's Disease\n    * Tardive dyskinesia\n    * History of recurrent migraine headaches\n    * Neuromuscular disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects must not be currently participating in another research study that would influence their safe participation in our study. Subjects must not be participating in a research study in which they do the following:\n\n    * Ingest experimental medication\n    * Give blood samples"]}, {"trialId": "NCT04280627", "trialName": "Changes in the Microbiome Associated With Transplantation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Outside of stated age range.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to give informed consent"]}, {"trialId": "NCT03969927", "trialName": "User-friendliness of a Portable Driving Simulator", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (25.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of traumatic brain injury or any other neurological condition apart from stroke, PD, and MS."]}, {"trialId": "NCT06627127", "trialName": "A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects meeting any of the following criteria will be excluded from participation in this study:", "Patient has no overlapping conditions/medications with exclusion criterion: Major anatomical or functional abnormalities that would impair the ability of the electrode arrays to be positioned.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant comorbidities that contraindicate surgery or general anesthesia/DISE", "Patient has no overlapping conditions/medications with exclusion criterion: Significant tongue weakness", "Patient has no overlapping conditions/medications with exclusion criterion: Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia/DISE in the judgment of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior surgery or treatments that could compromise the placement and effectiveness of the electrode array systems:\n\n  * Airway cancer surgery or radiation,\n  * Mandible or maxilla surgery in the previous 3 years (not counting dental treatments),", "Patient has no overlapping conditions/medications with exclusion criterion: Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),", "Patient has no overlapping conditions/medications with exclusion criterion: Prior hypoglossal nerve stimulation device implantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently pregnant, or breastfeeding during the study period"]}, {"trialId": "NCT06441227", "trialName": "Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who suffer from any serious clinical diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease or medical history that can interfere with the test results or any significant laboratory abnormality that is judged by researchers to be of clinical significance.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of malignant tumors.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have taken any prescription drugs, over-the-counter drugs and Chinese herbs within 14 days before taking the study drug, or within 5 half-life of the drug at the time of screening; those who plan to take non-study drugs during the trial period.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have participated in the clinical trial of any drug or medical device within 3 months before screening, or have not been within 5 half-life of the drug before screening (when both standards are met, the standard shall be based on the long-term standard).", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects received siRNA in the past 12 months, or antisense oligonucleotide drugs in the past six months.", "Patient has no overlapping conditions/medications with exclusion criterion: The abnormal upper limit of hypersensitive C-reactive protein during the screening period is \\>1.5 times the normal upper limit, or the normal upper limit of prothrombin time/international standard ratio (PT/INR), activated partial thrombin time (aPTT) \\> 1.25 times normal upper limit.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening for infectious diseases during the screening period (including hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, syphilis spirochete antibody).", "Patient has no overlapping conditions/medications with exclusion criterion: 12-lead electrocardiogram abnormal and clinical significance, or electrocardiogram QT interval (QTcF) male \\> 450 ms, female \\> 470 ms.", "Patient has no overlapping conditions/medications with exclusion criterion: The total amount of blood donated or blood loss ≥ 200 mL within 1 month before administration, or the total amount of blood donation or blood loss ≥ 400 mL within 3 months before administration, or received blood transfusion within 8 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have a serious infection, serious trauma or major surgery within 3 months before administration; those who plan to undergo surgery within two weeks during and after the end of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Suspected people with a history of allergy to research drugs or any ingredients in research drugs, allergies or previous history of serious drug allergies.", "Patient has no overlapping conditions/medications with exclusion criterion: People who have had blood collection difficulties or cannot tolerate venous punctures in the past, such as needle fainting and blood fainting.", "Patient has no overlapping conditions/medications with exclusion criterion: Glomerular filtration rate (eGFR) is lower than GFR 60 mL/min/1.73 m2.", "Patient has no overlapping conditions/medications with exclusion criterion: Smoke an average of ≥ 5 cigarettes per day in the first three months of administration; the average daily intake of alcohol in the first month before administration exceeded 15 grams.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening and visiting drug screening test is positive or alcohol breath test is positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Other circumstances in which the researcher believes that the subject is not suitable to participate in this experiment."]}, {"trialId": "NCT05763927", "trialName": "Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have previously received immune checkpoint inhibitors;", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reactions to PD-1 monoclonal antibody active ingredients, TKI inhibitor-related ingredients or any excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with organ bleeding or bleeding tendency, except for rectal primary tumor bleeding (need investigator to assess the risk of bleeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: years or at the same time have a history of other malignant tumors, but cured skin basal cell carcinoma and cervical carcinoma in situ and thyroid;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled epilepsy, central nervous system disease or mental disorders, the investigator judged that their clinical severity may hinder the signing of informed consent or affect the patient 's compliance with oral drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically serious (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalent daily) or other immunosuppressive agents (including organ transplant recipients) within 2 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other interventional drug clinical trials within 4 weeks before the first dose;", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery or severe trauma within 4 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Serious infection (CTCAE greater than grade 2) within 4 weeks before the first dose of study drug,Such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging suggests active pulmonary inflammation, symptoms and signs of infection within 2 weeks before the first dose of study drug, or the need for oral or intravenous antibiotics (excluding prophylactic antibiotics);", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes); autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone, using stable doses of insulin type 1 diabetes can be included; but excluding vitiligo or recovered childhood asthma/allergy, without any intervention in adults;", "Patient has no overlapping conditions/medications with exclusion criterion: History of immunodeficiency, including positive HIV test, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Active pulmonary tuberculosis infection found by medical history or CT examination, Or patients with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or patients with a history of active pulmonary tuberculosis infection but without regular treatment 1 year before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with active hepatitis (HBV DNA ≥ 2000 IU/ml or 10000 copies/ml), hepatitis C (hepatitis C antibody positive,HCV-RNA was above the lower limit of detection of the assay);", "Patient has no overlapping conditions/medications with exclusion criterion: Had a known history of psychotropic drug abuse, alcoholism, or drug use;", "Patient has no overlapping conditions/medications with exclusion criterion: Had a history, illness, treatment, or laboratory abnormality that could interfere with the results of the trial, prevent the subject from participating throughout the study, or the investigator considered participation to be in the subject 's best interest."]}, {"trialId": "NCT05264727", "trialName": "Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (25.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05555576", "trialName": "Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Opioid use 1 month prior to the ED visit;", "Patient has no overlapping conditions/medications with exclusion criterion: Already taking vitamin C supplement;", "Patient has no overlapping conditions/medications with exclusion criterion: Active cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for chronic pain;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for opioid use disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to fill out diary or unavailable for follow-up;", "Patient has no overlapping conditions/medications with exclusion criterion: Any allergy, intolerance or sensitivity to milk (lactose) or morphine", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with cyclosporin or coumadin", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)"]}, {"trialId": "NCT04557527", "trialName": "Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to hyaluronate or. HEALON5® PRO OVD", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\nStudy eye:", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of proliferative vitreoretinopathy (PVR) or any tractional RD", "Patient has no overlapping conditions/medications with exclusion criterion: Previous vitreoretinal surgery, open-globe injury or endophthalmitis", "Patient has no overlapping conditions/medications with exclusion criterion: Aphakia", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current congenital cataract", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current suprachoroidal haemorrhage", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment", "Patient has no overlapping conditions/medications with exclusion criterion: Current intraocular inflammation other than mild cellular activity thought to be secondary to RD", "Patient has no overlapping conditions/medications with exclusion criterion: Current ocular or periocular infection other than blepharitis"]}, {"trialId": "NCT05427227", "trialName": "Prospectively Predict the Efficacy and Explore the Mechanism of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous systemic therapy for metastatic GI cancer\n\n  * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.\n  * Allergic constitution or allergic history to protium biologic product or any investigating agents.\n  * Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.\n  * Pregnancy or lactation period\n  * Other previous malignancy within 5 year, except non-melanoma skin cancer\n  * Legal incapacity"]}, {"trialId": "NCT05628376", "trialName": "TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:", "Patient has no overlapping conditions/medications with exclusion criterion: Positive margins, incomplete resection or insufficient nodal sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B/C:", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)"]}, {"trialId": "NCT04620876", "trialName": "Bimodal and Coaxial High Resolution Ophtalmic Imaging", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (1.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05757076", "trialName": "Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of secondary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy status (verbal)"]}, {"trialId": "NCT04838327", "trialName": "Rare Subtypes of Gastrointestinal Cancers", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions precluding translational blood sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Another concomitant cancer"]}, {"trialId": "NCT03344276", "trialName": "Assessing Neurocognition After Cerebrovascular Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: patients \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: patients with without compatibility for MRI", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring carotid stenting for reasons not related to long-standing stenosis", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study."]}, {"trialId": "NCT06186427", "trialName": "A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who cannot tolerate puncture biopsy or surgical contraindications;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have undergone radiotherapy and chemotherapy in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Individuals who are allergic to multiple drugs or foods;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who refuse nuclear medicine examinations;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who do not agree to sign an informed consent form and are unable or willing to follow up."]}, {"trialId": "NCT04695327", "trialName": "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled cardiac or vascular diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hepatic dysfunction, hepatitis or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: History of coagulation disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant, breastfeeding or intend to become pregnant.", "Patient has no overlapping conditions/medications with exclusion criterion: Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.", "Patient has no overlapping conditions/medications with exclusion criterion: Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol)."]}, {"trialId": "NCT06339827", "trialName": "ASk Questions in GYnecologic Oncology (ASQ-GYO)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment discussion with a Gynecologic Oncologist"]}, {"trialId": "NCT03921827", "trialName": "External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (21.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with atrial fibrillation/ arrhythmias.", "Patient has no overlapping conditions/medications with exclusion criterion: Within 2 weeks of cardiac catheterization or arterial puncture at femoral puncture site.", "Patient has no overlapping conditions/medications with exclusion criterion: Decompensated heart failure , usually class 3 or 4", "Patient has no overlapping conditions/medications with exclusion criterion: LV EF \\<30%", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe AR", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent and uncontrolled hypertension (BP persistently \\>160/100 mmHg)", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding diathesis", "Patient has no overlapping conditions/medications with exclusion criterion: Active thrombophlebitis/ venous disease of lower limbs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe lower extremity vaso-occlusive disease", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a documented aortic aneurysm/ dissection requiring surgical repair", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy"]}, {"trialId": "NCT05312827", "trialName": "Training Intervention and Program of Support (TIPS): Fostering Family-centred Telehealth in Pediatric Rehabilitation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03529227", "trialName": "Gazyva Infusion Reaction Investigation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: The refusal of the patient to participate in the observational study and the withdrawal of informed consent that allow processing of personal data and data that refer to patient confidentiality."]}]}, {"patientId": "8250f0c9-a533-d1c9-69fb-ec9096795ec3", "eligibleTrials": [{"trialId": "NCT06286527", "trialName": "Quality of Sexual Life of PrEP Users", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unwilling to participate"]}, {"trialId": "NCT04484727", "trialName": "\"Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs\"", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients under 18 years", "Patient has no overlapping conditions/medications with exclusion criterion: ASA 4 and above", "Patient has no overlapping conditions/medications with exclusion criterion: severe COPD/emphysema/heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: PEEP\\>16 and/or FiO2 \\>80%", "Patient has no overlapping conditions/medications with exclusion criterion: elevated intracranial pressure", "Patient has no overlapping conditions/medications with exclusion criterion: defect coagulation", "Patient has no overlapping conditions/medications with exclusion criterion: non-treated known or suspected pneumothorax"]}, {"trialId": "NCT03869476", "trialName": "Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 99.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a diagnosis of secondary myelofibrosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman;", "Patient has no overlapping conditions/medications with exclusion criterion: Person prived of liberty by judicial or administrative decision;", "Patient has no overlapping conditions/medications with exclusion criterion: Person subject to a legal protection measure;"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (15.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT05690776", "trialName": "PMCF Study on the Safety, Performance and Clinical Benefits Data of the Quattro X Broadband", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of infection;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient or immature bone;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient blood supply or previous infections which may hinder the healing process;", "Patient has no overlapping conditions/medications with exclusion criterion: Foreign body sensitivity;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant);", "Patient has no overlapping conditions/medications with exclusion criterion: The subject is unwilling or unable to give consent or to comply with the follow-up program;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject meets any contraindications of the appropriate Instruction for Use."]}, {"trialId": "NCT06100276", "trialName": "Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.", "Patient has no overlapping conditions/medications with exclusion criterion: Pathogenic repeat expansion in the C9orf72 gene", "Patient has no overlapping conditions/medications with exclusion criterion: Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications."]}, {"trialId": "NCT06027827", "trialName": "Impact of Lateral Bone Grafting With Intraoperative Fusion in ACDF on Clinical Outcomes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 60.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Drug or alcohol abusers; those with abnormal liver or kidney function unsuitable for surgery; those with cardiac insufficiency unsuitable for surgery; those with severe metabolic and endocrine diseases unsuitable for surgery; those with severe lung disorders such as asthma and abnormal lung function unsuitable for surgery; pregnant and breastfeeding women as well as those who are planning to become pregnant in the near future; those who have participated in other clinical trials within 3 months; and those who are not suitable for participation in the experiment in the opinion of the investigator."]}, {"trialId": "NCT06597227", "trialName": "Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  <!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL/min;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects."]}, {"trialId": "NCT05731427", "trialName": "Research on the Mechanism Affecting Progression of Bronchiectasis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05666076", "trialName": "Peng Block or Suprascapular Nerve Block for Postoperative Analgesia in Shoulder Artroscopy ?", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with deformity and pathology in the shoulder region", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with known local anesthetic allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with BMI\\>35", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with alcohol and substance addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with opioid addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who cannot perceive and evaluate pain, such as psychiatric illness, mental retardation"]}, {"trialId": "NCT05398627", "trialName": "Neurofeedback for Borderline Personality Disorder", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Current moderate or severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild alcohol or substance use would also interfere with the effects of the intervention.", "Patient has no overlapping conditions/medications with exclusion criterion: have a history of traumatic brain injury", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)", "Patient has no overlapping conditions/medications with exclusion criterion: are currently pregnant or breast feeding", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete questionnaires written in English", "Patient has no overlapping conditions/medications with exclusion criterion: current (within 3 weeks of testing) use of any antipsychotics, benzodiazepines, beta-blockers, or other medications (except SSRI antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. Inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population", "Patient has no overlapping conditions/medications with exclusion criterion: have a DSM-5 diagnosis of psychotic or organic mental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: have any eye problems or difficulties in corrected vision.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious suidicial ideation"]}, {"trialId": "NCT05626127", "trialName": "MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Accompanied with other primary malignant tumors;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies;", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete imaging or medical history data."]}, {"trialId": "NCT05780827", "trialName": "Analysis of Clinical Data of Patients With Temporomandibular Joint Disorder", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (12.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have received orthodontic treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of maxillofacial trauma", "Patient has no overlapping conditions/medications with exclusion criterion: Maternity", "Patient has no overlapping conditions/medications with exclusion criterion: Those who take any medicine for a long time", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases such as tumors, endocrine diseases, psychosocial diseases and immune diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Other persons who are unable to cooperate with the project by themselves, such as action barriers.\n\nControl group\n\nInclusion Criteria:\n\nSuffer from symptoms and signs of oral and maxillofacial dysfunction"]}, {"trialId": "NCT06191627", "trialName": "Patient Experience and Quality of Patch Testing on the Legs vs Back", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 89.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is 17 or younger", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or breastfeeding", "Patient has no overlapping conditions/medications with exclusion criterion: Specialized patch testing with low number of patches (less than 90)", "Patient has no overlapping conditions/medications with exclusion criterion: Rash that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Large tattoos that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Limited space on thighs or back due to body habitus", "Patient has no overlapping conditions/medications with exclusion criterion: Patient has specific needs necessitating use of the thighs or back (event, breastfeeding, etc.)"]}, {"trialId": "NCT05890027", "trialName": "Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who refuse to consent.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.", "Patient has no overlapping conditions/medications with exclusion criterion: Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors"]}, {"trialId": "NCT05004727", "trialName": "Multi-Center PAMPA Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;", "Patient has no overlapping conditions/medications with exclusion criterion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);", "Patient has no overlapping conditions/medications with exclusion criterion: RA seropositivity (mid-high RF/ACPA titers);", "Patient has no overlapping conditions/medications with exclusion criterion: Current active malignancy;", "Patient has no overlapping conditions/medications with exclusion criterion: History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to the study agent."]}, {"trialId": "NCT06001827", "trialName": "SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Planned index procedure to revise or repair an existing fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Target artery inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Target vein inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound", "Patient has no overlapping conditions/medications with exclusion criterion: Known central venous stenosis of at least 50% on the side of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a stent or a stent graft within the access circuit", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected active infection at the time of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Congestive heart failure NYHA class 4", "Patient has no overlapping conditions/medications with exclusion criterion: Prior steal on the side of surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Life expectancy less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo kidney transplant surgery within 6 months of enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo home hemodialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Unwillingness or inability to give consent and/or comply with the study follow up schedule", "Patient has no overlapping conditions/medications with exclusion criterion: Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study."]}, {"trialId": "NCT03947827", "trialName": "Minocycline as Adjunctive Treatment for Treatment Resistant Depression", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 substance use disorder within past 3 months, moderate or severe, based on SCID-5", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant major unstable medical illness", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or intent to become pregnant during study period", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of psychotic disorder, bipolar disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) within last year", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of borderline personality disorder (BPD)", "Patient has no overlapping conditions/medications with exclusion criterion: Possible or probable dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or current intolerance or contraindication to tetracyclines", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal readings in hematology, liver, or renal function tests", "Patient has no overlapping conditions/medications with exclusion criterion: Have Myasthenia Gravis", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant treatment with anticoagulants, diuretics, retinoids, ergot alkaloids, antacids containing aluminium/calcium/magnesium, bismuth and zinc salts, or quinapril"]}, {"trialId": "NCT03015727", "trialName": "Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: WHO type I squamous cell carcinoma or adenocarcinoma", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>65 or \\<18", "Patient has no overlapping conditions/medications with exclusion criterion: With a history of renal disease", "Patient has no overlapping conditions/medications with exclusion criterion: Prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Peripheral neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Emotional disturbance"]}, {"trialId": "NCT05814627", "trialName": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to any janus kinase (JAK) inhibitor.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD)."]}, {"trialId": "NCT05286827", "trialName": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05840276", "trialName": "Cryoneurolysis Prior to Total Knee Arthroplasty", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications against ibuprofen or paracetamol, for example previous gastric ulcer, or known renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\< 100 bil/l); or against treatment with morphine", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuropathic pain", "Patient has no overlapping conditions/medications with exclusion criterion: Previous recipient of cryoneurolysis for the knee", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with daily use of high dose opioid (\\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled serious disease (cancer, diabetes, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disease associated with reactions to cold, such as cryoglobulinemia, cold urticarial and Reynaud's syndrome."]}, {"trialId": "NCT06111027", "trialName": "Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Regular intake of benzodiazepines", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive impairment: score \\< 27 on Mini-mental state examination", "Patient has no overlapping conditions/medications with exclusion criterion: Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis"]}, {"trialId": "NCT05706376", "trialName": "An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (13.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Families with individuals with significant mental or physical impairments precluding their ability to participate in groups"]}, {"trialId": "NCT05809427", "trialName": "High Frequency Intraoral Ultrasound Probe for Early Diagnosis of Periodontal Diseases", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03460327", "trialName": "Bariatric Surgery and Pharmacokinetics of Candesartan", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Having previously undergone resections in the GI-tract"]}, {"trialId": "NCT04886427", "trialName": "Implementation of a Multidimensional Quality Model", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Do not understand Dutch"]}, {"trialId": "NCT06265727", "trialName": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active of uncontrolled CNS metastases", "Patient has no overlapping conditions/medications with exclusion criterion: History of solid tumors other than the diseases under study", "Patient has no overlapping conditions/medications with exclusion criterion: History of and/or current cardiovascular events or conditions in the previous 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing \\>/= Grade 2 neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Hemoglobin A1C (HbA1C) \\>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active ocular disease at baseline", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic severe liver disease or live cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study", "Patient has no overlapping conditions/medications with exclusion criterion: Other significant cormorbidities."]}, {"trialId": "NCT06527027", "trialName": "LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,", "Patient has no overlapping conditions/medications with exclusion criterion: inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant."]}, {"trialId": "NCT05133076", "trialName": "Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: E1. Involvement in any investigational drug or device study within 30 days prior to this study,\n\nE2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in the study),\n\nE3. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation upon investigator judgment,\n\nE4. Surgery planned within the whole study period,\n\nE5. Evidence of active medical diseases affecting bowel transit,\n\nE6. Antibiotic treatment intake within the last month prior the study start (V0),\n\nE7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are permitted,\n\nE8. Any history of drug addiction in the past five years,\n\nE9. Pregnant or lactating women or intending to become pregnant,\n\nE10. Unwilling to maintain food habits and current physical activity for the whole study duration,\n\nE11. With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,\n\nE12. Having a lifestyle deemed incompatible with the study according to the investigator including drug and alcohol abuse,\n\nE13. Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n\nE14. Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,\n\nE15. Presenting a psychological or linguistic incapability to sign the informed consent,\n\nE16. Impossible to contact in case of emergency."]}, {"trialId": "NCT05555927", "trialName": "Adjunctive Duration-doubled tDCS for the Treatment of Depressive Patients With Suicidal Ideation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Assessed through applying the Mini-International Neuropsychiatric Interview (MINI)15 by professional psychiatrists that diagnosed any other current or past psychiatric axis-I disorders (except MDD in the patients);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver and kidney diseases, active endocrine diseases or clinical symptoms. Severe cardiovascular disease, respiratory system disease, haematologic diseases and cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal laboratory examination that may influence the health of participants;", "Patient has no overlapping conditions/medications with exclusion criterion: A history of any aignificant medical illness such as neurological disorders (such as cerebral trauma, seizure disorder, etc);", "Patient has no overlapping conditions/medications with exclusion criterion: Known current psychosis as determined by the DSM-5 or a history of a non-mood psychotic disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol and drug abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal scalp such as open wounds;", "Patient has no overlapping conditions/medications with exclusion criterion: HAMD-17 item 3 (suicide) score=4;", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving modified electroconvulsive therapy (MECT) or repetitive transcranial magnetic stimulation (rTMS) in the past 1 month;", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial concurrently or no more than 1 month prior to randomisation."]}, {"trialId": "NCT06504927", "trialName": "Biomarker Discovery in Lung Cancer - Malaysia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (30.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is pregnant or lactating (self-declaration).", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is unwilling or unable to provide signed informed consent"]}, {"trialId": "NCT04998227", "trialName": "Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (20.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: cardiogenic shock, pregnancy, end-stage renal disease"]}, {"trialId": "NCT05377827", "trialName": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from study entry for any of the following:", "Patient has no overlapping conditions/medications with exclusion criterion: Received systemic anticancer therapy (including investigational therapy) or radiotherapy \\< 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:\n\n  * \\< 100 days post alloHCT\n  * \\< 6 weeks from prior donor leukocyte infusion\n  * Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.\n  * \\< 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with any anti-CD7 directed therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to one or more of the study agents.", "Patient has no overlapping conditions/medications with exclusion criterion: Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Confirmed HIV infection.", "Patient has no overlapping conditions/medications with exclusion criterion: History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic, uncontrolled hypotension."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT03150576", "trialName": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: T0 tumour in absence of axillary node \\>10mm.", "Patient has no overlapping conditions/medications with exclusion criterion: TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with myelodysplastic syndrome/acute myeloid leukaemia.", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of distant metastasis apparent prior to randomisation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled seizures.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breast feeding women.", "Patient has no overlapping conditions/medications with exclusion criterion: Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:\n\nEvidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.", "Patient has no overlapping conditions/medications with exclusion criterion: ECG with mean resting QTc \\>470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).", "Patient has no overlapping conditions/medications with exclusion criterion: Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable)."]}, {"trialId": "NCT06356376", "trialName": "The Effects of Pain and Pain Relief on Peripheral Nerve Excitability", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain conditions", "Patient has no overlapping conditions/medications with exclusion criterion: Neurological or Psychiatric disease", "Patient has no overlapping conditions/medications with exclusion criterion: Other major diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Pain medication within the last 24 hours"]}, {"trialId": "NCT05248776", "trialName": "Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a c-peptide value less than 0.5 nmol/l.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic, or non-peripheral vascular surgery within 6 months prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cardiac arrhythmia, systolic dysfunction, congestive heart failure, angina, myocardial ischemia or infarction, or stroke within 1 year prior to the study, or the presence of an abnormal ECG that, in the investigator's opinion, is clinically significant.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of drug abuse or a history of alcohol abuse within 2 years prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to basal cell or stage I squamous cell carcinoma of the skin.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase level above normal range for the testing laboratory, active liver disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a total bilirubin greater or equal 2 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is/ was lifetime on any insulin treatment or takes other diabetes treatment (except metformin).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of proteinuria ≥300 mg/day on a 12- or 24-hour urine collection within last year or an albumin/creatinine ratio greater or equal 300 μg/mg.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of any clinically significant retinopathy, which is defined as more than moderate nonproliferative diabetic retinopathy, any stage of proliferative diabetic retinopathy or any history of laser-treated retinopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has clinically significant peripheral or autonomic neuropathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of ulcerative colitis or Crohn's disease, or has undergone gastric resection.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of a psychiatric disorder that, in Principal Investigator opinion, will affect the subject ability to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of angioedema.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an acute, clinically significant illness within 30 days prior to the study or any other condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is not able to comply with the study scheduled visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is participating in another investigational study or has taken any investigational drug within 90 days prior to the study."]}, {"trialId": "NCT03269227", "trialName": "Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 85.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous thorax radiotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Chemotherapy is allowed but completed 3 weeks before RT starts", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial with any investigational agents within 30 days prior to study screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with M1 have to be excluded to this study", "Patient has no overlapping conditions/medications with exclusion criterion: FEV1 \\< 50", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>85 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Respiratory needing oxygen therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial pneumopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active pneumonitis", "Patient has no overlapping conditions/medications with exclusion criterion: Fissural disease", "Patient has no overlapping conditions/medications with exclusion criterion: Contralateral mediastinum involvement (N3) and M1", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."]}, {"trialId": "NCT06552676", "trialName": "riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure of the percutaneous tracheostomy technique or recourse to surgical tracheostomy"]}, {"trialId": "NCT01521676", "trialName": "Predictive Clinical and Biological Parameters in Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: emergency"]}, {"trialId": "NCT04030676", "trialName": "QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Wardship patient and curatorial patient", "Patient has no overlapping conditions/medications with exclusion criterion: Patient unable to understand or sign the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Colectomy total or partial"]}, {"trialId": "NCT04560127", "trialName": "Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Any active autoimmune disease or history of autoimmune disease and expected recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis); subjects with skin diseases that does no need systemic treatment, for example, leukoderma, psoriasis, alopecia, those with controlled type I diabetes by insulin or those with asthma that has been completely resolved in childhood and with no need of any intervention can be enrolled; while subjects with asthma who need bronchodilator for medical intervention cannot be enrolled.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of strong CYP3A4/CYP2C19 inducers, including rifampicin (and its analogues) and St. John's Wort, or strong CYP3A4/CYP2C19 inhibitors within two weeks prior to signing informed consent form.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with other immune checkpoint inhibitors (include PD-1 antibody or other immunotherapy against PD-1/PD-L1).", "Patient has no overlapping conditions/medications with exclusion criterion: Known history of serious allergy to any monoclonal antibody or Apatinib.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwilling to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current presence of metastasis to central nervous system.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia or complications of severe pneumonia; oral or intravenous therapeutic antibiotics within two weeks prior to the start of study treatment (for example, subjects who are given with preventive antibiotics for prevention of urinary tract infection or exacerbation of chronic obstructive pulmonary disease are eligible for participation in the study).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women.", "Patient has no overlapping conditions/medications with exclusion criterion: Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators, such as alcoholism, drug abuse, other serious diseases (including mental disorders) requiring concomitant therapy, with serious laboratory examination abnormality, with family or social factors, that may affect subject's safety."]}, {"trialId": "NCT05078476", "trialName": "Rehabilitation of Finger Flexor Tendon Injuries", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\< 18 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients", "Patient has no overlapping conditions/medications with exclusion criterion: Replantation of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Primary tendon reconstructions"]}, {"trialId": "NCT06087627", "trialName": "A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have been treated for more than 7 days with dupilumab", "Patient has no overlapping conditions/medications with exclusion criterion: Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."]}, {"trialId": "NCT04853576", "trialName": "A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (12.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Available 10/10 HLA-matched related donor", "Patient has no overlapping conditions/medications with exclusion criterion: Prior HSCT or contraindications to autologous HSCT", "Patient has no overlapping conditions/medications with exclusion criterion: Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to receive red blood cell (RBC) transfusion for any reason", "Patient has no overlapping conditions/medications with exclusion criterion: Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine", "Patient has no overlapping conditions/medications with exclusion criterion: Any history of severe cerebral vasculopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate end organ function", "Patient has no overlapping conditions/medications with exclusion criterion: Advanced liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior or current malignancy or immunodeficiency disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Immediate family member with a known or suspected Familial Cancer Syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined inclusion/exclusion criteria may apply"]}, {"trialId": "NCT01341327", "trialName": "Observational Study for Left Main Disease Treatment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Protected left main stenosis"]}, {"trialId": "NCT06337227", "trialName": "Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients for whom biological material cannot be recovered for study purposes;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who refuse to participate in the study"]}, {"trialId": "NCT06312176", "trialName": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Has breast cancer amenable to treatment with curative intent", "Patient has no overlapping conditions/medications with exclusion criterion: Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune disease that has required systemic treatment in the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy"]}, {"trialId": "NCT06061627", "trialName": "A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Valvular heart disease that requires or has undergone surgical intervention", "Patient has no overlapping conditions/medications with exclusion criterion: After mechanical tricuspid valve replacement", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or permanent atrial fibrillation or atrial flutter", "Patient has no overlapping conditions/medications with exclusion criterion: Second or third degree atrioventricular block", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of acute myocardial infarction within 3 months prior to enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Patient's expected survival time is less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or planned to conceive", "Patient has no overlapping conditions/medications with exclusion criterion: Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with simple and persistent left superior vena cava", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with existing pacemaker implantation"]}, {"trialId": "NCT02907827", "trialName": "Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\\< 6weken)", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia", "Patient has no overlapping conditions/medications with exclusion criterion: Metallic devices implanted such as hip prostheses, since this can alter the imaging quality"]}, {"trialId": "NCT06291727", "trialName": "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients scheduled for bilateral TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Revision TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)", "Patient has no overlapping conditions/medications with exclusion criterion: Workers' Compensation patient", "Patient has no overlapping conditions/medications with exclusion criterion: Type I Diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Type II Diabetes requiring insulin medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-operative narcotics use with the exception of tramadol.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal insufficiency (GFR \\< 60) that may impact post-operative protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive deficiencies that prevent the patient from providing their own informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Language barrier preventing completion of study forms in English"]}, {"trialId": "NCT05650827", "trialName": "Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\< 18", "Patient has no overlapping conditions/medications with exclusion criterion: Living outside the greater Copenhagen area", "Patient has no overlapping conditions/medications with exclusion criterion: Any other malignancy requiring active treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Not eligible for chemotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Performance status \\> 2", "Patient has no overlapping conditions/medications with exclusion criterion: Not able to swallow liquids", "Patient has no overlapping conditions/medications with exclusion criterion: Parenteral nutrition or enteral nutrition via feeding tube", "Patient has no overlapping conditions/medications with exclusion criterion: Physical or mental disabilities that prohibit execution of test or training procedures", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to understand the Danish language"]}, {"trialId": "NCT06319027", "trialName": "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05536427", "trialName": "Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with immunodeficiency or a history of autoimmune disorders (e.g., rheumatoid arthropathy, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe concurrent medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, serious infection and infectious disease, active peptic ulcer, presence of active hemorrhage, and severe organ failure;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Grade III or IV cardiac failure defined by the New York Heart Association (NYHA), epileptic seizure, and mechanical or paralytic ileus within 6 months prior to the first administration of the investigational drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received chemotherapy and hormonal therapy within 28 days prior to signing the informed consent forms, or are currently taking other investigational drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with lymphoma, leukemia, myelodysplastic syndrome (MDS), or myelosuppression;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with allergy or a history of hypersensitivity to human blood albumin, or a history of allergy or hypersensitivity to any investigational drug or its excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with chronic diseases requiring immunotherapy or hormonal therapy; and subjects currently receiving corticosteroids for other diseases (except those using topical or inhaled steroids);", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with mental or neurological disorders that are not easily controlled;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects infected with human immunodeficiency virus (commonly known as AIDS) or treponema pallidum (commonly known as syphilis);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of other malignant tumors within the last 5 years;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with prior allogeneic stem cell transplantation or solid organ transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of drug or alcohol abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with any irAE of ≥ Grade 3 following prior immunotherapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who, in the judgment of the investigator, are not suitable to participate in this clinical study (e.g., with poor compliance)."]}, {"trialId": "NCT06093776", "trialName": "Rib Fracture Cryoanalgesia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age Pregnant Incarcerated Confounding injuries or significant pain attributed to secondary injury Patients with any of the following: cryoglobulinemia; paroxysmal cold hemoglobinuria; cold urticarial; Raynaud's disease; open and/or infected wounds at or near the treatment site"]}, {"trialId": "NCT06146127", "trialName": "Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unequivocal histological features"]}, {"trialId": "NCT06330727", "trialName": "Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 59.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with diagnosis of diabetes, or taking anti-diabetic medication;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy, planned pregnancy, or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease)."]}, {"trialId": "NCT04855227", "trialName": "A Prospective Evaluation of Pain After Non-complex Ventral Hernia Repair", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is contraindicated for general anesthesia or surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a ventral hernia that will require retromuscular mesh placement or employ a technique, including (but not limited to) external oblique release, Rives- Stoppa, eTEP Rives-Stoppa, transversus abdominis release, other component separation techniques (i.e. anterior component separation) or eTEP transversus abdominis release.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a recurrent hernia.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will have an emergent hernia repair.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of chronic pain and/or taking daily pain medications for \\>6 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of substance abuse (excluding marijuana) and/or current (within 30 days) narcotic use.", "Patient has no overlapping conditions/medications with exclusion criterion: Current marijuana use that the subject is unwilling to discontinue within the 14 days prior to surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of MRSA infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with HbA1c level \\> 8.5%.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Exparel during the surgical procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will undergo a concomitant hernia repair or any other concomitant procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Current nicotine use (including vaping) within the past 30 days.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a known bleeding or clotting disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or suspected pregnancy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject belonging to other vulnerable population, e.g, prisoner or ward of the state.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is currently participating in another interventional or investigational research study."]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT06072976", "trialName": "The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (0.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Infant has already been on feeds", "Patient has no overlapping conditions/medications with exclusion criterion: Infants \\<34 weeks gestation", "Patient has no overlapping conditions/medications with exclusion criterion: Parents with contraindications to providing milk (i.e. drug use-cocaine, fentanyl, meth BUT oxy/suboxone/marijuana OK)", "Patient has no overlapping conditions/medications with exclusion criterion: Complicated gastroschisis", "Patient has no overlapping conditions/medications with exclusion criterion: Short gut syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Additional congenital anomalies that affect ability to tolerate milk (i.e. cyanotic congenital heart disease BUT kidney disease ok)"]}, {"trialId": "NCT05752227", "trialName": "Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pure pleural lesions.", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical instability to reach the final diagnosis.", "Patient has no overlapping conditions/medications with exclusion criterion: Inaccessibility by ultrasound."]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (4.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05364827", "trialName": "CT Coronary Angiography Prior to CTO PCI", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: CTO with J-CTO score\\<2", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate/degraded CTCA images", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant/lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe contrast allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to provide written informed consent"]}, {"trialId": "NCT05038527", "trialName": "ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: ASA ≥ 4", "Patient has no overlapping conditions/medications with exclusion criterion: Formally diagnosed with a disease affecting the bone metabolism or wound healing (severe osteoporosis, osteomalacia, Pagets disease, hyperparathyreoidism etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disseminated cancer diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to any of the i-FACTOR Peptide Enhanced Bone Graft ingredients", "Patient has no overlapping conditions/medications with exclusion criterion: Smoking, extensive alcohol use or abuse of hallucinating drugs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver or kidney disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or breastfeeding patients", "Patient has no overlapping conditions/medications with exclusion criterion: Patients estimated not to be able to understand the information sheet or patients, who do not consent to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe psychiatric diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Ongoing infections"]}, {"trialId": "NCT06200376", "trialName": "A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating, or plan to pregnant or give birth during the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;", "Patient has no overlapping conditions/medications with exclusion criterion: History of splenectomy or organ transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;", "Patient has no overlapping conditions/medications with exclusion criterion: Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of high risk cardiovascular disease, including but not limited to:\n\n    * Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);\n    * Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;\n    * Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;\n    * Rating of heart function as defined by the New York Heart Association (NYHA) standards\\>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;\n    * Left ventricular ejection fraction (LVEF) \\< the center lower limit. If no lower limit existed, LVEF\\<50%;\n    * Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);", "Patient has no overlapping conditions/medications with exclusion criterion: History of another malignant tumor, except the following:\n\n    * Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;\n    * Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;\n    * Adequately treated carcinoma in situ without evidence of disease;", "Patient has no overlapping conditions/medications with exclusion criterion: Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Unexplained \\>38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment"]}, {"trialId": "NCT06040827", "trialName": "A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06144476", "trialName": "Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.", "Patient has no overlapping conditions/medications with exclusion criterion: Surgery within the preceding 6 weeks", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection", "Patient has no overlapping conditions/medications with exclusion criterion: Alcohol or recreational drug abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency requiring treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to read or write English", "Patient has no overlapping conditions/medications with exclusion criterion: Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study"]}, {"trialId": "NCT03317327", "trialName": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB and stage I prostate cancer considered not necessary to treat", "Patient has no overlapping conditions/medications with exclusion criterion: Disease suitable for curative salvage surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 4 weeks prior to first administration of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant cardiac, pulmonary or other medical illness that would limit activity or survival", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to any of the components of the investigational product", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who test positive for hepatitis B, C or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of immunosuppressive therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease that has required systemic therapy within the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: Any reason why, in the opinion of the investigator, the patient should not participate"]}, {"trialId": "NCT04257227", "trialName": "Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Documented brain lesions", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to remain still while sitting up (45 degrees) for the duration of therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold"]}, {"trialId": "NCT05601427", "trialName": "Intra-Operative Adductor Canal Blocks", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or refusal to sign informed consent form", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.", "Patient has no overlapping conditions/medications with exclusion criterion: Non-osteoarthritis primary diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to analgesic medications", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal and/or regional anaesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Any use of opioid pain medication within four weeks of the index procedure(13)", "Patient has no overlapping conditions/medications with exclusion criterion: Pain catastrophizing scale score ≥16 (8, 9, 14)", "Patient has no overlapping conditions/medications with exclusion criterion: History of cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: History renal insufficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History or sensory and/or motor neuropathy to the ipsilateral limb", "Patient has no overlapping conditions/medications with exclusion criterion: Simultaneous, bilateral TKA", "Patient has no overlapping conditions/medications with exclusion criterion: Non-TKA prosthesis", "Patient has no overlapping conditions/medications with exclusion criterion: Scheduled for non-SDD TKA.", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative varus/valgus of \\>10 degrees.", "Patient has no overlapping conditions/medications with exclusion criterion: Planned General Anaesthetic", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Intrathecal Morphine"]}, {"trialId": "NCT03072927", "trialName": "MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (13.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT06585527", "trialName": "Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with encephalitis disease, multiple sclerosis, or other CNS (Central Nervous System) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of organ transplantation or waiting for organ transplantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled infectious diseases or other serious diseases, such as HIV positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with any unstable systemic illness (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris beginning within the last 3 months, congestive heart failure, myocardial infarction occurring within 12 months before enrollment, severe arrhythmia requiring medical treatment, liver or kidney failure, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with systemic autoimmune diseases or immunodeficiency diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe allergic constitution.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases requiring long-term treatment with immune agents or glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with mental disorders."]}, {"trialId": "NCT05956327", "trialName": "Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Lack of reliability and sanity (examined by an independent psychiatrist)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive urine drug screen for illicit drugs (except benzodiazepines)", "Patient has no overlapping conditions/medications with exclusion criterion: Acute suicide risk", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant psychiatric axis-I disorders according to the diagnostic testing procedure (Mini International Neuropsychiatric Interview, MINI)", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant neurological or other disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation"]}, {"trialId": "NCT03916627", "trialName": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with metastatic disease for whom the intent of surgery would not be curative", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 1 year", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply"]}, {"trialId": "NCT03712527", "trialName": "Intra-discal Injection of PRP for Low Back Pain", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 60.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: - Patient with Modic 1 discopathy in different vertebral levels", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a Modic I signal abnormality related to a static spinal disorder (such as previous vertebral fractures, or isthmic lysis, or spondyloarthritis)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a history of lumbar spine surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with suspected spondylodiscitis or other infection", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under anticoagulant or antiaggregant therapy, or with a coagulation disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with allergy to iodine or to any of the components of Xylocaine", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to MRI: Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with anatomical difficulty of access to the injection area (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with an uncontrolled severe disease (i.e. heart, pulmonary, gastro-intestinal, neurologic, endocrine, auto-immune affections) limiting the patient's safety (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with previous malignancy less than 5 years (except for non-melanoma skin cancer)", "Patient has no overlapping conditions/medications with exclusion criterion: Prior to the screening visit:", "Patient has no overlapping conditions/medications with exclusion criterion: a current and recent use of morphine (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: a systemic or local corticosteroid therapy (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: Porphyria", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with sphincter disorders indicating a cauda equina syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Psychotic state not controlled by a treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (βHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age", "Patient has no overlapping conditions/medications with exclusion criterion: Vulnerable persons protected by law", "Patient has no overlapping conditions/medications with exclusion criterion: Persons under guardianship", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who are in a dependency or employment with the sponsor or the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Subject unable to read or/and write"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT04519476", "trialName": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n  1. Has received selinexor or another XPO1 inhibitor previously.\n  2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \\>5 years previously and without evidence of recurrence will be allowed.\n  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \\[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\\], primary amyloidosis, etc.) that is likely to interfere with study procedures.\n  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.\n  6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.\n  7. Concurrent use of other anti-cancer agents or treatments.\n  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\n  9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin\n  10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n  11. Pregnant or breastfeeding females.\n  12. BSA \\<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.\n  13. Life expectancy of less than 3 months.\n  14. Major surgery within 4 weeks prior to C1D1.\n  15. Active, unstable cardiovascular function, as indicated by the presence of:\n\n  1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.\n\n  18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.\n\n  19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).\n\n  20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n\n  21. Contraindication to any of the required concomitant drugs or supportive treatments.\n\n  22. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT06508827", "trialName": "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemoglobinopathies", "Patient has no overlapping conditions/medications with exclusion criterion: Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemochromatosis", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating female adults", "Patient has no overlapping conditions/medications with exclusion criterion: Active infections which in research teams' opinion increases risk for toxicities", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures."]}, {"trialId": "NCT05900427", "trialName": "Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Ages: \\<18 and \\>90", "Patient has no overlapping conditions/medications with exclusion criterion: Weight \\< 60 kg", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple surgeries during one hospital stay", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or any contraindication to local anesthetics used in trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindicated for use of liposomal bupivacaine", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver/kidney disease", "Patient has no overlapping conditions/medications with exclusion criterion: Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who received another local anesthetic block prior to the interscalene block.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to consent in English"]}, {"trialId": "NCT05422027", "trialName": "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who meet any of the following criteria will not be enrolled:\n\n  1. Plasma cell leukemia.\n  2. Documented active amyloidosis.\n  3. Involvement of the central nervous system(CNS) by Multiple myeloma.\n  4. Prior exposure to a SINE compound, including ATG-010.\n  5. Currently, whether or not the patient is on medication, \\> Grade 2 peripheral neuropathy or ≥ Grade ≥ 2 painful neuropathy at baseline.\n  6. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and Selinexor (ATG-010) .\n  7. Active, unstable cardiovascular function, as indicated by the presence of:\n\n     1. Symptomatic ischemia, or\n     2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or\n     3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\<40%, or\n     4. Myocardial infarction within 6 months prior to C1D1.\n  8. Known positive serology for HIV or HIV seropositivity.\n  9. Known active hepatitis A, B, or C infection; eg. positive for HCV RNA or HBV-DNA.\n  10. Women who are pregnant or nursing.\n  11. Life expectancy of less than 6 months.\n  12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.\n  13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n  14. Contraindication to any of the required concomitant drugs or supportive treatments.\n  15. Has any concurrent diseases or complications that is likely to interfere with the study procedures.\n  16. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT05284227", "trialName": "Artificial Intelligence-augmented Perioperative Clinical Decision Support", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT06049927", "trialName": "A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (6.0, 35.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from seasonal influenza in the past 6 moths;", "Patient has no overlapping conditions/medications with exclusion criterion: Axillary temperature \\>37.0°C;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma;", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;", "Patient has no overlapping conditions/medications with exclusion criterion: Severe chronic diseases(Such as down syndrome, diabetes, sickle cell anaemia or neurological disorders);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease (such as systemic lupus erythematosus) or immunodeficiency / immunosuppression (such as HIV, after organ transplantation)", "Patient has no overlapping conditions/medications with exclusion criterion: Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;", "Patient has no overlapping conditions/medications with exclusion criterion: Continuous use of corticosteroids or other immunosuppressive agents for ≥ 14 days within the past 6 months (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) and cytotoxic therapy in the past 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Acute diseases or acute exacerbation of chronic diseases in the past 3 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of blood products within in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of other investigational drugs in the past 30 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of attenuated live vaccines in the past 14 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of inactivated or subunit vaccines in the past 7 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other clinical trials before enrollment and in the follow-up period, or plans to participate in other clinical trials during the clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial"]}, {"trialId": "NCT05057676", "trialName": "Autoimmune Intervention Mastery Course Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04772027", "trialName": "Motor Parameters in Patients With Limb Girdle Muscular Dystrophy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: § For all:", "Patient has no overlapping conditions/medications with exclusion criterion: Without associated neuromuscular disorders such as respiratory or muscular-squeletic diseases, apart from the consequences of dystrophy;", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to the tests;", "Patient has no overlapping conditions/medications with exclusion criterion: Noncontrol cardiac rhythm disorders;", "Patient has no overlapping conditions/medications with exclusion criterion: Lying down position intolerance due to severe respiratory troubles;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman."]}, {"trialId": "NCT05159427", "trialName": "Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to independently provide an informed consent for themselves or mentally incapacitated.", "Patient has no overlapping conditions/medications with exclusion criterion: Physical disability (including blindness or deafness) that requires special arrangements.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant clinical illness, including cardiovascular disease, neurological disease, organ failure, or malignancy in the opinion of the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Any surgical procedure within 3 weeks prior to screening", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of severe seasonal allergies or severe allergic diseases including drug allergies, food allergies and allergy against the SmartPill® device", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to any of the study drugs or the products' excipients", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Sulfonamide derivatives", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Lidocaine", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of XIFAXAN", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to acrylate or methacrylate, commonly used components of medical adhesives", "Patient has no overlapping conditions/medications with exclusion criterion: Any other factor, condition, or disease, including, but not limited to, cardiovascular, respiratory, hematological, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the patient, alter drug absorption and pharmacokinetics or impact the validity of the study results.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Type 1 Diabetes Mellitus (DM), diabetic ketoacidosis, with or without coma", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Glucose 6-phosphate dehydrogenase (G6PD) deficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of drug addiction or alcohol abuse within the past 12 months.", "Patient has no overlapping conditions/medications with exclusion criterion: History of significant psychiatric or neurological illness, including seizure disorders.", "Patient has no overlapping conditions/medications with exclusion criterion: Any medical or surgical conditions which might significantly interfere with the functions of gastrointestinal tract (e.g., gastric/intestinal bypass surgeries, fistulas, strictures, stenosis, or physiological/mechanical obstruction of the G.I tract, gastric bezoars, irritable bowel disease, crohn's disease, diverticulosis, or chronic narcotic use).", "Patient has no overlapping conditions/medications with exclusion criterion: History of dysphagia to liquids, food, or pills", "Patient has no overlapping conditions/medications with exclusion criterion: History of abdominal radiation therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating females", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal lab values during screening in the opinion of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of alcohol and/or nicotine containing products 48 hours prior to dosing visits, and throughout PK sampling visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any medications and/or supplements, prescriptions or over the counter 1 week prior to beginning the study, and throughout the study except for birth control with approved methods of contraception when used consistently and correctly (Implants (i.e. Implanon, Nexplanon), Injectables (i.e. Depo-Provera), Combined, Oral Contraceptives, Intrauterine Devices (IUD's) (i.e. Mirena, ParaGard), and Sexual Abstinence are accepted).", "Patient has no overlapping conditions/medications with exclusion criterion: Use of aspirin or any blood thinner medications.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteers unwilling or unable to take the proposed drugs or undergo G.I intubation", "Patient has no overlapping conditions/medications with exclusion criterion: Enrollment in a clinical trial in the past 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Current enrollment in a clinical trial with another study drug, vaccine or medical device", "Patient has no overlapping conditions/medications with exclusion criterion: Fasting blood glucose level \\< 80 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwillingness to fast for 19 hours.", "Patient has no overlapping conditions/medications with exclusion criterion: Blood donations in the past 8 weeks except for apheresis.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer shows a positive result of COVID-19 Antigen Rapid test in dosing visits", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having any of the following symptoms:\n\n    * Fever (over 100.4 oF or 38 oC) or feeling feverish\n    * New cough\n    * New shortness of breath", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having two of any of these symptoms:\n\n    * Chills\n    * Muscle aches\n    * New URI symptom(s) (runny nose, nasal congestion, and/or sore throat)\n    * New loss of sense of smell or sense of taste\n    * New headache", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has been in close contact in the last 14 days with someone recently diagnosed with COVID-19", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has returned from international travel within the past 10 days"]}, {"trialId": "NCT05525676", "trialName": "Relationship Checkups to Reduce Veteran Suicide Risk", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports severe intimate partner violence in the last year.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports experiencing suicidal intent requiring hospitalization.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER experiences past-month psychosis or mania.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years."]}, {"trialId": "NCT05763576", "trialName": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Healthy volunteers:", "Patient has no overlapping conditions/medications with exclusion criterion: History of any clinically significant disease", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant disease that could interfere with treatment or conduct of study", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)\n\nCHB participants:", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of liver cirrhosis or decompensated liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: History or suspicion of hepatocellular carcinoma (HCC)", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study."]}, {"trialId": "NCT05780476", "trialName": "A Novel VIRTUAL Reality Intervention for CAREgivers of People With Dementia (VirtualCare)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving daily assistance for more than 10 hours from formal CGs;", "Patient has no overlapping conditions/medications with exclusion criterion: Being formal CGs (i.e., nurse or another paid figure);", "Patient has no overlapping conditions/medications with exclusion criterion: Being informal CGs of i) persons with moderate-to-severe AD, or ii) persons with non-AD diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Not having or being able to use a device connected to internet (e.g., smartphones or PC).", "Patient has no overlapping conditions/medications with exclusion criterion: Having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs.", "Patient has no overlapping conditions/medications with exclusion criterion: Only a family member for person with dementia is accepted.\n\nExclusion Criteria for experimental group (Psychoeducation + VR):", "Patient has no overlapping conditions/medications with exclusion criterion: Medical history of epilepsy.\n\nExclusion Criteria for subsample of caregivers assess with MRI:", "Patient has no overlapping conditions/medications with exclusion criterion: Metal implants, artificial prostheses, pace-makers, prosthetic heart valves;", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy."]}, {"trialId": "NCT03990727", "trialName": "Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (2.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: 1) Not willing to visit every year."]}, {"trialId": "NCT05721027", "trialName": "Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Not available for follow-up", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergic to or intolerant of investigational medications", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic steroid use", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney disease (GFR \\<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x the upper limit of normal)"]}, {"trialId": "NCT06550427", "trialName": "Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT04802876", "trialName": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior systemic anti-cancer therapy, including investigational agents within 2 weeks. Medical Monitor could consider shorter interval for kinase inhibitors or other short half-life drugs prior to allocation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants with ≤Grade 2 neuropathy may be eligible.\n\n   Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study treatment.\n\n   Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose of the previous investigational agent.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with thymoma are not eligible. Patients with active CNS metastases and/or carcinomatous meningitis are not eligible. Subjects with up to three cerebral metastases are eligible, if all lesions are stable and have been definitively treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any of its excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior allogeneic stem cell transplantation or organ transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history of interstitial lung disease, (non-infectious) pneumonitis that required steroids or has current pneumonitis, uncontrolled lung including pulmonary fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Human Immunodeficiency Virus (HIV).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of active TBC (Bacillus Tuberculosis).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of trial treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with spartalizumab or tislelizumab. Highly effective contraception methods include:\n\n    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n    4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.\n\n    Notes:\n    * Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.\n    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.", "Patient has no overlapping conditions/medications with exclusion criterion: Sexually active males, unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with spartalizumab or tislelizumab should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen."]}, {"trialId": "NCT04816227", "trialName": "Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusing to participate in the study", "Patient has no overlapping conditions/medications with exclusion criterion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research", "Patient has no overlapping conditions/medications with exclusion criterion: Being pregnant or breastfeeding"]}, {"trialId": "NCT06187727", "trialName": "Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Mechanical complications;", "Patient has no overlapping conditions/medications with exclusion criterion: Cardiogenic shock;", "Patient has no overlapping conditions/medications with exclusion criterion: Experienced myocardial infarction within 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Aortic dissection;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included", "Patient has no overlapping conditions/medications with exclusion criterion: Urinary system infection"]}, {"trialId": "NCT04167527", "trialName": "Endovascular Therapy for Low NIHSS Ischemic Strokes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: NIHSS ≥6", "Patient has no overlapping conditions/medications with exclusion criterion: Any sign of intracranial hemorrhage on baseline CT/MR (SDH/SAH/ICH)", "Patient has no overlapping conditions/medications with exclusion criterion: Any imaging findings suggestive of futile recanalization in the judgment of the local investigator", "Patient has no overlapping conditions/medications with exclusion criterion: High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD", "Patient has no overlapping conditions/medications with exclusion criterion: Premorbid disability (mRS ≥3)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to randomize within 8 hours of last known well", "Patient has no overlapping conditions/medications with exclusion criterion: Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS", "Patient has no overlapping conditions/medications with exclusion criterion: Baseline blood glucose of \\<50 mg/dL (2.78 mmol) or \\>400 mg/dL (22.20 mmol)", "Patient has no overlapping conditions/medications with exclusion criterion: Known coagulation disorders as defined as platelet count \\<100,000/uL", "Patient has no overlapping conditions/medications with exclusion criterion: Known renal failure as defined as serum creatinine levels \\> 3.0 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Presumed septic embolus or suspicion of bacterial endocarditis", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another investigational treatment study in the previous 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Intubation and mechanical ventilation prior to study enrollment is medically indicated", "Patient has no overlapping conditions/medications with exclusion criterion: History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Site investigator does not have equipoise towards the ideal treatment concept (thrombectomy vs. best medical management)", "Patient has no overlapping conditions/medications with exclusion criterion: Known pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Prisoner or incarceration", "Patient has no overlapping conditions/medications with exclusion criterion: Known acute symptomatic COVID-19 infection"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT06218576", "trialName": "Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: age \\< 18 years"]}, {"trialId": "NCT03050476", "trialName": "Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (21.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Already on renal replacement therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic kidney disease defined as estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m2 \\[ CKD stage \\> 3 \\]", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Concurrent enrollment in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with ongoing infections or current use of steroids", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with high-risk emergency surgery or with follow-up procedures already planned at admission (like e.g. TEVAR)"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT05500027", "trialName": "sCD8, as a Novel Biomarker for Pancreatic Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 85.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusal to participate", "Patient has no overlapping conditions/medications with exclusion criterion: Age less than 18-year old and over 85-year old"]}, {"trialId": "NCT05755776", "trialName": "The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Men and women of childbearing potential who are unwilling to use an \"effective\" method of contraception as defined in the protocol during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have received a solid organ or bone marrow transplant", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or existing clinical liver failure (Child-Pugh score ≥ grade B)."]}, {"trialId": "NCT05887076", "trialName": "Postoperative Delirium After Kidney Transplantation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete data records of the parameters to be determined", "Patient has no overlapping conditions/medications with exclusion criterion: Underage Patients"]}, {"trialId": "NCT05272176", "trialName": "Veterans Coordinated Community Care (3C) Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired decision-making capacity", "Patient has no overlapping conditions/medications with exclusion criterion: Limited or no English language proficiency", "Patient has no overlapping conditions/medications with exclusion criterion: Terminal illness"]}, {"trialId": "NCT05968976", "trialName": "Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Legally incompetent adults;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous tremor-neurosurgery (e.g., DBS, thalamotomy);", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;", "Patient has no overlapping conditions/medications with exclusion criterion: Psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Current depression;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent."]}, {"trialId": "NCT06182527", "trialName": "Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: diabetes mellitus", "Patient has no overlapping conditions/medications with exclusion criterion: use of medication interfering with glucose metabolism (steroid, antidiabetic medications)", "Patient has no overlapping conditions/medications with exclusion criterion: surgery of upper GI-tract", "Patient has no overlapping conditions/medications with exclusion criterion: known plaster allergies", "Patient has no overlapping conditions/medications with exclusion criterion: any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion"]}, {"trialId": "NCT06222827", "trialName": "Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, any major comorbidities (diabetes mellitus, cancer, severe autoimmune diseases, chronic renal failure, articular diseases that restricts exercise or participation in study assessments in the physician's opinion...), a history of relevant drug or food allergies; history of cardiovascular, respiratory, central nervous system disease; neuromuscular diseases except FSHD (e.g., myopathy, neuropathy, neuromuscular junction disorders)", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who are on drug(s) or supplements that may affect muscle function, as determined by the treating physician must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Orthopedic conditions, such as unresolved fracture or arthrosis, interfering or precluding testing of muscle function", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to muscle MRI as per clinic standard practice", "Patient has no overlapping conditions/medications with exclusion criterion: Articular contracture limiting movements, scapular fixation or other surgeries, preceding or planned", "Patient has no overlapping conditions/medications with exclusion criterion: Any known hypersensitivity to satralizumab or any of its components and/or history of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of latent or active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection for at least 4 weeks prior to enrollment), active opportunistic or life-threatening infections", "Patient has no overlapping conditions/medications with exclusion criterion: History of diverticulitis or concurrent severe GI disorders (such as symptomatic diverticulosis) that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation. Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit (Visit 1, week 0)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody.", "Patient has no overlapping conditions/medications with exclusion criterion: Acute or chronic history of liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal laboratory results with: White blood cells (WBC) \\< 3.0x 10\\^9/L ; Absolute Neutrophils Counts (ANC)\\< 2.0x 10\\^9/L ; Platelet count \\< 10x10\\^4/µl ; Absolute lymphocyte count (ALC) \\< 0.8x 10\\^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 times the upper limit of normal (ULN)", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment (defined as a glomerular filtration rate of \\<30mL/min/1.73m²)", "Patient has no overlapping conditions/medications with exclusion criterion: Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation", "Patient has no overlapping conditions/medications with exclusion criterion: For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier \\[patient or partner\\] in conjunction with a spermicidal product, contraceptive pill, patch, injectable, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of another investigational product within 6 months or 5 half-lives (whichever is longer), or currently participating in a prospective study with an investigational product, whether it concerns an experimental drug or a medical device. Note: concurrent participation in natural history studies (non-drug, non-device studies) is not allowed during the course of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior treatment with any agent targeting the IL-6 inhibition pathway (e.g. tocilizumab, sarilumab), alemtuzumab treatment, total body irradiation, or bone marrow transplantation; treatment in the past 24 weeks with an anti-B-lymphocyte antigen CD20 (e.g. rituximab, ocrelizumab), eculizumab, anti-B-lymphocyte stimulator, or any other multiple sclerosis disease-modifying treatment; treatment in the past 2 years with an anti-T-cell surface glycoprotein CD4, cladribine, cyclophosphamide, or mitoxantrone; or treatment with any other investigational drug within 3 months prior to baseline. See section 4.4.4 for details on the vaccination and immunization.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject, or close relative of the subject, is the investigator or a coinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code."]}, {"trialId": "NCT05505227", "trialName": "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: currently prescribing buprenorphine at full capacity"]}, {"trialId": "NCT05782127", "trialName": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous diagnosis of:\n\n   * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)\n   * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: History of active malignancy within the past year prior to screening, with the exception of:\n\n   * Adequately treated carcinoma in situ of the uterine cervix\n   * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n   * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.\n\n   Patients with ongoing horomonotherapy could be included.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.", "Patient has no overlapping conditions/medications with exclusion criterion: Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.", "Patient has no overlapping conditions/medications with exclusion criterion: Received live attenuated vaccines prior to initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions that could interfere with drug absorption including short gut syndrome, dysphagia, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mmHg or diastolic BP \\> 100 mmHg) or has not been stable for at least 1 month prior to treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:\n\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Unstable angina or angina requiring surgical or medical intervention\n    * Significant cardiac arrhythmia\n    * And/or myocardial infarction", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is a pregnant or lactating female.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has known or suspected to have hypersensitivity to any of the components of the assigned study treatments.", "Patient has no overlapping conditions/medications with exclusion criterion: Positive test result(s) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B surface \\[HBs\\] antibody positive and anti-hepatitis B core \\[HBc\\] antibody negative) may participate.", "Patient has no overlapping conditions/medications with exclusion criterion: Absence of social security affiliation."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT06524427", "trialName": "Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with the previous history of other malignancies;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with secondary primary cancer when enrolled;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as pure ground glass opacity (GGO) before surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as mixed GGO whose solid part \\<= 50% and Maximum diameter of tumor \\<= 2cm;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with small cell lung cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with prior unilateral open thoracic surgical procedures;", "Patient has no overlapping conditions/medications with exclusion criterion: Woman who is pregnant or breastfeeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with an active bacterial or fungal infection that is difficult to control;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with serious psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months."]}, {"trialId": "NCT05537376", "trialName": "A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Veteran"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT05189327", "trialName": "Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient takes part in an interventional clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is unable to follow the schedule of the visits;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that the PI believes would prevent a study participant from participating in the study."]}, {"trialId": "NCT06447727", "trialName": "Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: After liver metastasis was diagnosed, the liver underwent external radiation therapy and transhepatic arterial chemoembolization", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with extrahepatic metastases", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe arrhythmia or heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: Other researchers considered it inappropriate to participate in this study"]}, {"trialId": "NCT06176027", "trialName": "Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women"]}, {"trialId": "NCT05775627", "trialName": "Sleep and Metabolism", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dietary restrictions\n\n   Participants must not have dietary restrictions that could systematically bias their macronutrient intake. The following will exclude participants from enrolling in the study based on their diet:\n   * Participants who choose not to or cannot consume dairy products (milk, yogurt, cheese, ice cream)", "Patient has no overlapping conditions/medications with exclusion criterion: Body Composition\n\n   A body mass index (BMI) of 18.5\\< \\[BMI\\] \\< 25 kg/m2 and a waist circumference \\<94/80cm.", "Patient has no overlapping conditions/medications with exclusion criterion: Psychiatric/psychological suitability\n\n   Each participant will undergo a structured interview (Mini International Neuropsychiatric Interview) with a qualified OHSU physician. This physician will supervise the administration and scoring of a Beck Depression Inventory II (BDI-II) questionnaire for each potential participant. The following will exclude individuals from participating based on their psychiatric or psychological evaluation:\n   * Individuals with evidence of psychopathology on the BDI-II, or in a structured clinical interview with the physician\n   * A history of severe psychiatric illnesses\n   * Alcoholism\n   * Drug dependency\n   * Major depression\n   * Manic depressive illness\n   * Schizophrenic disorders\n   * Panic disorder\n   * Generalized anxiety disorder\n   * Post-traumatic stress disorder\n   * Agoraphobia\n   * Claustrophobia\n   * Paranoid personality disorder\n   * Schizoid personality disorder\n   * Schizotypal personality disorder\n   * Borderline personality disorder\n   * Antisocial personality disorder.\n   * History of using antidepressant medication\n   * History of using neuroleptic medication\n   * History of using tranquilizers", "Patient has no overlapping conditions/medications with exclusion criterion: Drug/alcohol use\n\n   Volunteers must be drug-free (including caffeine, nicotine, alcohol and herbal medications) for the entire duration of the outpatient and in-laboratory study period, with no history of drug or alcohol dependency. All participants must be:\n   * Current non-smokers, and are required to have a history of less than 5 'pack years' of smoking", "Patient has no overlapping conditions/medications with exclusion criterion: Medication/drug use\n\n   Volunteers must not be taking any prescribed medications or over the counter medications, with an exception for birth control.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior shift work\n\n   For stability of endogenous circadian rhythmicity, volunteers must have no history of the following 1 year prior to the study:\n   * Working irregular day and night hours\n   * Regular night work\n   * Rotating shift work f\n   * Not have traveled more than 1 time zone during 3 months prior to the study", "Patient has no overlapping conditions/medications with exclusion criterion: Chronobiologic and sleep disorders\n\n   * Hypernychthemeral sleep/wake cycle\n   * Delayed sleep phase syndrome (wake time \\> 2 hours later than desired or habitually after 10:00 AM)\n   * Advanced sleep phase syndrome (wake time \\> 2 h earlier than desired or habitually before 5:00 AM)\n   * Narcolepsy\n   * Sleep apnea (apnea index \\>15)\n   * Insomnia (sleep complaint by history or polygraphically recorded sleep efficiency \\< 80%)\n   * Hypersomnia\n   * Periodic Limb Movement (PLMS) (PLMS index \\>15)\n   * Nocturnal Paroxysmal Dystonia\n   * REM-sleep behavior disorder\n   * Nocturnal Enuresis; (self-report and first night in the laboratory)\n   * Obstructive sleep apnea (apnea/hypopnea index \\>5/h as determined by at-home monitoring)\n   * The investigators will also exclude individuals with extreme chronotype using the Horne-Ostberg Morningness/Eveningness questionnaire (i.e., the Owl/Lark Questionnaire)", "Patient has no overlapping conditions/medications with exclusion criterion: Diseases of the Cardiovascular System\n\n   * Hypertension (systolic blood pressure \\> 140 or diastolic blood pressure \\> 90)\n   * Heart failure\n   * Cardiomyopathy\n   * Cor pulmonale\n   * Ischemic heart disease\n   * Valvular heart disease\n   * History of heart transplantation\n   * Cardiac tumors\n   * Pericardial disease", "Patient has no overlapping conditions/medications with exclusion criterion: Metabolic Syndrome\n\n   Following American Heart Association cutoffs, participants who have, in addition to abdominal fat (obese exclusion criteria), two or more of these factors will be excluded from the study:\n   * HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women\n   * Systolic blood pressure \\>135 mmHg or diastolic blood pressure \\>85 mmHg\n   * Fasting blood glucose ≥ 100 mg/dL\n   * Triglycerides ≥ 150 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-Diabetes/Diabetes\n\n    For participants who have a fasting blood glucose level of ≥ 100 mg/dL the investigators will measure hemoglobin A1c to exclude for diabetes (HbA1c\\>5.7%).", "Patient has no overlapping conditions/medications with exclusion criterion: Hypertension\n\n    An upper cut off of 140/90 mmHg during an office blood pressure measure will be used as an exclusion criterion. After 5 minutes of rest in a seated position, blood pressure will be measured 3 times, taken 1 minute apart. The average will be used to confirm eligibility criteria. Current or history of beta blocker use will also be exclusionary.", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Respiratory System\n\n    * Asthma\n    * Cystic fibroses\n    * Chronic bronchitis\n    * Emphysema\n    * Airway obstruction\n    * Interstitial lung diseases\n    * Pulmonary hypertension\n    * Lung neoplasms\n    * ARDS", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Kidney and Urinary Tract\n\n    * Acute or chronic renal failure\n    * History of renal transplantation\n    * Tubulointerstitial diseases of the kidney\n    * Urinary tract obstruction\n    * Tumors of the urinary tract", "Patient has no overlapping conditions/medications with exclusion criterion: Infectious Diseases\n\n    * Infective endocarditis\n    * HIV infection\n    * Sexually transmitted diseases \\[e.g., syphilis (including congenital syphilis and its sequelae), gonorrhea\\],\n    * Urinary tract infection\n    * Osteomyelitis\n    * Brucellosis\n    * Toxoplasmosis,\n    * Tuberculosis\n    * Leptospirosis\n    * Lyme disease\n    * Mononucleosis\n    * Hepatitis\n    * Parasitic infections such as malaria, toxoplasmosis, giardiasis, schistosomiasis, leishmaniasis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Gastrointestinal System\n\n    * Esophagitis\n    * Peptic ulcer and gastritis\n    * Neoplasms of the esophagus, stomach or bowel\n    * Disorders of absorption\n    * Inflammatory bowel disease\n    * Diseases of the small and large intestine\n    * Acute appendicitis\n    * Cirrhosis or neoplasms of the liver\n    * History of liver transplantation\n    * Diseases of the gallbladder and bile ducts\n    * Pancreatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Immune System, Connective Tissue and Joints\n\n    * AIDS\n    * Systemic lupus erythematosus\n    * Rheumatoid arthritis\n    * Scleroderma\n    * Ankylosing spondylitis\n    * Vasculitis\n    * Sarcoidosis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Hematopoietic System\n\n    * Anemia\n    * Leukemia\n    * Myeloproliferative diseases\n    * History of bone marrow transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Neoplastic Diseases\n\n    * Lymphoma\n    * Carcinoma\n    * Melanoma\n    * Any other neoplastic diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Endocrine and Metabolic Diseases\n\n    * Thyroid disease\n    * Addison's Disease\n    * Cushing's Syndrome\n    * Aldosteronism\n    * Hypoaldosteronism\n    * Pheochromocytoma\n    * Disorders of sexual differentiation that require hormone supplementation that may alter body weight\n    * Disorders of neuroendocrine regulation\n    * Diseases of the anterior pituitary and hypothalamus\n    * Hemochromatosis porphyria\n    * Wilson's Disease\n    * Glycogen storage diseases\n    * Diseases of the parathyroid gland\n    * Metabolic bone disease\n    * Disorders of phosphorus or magnesium metabolism\n    * Paget's Disease", "Patient has no overlapping conditions/medications with exclusion criterion: Neurologic Disorders\n\n    * Epilepsy and disorders of consciousness\n    * Dementia\n    * Amnesic disorders\n    * Neoplastic diseases of the central nervous system\n    * Demyelinating diseases\n    * Parkinson's Disease\n    * Muscular dystrophy\n    * Myasthenia gravis\n    * Periodic paralysis\n    * Dermatomyositis\n    * Polymyositis\n    * Infections of the nervous system\n    * Stroke\n    * History of transient ischemic attacks\n    * Hydrocephalus\n    * Tumors of the pituitary gland\n    * Pinealoma\n    * Intervertebral disc disease\n    * Ataxia\n    * Gilles de la Tourette Syndrome\n    * Huntington's Disease\n    * Tardive dyskinesia\n    * History of recurrent migraine headaches\n    * Neuromuscular disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects must not be currently participating in another research study that would influence their safe participation in our study. Subjects must not be participating in a research study in which they do the following:\n\n    * Ingest experimental medication\n    * Give blood samples"]}, {"trialId": "NCT04280627", "trialName": "Changes in the Microbiome Associated With Transplantation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Outside of stated age range.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to give informed consent"]}, {"trialId": "NCT03969927", "trialName": "User-friendliness of a Portable Driving Simulator", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (25.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of traumatic brain injury or any other neurological condition apart from stroke, PD, and MS."]}, {"trialId": "NCT06627127", "trialName": "A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects meeting any of the following criteria will be excluded from participation in this study:", "Patient has no overlapping conditions/medications with exclusion criterion: Major anatomical or functional abnormalities that would impair the ability of the electrode arrays to be positioned.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant comorbidities that contraindicate surgery or general anesthesia/DISE", "Patient has no overlapping conditions/medications with exclusion criterion: Significant tongue weakness", "Patient has no overlapping conditions/medications with exclusion criterion: Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia/DISE in the judgment of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior surgery or treatments that could compromise the placement and effectiveness of the electrode array systems:\n\n  * Airway cancer surgery or radiation,\n  * Mandible or maxilla surgery in the previous 3 years (not counting dental treatments),", "Patient has no overlapping conditions/medications with exclusion criterion: Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),", "Patient has no overlapping conditions/medications with exclusion criterion: Prior hypoglossal nerve stimulation device implantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently pregnant, or breastfeeding during the study period"]}, {"trialId": "NCT06441227", "trialName": "Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who suffer from any serious clinical diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease or medical history that can interfere with the test results or any significant laboratory abnormality that is judged by researchers to be of clinical significance.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of malignant tumors.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have taken any prescription drugs, over-the-counter drugs and Chinese herbs within 14 days before taking the study drug, or within 5 half-life of the drug at the time of screening; those who plan to take non-study drugs during the trial period.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have participated in the clinical trial of any drug or medical device within 3 months before screening, or have not been within 5 half-life of the drug before screening (when both standards are met, the standard shall be based on the long-term standard).", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects received siRNA in the past 12 months, or antisense oligonucleotide drugs in the past six months.", "Patient has no overlapping conditions/medications with exclusion criterion: The abnormal upper limit of hypersensitive C-reactive protein during the screening period is \\>1.5 times the normal upper limit, or the normal upper limit of prothrombin time/international standard ratio (PT/INR), activated partial thrombin time (aPTT) \\> 1.25 times normal upper limit.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening for infectious diseases during the screening period (including hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, syphilis spirochete antibody).", "Patient has no overlapping conditions/medications with exclusion criterion: 12-lead electrocardiogram abnormal and clinical significance, or electrocardiogram QT interval (QTcF) male \\> 450 ms, female \\> 470 ms.", "Patient has no overlapping conditions/medications with exclusion criterion: The total amount of blood donated or blood loss ≥ 200 mL within 1 month before administration, or the total amount of blood donation or blood loss ≥ 400 mL within 3 months before administration, or received blood transfusion within 8 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have a serious infection, serious trauma or major surgery within 3 months before administration; those who plan to undergo surgery within two weeks during and after the end of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Suspected people with a history of allergy to research drugs or any ingredients in research drugs, allergies or previous history of serious drug allergies.", "Patient has no overlapping conditions/medications with exclusion criterion: People who have had blood collection difficulties or cannot tolerate venous punctures in the past, such as needle fainting and blood fainting.", "Patient has no overlapping conditions/medications with exclusion criterion: Glomerular filtration rate (eGFR) is lower than GFR 60 mL/min/1.73 m2.", "Patient has no overlapping conditions/medications with exclusion criterion: Smoke an average of ≥ 5 cigarettes per day in the first three months of administration; the average daily intake of alcohol in the first month before administration exceeded 15 grams.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening and visiting drug screening test is positive or alcohol breath test is positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Other circumstances in which the researcher believes that the subject is not suitable to participate in this experiment."]}, {"trialId": "NCT05763927", "trialName": "Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have previously received immune checkpoint inhibitors;", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reactions to PD-1 monoclonal antibody active ingredients, TKI inhibitor-related ingredients or any excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with organ bleeding or bleeding tendency, except for rectal primary tumor bleeding (need investigator to assess the risk of bleeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: years or at the same time have a history of other malignant tumors, but cured skin basal cell carcinoma and cervical carcinoma in situ and thyroid;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled epilepsy, central nervous system disease or mental disorders, the investigator judged that their clinical severity may hinder the signing of informed consent or affect the patient 's compliance with oral drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically serious (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalent daily) or other immunosuppressive agents (including organ transplant recipients) within 2 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other interventional drug clinical trials within 4 weeks before the first dose;", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery or severe trauma within 4 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Serious infection (CTCAE greater than grade 2) within 4 weeks before the first dose of study drug,Such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging suggests active pulmonary inflammation, symptoms and signs of infection within 2 weeks before the first dose of study drug, or the need for oral or intravenous antibiotics (excluding prophylactic antibiotics);", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes); autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone, using stable doses of insulin type 1 diabetes can be included; but excluding vitiligo or recovered childhood asthma/allergy, without any intervention in adults;", "Patient has no overlapping conditions/medications with exclusion criterion: History of immunodeficiency, including positive HIV test, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Active pulmonary tuberculosis infection found by medical history or CT examination, Or patients with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or patients with a history of active pulmonary tuberculosis infection but without regular treatment 1 year before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with active hepatitis (HBV DNA ≥ 2000 IU/ml or 10000 copies/ml), hepatitis C (hepatitis C antibody positive,HCV-RNA was above the lower limit of detection of the assay);", "Patient has no overlapping conditions/medications with exclusion criterion: Had a known history of psychotropic drug abuse, alcoholism, or drug use;", "Patient has no overlapping conditions/medications with exclusion criterion: Had a history, illness, treatment, or laboratory abnormality that could interfere with the results of the trial, prevent the subject from participating throughout the study, or the investigator considered participation to be in the subject 's best interest."]}, {"trialId": "NCT05264727", "trialName": "Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (25.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05555576", "trialName": "Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Opioid use 1 month prior to the ED visit;", "Patient has no overlapping conditions/medications with exclusion criterion: Already taking vitamin C supplement;", "Patient has no overlapping conditions/medications with exclusion criterion: Active cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for chronic pain;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for opioid use disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to fill out diary or unavailable for follow-up;", "Patient has no overlapping conditions/medications with exclusion criterion: Any allergy, intolerance or sensitivity to milk (lactose) or morphine", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with cyclosporin or coumadin", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)"]}, {"trialId": "NCT04557527", "trialName": "Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to hyaluronate or. HEALON5® PRO OVD", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\nStudy eye:", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of proliferative vitreoretinopathy (PVR) or any tractional RD", "Patient has no overlapping conditions/medications with exclusion criterion: Previous vitreoretinal surgery, open-globe injury or endophthalmitis", "Patient has no overlapping conditions/medications with exclusion criterion: Aphakia", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current congenital cataract", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current suprachoroidal haemorrhage", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment", "Patient has no overlapping conditions/medications with exclusion criterion: Current intraocular inflammation other than mild cellular activity thought to be secondary to RD", "Patient has no overlapping conditions/medications with exclusion criterion: Current ocular or periocular infection other than blepharitis"]}, {"trialId": "NCT05427227", "trialName": "Prospectively Predict the Efficacy and Explore the Mechanism of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous systemic therapy for metastatic GI cancer\n\n  * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.\n  * Allergic constitution or allergic history to protium biologic product or any investigating agents.\n  * Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.\n  * Pregnancy or lactation period\n  * Other previous malignancy within 5 year, except non-melanoma skin cancer\n  * Legal incapacity"]}, {"trialId": "NCT05628376", "trialName": "TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:", "Patient has no overlapping conditions/medications with exclusion criterion: Positive margins, incomplete resection or insufficient nodal sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B/C:", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)"]}, {"trialId": "NCT04620876", "trialName": "Bimodal and Coaxial High Resolution Ophtalmic Imaging", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (1.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05757076", "trialName": "Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of secondary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy status (verbal)"]}, {"trialId": "NCT04838327", "trialName": "Rare Subtypes of Gastrointestinal Cancers", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions precluding translational blood sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Another concomitant cancer"]}, {"trialId": "NCT03344276", "trialName": "Assessing Neurocognition After Cerebrovascular Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: patients \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: patients with without compatibility for MRI", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring carotid stenting for reasons not related to long-standing stenosis", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study."]}, {"trialId": "NCT06186427", "trialName": "A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who cannot tolerate puncture biopsy or surgical contraindications;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have undergone radiotherapy and chemotherapy in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Individuals who are allergic to multiple drugs or foods;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who refuse nuclear medicine examinations;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who do not agree to sign an informed consent form and are unable or willing to follow up."]}, {"trialId": "NCT04695327", "trialName": "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled cardiac or vascular diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hepatic dysfunction, hepatitis or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: History of coagulation disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant, breastfeeding or intend to become pregnant.", "Patient has no overlapping conditions/medications with exclusion criterion: Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.", "Patient has no overlapping conditions/medications with exclusion criterion: Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol)."]}, {"trialId": "NCT06339827", "trialName": "ASk Questions in GYnecologic Oncology (ASQ-GYO)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment discussion with a Gynecologic Oncologist"]}, {"trialId": "NCT03921827", "trialName": "External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (21.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with atrial fibrillation/ arrhythmias.", "Patient has no overlapping conditions/medications with exclusion criterion: Within 2 weeks of cardiac catheterization or arterial puncture at femoral puncture site.", "Patient has no overlapping conditions/medications with exclusion criterion: Decompensated heart failure , usually class 3 or 4", "Patient has no overlapping conditions/medications with exclusion criterion: LV EF \\<30%", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe AR", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent and uncontrolled hypertension (BP persistently \\>160/100 mmHg)", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding diathesis", "Patient has no overlapping conditions/medications with exclusion criterion: Active thrombophlebitis/ venous disease of lower limbs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe lower extremity vaso-occlusive disease", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a documented aortic aneurysm/ dissection requiring surgical repair", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy"]}, {"trialId": "NCT05312827", "trialName": "Training Intervention and Program of Support (TIPS): Fostering Family-centred Telehealth in Pediatric Rehabilitation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03529227", "trialName": "Gazyva Infusion Reaction Investigation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: The refusal of the patient to participate in the observational study and the withdrawal of informed consent that allow processing of personal data and data that refer to patient confidentiality."]}]}, {"patientId": "829eb3d9-54fd-2516-d17e-a0fb596e1946", "eligibleTrials": [{"trialId": "NCT06286527", "trialName": "Quality of Sexual Life of PrEP Users", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unwilling to participate"]}, {"trialId": "NCT04484727", "trialName": "\"Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs\"", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients under 18 years", "Patient has no overlapping conditions/medications with exclusion criterion: ASA 4 and above", "Patient has no overlapping conditions/medications with exclusion criterion: severe COPD/emphysema/heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: PEEP\\>16 and/or FiO2 \\>80%", "Patient has no overlapping conditions/medications with exclusion criterion: elevated intracranial pressure", "Patient has no overlapping conditions/medications with exclusion criterion: defect coagulation", "Patient has no overlapping conditions/medications with exclusion criterion: non-treated known or suspected pneumothorax"]}, {"trialId": "NCT03869476", "trialName": "Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 99.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a diagnosis of secondary myelofibrosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman;", "Patient has no overlapping conditions/medications with exclusion criterion: Person prived of liberty by judicial or administrative decision;", "Patient has no overlapping conditions/medications with exclusion criterion: Person subject to a legal protection measure;"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (15.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT05690776", "trialName": "PMCF Study on the Safety, Performance and Clinical Benefits Data of the Quattro X Broadband", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of infection;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient or immature bone;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient blood supply or previous infections which may hinder the healing process;", "Patient has no overlapping conditions/medications with exclusion criterion: Foreign body sensitivity;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant);", "Patient has no overlapping conditions/medications with exclusion criterion: The subject is unwilling or unable to give consent or to comply with the follow-up program;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject meets any contraindications of the appropriate Instruction for Use."]}, {"trialId": "NCT06100276", "trialName": "Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.", "Patient has no overlapping conditions/medications with exclusion criterion: Pathogenic repeat expansion in the C9orf72 gene", "Patient has no overlapping conditions/medications with exclusion criterion: Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications."]}, {"trialId": "NCT06027827", "trialName": "Impact of Lateral Bone Grafting With Intraoperative Fusion in ACDF on Clinical Outcomes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 60.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Drug or alcohol abusers; those with abnormal liver or kidney function unsuitable for surgery; those with cardiac insufficiency unsuitable for surgery; those with severe metabolic and endocrine diseases unsuitable for surgery; those with severe lung disorders such as asthma and abnormal lung function unsuitable for surgery; pregnant and breastfeeding women as well as those who are planning to become pregnant in the near future; those who have participated in other clinical trials within 3 months; and those who are not suitable for participation in the experiment in the opinion of the investigator."]}, {"trialId": "NCT06597227", "trialName": "Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  <!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL/min;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects."]}, {"trialId": "NCT05731427", "trialName": "Research on the Mechanism Affecting Progression of Bronchiectasis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05666076", "trialName": "Peng Block or Suprascapular Nerve Block for Postoperative Analgesia in Shoulder Artroscopy ?", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with deformity and pathology in the shoulder region", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with known local anesthetic allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with BMI\\>35", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with alcohol and substance addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with opioid addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who cannot perceive and evaluate pain, such as psychiatric illness, mental retardation"]}, {"trialId": "NCT05398627", "trialName": "Neurofeedback for Borderline Personality Disorder", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Current moderate or severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild alcohol or substance use would also interfere with the effects of the intervention.", "Patient has no overlapping conditions/medications with exclusion criterion: have a history of traumatic brain injury", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)", "Patient has no overlapping conditions/medications with exclusion criterion: are currently pregnant or breast feeding", "Patient has no overlapping conditions/medications with exclusion criterion: are unable to complete questionnaires written in English", "Patient has no overlapping conditions/medications with exclusion criterion: current (within 3 weeks of testing) use of any antipsychotics, benzodiazepines, beta-blockers, or other medications (except SSRI antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. Inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population", "Patient has no overlapping conditions/medications with exclusion criterion: have a DSM-5 diagnosis of psychotic or organic mental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: have any eye problems or difficulties in corrected vision.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious suidicial ideation"]}, {"trialId": "NCT05626127", "trialName": "MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Accompanied with other primary malignant tumors;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies;", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete imaging or medical history data."]}, {"trialId": "NCT05780827", "trialName": "Analysis of Clinical Data of Patients With Temporomandibular Joint Disorder", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (12.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have received orthodontic treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of maxillofacial trauma", "Patient has no overlapping conditions/medications with exclusion criterion: Maternity", "Patient has no overlapping conditions/medications with exclusion criterion: Those who take any medicine for a long time", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases such as tumors, endocrine diseases, psychosocial diseases and immune diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Other persons who are unable to cooperate with the project by themselves, such as action barriers.\n\nControl group\n\nInclusion Criteria:\n\nSuffer from symptoms and signs of oral and maxillofacial dysfunction"]}, {"trialId": "NCT06191627", "trialName": "Patient Experience and Quality of Patch Testing on the Legs vs Back", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 89.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is 17 or younger", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or breastfeeding", "Patient has no overlapping conditions/medications with exclusion criterion: Specialized patch testing with low number of patches (less than 90)", "Patient has no overlapping conditions/medications with exclusion criterion: Rash that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Large tattoos that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Limited space on thighs or back due to body habitus", "Patient has no overlapping conditions/medications with exclusion criterion: Patient has specific needs necessitating use of the thighs or back (event, breastfeeding, etc.)"]}, {"trialId": "NCT05890027", "trialName": "Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who refuse to consent.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.", "Patient has no overlapping conditions/medications with exclusion criterion: Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors"]}, {"trialId": "NCT05004727", "trialName": "Multi-Center PAMPA Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;", "Patient has no overlapping conditions/medications with exclusion criterion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);", "Patient has no overlapping conditions/medications with exclusion criterion: RA seropositivity (mid-high RF/ACPA titers);", "Patient has no overlapping conditions/medications with exclusion criterion: Current active malignancy;", "Patient has no overlapping conditions/medications with exclusion criterion: History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to the study agent."]}, {"trialId": "NCT06001827", "trialName": "SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Planned index procedure to revise or repair an existing fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Target artery inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Target vein inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound", "Patient has no overlapping conditions/medications with exclusion criterion: Known central venous stenosis of at least 50% on the side of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a stent or a stent graft within the access circuit", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected active infection at the time of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Congestive heart failure NYHA class 4", "Patient has no overlapping conditions/medications with exclusion criterion: Prior steal on the side of surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Life expectancy less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo kidney transplant surgery within 6 months of enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo home hemodialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Unwillingness or inability to give consent and/or comply with the study follow up schedule", "Patient has no overlapping conditions/medications with exclusion criterion: Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study."]}, {"trialId": "NCT03947827", "trialName": "Minocycline as Adjunctive Treatment for Treatment Resistant Depression", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 substance use disorder within past 3 months, moderate or severe, based on SCID-5", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant major unstable medical illness", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or intent to become pregnant during study period", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of psychotic disorder, bipolar disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) within last year", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of borderline personality disorder (BPD)", "Patient has no overlapping conditions/medications with exclusion criterion: Possible or probable dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or current intolerance or contraindication to tetracyclines", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal readings in hematology, liver, or renal function tests", "Patient has no overlapping conditions/medications with exclusion criterion: Have Myasthenia Gravis", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant treatment with anticoagulants, diuretics, retinoids, ergot alkaloids, antacids containing aluminium/calcium/magnesium, bismuth and zinc salts, or quinapril"]}, {"trialId": "NCT03015727", "trialName": "Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: WHO type I squamous cell carcinoma or adenocarcinoma", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>65 or \\<18", "Patient has no overlapping conditions/medications with exclusion criterion: With a history of renal disease", "Patient has no overlapping conditions/medications with exclusion criterion: Prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Peripheral neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Emotional disturbance"]}, {"trialId": "NCT05814627", "trialName": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to any janus kinase (JAK) inhibitor.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD)."]}, {"trialId": "NCT05286827", "trialName": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05840276", "trialName": "Cryoneurolysis Prior to Total Knee Arthroplasty", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications against ibuprofen or paracetamol, for example previous gastric ulcer, or known renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\< 100 bil/l); or against treatment with morphine", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuropathic pain", "Patient has no overlapping conditions/medications with exclusion criterion: Previous recipient of cryoneurolysis for the knee", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with daily use of high dose opioid (\\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled serious disease (cancer, diabetes, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disease associated with reactions to cold, such as cryoglobulinemia, cold urticarial and Reynaud's syndrome."]}, {"trialId": "NCT06111027", "trialName": "Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Regular intake of benzodiazepines", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive impairment: score \\< 27 on Mini-mental state examination", "Patient has no overlapping conditions/medications with exclusion criterion: Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis"]}, {"trialId": "NCT05706376", "trialName": "An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (13.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Families with individuals with significant mental or physical impairments precluding their ability to participate in groups"]}, {"trialId": "NCT05809427", "trialName": "High Frequency Intraoral Ultrasound Probe for Early Diagnosis of Periodontal Diseases", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03460327", "trialName": "Bariatric Surgery and Pharmacokinetics of Candesartan", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Having previously undergone resections in the GI-tract"]}, {"trialId": "NCT04886427", "trialName": "Implementation of a Multidimensional Quality Model", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Do not understand Dutch"]}, {"trialId": "NCT06265727", "trialName": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active of uncontrolled CNS metastases", "Patient has no overlapping conditions/medications with exclusion criterion: History of solid tumors other than the diseases under study", "Patient has no overlapping conditions/medications with exclusion criterion: History of and/or current cardiovascular events or conditions in the previous 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing \\>/= Grade 2 neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Hemoglobin A1C (HbA1C) \\>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active ocular disease at baseline", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic severe liver disease or live cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study", "Patient has no overlapping conditions/medications with exclusion criterion: Other significant cormorbidities."]}, {"trialId": "NCT06527027", "trialName": "LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,", "Patient has no overlapping conditions/medications with exclusion criterion: inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant."]}, {"trialId": "NCT05133076", "trialName": "Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: E1. Involvement in any investigational drug or device study within 30 days prior to this study,\n\nE2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in the study),\n\nE3. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation upon investigator judgment,\n\nE4. Surgery planned within the whole study period,\n\nE5. Evidence of active medical diseases affecting bowel transit,\n\nE6. Antibiotic treatment intake within the last month prior the study start (V0),\n\nE7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are permitted,\n\nE8. Any history of drug addiction in the past five years,\n\nE9. Pregnant or lactating women or intending to become pregnant,\n\nE10. Unwilling to maintain food habits and current physical activity for the whole study duration,\n\nE11. With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,\n\nE12. Having a lifestyle deemed incompatible with the study according to the investigator including drug and alcohol abuse,\n\nE13. Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n\nE14. Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,\n\nE15. Presenting a psychological or linguistic incapability to sign the informed consent,\n\nE16. Impossible to contact in case of emergency."]}, {"trialId": "NCT05555927", "trialName": "Adjunctive Duration-doubled tDCS for the Treatment of Depressive Patients With Suicidal Ideation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Assessed through applying the Mini-International Neuropsychiatric Interview (MINI)15 by professional psychiatrists that diagnosed any other current or past psychiatric axis-I disorders (except MDD in the patients);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver and kidney diseases, active endocrine diseases or clinical symptoms. Severe cardiovascular disease, respiratory system disease, haematologic diseases and cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal laboratory examination that may influence the health of participants;", "Patient has no overlapping conditions/medications with exclusion criterion: A history of any aignificant medical illness such as neurological disorders (such as cerebral trauma, seizure disorder, etc);", "Patient has no overlapping conditions/medications with exclusion criterion: Known current psychosis as determined by the DSM-5 or a history of a non-mood psychotic disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol and drug abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal scalp such as open wounds;", "Patient has no overlapping conditions/medications with exclusion criterion: HAMD-17 item 3 (suicide) score=4;", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving modified electroconvulsive therapy (MECT) or repetitive transcranial magnetic stimulation (rTMS) in the past 1 month;", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial concurrently or no more than 1 month prior to randomisation."]}, {"trialId": "NCT06504927", "trialName": "Biomarker Discovery in Lung Cancer - Malaysia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (30.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is pregnant or lactating (self-declaration).", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is unwilling or unable to provide signed informed consent"]}, {"trialId": "NCT04998227", "trialName": "Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (20.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: cardiogenic shock, pregnancy, end-stage renal disease"]}, {"trialId": "NCT05377827", "trialName": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from study entry for any of the following:", "Patient has no overlapping conditions/medications with exclusion criterion: Received systemic anticancer therapy (including investigational therapy) or radiotherapy \\< 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:\n\n  * \\< 100 days post alloHCT\n  * \\< 6 weeks from prior donor leukocyte infusion\n  * Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.\n  * \\< 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with any anti-CD7 directed therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to one or more of the study agents.", "Patient has no overlapping conditions/medications with exclusion criterion: Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Confirmed HIV infection.", "Patient has no overlapping conditions/medications with exclusion criterion: History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic, uncontrolled hypotension."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT03150576", "trialName": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: T0 tumour in absence of axillary node \\>10mm.", "Patient has no overlapping conditions/medications with exclusion criterion: TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with myelodysplastic syndrome/acute myeloid leukaemia.", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of distant metastasis apparent prior to randomisation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled seizures.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breast feeding women.", "Patient has no overlapping conditions/medications with exclusion criterion: Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:\n\nEvidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.", "Patient has no overlapping conditions/medications with exclusion criterion: ECG with mean resting QTc \\>470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).", "Patient has no overlapping conditions/medications with exclusion criterion: Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable)."]}, {"trialId": "NCT06356376", "trialName": "The Effects of Pain and Pain Relief on Peripheral Nerve Excitability", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain conditions", "Patient has no overlapping conditions/medications with exclusion criterion: Neurological or Psychiatric disease", "Patient has no overlapping conditions/medications with exclusion criterion: Other major diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Pain medication within the last 24 hours"]}, {"trialId": "NCT05248776", "trialName": "Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a c-peptide value less than 0.5 nmol/l.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic, or non-peripheral vascular surgery within 6 months prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cardiac arrhythmia, systolic dysfunction, congestive heart failure, angina, myocardial ischemia or infarction, or stroke within 1 year prior to the study, or the presence of an abnormal ECG that, in the investigator's opinion, is clinically significant.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of drug abuse or a history of alcohol abuse within 2 years prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to basal cell or stage I squamous cell carcinoma of the skin.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase level above normal range for the testing laboratory, active liver disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a total bilirubin greater or equal 2 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is/ was lifetime on any insulin treatment or takes other diabetes treatment (except metformin).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of proteinuria ≥300 mg/day on a 12- or 24-hour urine collection within last year or an albumin/creatinine ratio greater or equal 300 μg/mg.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of any clinically significant retinopathy, which is defined as more than moderate nonproliferative diabetic retinopathy, any stage of proliferative diabetic retinopathy or any history of laser-treated retinopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has clinically significant peripheral or autonomic neuropathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of ulcerative colitis or Crohn's disease, or has undergone gastric resection.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of a psychiatric disorder that, in Principal Investigator opinion, will affect the subject ability to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of angioedema.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an acute, clinically significant illness within 30 days prior to the study or any other condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is not able to comply with the study scheduled visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is participating in another investigational study or has taken any investigational drug within 90 days prior to the study."]}, {"trialId": "NCT03269227", "trialName": "Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 85.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous thorax radiotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Chemotherapy is allowed but completed 3 weeks before RT starts", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial with any investigational agents within 30 days prior to study screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with M1 have to be excluded to this study", "Patient has no overlapping conditions/medications with exclusion criterion: FEV1 \\< 50", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>85 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Respiratory needing oxygen therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial pneumopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active pneumonitis", "Patient has no overlapping conditions/medications with exclusion criterion: Fissural disease", "Patient has no overlapping conditions/medications with exclusion criterion: Contralateral mediastinum involvement (N3) and M1", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."]}, {"trialId": "NCT06552676", "trialName": "riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure of the percutaneous tracheostomy technique or recourse to surgical tracheostomy"]}, {"trialId": "NCT01521676", "trialName": "Predictive Clinical and Biological Parameters in Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: emergency"]}, {"trialId": "NCT04030676", "trialName": "QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Wardship patient and curatorial patient", "Patient has no overlapping conditions/medications with exclusion criterion: Patient unable to understand or sign the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Colectomy total or partial"]}, {"trialId": "NCT04560127", "trialName": "Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Any active autoimmune disease or history of autoimmune disease and expected recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis); subjects with skin diseases that does no need systemic treatment, for example, leukoderma, psoriasis, alopecia, those with controlled type I diabetes by insulin or those with asthma that has been completely resolved in childhood and with no need of any intervention can be enrolled; while subjects with asthma who need bronchodilator for medical intervention cannot be enrolled.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of strong CYP3A4/CYP2C19 inducers, including rifampicin (and its analogues) and St. John's Wort, or strong CYP3A4/CYP2C19 inhibitors within two weeks prior to signing informed consent form.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with other immune checkpoint inhibitors (include PD-1 antibody or other immunotherapy against PD-1/PD-L1).", "Patient has no overlapping conditions/medications with exclusion criterion: Known history of serious allergy to any monoclonal antibody or Apatinib.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwilling to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current presence of metastasis to central nervous system.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia or complications of severe pneumonia; oral or intravenous therapeutic antibiotics within two weeks prior to the start of study treatment (for example, subjects who are given with preventive antibiotics for prevention of urinary tract infection or exacerbation of chronic obstructive pulmonary disease are eligible for participation in the study).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women.", "Patient has no overlapping conditions/medications with exclusion criterion: Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators, such as alcoholism, drug abuse, other serious diseases (including mental disorders) requiring concomitant therapy, with serious laboratory examination abnormality, with family or social factors, that may affect subject's safety."]}, {"trialId": "NCT05078476", "trialName": "Rehabilitation of Finger Flexor Tendon Injuries", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\< 18 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients", "Patient has no overlapping conditions/medications with exclusion criterion: Replantation of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Primary tendon reconstructions"]}, {"trialId": "NCT06087627", "trialName": "A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have been treated for more than 7 days with dupilumab", "Patient has no overlapping conditions/medications with exclusion criterion: Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."]}, {"trialId": "NCT04853576", "trialName": "A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (12.0, 50.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Available 10/10 HLA-matched related donor", "Patient has no overlapping conditions/medications with exclusion criterion: Prior HSCT or contraindications to autologous HSCT", "Patient has no overlapping conditions/medications with exclusion criterion: Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to receive red blood cell (RBC) transfusion for any reason", "Patient has no overlapping conditions/medications with exclusion criterion: Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine", "Patient has no overlapping conditions/medications with exclusion criterion: Any history of severe cerebral vasculopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate end organ function", "Patient has no overlapping conditions/medications with exclusion criterion: Advanced liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior or current malignancy or immunodeficiency disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Immediate family member with a known or suspected Familial Cancer Syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined inclusion/exclusion criteria may apply"]}, {"trialId": "NCT01341327", "trialName": "Observational Study for Left Main Disease Treatment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Protected left main stenosis"]}, {"trialId": "NCT06337227", "trialName": "Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients for whom biological material cannot be recovered for study purposes;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who refuse to participate in the study"]}, {"trialId": "NCT06312176", "trialName": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Has breast cancer amenable to treatment with curative intent", "Patient has no overlapping conditions/medications with exclusion criterion: Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune disease that has required systemic treatment in the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy"]}, {"trialId": "NCT06061627", "trialName": "A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Valvular heart disease that requires or has undergone surgical intervention", "Patient has no overlapping conditions/medications with exclusion criterion: After mechanical tricuspid valve replacement", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or permanent atrial fibrillation or atrial flutter", "Patient has no overlapping conditions/medications with exclusion criterion: Second or third degree atrioventricular block", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of acute myocardial infarction within 3 months prior to enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Patient's expected survival time is less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or planned to conceive", "Patient has no overlapping conditions/medications with exclusion criterion: Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with simple and persistent left superior vena cava", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with existing pacemaker implantation"]}, {"trialId": "NCT02907827", "trialName": "Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\\< 6weken)", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia", "Patient has no overlapping conditions/medications with exclusion criterion: Metallic devices implanted such as hip prostheses, since this can alter the imaging quality"]}, {"trialId": "NCT06291727", "trialName": "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients scheduled for bilateral TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Revision TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)", "Patient has no overlapping conditions/medications with exclusion criterion: Workers' Compensation patient", "Patient has no overlapping conditions/medications with exclusion criterion: Type I Diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Type II Diabetes requiring insulin medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-operative narcotics use with the exception of tramadol.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal insufficiency (GFR \\< 60) that may impact post-operative protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive deficiencies that prevent the patient from providing their own informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Language barrier preventing completion of study forms in English"]}, {"trialId": "NCT05650827", "trialName": "Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\< 18", "Patient has no overlapping conditions/medications with exclusion criterion: Living outside the greater Copenhagen area", "Patient has no overlapping conditions/medications with exclusion criterion: Any other malignancy requiring active treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Not eligible for chemotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Performance status \\> 2", "Patient has no overlapping conditions/medications with exclusion criterion: Not able to swallow liquids", "Patient has no overlapping conditions/medications with exclusion criterion: Parenteral nutrition or enteral nutrition via feeding tube", "Patient has no overlapping conditions/medications with exclusion criterion: Physical or mental disabilities that prohibit execution of test or training procedures", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to understand the Danish language"]}, {"trialId": "NCT06319027", "trialName": "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05536427", "trialName": "Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with immunodeficiency or a history of autoimmune disorders (e.g., rheumatoid arthropathy, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe concurrent medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, serious infection and infectious disease, active peptic ulcer, presence of active hemorrhage, and severe organ failure;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Grade III or IV cardiac failure defined by the New York Heart Association (NYHA), epileptic seizure, and mechanical or paralytic ileus within 6 months prior to the first administration of the investigational drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received chemotherapy and hormonal therapy within 28 days prior to signing the informed consent forms, or are currently taking other investigational drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with lymphoma, leukemia, myelodysplastic syndrome (MDS), or myelosuppression;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with allergy or a history of hypersensitivity to human blood albumin, or a history of allergy or hypersensitivity to any investigational drug or its excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with chronic diseases requiring immunotherapy or hormonal therapy; and subjects currently receiving corticosteroids for other diseases (except those using topical or inhaled steroids);", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with mental or neurological disorders that are not easily controlled;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects infected with human immunodeficiency virus (commonly known as AIDS) or treponema pallidum (commonly known as syphilis);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of other malignant tumors within the last 5 years;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with prior allogeneic stem cell transplantation or solid organ transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of drug or alcohol abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with any irAE of ≥ Grade 3 following prior immunotherapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who, in the judgment of the investigator, are not suitable to participate in this clinical study (e.g., with poor compliance)."]}, {"trialId": "NCT06093776", "trialName": "Rib Fracture Cryoanalgesia", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age Pregnant Incarcerated Confounding injuries or significant pain attributed to secondary injury Patients with any of the following: cryoglobulinemia; paroxysmal cold hemoglobinuria; cold urticarial; Raynaud's disease; open and/or infected wounds at or near the treatment site"]}, {"trialId": "NCT06146127", "trialName": "Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unequivocal histological features"]}, {"trialId": "NCT06330727", "trialName": "Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 59.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with diagnosis of diabetes, or taking anti-diabetic medication;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy, planned pregnancy, or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease)."]}, {"trialId": "NCT04855227", "trialName": "A Prospective Evaluation of Pain After Non-complex Ventral Hernia Repair", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is contraindicated for general anesthesia or surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a ventral hernia that will require retromuscular mesh placement or employ a technique, including (but not limited to) external oblique release, Rives- Stoppa, eTEP Rives-Stoppa, transversus abdominis release, other component separation techniques (i.e. anterior component separation) or eTEP transversus abdominis release.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a recurrent hernia.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will have an emergent hernia repair.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of chronic pain and/or taking daily pain medications for \\>6 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of substance abuse (excluding marijuana) and/or current (within 30 days) narcotic use.", "Patient has no overlapping conditions/medications with exclusion criterion: Current marijuana use that the subject is unwilling to discontinue within the 14 days prior to surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of MRSA infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with HbA1c level \\> 8.5%.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Exparel during the surgical procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will undergo a concomitant hernia repair or any other concomitant procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Current nicotine use (including vaping) within the past 30 days.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a known bleeding or clotting disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or suspected pregnancy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject belonging to other vulnerable population, e.g, prisoner or ward of the state.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is currently participating in another interventional or investigational research study."]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT06072976", "trialName": "The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (0.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Infant has already been on feeds", "Patient has no overlapping conditions/medications with exclusion criterion: Infants \\<34 weeks gestation", "Patient has no overlapping conditions/medications with exclusion criterion: Parents with contraindications to providing milk (i.e. drug use-cocaine, fentanyl, meth BUT oxy/suboxone/marijuana OK)", "Patient has no overlapping conditions/medications with exclusion criterion: Complicated gastroschisis", "Patient has no overlapping conditions/medications with exclusion criterion: Short gut syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Additional congenital anomalies that affect ability to tolerate milk (i.e. cyanotic congenital heart disease BUT kidney disease ok)"]}, {"trialId": "NCT05752227", "trialName": "Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pure pleural lesions.", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical instability to reach the final diagnosis.", "Patient has no overlapping conditions/medications with exclusion criterion: Inaccessibility by ultrasound."]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (4.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05364827", "trialName": "CT Coronary Angiography Prior to CTO PCI", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: CTO with J-CTO score\\<2", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate/degraded CTCA images", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant/lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe contrast allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to provide written informed consent"]}, {"trialId": "NCT05038527", "trialName": "ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: ASA ≥ 4", "Patient has no overlapping conditions/medications with exclusion criterion: Formally diagnosed with a disease affecting the bone metabolism or wound healing (severe osteoporosis, osteomalacia, Pagets disease, hyperparathyreoidism etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disseminated cancer diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to any of the i-FACTOR Peptide Enhanced Bone Graft ingredients", "Patient has no overlapping conditions/medications with exclusion criterion: Smoking, extensive alcohol use or abuse of hallucinating drugs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver or kidney disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or breastfeeding patients", "Patient has no overlapping conditions/medications with exclusion criterion: Patients estimated not to be able to understand the information sheet or patients, who do not consent to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe psychiatric diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Ongoing infections"]}, {"trialId": "NCT06200376", "trialName": "A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating, or plan to pregnant or give birth during the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;", "Patient has no overlapping conditions/medications with exclusion criterion: History of splenectomy or organ transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;", "Patient has no overlapping conditions/medications with exclusion criterion: Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of high risk cardiovascular disease, including but not limited to:\n\n    * Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);\n    * Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;\n    * Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;\n    * Rating of heart function as defined by the New York Heart Association (NYHA) standards\\>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;\n    * Left ventricular ejection fraction (LVEF) \\< the center lower limit. If no lower limit existed, LVEF\\<50%;\n    * Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);", "Patient has no overlapping conditions/medications with exclusion criterion: History of another malignant tumor, except the following:\n\n    * Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;\n    * Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;\n    * Adequately treated carcinoma in situ without evidence of disease;", "Patient has no overlapping conditions/medications with exclusion criterion: Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Unexplained \\>38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment"]}, {"trialId": "NCT06040827", "trialName": "A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06144476", "trialName": "Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.", "Patient has no overlapping conditions/medications with exclusion criterion: Surgery within the preceding 6 weeks", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection", "Patient has no overlapping conditions/medications with exclusion criterion: Alcohol or recreational drug abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency requiring treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to read or write English", "Patient has no overlapping conditions/medications with exclusion criterion: Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study"]}, {"trialId": "NCT03317327", "trialName": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB and stage I prostate cancer considered not necessary to treat", "Patient has no overlapping conditions/medications with exclusion criterion: Disease suitable for curative salvage surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 4 weeks prior to first administration of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant cardiac, pulmonary or other medical illness that would limit activity or survival", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to any of the components of the investigational product", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who test positive for hepatitis B, C or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of immunosuppressive therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease that has required systemic therapy within the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: Any reason why, in the opinion of the investigator, the patient should not participate"]}, {"trialId": "NCT04257227", "trialName": "Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Documented brain lesions", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to remain still while sitting up (45 degrees) for the duration of therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold"]}, {"trialId": "NCT05601427", "trialName": "Intra-Operative Adductor Canal Blocks", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or refusal to sign informed consent form", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.", "Patient has no overlapping conditions/medications with exclusion criterion: Non-osteoarthritis primary diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to analgesic medications", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal and/or regional anaesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Any use of opioid pain medication within four weeks of the index procedure(13)", "Patient has no overlapping conditions/medications with exclusion criterion: Pain catastrophizing scale score ≥16 (8, 9, 14)", "Patient has no overlapping conditions/medications with exclusion criterion: History of cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: History renal insufficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History or sensory and/or motor neuropathy to the ipsilateral limb", "Patient has no overlapping conditions/medications with exclusion criterion: Simultaneous, bilateral TKA", "Patient has no overlapping conditions/medications with exclusion criterion: Non-TKA prosthesis", "Patient has no overlapping conditions/medications with exclusion criterion: Scheduled for non-SDD TKA.", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative varus/valgus of \\>10 degrees.", "Patient has no overlapping conditions/medications with exclusion criterion: Planned General Anaesthetic", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Intrathecal Morphine"]}, {"trialId": "NCT03072927", "trialName": "MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (13.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT06585527", "trialName": "Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with encephalitis disease, multiple sclerosis, or other CNS (Central Nervous System) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of organ transplantation or waiting for organ transplantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled infectious diseases or other serious diseases, such as HIV positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with any unstable systemic illness (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris beginning within the last 3 months, congestive heart failure, myocardial infarction occurring within 12 months before enrollment, severe arrhythmia requiring medical treatment, liver or kidney failure, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with systemic autoimmune diseases or immunodeficiency diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe allergic constitution.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases requiring long-term treatment with immune agents or glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with mental disorders."]}, {"trialId": "NCT05956327", "trialName": "Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Lack of reliability and sanity (examined by an independent psychiatrist)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive urine drug screen for illicit drugs (except benzodiazepines)", "Patient has no overlapping conditions/medications with exclusion criterion: Acute suicide risk", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant psychiatric axis-I disorders according to the diagnostic testing procedure (Mini International Neuropsychiatric Interview, MINI)", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant neurological or other disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation"]}, {"trialId": "NCT03916627", "trialName": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with metastatic disease for whom the intent of surgery would not be curative", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 1 year", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply"]}, {"trialId": "NCT03712527", "trialName": "Intra-discal Injection of PRP for Low Back Pain", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 60.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: - Patient with Modic 1 discopathy in different vertebral levels", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a Modic I signal abnormality related to a static spinal disorder (such as previous vertebral fractures, or isthmic lysis, or spondyloarthritis)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a history of lumbar spine surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with suspected spondylodiscitis or other infection", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under anticoagulant or antiaggregant therapy, or with a coagulation disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with allergy to iodine or to any of the components of Xylocaine", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to MRI: Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with anatomical difficulty of access to the injection area (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with an uncontrolled severe disease (i.e. heart, pulmonary, gastro-intestinal, neurologic, endocrine, auto-immune affections) limiting the patient's safety (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with previous malignancy less than 5 years (except for non-melanoma skin cancer)", "Patient has no overlapping conditions/medications with exclusion criterion: Prior to the screening visit:", "Patient has no overlapping conditions/medications with exclusion criterion: a current and recent use of morphine (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: a systemic or local corticosteroid therapy (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: Porphyria", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with sphincter disorders indicating a cauda equina syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Psychotic state not controlled by a treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (βHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age", "Patient has no overlapping conditions/medications with exclusion criterion: Vulnerable persons protected by law", "Patient has no overlapping conditions/medications with exclusion criterion: Persons under guardianship", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who are in a dependency or employment with the sponsor or the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Subject unable to read or/and write"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT04519476", "trialName": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n  1. Has received selinexor or another XPO1 inhibitor previously.\n  2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \\>5 years previously and without evidence of recurrence will be allowed.\n  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \\[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\\], primary amyloidosis, etc.) that is likely to interfere with study procedures.\n  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.\n  6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.\n  7. Concurrent use of other anti-cancer agents or treatments.\n  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\n  9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin\n  10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n  11. Pregnant or breastfeeding females.\n  12. BSA \\<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.\n  13. Life expectancy of less than 3 months.\n  14. Major surgery within 4 weeks prior to C1D1.\n  15. Active, unstable cardiovascular function, as indicated by the presence of:\n\n  1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.\n\n  18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.\n\n  19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).\n\n  20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n\n  21. Contraindication to any of the required concomitant drugs or supportive treatments.\n\n  22. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT06508827", "trialName": "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemoglobinopathies", "Patient has no overlapping conditions/medications with exclusion criterion: Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemochromatosis", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating female adults", "Patient has no overlapping conditions/medications with exclusion criterion: Active infections which in research teams' opinion increases risk for toxicities", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures."]}, {"trialId": "NCT05900427", "trialName": "Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Ages: \\<18 and \\>90", "Patient has no overlapping conditions/medications with exclusion criterion: Weight \\< 60 kg", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple surgeries during one hospital stay", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or any contraindication to local anesthetics used in trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindicated for use of liposomal bupivacaine", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver/kidney disease", "Patient has no overlapping conditions/medications with exclusion criterion: Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who received another local anesthetic block prior to the interscalene block.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to consent in English"]}, {"trialId": "NCT05422027", "trialName": "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who meet any of the following criteria will not be enrolled:\n\n  1. Plasma cell leukemia.\n  2. Documented active amyloidosis.\n  3. Involvement of the central nervous system(CNS) by Multiple myeloma.\n  4. Prior exposure to a SINE compound, including ATG-010.\n  5. Currently, whether or not the patient is on medication, \\> Grade 2 peripheral neuropathy or ≥ Grade ≥ 2 painful neuropathy at baseline.\n  6. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and Selinexor (ATG-010) .\n  7. Active, unstable cardiovascular function, as indicated by the presence of:\n\n     1. Symptomatic ischemia, or\n     2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or\n     3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\<40%, or\n     4. Myocardial infarction within 6 months prior to C1D1.\n  8. Known positive serology for HIV or HIV seropositivity.\n  9. Known active hepatitis A, B, or C infection; eg. positive for HCV RNA or HBV-DNA.\n  10. Women who are pregnant or nursing.\n  11. Life expectancy of less than 6 months.\n  12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.\n  13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n  14. Contraindication to any of the required concomitant drugs or supportive treatments.\n  15. Has any concurrent diseases or complications that is likely to interfere with the study procedures.\n  16. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT05284227", "trialName": "Artificial Intelligence-augmented Perioperative Clinical Decision Support", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT06049927", "trialName": "A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (6.0, 35.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from seasonal influenza in the past 6 moths;", "Patient has no overlapping conditions/medications with exclusion criterion: Axillary temperature \\>37.0°C;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma;", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;", "Patient has no overlapping conditions/medications with exclusion criterion: Severe chronic diseases(Such as down syndrome, diabetes, sickle cell anaemia or neurological disorders);", "Patient has no overlapping conditions/medications with exclusion criterion: Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease (such as systemic lupus erythematosus) or immunodeficiency / immunosuppression (such as HIV, after organ transplantation)", "Patient has no overlapping conditions/medications with exclusion criterion: Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;", "Patient has no overlapping conditions/medications with exclusion criterion: Continuous use of corticosteroids or other immunosuppressive agents for ≥ 14 days within the past 6 months (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) and cytotoxic therapy in the past 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Acute diseases or acute exacerbation of chronic diseases in the past 3 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of blood products within in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of other investigational drugs in the past 30 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of attenuated live vaccines in the past 14 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Receipt of inactivated or subunit vaccines in the past 7 days;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other clinical trials before enrollment and in the follow-up period, or plans to participate in other clinical trials during the clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial"]}, {"trialId": "NCT05057676", "trialName": "Autoimmune Intervention Mastery Course Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04772027", "trialName": "Motor Parameters in Patients With Limb Girdle Muscular Dystrophy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: § For all:", "Patient has no overlapping conditions/medications with exclusion criterion: Without associated neuromuscular disorders such as respiratory or muscular-squeletic diseases, apart from the consequences of dystrophy;", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to the tests;", "Patient has no overlapping conditions/medications with exclusion criterion: Noncontrol cardiac rhythm disorders;", "Patient has no overlapping conditions/medications with exclusion criterion: Lying down position intolerance due to severe respiratory troubles;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman."]}, {"trialId": "NCT05159427", "trialName": "Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to independently provide an informed consent for themselves or mentally incapacitated.", "Patient has no overlapping conditions/medications with exclusion criterion: Physical disability (including blindness or deafness) that requires special arrangements.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant clinical illness, including cardiovascular disease, neurological disease, organ failure, or malignancy in the opinion of the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Any surgical procedure within 3 weeks prior to screening", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of severe seasonal allergies or severe allergic diseases including drug allergies, food allergies and allergy against the SmartPill® device", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to any of the study drugs or the products' excipients", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Sulfonamide derivatives", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to Lidocaine", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of XIFAXAN", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of hypersensitivity to acrylate or methacrylate, commonly used components of medical adhesives", "Patient has no overlapping conditions/medications with exclusion criterion: Any other factor, condition, or disease, including, but not limited to, cardiovascular, respiratory, hematological, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the patient, alter drug absorption and pharmacokinetics or impact the validity of the study results.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Type 1 Diabetes Mellitus (DM), diabetic ketoacidosis, with or without coma", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with Glucose 6-phosphate dehydrogenase (G6PD) deficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or presence of drug addiction or alcohol abuse within the past 12 months.", "Patient has no overlapping conditions/medications with exclusion criterion: History of significant psychiatric or neurological illness, including seizure disorders.", "Patient has no overlapping conditions/medications with exclusion criterion: Any medical or surgical conditions which might significantly interfere with the functions of gastrointestinal tract (e.g., gastric/intestinal bypass surgeries, fistulas, strictures, stenosis, or physiological/mechanical obstruction of the G.I tract, gastric bezoars, irritable bowel disease, crohn's disease, diverticulosis, or chronic narcotic use).", "Patient has no overlapping conditions/medications with exclusion criterion: History of dysphagia to liquids, food, or pills", "Patient has no overlapping conditions/medications with exclusion criterion: History of abdominal radiation therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating females", "Patient has no overlapping conditions/medications with exclusion criterion: Any clinically significant abnormal lab values during screening in the opinion of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of alcohol and/or nicotine containing products 48 hours prior to dosing visits, and throughout PK sampling visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any medications and/or supplements, prescriptions or over the counter 1 week prior to beginning the study, and throughout the study except for birth control with approved methods of contraception when used consistently and correctly (Implants (i.e. Implanon, Nexplanon), Injectables (i.e. Depo-Provera), Combined, Oral Contraceptives, Intrauterine Devices (IUD's) (i.e. Mirena, ParaGard), and Sexual Abstinence are accepted).", "Patient has no overlapping conditions/medications with exclusion criterion: Use of aspirin or any blood thinner medications.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteers unwilling or unable to take the proposed drugs or undergo G.I intubation", "Patient has no overlapping conditions/medications with exclusion criterion: Enrollment in a clinical trial in the past 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Current enrollment in a clinical trial with another study drug, vaccine or medical device", "Patient has no overlapping conditions/medications with exclusion criterion: Fasting blood glucose level \\< 80 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwillingness to fast for 19 hours.", "Patient has no overlapping conditions/medications with exclusion criterion: Blood donations in the past 8 weeks except for apheresis.", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer shows a positive result of COVID-19 Antigen Rapid test in dosing visits", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having any of the following symptoms:\n\n    * Fever (over 100.4 oF or 38 oC) or feeling feverish\n    * New cough\n    * New shortness of breath", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer is having two of any of these symptoms:\n\n    * Chills\n    * Muscle aches\n    * New URI symptom(s) (runny nose, nasal congestion, and/or sore throat)\n    * New loss of sense of smell or sense of taste\n    * New headache", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has been in close contact in the last 14 days with someone recently diagnosed with COVID-19", "Patient has no overlapping conditions/medications with exclusion criterion: Volunteer has returned from international travel within the past 10 days"]}, {"trialId": "NCT05525676", "trialName": "Relationship Checkups to Reduce Veteran Suicide Risk", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports severe intimate partner violence in the last year.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports experiencing suicidal intent requiring hospitalization.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER experiences past-month psychosis or mania.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years."]}, {"trialId": "NCT05763576", "trialName": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Healthy volunteers:", "Patient has no overlapping conditions/medications with exclusion criterion: History of any clinically significant disease", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant disease that could interfere with treatment or conduct of study", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)\n\nCHB participants:", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of liver cirrhosis or decompensated liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: History or suspicion of hepatocellular carcinoma (HCC)", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study."]}, {"trialId": "NCT05780476", "trialName": "A Novel VIRTUAL Reality Intervention for CAREgivers of People With Dementia (VirtualCare)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving daily assistance for more than 10 hours from formal CGs;", "Patient has no overlapping conditions/medications with exclusion criterion: Being formal CGs (i.e., nurse or another paid figure);", "Patient has no overlapping conditions/medications with exclusion criterion: Being informal CGs of i) persons with moderate-to-severe AD, or ii) persons with non-AD diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Not having or being able to use a device connected to internet (e.g., smartphones or PC).", "Patient has no overlapping conditions/medications with exclusion criterion: Having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs.", "Patient has no overlapping conditions/medications with exclusion criterion: Only a family member for person with dementia is accepted.\n\nExclusion Criteria for experimental group (Psychoeducation + VR):", "Patient has no overlapping conditions/medications with exclusion criterion: Medical history of epilepsy.\n\nExclusion Criteria for subsample of caregivers assess with MRI:", "Patient has no overlapping conditions/medications with exclusion criterion: Metal implants, artificial prostheses, pace-makers, prosthetic heart valves;", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy."]}, {"trialId": "NCT03990727", "trialName": "Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (2.0, 90.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: 1) Not willing to visit every year."]}, {"trialId": "NCT05721027", "trialName": "Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 70.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Not available for follow-up", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergic to or intolerant of investigational medications", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic steroid use", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney disease (GFR \\<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x the upper limit of normal)"]}, {"trialId": "NCT06550427", "trialName": "Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT04802876", "trialName": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior systemic anti-cancer therapy, including investigational agents within 2 weeks. Medical Monitor could consider shorter interval for kinase inhibitors or other short half-life drugs prior to allocation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants with ≤Grade 2 neuropathy may be eligible.\n\n   Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study treatment.\n\n   Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose of the previous investigational agent.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with thymoma are not eligible. Patients with active CNS metastases and/or carcinomatous meningitis are not eligible. Subjects with up to three cerebral metastases are eligible, if all lesions are stable and have been definitively treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any of its excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior allogeneic stem cell transplantation or organ transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history of interstitial lung disease, (non-infectious) pneumonitis that required steroids or has current pneumonitis, uncontrolled lung including pulmonary fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Human Immunodeficiency Virus (HIV).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of active TBC (Bacillus Tuberculosis).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of trial treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with spartalizumab or tislelizumab. Highly effective contraception methods include:\n\n    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n    4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.\n\n    Notes:\n    * Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.\n    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.", "Patient has no overlapping conditions/medications with exclusion criterion: Sexually active males, unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with spartalizumab or tislelizumab should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen."]}, {"trialId": "NCT04816227", "trialName": "Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusing to participate in the study", "Patient has no overlapping conditions/medications with exclusion criterion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research", "Patient has no overlapping conditions/medications with exclusion criterion: Being pregnant or breastfeeding"]}, {"trialId": "NCT06187727", "trialName": "Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Mechanical complications;", "Patient has no overlapping conditions/medications with exclusion criterion: Cardiogenic shock;", "Patient has no overlapping conditions/medications with exclusion criterion: Experienced myocardial infarction within 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Aortic dissection;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included", "Patient has no overlapping conditions/medications with exclusion criterion: Urinary system infection"]}, {"trialId": "NCT04167527", "trialName": "Endovascular Therapy for Low NIHSS Ischemic Strokes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: NIHSS ≥6", "Patient has no overlapping conditions/medications with exclusion criterion: Any sign of intracranial hemorrhage on baseline CT/MR (SDH/SAH/ICH)", "Patient has no overlapping conditions/medications with exclusion criterion: Any imaging findings suggestive of futile recanalization in the judgment of the local investigator", "Patient has no overlapping conditions/medications with exclusion criterion: High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD", "Patient has no overlapping conditions/medications with exclusion criterion: Premorbid disability (mRS ≥3)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to randomize within 8 hours of last known well", "Patient has no overlapping conditions/medications with exclusion criterion: Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS", "Patient has no overlapping conditions/medications with exclusion criterion: Baseline blood glucose of \\<50 mg/dL (2.78 mmol) or \\>400 mg/dL (22.20 mmol)", "Patient has no overlapping conditions/medications with exclusion criterion: Known coagulation disorders as defined as platelet count \\<100,000/uL", "Patient has no overlapping conditions/medications with exclusion criterion: Known renal failure as defined as serum creatinine levels \\> 3.0 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Presumed septic embolus or suspicion of bacterial endocarditis", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another investigational treatment study in the previous 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Intubation and mechanical ventilation prior to study enrollment is medically indicated", "Patient has no overlapping conditions/medications with exclusion criterion: History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Site investigator does not have equipoise towards the ideal treatment concept (thrombectomy vs. best medical management)", "Patient has no overlapping conditions/medications with exclusion criterion: Known pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Prisoner or incarceration", "Patient has no overlapping conditions/medications with exclusion criterion: Known acute symptomatic COVID-19 infection"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (16.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT06218576", "trialName": "Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: age \\< 18 years"]}, {"trialId": "NCT03050476", "trialName": "Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (21.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Already on renal replacement therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic kidney disease defined as estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m2 \\[ CKD stage \\> 3 \\]", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Concurrent enrollment in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with ongoing infections or current use of steroids", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with high-risk emergency surgery or with follow-up procedures already planned at admission (like e.g. TEVAR)"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT05500027", "trialName": "sCD8, as a Novel Biomarker for Pancreatic Cancer", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 85.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusal to participate", "Patient has no overlapping conditions/medications with exclusion criterion: Age less than 18-year old and over 85-year old"]}, {"trialId": "NCT05755776", "trialName": "The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Men and women of childbearing potential who are unwilling to use an \"effective\" method of contraception as defined in the protocol during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have received a solid organ or bone marrow transplant", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or existing clinical liver failure (Child-Pugh score ≥ grade B)."]}, {"trialId": "NCT05887076", "trialName": "Postoperative Delirium After Kidney Transplantation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete data records of the parameters to be determined", "Patient has no overlapping conditions/medications with exclusion criterion: Underage Patients"]}, {"trialId": "NCT05272176", "trialName": "Veterans Coordinated Community Care (3C) Study", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired decision-making capacity", "Patient has no overlapping conditions/medications with exclusion criterion: Limited or no English language proficiency", "Patient has no overlapping conditions/medications with exclusion criterion: Terminal illness"]}, {"trialId": "NCT05968976", "trialName": "Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Legally incompetent adults;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous tremor-neurosurgery (e.g., DBS, thalamotomy);", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;", "Patient has no overlapping conditions/medications with exclusion criterion: Psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Current depression;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent."]}, {"trialId": "NCT06182527", "trialName": "Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: diabetes mellitus", "Patient has no overlapping conditions/medications with exclusion criterion: use of medication interfering with glucose metabolism (steroid, antidiabetic medications)", "Patient has no overlapping conditions/medications with exclusion criterion: surgery of upper GI-tract", "Patient has no overlapping conditions/medications with exclusion criterion: known plaster allergies", "Patient has no overlapping conditions/medications with exclusion criterion: any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion"]}, {"trialId": "NCT06222827", "trialName": "Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, any major comorbidities (diabetes mellitus, cancer, severe autoimmune diseases, chronic renal failure, articular diseases that restricts exercise or participation in study assessments in the physician's opinion...), a history of relevant drug or food allergies; history of cardiovascular, respiratory, central nervous system disease; neuromuscular diseases except FSHD (e.g., myopathy, neuropathy, neuromuscular junction disorders)", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who are on drug(s) or supplements that may affect muscle function, as determined by the treating physician must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Orthopedic conditions, such as unresolved fracture or arthrosis, interfering or precluding testing of muscle function", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to muscle MRI as per clinic standard practice", "Patient has no overlapping conditions/medications with exclusion criterion: Articular contracture limiting movements, scapular fixation or other surgeries, preceding or planned", "Patient has no overlapping conditions/medications with exclusion criterion: Any known hypersensitivity to satralizumab or any of its components and/or history of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of latent or active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection for at least 4 weeks prior to enrollment), active opportunistic or life-threatening infections", "Patient has no overlapping conditions/medications with exclusion criterion: History of diverticulitis or concurrent severe GI disorders (such as symptomatic diverticulosis) that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation. Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit (Visit 1, week 0)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody.", "Patient has no overlapping conditions/medications with exclusion criterion: Acute or chronic history of liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal laboratory results with: White blood cells (WBC) \\< 3.0x 10\\^9/L ; Absolute Neutrophils Counts (ANC)\\< 2.0x 10\\^9/L ; Platelet count \\< 10x10\\^4/µl ; Absolute lymphocyte count (ALC) \\< 0.8x 10\\^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 times the upper limit of normal (ULN)", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment (defined as a glomerular filtration rate of \\<30mL/min/1.73m²)", "Patient has no overlapping conditions/medications with exclusion criterion: Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation", "Patient has no overlapping conditions/medications with exclusion criterion: For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier \\[patient or partner\\] in conjunction with a spermicidal product, contraceptive pill, patch, injectable, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of another investigational product within 6 months or 5 half-lives (whichever is longer), or currently participating in a prospective study with an investigational product, whether it concerns an experimental drug or a medical device. Note: concurrent participation in natural history studies (non-drug, non-device studies) is not allowed during the course of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior treatment with any agent targeting the IL-6 inhibition pathway (e.g. tocilizumab, sarilumab), alemtuzumab treatment, total body irradiation, or bone marrow transplantation; treatment in the past 24 weeks with an anti-B-lymphocyte antigen CD20 (e.g. rituximab, ocrelizumab), eculizumab, anti-B-lymphocyte stimulator, or any other multiple sclerosis disease-modifying treatment; treatment in the past 2 years with an anti-T-cell surface glycoprotein CD4, cladribine, cyclophosphamide, or mitoxantrone; or treatment with any other investigational drug within 3 months prior to baseline. See section 4.4.4 for details on the vaccination and immunization.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject, or close relative of the subject, is the investigator or a coinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code."]}, {"trialId": "NCT05505227", "trialName": "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: currently prescribing buprenorphine at full capacity"]}, {"trialId": "NCT05782127", "trialName": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous diagnosis of:\n\n   * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)\n   * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: History of active malignancy within the past year prior to screening, with the exception of:\n\n   * Adequately treated carcinoma in situ of the uterine cervix\n   * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n   * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.\n\n   Patients with ongoing horomonotherapy could be included.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.", "Patient has no overlapping conditions/medications with exclusion criterion: Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.", "Patient has no overlapping conditions/medications with exclusion criterion: Received live attenuated vaccines prior to initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions that could interfere with drug absorption including short gut syndrome, dysphagia, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mmHg or diastolic BP \\> 100 mmHg) or has not been stable for at least 1 month prior to treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:\n\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Unstable angina or angina requiring surgical or medical intervention\n    * Significant cardiac arrhythmia\n    * And/or myocardial infarction", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is a pregnant or lactating female.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has known or suspected to have hypersensitivity to any of the components of the assigned study treatments.", "Patient has no overlapping conditions/medications with exclusion criterion: Positive test result(s) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B surface \\[HBs\\] antibody positive and anti-hepatitis B core \\[HBc\\] antibody negative) may participate.", "Patient has no overlapping conditions/medications with exclusion criterion: Absence of social security affiliation."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT06524427", "trialName": "Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with the previous history of other malignancies;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with secondary primary cancer when enrolled;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as pure ground glass opacity (GGO) before surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as mixed GGO whose solid part \\<= 50% and Maximum diameter of tumor \\<= 2cm;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with small cell lung cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with prior unilateral open thoracic surgical procedures;", "Patient has no overlapping conditions/medications with exclusion criterion: Woman who is pregnant or breastfeeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with an active bacterial or fungal infection that is difficult to control;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with serious psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months."]}, {"trialId": "NCT05537376", "trialName": "A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Veteran"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT05189327", "trialName": "Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient takes part in an interventional clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is unable to follow the schedule of the visits;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that the PI believes would prevent a study participant from participating in the study."]}, {"trialId": "NCT06447727", "trialName": "Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: After liver metastasis was diagnosed, the liver underwent external radiation therapy and transhepatic arterial chemoembolization", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with extrahepatic metastases", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe arrhythmia or heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: Other researchers considered it inappropriate to participate in this study"]}, {"trialId": "NCT06176027", "trialName": "Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women"]}, {"trialId": "NCT05775627", "trialName": "Sleep and Metabolism", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 40.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dietary restrictions\n\n   Participants must not have dietary restrictions that could systematically bias their macronutrient intake. The following will exclude participants from enrolling in the study based on their diet:\n   * Participants who choose not to or cannot consume dairy products (milk, yogurt, cheese, ice cream)", "Patient has no overlapping conditions/medications with exclusion criterion: Body Composition\n\n   A body mass index (BMI) of 18.5\\< \\[BMI\\] \\< 25 kg/m2 and a waist circumference \\<94/80cm.", "Patient has no overlapping conditions/medications with exclusion criterion: Psychiatric/psychological suitability\n\n   Each participant will undergo a structured interview (Mini International Neuropsychiatric Interview) with a qualified OHSU physician. This physician will supervise the administration and scoring of a Beck Depression Inventory II (BDI-II) questionnaire for each potential participant. The following will exclude individuals from participating based on their psychiatric or psychological evaluation:\n   * Individuals with evidence of psychopathology on the BDI-II, or in a structured clinical interview with the physician\n   * A history of severe psychiatric illnesses\n   * Alcoholism\n   * Drug dependency\n   * Major depression\n   * Manic depressive illness\n   * Schizophrenic disorders\n   * Panic disorder\n   * Generalized anxiety disorder\n   * Post-traumatic stress disorder\n   * Agoraphobia\n   * Claustrophobia\n   * Paranoid personality disorder\n   * Schizoid personality disorder\n   * Schizotypal personality disorder\n   * Borderline personality disorder\n   * Antisocial personality disorder.\n   * History of using antidepressant medication\n   * History of using neuroleptic medication\n   * History of using tranquilizers", "Patient has no overlapping conditions/medications with exclusion criterion: Drug/alcohol use\n\n   Volunteers must be drug-free (including caffeine, nicotine, alcohol and herbal medications) for the entire duration of the outpatient and in-laboratory study period, with no history of drug or alcohol dependency. All participants must be:\n   * Current non-smokers, and are required to have a history of less than 5 'pack years' of smoking", "Patient has no overlapping conditions/medications with exclusion criterion: Medication/drug use\n\n   Volunteers must not be taking any prescribed medications or over the counter medications, with an exception for birth control.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior shift work\n\n   For stability of endogenous circadian rhythmicity, volunteers must have no history of the following 1 year prior to the study:\n   * Working irregular day and night hours\n   * Regular night work\n   * Rotating shift work f\n   * Not have traveled more than 1 time zone during 3 months prior to the study", "Patient has no overlapping conditions/medications with exclusion criterion: Chronobiologic and sleep disorders\n\n   * Hypernychthemeral sleep/wake cycle\n   * Delayed sleep phase syndrome (wake time \\> 2 hours later than desired or habitually after 10:00 AM)\n   * Advanced sleep phase syndrome (wake time \\> 2 h earlier than desired or habitually before 5:00 AM)\n   * Narcolepsy\n   * Sleep apnea (apnea index \\>15)\n   * Insomnia (sleep complaint by history or polygraphically recorded sleep efficiency \\< 80%)\n   * Hypersomnia\n   * Periodic Limb Movement (PLMS) (PLMS index \\>15)\n   * Nocturnal Paroxysmal Dystonia\n   * REM-sleep behavior disorder\n   * Nocturnal Enuresis; (self-report and first night in the laboratory)\n   * Obstructive sleep apnea (apnea/hypopnea index \\>5/h as determined by at-home monitoring)\n   * The investigators will also exclude individuals with extreme chronotype using the Horne-Ostberg Morningness/Eveningness questionnaire (i.e., the Owl/Lark Questionnaire)", "Patient has no overlapping conditions/medications with exclusion criterion: Diseases of the Cardiovascular System\n\n   * Hypertension (systolic blood pressure \\> 140 or diastolic blood pressure \\> 90)\n   * Heart failure\n   * Cardiomyopathy\n   * Cor pulmonale\n   * Ischemic heart disease\n   * Valvular heart disease\n   * History of heart transplantation\n   * Cardiac tumors\n   * Pericardial disease", "Patient has no overlapping conditions/medications with exclusion criterion: Metabolic Syndrome\n\n   Following American Heart Association cutoffs, participants who have, in addition to abdominal fat (obese exclusion criteria), two or more of these factors will be excluded from the study:\n   * HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women\n   * Systolic blood pressure \\>135 mmHg or diastolic blood pressure \\>85 mmHg\n   * Fasting blood glucose ≥ 100 mg/dL\n   * Triglycerides ≥ 150 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-Diabetes/Diabetes\n\n    For participants who have a fasting blood glucose level of ≥ 100 mg/dL the investigators will measure hemoglobin A1c to exclude for diabetes (HbA1c\\>5.7%).", "Patient has no overlapping conditions/medications with exclusion criterion: Hypertension\n\n    An upper cut off of 140/90 mmHg during an office blood pressure measure will be used as an exclusion criterion. After 5 minutes of rest in a seated position, blood pressure will be measured 3 times, taken 1 minute apart. The average will be used to confirm eligibility criteria. Current or history of beta blocker use will also be exclusionary.", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Respiratory System\n\n    * Asthma\n    * Cystic fibroses\n    * Chronic bronchitis\n    * Emphysema\n    * Airway obstruction\n    * Interstitial lung diseases\n    * Pulmonary hypertension\n    * Lung neoplasms\n    * ARDS", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Kidney and Urinary Tract\n\n    * Acute or chronic renal failure\n    * History of renal transplantation\n    * Tubulointerstitial diseases of the kidney\n    * Urinary tract obstruction\n    * Tumors of the urinary tract", "Patient has no overlapping conditions/medications with exclusion criterion: Infectious Diseases\n\n    * Infective endocarditis\n    * HIV infection\n    * Sexually transmitted diseases \\[e.g., syphilis (including congenital syphilis and its sequelae), gonorrhea\\],\n    * Urinary tract infection\n    * Osteomyelitis\n    * Brucellosis\n    * Toxoplasmosis,\n    * Tuberculosis\n    * Leptospirosis\n    * Lyme disease\n    * Mononucleosis\n    * Hepatitis\n    * Parasitic infections such as malaria, toxoplasmosis, giardiasis, schistosomiasis, leishmaniasis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Gastrointestinal System\n\n    * Esophagitis\n    * Peptic ulcer and gastritis\n    * Neoplasms of the esophagus, stomach or bowel\n    * Disorders of absorption\n    * Inflammatory bowel disease\n    * Diseases of the small and large intestine\n    * Acute appendicitis\n    * Cirrhosis or neoplasms of the liver\n    * History of liver transplantation\n    * Diseases of the gallbladder and bile ducts\n    * Pancreatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Immune System, Connective Tissue and Joints\n\n    * AIDS\n    * Systemic lupus erythematosus\n    * Rheumatoid arthritis\n    * Scleroderma\n    * Ankylosing spondylitis\n    * Vasculitis\n    * Sarcoidosis", "Patient has no overlapping conditions/medications with exclusion criterion: Disorders of the Hematopoietic System\n\n    * Anemia\n    * Leukemia\n    * Myeloproliferative diseases\n    * History of bone marrow transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Neoplastic Diseases\n\n    * Lymphoma\n    * Carcinoma\n    * Melanoma\n    * Any other neoplastic diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Endocrine and Metabolic Diseases\n\n    * Thyroid disease\n    * Addison's Disease\n    * Cushing's Syndrome\n    * Aldosteronism\n    * Hypoaldosteronism\n    * Pheochromocytoma\n    * Disorders of sexual differentiation that require hormone supplementation that may alter body weight\n    * Disorders of neuroendocrine regulation\n    * Diseases of the anterior pituitary and hypothalamus\n    * Hemochromatosis porphyria\n    * Wilson's Disease\n    * Glycogen storage diseases\n    * Diseases of the parathyroid gland\n    * Metabolic bone disease\n    * Disorders of phosphorus or magnesium metabolism\n    * Paget's Disease", "Patient has no overlapping conditions/medications with exclusion criterion: Neurologic Disorders\n\n    * Epilepsy and disorders of consciousness\n    * Dementia\n    * Amnesic disorders\n    * Neoplastic diseases of the central nervous system\n    * Demyelinating diseases\n    * Parkinson's Disease\n    * Muscular dystrophy\n    * Myasthenia gravis\n    * Periodic paralysis\n    * Dermatomyositis\n    * Polymyositis\n    * Infections of the nervous system\n    * Stroke\n    * History of transient ischemic attacks\n    * Hydrocephalus\n    * Tumors of the pituitary gland\n    * Pinealoma\n    * Intervertebral disc disease\n    * Ataxia\n    * Gilles de la Tourette Syndrome\n    * Huntington's Disease\n    * Tardive dyskinesia\n    * History of recurrent migraine headaches\n    * Neuromuscular disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects must not be currently participating in another research study that would influence their safe participation in our study. Subjects must not be participating in a research study in which they do the following:\n\n    * Ingest experimental medication\n    * Give blood samples"]}, {"trialId": "NCT04280627", "trialName": "Changes in the Microbiome Associated With Transplantation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Outside of stated age range.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to give informed consent"]}, {"trialId": "NCT03969927", "trialName": "User-friendliness of a Portable Driving Simulator", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (25.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of traumatic brain injury or any other neurological condition apart from stroke, PD, and MS."]}, {"trialId": "NCT06627127", "trialName": "A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects meeting any of the following criteria will be excluded from participation in this study:", "Patient has no overlapping conditions/medications with exclusion criterion: Major anatomical or functional abnormalities that would impair the ability of the electrode arrays to be positioned.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant comorbidities that contraindicate surgery or general anesthesia/DISE", "Patient has no overlapping conditions/medications with exclusion criterion: Significant tongue weakness", "Patient has no overlapping conditions/medications with exclusion criterion: Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia/DISE in the judgment of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior surgery or treatments that could compromise the placement and effectiveness of the electrode array systems:\n\n  * Airway cancer surgery or radiation,\n  * Mandible or maxilla surgery in the previous 3 years (not counting dental treatments),", "Patient has no overlapping conditions/medications with exclusion criterion: Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),", "Patient has no overlapping conditions/medications with exclusion criterion: Prior hypoglossal nerve stimulation device implantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently pregnant, or breastfeeding during the study period"]}, {"trialId": "NCT06441227", "trialName": "Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 55.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who suffer from any serious clinical diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease or medical history that can interfere with the test results or any significant laboratory abnormality that is judged by researchers to be of clinical significance.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of malignant tumors.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have taken any prescription drugs, over-the-counter drugs and Chinese herbs within 14 days before taking the study drug, or within 5 half-life of the drug at the time of screening; those who plan to take non-study drugs during the trial period.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have participated in the clinical trial of any drug or medical device within 3 months before screening, or have not been within 5 half-life of the drug before screening (when both standards are met, the standard shall be based on the long-term standard).", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects received siRNA in the past 12 months, or antisense oligonucleotide drugs in the past six months.", "Patient has no overlapping conditions/medications with exclusion criterion: The abnormal upper limit of hypersensitive C-reactive protein during the screening period is \\>1.5 times the normal upper limit, or the normal upper limit of prothrombin time/international standard ratio (PT/INR), activated partial thrombin time (aPTT) \\> 1.25 times normal upper limit.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening for infectious diseases during the screening period (including hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, syphilis spirochete antibody).", "Patient has no overlapping conditions/medications with exclusion criterion: 12-lead electrocardiogram abnormal and clinical significance, or electrocardiogram QT interval (QTcF) male \\> 450 ms, female \\> 470 ms.", "Patient has no overlapping conditions/medications with exclusion criterion: The total amount of blood donated or blood loss ≥ 200 mL within 1 month before administration, or the total amount of blood donation or blood loss ≥ 400 mL within 3 months before administration, or received blood transfusion within 8 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have a serious infection, serious trauma or major surgery within 3 months before administration; those who plan to undergo surgery within two weeks during and after the end of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Suspected people with a history of allergy to research drugs or any ingredients in research drugs, allergies or previous history of serious drug allergies.", "Patient has no overlapping conditions/medications with exclusion criterion: People who have had blood collection difficulties or cannot tolerate venous punctures in the past, such as needle fainting and blood fainting.", "Patient has no overlapping conditions/medications with exclusion criterion: Glomerular filtration rate (eGFR) is lower than GFR 60 mL/min/1.73 m2.", "Patient has no overlapping conditions/medications with exclusion criterion: Smoke an average of ≥ 5 cigarettes per day in the first three months of administration; the average daily intake of alcohol in the first month before administration exceeded 15 grams.", "Patient has no overlapping conditions/medications with exclusion criterion: Screening and visiting drug screening test is positive or alcohol breath test is positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Other circumstances in which the researcher believes that the subject is not suitable to participate in this experiment."]}, {"trialId": "NCT05763927", "trialName": "Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 75.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have previously received immune checkpoint inhibitors;", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reactions to PD-1 monoclonal antibody active ingredients, TKI inhibitor-related ingredients or any excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with organ bleeding or bleeding tendency, except for rectal primary tumor bleeding (need investigator to assess the risk of bleeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: years or at the same time have a history of other malignant tumors, but cured skin basal cell carcinoma and cervical carcinoma in situ and thyroid;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled epilepsy, central nervous system disease or mental disorders, the investigator judged that their clinical severity may hinder the signing of informed consent or affect the patient 's compliance with oral drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically serious (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalent daily) or other immunosuppressive agents (including organ transplant recipients) within 2 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other interventional drug clinical trials within 4 weeks before the first dose;", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery or severe trauma within 4 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Serious infection (CTCAE greater than grade 2) within 4 weeks before the first dose of study drug,Such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging suggests active pulmonary inflammation, symptoms and signs of infection within 2 weeks before the first dose of study drug, or the need for oral or intravenous antibiotics (excluding prophylactic antibiotics);", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes); autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone, using stable doses of insulin type 1 diabetes can be included; but excluding vitiligo or recovered childhood asthma/allergy, without any intervention in adults;", "Patient has no overlapping conditions/medications with exclusion criterion: History of immunodeficiency, including positive HIV test, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Active pulmonary tuberculosis infection found by medical history or CT examination, Or patients with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or patients with a history of active pulmonary tuberculosis infection but without regular treatment 1 year before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with active hepatitis (HBV DNA ≥ 2000 IU/ml or 10000 copies/ml), hepatitis C (hepatitis C antibody positive,HCV-RNA was above the lower limit of detection of the assay);", "Patient has no overlapping conditions/medications with exclusion criterion: Had a known history of psychotropic drug abuse, alcoholism, or drug use;", "Patient has no overlapping conditions/medications with exclusion criterion: Had a history, illness, treatment, or laboratory abnormality that could interfere with the results of the trial, prevent the subject from participating throughout the study, or the investigator considered participation to be in the subject 's best interest."]}, {"trialId": "NCT05264727", "trialName": "Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (25.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05555576", "trialName": "Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Opioid use 1 month prior to the ED visit;", "Patient has no overlapping conditions/medications with exclusion criterion: Already taking vitamin C supplement;", "Patient has no overlapping conditions/medications with exclusion criterion: Active cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for chronic pain;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for opioid use disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to fill out diary or unavailable for follow-up;", "Patient has no overlapping conditions/medications with exclusion criterion: Any allergy, intolerance or sensitivity to milk (lactose) or morphine", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with cyclosporin or coumadin", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)"]}, {"trialId": "NCT04557527", "trialName": "Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to hyaluronate or. HEALON5® PRO OVD", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\nStudy eye:", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of proliferative vitreoretinopathy (PVR) or any tractional RD", "Patient has no overlapping conditions/medications with exclusion criterion: Previous vitreoretinal surgery, open-globe injury or endophthalmitis", "Patient has no overlapping conditions/medications with exclusion criterion: Aphakia", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current congenital cataract", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current suprachoroidal haemorrhage", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment", "Patient has no overlapping conditions/medications with exclusion criterion: Current intraocular inflammation other than mild cellular activity thought to be secondary to RD", "Patient has no overlapping conditions/medications with exclusion criterion: Current ocular or periocular infection other than blepharitis"]}, {"trialId": "NCT05427227", "trialName": "Prospectively Predict the Efficacy and Explore the Mechanism of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous systemic therapy for metastatic GI cancer\n\n  * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.\n  * Allergic constitution or allergic history to protium biologic product or any investigating agents.\n  * Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.\n  * Pregnancy or lactation period\n  * Other previous malignancy within 5 year, except non-melanoma skin cancer\n  * Legal incapacity"]}, {"trialId": "NCT05628376", "trialName": "TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:", "Patient has no overlapping conditions/medications with exclusion criterion: Positive margins, incomplete resection or insufficient nodal sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B/C:", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)"]}, {"trialId": "NCT04620876", "trialName": "Bimodal and Coaxial High Resolution Ophtalmic Imaging", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (1.0, 100.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05757076", "trialName": "Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 65.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of secondary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy status (verbal)"]}, {"trialId": "NCT04838327", "trialName": "Rare Subtypes of Gastrointestinal Cancers", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions precluding translational blood sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Another concomitant cancer"]}, {"trialId": "NCT03344276", "trialName": "Assessing Neurocognition After Cerebrovascular Intervention", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: patients \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: patients with without compatibility for MRI", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring carotid stenting for reasons not related to long-standing stenosis", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study."]}, {"trialId": "NCT06186427", "trialName": "A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, 80.0)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who cannot tolerate puncture biopsy or surgical contraindications;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have undergone radiotherapy and chemotherapy in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Individuals who are allergic to multiple drugs or foods;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who refuse nuclear medicine examinations;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who do not agree to sign an informed consent form and are unable or willing to follow up."]}, {"trialId": "NCT04695327", "trialName": "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled cardiac or vascular diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hepatic dysfunction, hepatitis or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: History of coagulation disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant, breastfeeding or intend to become pregnant.", "Patient has no overlapping conditions/medications with exclusion criterion: Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.", "Patient has no overlapping conditions/medications with exclusion criterion: Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol)."]}, {"trialId": "NCT06339827", "trialName": "ASk Questions in GYnecologic Oncology (ASQ-GYO)", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment discussion with a Gynecologic Oncologist"]}, {"trialId": "NCT03921827", "trialName": "External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (21.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with atrial fibrillation/ arrhythmias.", "Patient has no overlapping conditions/medications with exclusion criterion: Within 2 weeks of cardiac catheterization or arterial puncture at femoral puncture site.", "Patient has no overlapping conditions/medications with exclusion criterion: Decompensated heart failure , usually class 3 or 4", "Patient has no overlapping conditions/medications with exclusion criterion: LV EF \\<30%", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe AR", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent and uncontrolled hypertension (BP persistently \\>160/100 mmHg)", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding diathesis", "Patient has no overlapping conditions/medications with exclusion criterion: Active thrombophlebitis/ venous disease of lower limbs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe lower extremity vaso-occlusive disease", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a documented aortic aneurysm/ dissection requiring surgical repair", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy"]}, {"trialId": "NCT05312827", "trialName": "Training Intervention and Program of Support (TIPS): Fostering Family-centred Telehealth in Pediatric Rehabilitation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03529227", "trialName": "Gazyva Infusion Reaction Investigation", "eligibilityCriteriaMet": ["Patient Age (34) matches Expected Range (18.0, Not Specified)", "Patient Sex (M) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: The refusal of the patient to participate in the observational study and the withdrawal of informed consent that allow processing of personal data and data that refer to patient confidentiality."]}]}, {"patientId": "86da3bcb-7279-ebe4-fdd6-3ccd73eb31fa", "eligibleTrials": [{"trialId": "NCT06286527", "trialName": "Quality of Sexual Life of PrEP Users", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unwilling to participate"]}, {"trialId": "NCT04484727", "trialName": "\"Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs\"", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients under 18 years", "Patient has no overlapping conditions/medications with exclusion criterion: ASA 4 and above", "Patient has no overlapping conditions/medications with exclusion criterion: severe COPD/emphysema/heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: PEEP\\>16 and/or FiO2 \\>80%", "Patient has no overlapping conditions/medications with exclusion criterion: elevated intracranial pressure", "Patient has no overlapping conditions/medications with exclusion criterion: defect coagulation", "Patient has no overlapping conditions/medications with exclusion criterion: non-treated known or suspected pneumothorax"]}, {"trialId": "NCT03869476", "trialName": "Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 99.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a diagnosis of secondary myelofibrosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman;", "Patient has no overlapping conditions/medications with exclusion criterion: Person prived of liberty by judicial or administrative decision;", "Patient has no overlapping conditions/medications with exclusion criterion: Person subject to a legal protection measure;"]}, {"trialId": "NCT06113276", "trialName": "Quantitative Computed Tomography for Mortality Risk Stratification in ARDS", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (15.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of contrast agent during computed tomography acquisition", "Patient has no overlapping conditions/medications with exclusion criterion: ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours", "Patient has no overlapping conditions/medications with exclusion criterion: Proven COPD", "Patient has no overlapping conditions/medications with exclusion criterion: Pneumothorax or bronchopleural fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses", "Patient has no overlapping conditions/medications with exclusion criterion: Previous inclusion in current study", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under a legal protective measure"]}, {"trialId": "NCT05690776", "trialName": "PMCF Study on the Safety, Performance and Clinical Benefits Data of the Quattro X Broadband", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of infection;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient or immature bone;", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient blood supply or previous infections which may hinder the healing process;", "Patient has no overlapping conditions/medications with exclusion criterion: Foreign body sensitivity;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant);", "Patient has no overlapping conditions/medications with exclusion criterion: The subject is unwilling or unable to give consent or to comply with the follow-up program;", "Patient has no overlapping conditions/medications with exclusion criterion: Subject meets any contraindications of the appropriate Instruction for Use."]}, {"trialId": "NCT06100276", "trialName": "Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.", "Patient has no overlapping conditions/medications with exclusion criterion: Pathogenic repeat expansion in the C9orf72 gene", "Patient has no overlapping conditions/medications with exclusion criterion: Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications."]}, {"trialId": "NCT04666727", "trialName": "Role of Diet on the Microbiome of the Digestive System", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (45.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: • Current smokers (nicotine abuse only)\n\n  * Positive family history of colon cancer or colon cancer related syndromes\n  * Recent use of antibiotics in 1 month\n  * History of inflammatory bowel disease, and/or radiation enteritis or colitis\n  * Pregnant and breastfeeding women\n  * Women of child-bearing potential who have positive urine or serum pregnancy test\n  * Heavy drinker (defined as more than 14 drinks per week)\n  * Currently using anti-flatulence medications, probiotics and/or fiber supplements\n  * Major dietary restrictions and/or following a special diet\n  * Patient with positive fecal test/symptoms"]}, {"trialId": "NCT06027827", "trialName": "Impact of Lateral Bone Grafting With Intraoperative Fusion in ACDF on Clinical Outcomes", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 60.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Drug or alcohol abusers; those with abnormal liver or kidney function unsuitable for surgery; those with cardiac insufficiency unsuitable for surgery; those with severe metabolic and endocrine diseases unsuitable for surgery; those with severe lung disorders such as asthma and abnormal lung function unsuitable for surgery; pregnant and breastfeeding women as well as those who are planning to become pregnant in the near future; those who have participated in other clinical trials within 3 months; and those who are not suitable for participation in the experiment in the opinion of the investigator."]}, {"trialId": "NCT06597227", "trialName": "Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  <!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL/min;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects."]}, {"trialId": "NCT05731427", "trialName": "Research on the Mechanism Affecting Progression of Bronchiectasis", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05666076", "trialName": "Peng Block or Suprascapular Nerve Block for Postoperative Analgesia in Shoulder Artroscopy ?", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with deformity and pathology in the shoulder region", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with known local anesthetic allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with BMI\\>35", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with alcohol and substance addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with opioid addiction", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who cannot perceive and evaluate pain, such as psychiatric illness, mental retardation"]}, {"trialId": "NCT05626127", "trialName": "MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Accompanied with other primary malignant tumors;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies;", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete imaging or medical history data."]}, {"trialId": "NCT06191627", "trialName": "Patient Experience and Quality of Patch Testing on the Legs vs Back", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 89.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is 17 or younger", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or breastfeeding", "Patient has no overlapping conditions/medications with exclusion criterion: Specialized patch testing with low number of patches (less than 90)", "Patient has no overlapping conditions/medications with exclusion criterion: Rash that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Large tattoos that would preclude testing on thighs or back", "Patient has no overlapping conditions/medications with exclusion criterion: Limited space on thighs or back due to body habitus", "Patient has no overlapping conditions/medications with exclusion criterion: Patient has specific needs necessitating use of the thighs or back (event, breastfeeding, etc.)"]}, {"trialId": "NCT05890027", "trialName": "Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who refuse to consent.", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.", "Patient has no overlapping conditions/medications with exclusion criterion: Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease", "Patient has no overlapping conditions/medications with exclusion criterion: This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors"]}, {"trialId": "NCT05004727", "trialName": "Multi-Center PAMPA Study", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;", "Patient has no overlapping conditions/medications with exclusion criterion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);", "Patient has no overlapping conditions/medications with exclusion criterion: RA seropositivity (mid-high RF/ACPA titers);", "Patient has no overlapping conditions/medications with exclusion criterion: Current active malignancy;", "Patient has no overlapping conditions/medications with exclusion criterion: History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to the study agent."]}, {"trialId": "NCT06001827", "trialName": "SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Planned index procedure to revise or repair an existing fistula", "Patient has no overlapping conditions/medications with exclusion criterion: Target artery inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Target vein inner diameter \\< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound", "Patient has no overlapping conditions/medications with exclusion criterion: Known central venous stenosis of at least 50% on the side of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a stent or a stent graft within the access circuit", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected active infection at the time of surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Congestive heart failure NYHA class 4", "Patient has no overlapping conditions/medications with exclusion criterion: Prior steal on the side of surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Life expectancy less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo kidney transplant surgery within 6 months of enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Expected to undergo home hemodialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study", "Patient has no overlapping conditions/medications with exclusion criterion: Unwillingness or inability to give consent and/or comply with the study follow up schedule", "Patient has no overlapping conditions/medications with exclusion criterion: Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study."]}, {"trialId": "NCT03947827", "trialName": "Minocycline as Adjunctive Treatment for Treatment Resistant Depression", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 substance use disorder within past 3 months, moderate or severe, based on SCID-5", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant major unstable medical illness", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or intent to become pregnant during study period", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of psychotic disorder, bipolar disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) within last year", "Patient has no overlapping conditions/medications with exclusion criterion: DSM-5 diagnosis of borderline personality disorder (BPD)", "Patient has no overlapping conditions/medications with exclusion criterion: Possible or probable dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or current intolerance or contraindication to tetracyclines", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal readings in hematology, liver, or renal function tests", "Patient has no overlapping conditions/medications with exclusion criterion: Have Myasthenia Gravis", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant treatment with anticoagulants, diuretics, retinoids, ergot alkaloids, antacids containing aluminium/calcium/magnesium, bismuth and zinc salts, or quinapril"]}, {"trialId": "NCT03015727", "trialName": "Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: WHO type I squamous cell carcinoma or adenocarcinoma", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>65 or \\<18", "Patient has no overlapping conditions/medications with exclusion criterion: With a history of renal disease", "Patient has no overlapping conditions/medications with exclusion criterion: Prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Peripheral neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Emotional disturbance"]}, {"trialId": "NCT05814627", "trialName": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to any janus kinase (JAK) inhibitor.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD)."]}, {"trialId": "NCT05286827", "trialName": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05840276", "trialName": "Cryoneurolysis Prior to Total Knee Arthroplasty", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications against ibuprofen or paracetamol, for example previous gastric ulcer, or known renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\< 100 bil/l); or against treatment with morphine", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuropathic pain", "Patient has no overlapping conditions/medications with exclusion criterion: Previous recipient of cryoneurolysis for the knee", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with daily use of high dose opioid (\\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled serious disease (cancer, diabetes, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disease associated with reactions to cold, such as cryoglobulinemia, cold urticarial and Reynaud's syndrome."]}, {"trialId": "NCT06111027", "trialName": "Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Regular intake of benzodiazepines", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive impairment: score \\< 27 on Mini-mental state examination", "Patient has no overlapping conditions/medications with exclusion criterion: Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis"]}, {"trialId": "NCT05706376", "trialName": "An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (13.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Families with individuals with significant mental or physical impairments precluding their ability to participate in groups"]}, {"trialId": "NCT05809427", "trialName": "High Frequency Intraoral Ultrasound Probe for Early Diagnosis of Periodontal Diseases", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03460327", "trialName": "Bariatric Surgery and Pharmacokinetics of Candesartan", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Having previously undergone resections in the GI-tract"]}, {"trialId": "NCT04886427", "trialName": "Implementation of a Multidimensional Quality Model", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Do not understand Dutch"]}, {"trialId": "NCT06265727", "trialName": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active of uncontrolled CNS metastases", "Patient has no overlapping conditions/medications with exclusion criterion: History of solid tumors other than the diseases under study", "Patient has no overlapping conditions/medications with exclusion criterion: History of and/or current cardiovascular events or conditions in the previous 6 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing \\>/= Grade 2 neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Hemoglobin A1C (HbA1C) \\>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active ocular disease at baseline", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic severe liver disease or live cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study", "Patient has no overlapping conditions/medications with exclusion criterion: Other significant cormorbidities."]}, {"trialId": "NCT04448327", "trialName": "Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (50.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of neuroleptic use", "Patient has no overlapping conditions/medications with exclusion criterion: Any psychiatric disorder involving a history of psychosis (e.g. schizophrenia, bipolar I disorder)", "Patient has no overlapping conditions/medications with exclusion criterion: Active suicidal ideation with intent and/or plan or history of a suicide attempt within the last year", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe substance use disorder within the past 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of significant cardiovascular or cerebrovascular disease (e.g. congestive heart failure, stroke, cardiac conduction disorders, history of asystole or non-sustained ventricular tachycardia)", "Patient has no overlapping conditions/medications with exclusion criterion: Diseases affecting the CNS (e.g. MS, epilepsy, neurodegenerative diseases, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Traumatic brain injury with cognitive sequelae", "Patient has no overlapping conditions/medications with exclusion criterion: MRI or tVNS contraindications (e.g. claustrophobia, metallic implants or devices)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (uncommon, given the age of this cohort is 50+ years) due to unknown health risks for the fetus"]}, {"trialId": "NCT06527027", "trialName": "LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,", "Patient has no overlapping conditions/medications with exclusion criterion: inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant."]}, {"trialId": "NCT05133076", "trialName": "Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: E1. Involvement in any investigational drug or device study within 30 days prior to this study,\n\nE2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in the study),\n\nE3. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation upon investigator judgment,\n\nE4. Surgery planned within the whole study period,\n\nE5. Evidence of active medical diseases affecting bowel transit,\n\nE6. Antibiotic treatment intake within the last month prior the study start (V0),\n\nE7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are permitted,\n\nE8. Any history of drug addiction in the past five years,\n\nE9. Pregnant or lactating women or intending to become pregnant,\n\nE10. Unwilling to maintain food habits and current physical activity for the whole study duration,\n\nE11. With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,\n\nE12. Having a lifestyle deemed incompatible with the study according to the investigator including drug and alcohol abuse,\n\nE13. Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n\nE14. Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,\n\nE15. Presenting a psychological or linguistic incapability to sign the informed consent,\n\nE16. Impossible to contact in case of emergency."]}, {"trialId": "NCT06504927", "trialName": "Biomarker Discovery in Lung Cancer - Malaysia", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (30.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is pregnant or lactating (self-declaration).", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is unwilling or unable to provide signed informed consent"]}, {"trialId": "NCT04998227", "trialName": "Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (20.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: cardiogenic shock, pregnancy, end-stage renal disease"]}, {"trialId": "NCT05377827", "trialName": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from study entry for any of the following:", "Patient has no overlapping conditions/medications with exclusion criterion: Received systemic anticancer therapy (including investigational therapy) or radiotherapy \\< 28 days or 5 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy with the exception of bridging treatment as defined by protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: Received any T-cell lytic or toxic antibody (e.g., alemtuzumab) within 8 weeks prior to lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received a prior allogeneic HCT are excluded if any of the following criteria are present:\n\n  * \\< 100 days post alloHCT\n  * \\< 6 weeks from prior donor leukocyte infusion\n  * Presence of acute or extensive chronic GVHD requiring systemic immunosuppression except for prednisone ≤ 10 mg or equivalent.\n  * \\< 28 days from last dose of systemic immunosuppressive therapy (eg. calcineurin inhibitors, immunosuppressive antibodies, mycophenolate mofetil, ruxolitinib, ibrutinib) except for prednisone ≤ 10 mg or equivalent.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with any anti-CD7 directed therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to one or more of the study agents.", "Patient has no overlapping conditions/medications with exclusion criterion: Active or latent Hepatitis B or active Hepatitis C without previous curative treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Confirmed HIV infection.", "Patient has no overlapping conditions/medications with exclusion criterion: History of concurrent second cancers requiring active, ongoing systemic treatment with the exception of adjuvant hormonal therapy for breast or prostate cancer.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test at time of enrollment and within 7 days of starting lymphodepleting chemotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Serious active infection or another serious underlying medical condition that in the opinion of the treating physician would impair the ability of the patient to receive protocol treatment including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia or serious, unstable neurologic symptoms.", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic, uncontrolled hypotension."]}, {"trialId": "NCT05072327", "trialName": "Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Any previous treatment in the study eye", "Patient has no overlapping conditions/medications with exclusion criterion: Tumor complicated with infection", "Patient has no overlapping conditions/medications with exclusion criterion: Any other tumors of the paticipants", "Patient has no overlapping conditions/medications with exclusion criterion: Intolerate of surgery or anesthesia"]}, {"trialId": "NCT03150576", "trialName": "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (16.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: T0 tumour in absence of axillary node \\>10mm.", "Patient has no overlapping conditions/medications with exclusion criterion: TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with myelodysplastic syndrome/acute myeloid leukaemia.", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of distant metastasis apparent prior to randomisation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled seizures.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breast feeding women.", "Patient has no overlapping conditions/medications with exclusion criterion: Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:\n\nEvidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.", "Patient has no overlapping conditions/medications with exclusion criterion: ECG with mean resting QTc \\>470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).", "Patient has no overlapping conditions/medications with exclusion criterion: Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable)."]}, {"trialId": "NCT06356376", "trialName": "The Effects of Pain and Pain Relief on Peripheral Nerve Excitability", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain conditions", "Patient has no overlapping conditions/medications with exclusion criterion: Neurological or Psychiatric disease", "Patient has no overlapping conditions/medications with exclusion criterion: Other major diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Pain medication within the last 24 hours"]}, {"trialId": "NCT05248776", "trialName": "Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a c-peptide value less than 0.5 nmol/l.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic, or non-peripheral vascular surgery within 6 months prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cardiac arrhythmia, systolic dysfunction, congestive heart failure, angina, myocardial ischemia or infarction, or stroke within 1 year prior to the study, or the presence of an abnormal ECG that, in the investigator's opinion, is clinically significant.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of drug abuse or a history of alcohol abuse within 2 years prior to the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to basal cell or stage I squamous cell carcinoma of the skin.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase level above normal range for the testing laboratory, active liver disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a total bilirubin greater or equal 2 mg/dL.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is/ was lifetime on any insulin treatment or takes other diabetes treatment (except metformin).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of proteinuria ≥300 mg/day on a 12- or 24-hour urine collection within last year or an albumin/creatinine ratio greater or equal 300 μg/mg.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of any clinically significant retinopathy, which is defined as more than moderate nonproliferative diabetic retinopathy, any stage of proliferative diabetic retinopathy or any history of laser-treated retinopathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has clinically significant peripheral or autonomic neuropathy.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of ulcerative colitis or Crohn's disease, or has undergone gastric resection.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a history of a psychiatric disorder that, in Principal Investigator opinion, will affect the subject ability to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has a lifetime history of angioedema.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an acute, clinically significant illness within 30 days prior to the study or any other condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is not able to comply with the study scheduled visits.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is participating in another investigational study or has taken any investigational drug within 90 days prior to the study."]}, {"trialId": "NCT03269227", "trialName": "Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous thorax radiotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Chemotherapy is allowed but completed 3 weeks before RT starts", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial with any investigational agents within 30 days prior to study screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with M1 have to be excluded to this study", "Patient has no overlapping conditions/medications with exclusion criterion: FEV1 \\< 50", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\>85 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Respiratory needing oxygen therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Interstitial pneumopathy", "Patient has no overlapping conditions/medications with exclusion criterion: Active pneumonitis", "Patient has no overlapping conditions/medications with exclusion criterion: Fissural disease", "Patient has no overlapping conditions/medications with exclusion criterion: Contralateral mediastinum involvement (N3) and M1", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."]}, {"trialId": "NCT06552676", "trialName": "riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Failure of the percutaneous tracheostomy technique or recourse to surgical tracheostomy"]}, {"trialId": "NCT05309876", "trialName": "Secondary Prevention With the Lifestyle Tool", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (35.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: conditions or treatments that in the judgement of the Investigator could affect the study evaluation"]}, {"trialId": "NCT01521676", "trialName": "Predictive Clinical and Biological Parameters in Breast Cancer", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: emergency"]}, {"trialId": "NCT04030676", "trialName": "QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Wardship patient and curatorial patient", "Patient has no overlapping conditions/medications with exclusion criterion: Patient unable to understand or sign the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Colectomy total or partial"]}, {"trialId": "NCT04560127", "trialName": "Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Any active autoimmune disease or history of autoimmune disease and expected recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis); subjects with skin diseases that does no need systemic treatment, for example, leukoderma, psoriasis, alopecia, those with controlled type I diabetes by insulin or those with asthma that has been completely resolved in childhood and with no need of any intervention can be enrolled; while subjects with asthma who need bronchodilator for medical intervention cannot be enrolled.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of strong CYP3A4/CYP2C19 inducers, including rifampicin (and its analogues) and St. John's Wort, or strong CYP3A4/CYP2C19 inhibitors within two weeks prior to signing informed consent form.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment with other immune checkpoint inhibitors (include PD-1 antibody or other immunotherapy against PD-1/PD-L1).", "Patient has no overlapping conditions/medications with exclusion criterion: Known history of serious allergy to any monoclonal antibody or Apatinib.", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or unwilling to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current presence of metastasis to central nervous system.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia or complications of severe pneumonia; oral or intravenous therapeutic antibiotics within two weeks prior to the start of study treatment (for example, subjects who are given with preventive antibiotics for prevention of urinary tract infection or exacerbation of chronic obstructive pulmonary disease are eligible for participation in the study).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women.", "Patient has no overlapping conditions/medications with exclusion criterion: Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators, such as alcoholism, drug abuse, other serious diseases (including mental disorders) requiring concomitant therapy, with serious laboratory examination abnormality, with family or social factors, that may affect subject's safety."]}, {"trialId": "NCT05078476", "trialName": "Rehabilitation of Finger Flexor Tendon Injuries", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\< 18 years old", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients", "Patient has no overlapping conditions/medications with exclusion criterion: Replantation of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Fracture of the injured finger", "Patient has no overlapping conditions/medications with exclusion criterion: Primary tendon reconstructions"]}, {"trialId": "NCT06087627", "trialName": "A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have been treated for more than 7 days with dupilumab", "Patient has no overlapping conditions/medications with exclusion criterion: Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."]}, {"trialId": "NCT01341327", "trialName": "Observational Study for Left Main Disease Treatment", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Protected left main stenosis"]}, {"trialId": "NCT06337227", "trialName": "Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients for whom biological material cannot be recovered for study purposes;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who refuse to participate in the study"]}, {"trialId": "NCT06312176", "trialName": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Has breast cancer amenable to treatment with curative intent", "Patient has no overlapping conditions/medications with exclusion criterion: Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune disease that has required systemic treatment in the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy"]}, {"trialId": "NCT06061627", "trialName": "A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Valvular heart disease that requires or has undergone surgical intervention", "Patient has no overlapping conditions/medications with exclusion criterion: After mechanical tricuspid valve replacement", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or permanent atrial fibrillation or atrial flutter", "Patient has no overlapping conditions/medications with exclusion criterion: Second or third degree atrioventricular block", "Patient has no overlapping conditions/medications with exclusion criterion: Have a history of acute myocardial infarction within 3 months prior to enrollment", "Patient has no overlapping conditions/medications with exclusion criterion: Patient's expected survival time is less than 12 months", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or planned to conceive", "Patient has no overlapping conditions/medications with exclusion criterion: Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with simple and persistent left superior vena cava", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with existing pacemaker implantation"]}, {"trialId": "NCT02907827", "trialName": "Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\\< 6weken)", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia", "Patient has no overlapping conditions/medications with exclusion criterion: Metallic devices implanted such as hip prostheses, since this can alter the imaging quality"]}, {"trialId": "NCT06291727", "trialName": "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients scheduled for bilateral TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal anesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Revision TKAs", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)", "Patient has no overlapping conditions/medications with exclusion criterion: Workers' Compensation patient", "Patient has no overlapping conditions/medications with exclusion criterion: Type I Diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Type II Diabetes requiring insulin medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Pre-operative narcotics use with the exception of tramadol.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal insufficiency (GFR \\< 60) that may impact post-operative protocol", "Patient has no overlapping conditions/medications with exclusion criterion: Cognitive deficiencies that prevent the patient from providing their own informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Language barrier preventing completion of study forms in English"]}, {"trialId": "NCT05650827", "trialName": "Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Age \\< 18", "Patient has no overlapping conditions/medications with exclusion criterion: Living outside the greater Copenhagen area", "Patient has no overlapping conditions/medications with exclusion criterion: Any other malignancy requiring active treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Not eligible for chemotherapy", "Patient has no overlapping conditions/medications with exclusion criterion: Performance status \\> 2", "Patient has no overlapping conditions/medications with exclusion criterion: Not able to swallow liquids", "Patient has no overlapping conditions/medications with exclusion criterion: Parenteral nutrition or enteral nutrition via feeding tube", "Patient has no overlapping conditions/medications with exclusion criterion: Physical or mental disabilities that prohibit execution of test or training procedures", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to understand the Danish language"]}, {"trialId": "NCT06319027", "trialName": "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05536427", "trialName": "Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with immunodeficiency or a history of autoimmune disorders (e.g., rheumatoid arthropathy, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with severe concurrent medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, serious infection and infectious disease, active peptic ulcer, presence of active hemorrhage, and severe organ failure;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Grade III or IV cardiac failure defined by the New York Heart Association (NYHA), epileptic seizure, and mechanical or paralytic ileus within 6 months prior to the first administration of the investigational drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who have received chemotherapy and hormonal therapy within 28 days prior to signing the informed consent forms, or are currently taking other investigational drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with lymphoma, leukemia, myelodysplastic syndrome (MDS), or myelosuppression;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with allergy or a history of hypersensitivity to human blood albumin, or a history of allergy or hypersensitivity to any investigational drug or its excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with chronic diseases requiring immunotherapy or hormonal therapy; and subjects currently receiving corticosteroids for other diseases (except those using topical or inhaled steroids);", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with mental or neurological disorders that are not easily controlled;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects infected with human immunodeficiency virus (commonly known as AIDS) or treponema pallidum (commonly known as syphilis);", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of other malignant tumors within the last 5 years;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with prior allogeneic stem cell transplantation or solid organ transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a history of drug or alcohol abuse;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with any irAE of ≥ Grade 3 following prior immunotherapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who, in the judgment of the investigator, are not suitable to participate in this clinical study (e.g., with poor compliance)."]}, {"trialId": "NCT06093776", "trialName": "Rib Fracture Cryoanalgesia", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age Pregnant Incarcerated Confounding injuries or significant pain attributed to secondary injury Patients with any of the following: cryoglobulinemia; paroxysmal cold hemoglobinuria; cold urticarial; Raynaud's disease; open and/or infected wounds at or near the treatment site"]}, {"trialId": "NCT06146127", "trialName": "Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: unequivocal histological features"]}, {"trialId": "NCT06330727", "trialName": "Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 59.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with diagnosis of diabetes, or taking anti-diabetic medication;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy, planned pregnancy, or lactation;", "Patient has no overlapping conditions/medications with exclusion criterion: Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease)."]}, {"trialId": "NCT04855227", "trialName": "A Prospective Evaluation of Pain After Non-complex Ventral Hernia Repair", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is contraindicated for general anesthesia or surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a ventral hernia that will require retromuscular mesh placement or employ a technique, including (but not limited to) external oblique release, Rives- Stoppa, eTEP Rives-Stoppa, transversus abdominis release, other component separation techniques (i.e. anterior component separation) or eTEP transversus abdominis release.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a recurrent hernia.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will have an emergent hernia repair.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of chronic pain and/or taking daily pain medications for \\>6 weeks.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of substance abuse (excluding marijuana) and/or current (within 30 days) narcotic use.", "Patient has no overlapping conditions/medications with exclusion criterion: Current marijuana use that the subject is unwilling to discontinue within the 14 days prior to surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with a history of MRSA infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject with HbA1c level \\> 8.5%.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Exparel during the surgical procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who will undergo a concomitant hernia repair or any other concomitant procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Current nicotine use (including vaping) within the past 30 days.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject has a known bleeding or clotting disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or suspected pregnancy.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject belonging to other vulnerable population, e.g, prisoner or ward of the state.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject is currently participating in another interventional or investigational research study."]}, {"trialId": "NCT03511976", "trialName": "Adaptive Response to Intervention (RTI) for Students With ADHD", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Child or sibling living in the same home has history of sustained successful treatment of ADHD with stimulant medication", "Patient has no overlapping conditions/medications with exclusion criterion: Child currently has a special education placement involving placement in reduced ratio classroom or having a part or full-time aid due to behavior problems", "Patient has no overlapping conditions/medications with exclusion criterion: Child has an IQ less than 70", "Patient has no overlapping conditions/medications with exclusion criterion: Child has psychosis or a pervasive developmental disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Child is in a classroom that already has a study participant", "Patient has no overlapping conditions/medications with exclusion criterion: Child is home-schooled"]}, {"trialId": "NCT05752227", "trialName": "Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pure pleural lesions.", "Patient has no overlapping conditions/medications with exclusion criterion: Clinical instability to reach the final diagnosis.", "Patient has no overlapping conditions/medications with exclusion criterion: Inaccessibility by ultrasound."]}, {"trialId": "NCT03739827", "trialName": "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (4.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05364827", "trialName": "CT Coronary Angiography Prior to CTO PCI", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: CTO with J-CTO score\\<2", "Patient has no overlapping conditions/medications with exclusion criterion: Inadequate/degraded CTCA images", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant/lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe contrast allergy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients unable to provide written informed consent"]}, {"trialId": "NCT05038527", "trialName": "ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: ASA ≥ 4", "Patient has no overlapping conditions/medications with exclusion criterion: Formally diagnosed with a disease affecting the bone metabolism or wound healing (severe osteoporosis, osteomalacia, Pagets disease, hyperparathyreoidism etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Disseminated cancer diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to any of the i-FACTOR Peptide Enhanced Bone Graft ingredients", "Patient has no overlapping conditions/medications with exclusion criterion: Smoking, extensive alcohol use or abuse of hallucinating drugs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver or kidney disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or breastfeeding patients", "Patient has no overlapping conditions/medications with exclusion criterion: Patients estimated not to be able to understand the information sheet or patients, who do not consent to participate in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe psychiatric diseases", "Patient has no overlapping conditions/medications with exclusion criterion: Ongoing infections"]}, {"trialId": "NCT06200376", "trialName": "A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating, or plan to pregnant or give birth during the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;", "Patient has no overlapping conditions/medications with exclusion criterion: History of splenectomy or organ transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;", "Patient has no overlapping conditions/medications with exclusion criterion: Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;", "Patient has no overlapping conditions/medications with exclusion criterion: History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;", "Patient has no overlapping conditions/medications with exclusion criterion: History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of high risk cardiovascular disease, including but not limited to:\n\n    * Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);\n    * Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;\n    * Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;\n    * Rating of heart function as defined by the New York Heart Association (NYHA) standards\\>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;\n    * Left ventricular ejection fraction (LVEF) \\< the center lower limit. If no lower limit existed, LVEF\\<50%;\n    * Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);", "Patient has no overlapping conditions/medications with exclusion criterion: History of another malignant tumor, except the following:\n\n    * Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;\n    * Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;\n    * Adequately treated carcinoma in situ without evidence of disease;", "Patient has no overlapping conditions/medications with exclusion criterion: Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Unexplained \\>38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment"]}, {"trialId": "NCT06040827", "trialName": "A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT06144476", "trialName": "Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.", "Patient has no overlapping conditions/medications with exclusion criterion: Surgery within the preceding 6 weeks", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection", "Patient has no overlapping conditions/medications with exclusion criterion: Alcohol or recreational drug abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency requiring treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to read or write English", "Patient has no overlapping conditions/medications with exclusion criterion: Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study"]}, {"trialId": "NCT03317327", "trialName": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB and stage I prostate cancer considered not necessary to treat", "Patient has no overlapping conditions/medications with exclusion criterion: Disease suitable for curative salvage surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 4 weeks prior to first administration of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant cardiac, pulmonary or other medical illness that would limit activity or survival", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation.", "Patient has no overlapping conditions/medications with exclusion criterion: Known hypersensitivity to any of the components of the investigational product", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who test positive for hepatitis B, C or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of immunosuppressive therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Autoimmune disease that has required systemic therapy within the past 2 years", "Patient has no overlapping conditions/medications with exclusion criterion: Any reason why, in the opinion of the investigator, the patient should not participate"]}, {"trialId": "NCT04257227", "trialName": "Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Documented brain lesions", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to remain still while sitting up (45 degrees) for the duration of therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold"]}, {"trialId": "NCT05601427", "trialName": "Intra-Operative Adductor Canal Blocks", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability or refusal to sign informed consent form", "Patient has no overlapping conditions/medications with exclusion criterion: Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.", "Patient has no overlapping conditions/medications with exclusion criterion: Non-osteoarthritis primary diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to analgesic medications", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to spinal and/or regional anaesthesia", "Patient has no overlapping conditions/medications with exclusion criterion: Any use of opioid pain medication within four weeks of the index procedure(13)", "Patient has no overlapping conditions/medications with exclusion criterion: Pain catastrophizing scale score ≥16 (8, 9, 14)", "Patient has no overlapping conditions/medications with exclusion criterion: History of cirrhosis", "Patient has no overlapping conditions/medications with exclusion criterion: History renal insufficiency", "Patient has no overlapping conditions/medications with exclusion criterion: History or sensory and/or motor neuropathy to the ipsilateral limb", "Patient has no overlapping conditions/medications with exclusion criterion: Simultaneous, bilateral TKA", "Patient has no overlapping conditions/medications with exclusion criterion: Non-TKA prosthesis", "Patient has no overlapping conditions/medications with exclusion criterion: Scheduled for non-SDD TKA.", "Patient has no overlapping conditions/medications with exclusion criterion: Preoperative varus/valgus of \\>10 degrees.", "Patient has no overlapping conditions/medications with exclusion criterion: Planned General Anaesthetic", "Patient has no overlapping conditions/medications with exclusion criterion: Use of Intrathecal Morphine"]}, {"trialId": "NCT03072927", "trialName": "MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that have received a laminectomy, laminotomy, fusion, interspinous process decompression, or MILD in the lumbar region during the 12 months prior to the index date"]}, {"trialId": "NCT05322876", "trialName": "Feasibility of Reducing Cardiovascular Disease Risk Factors in Hispanics Through a Family-Based Community Intervention", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (13.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling to wear Fitbit devices daily for 6 months except when charging and sleeping", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot read or understand either English or Spanish", "Patient has no overlapping conditions/medications with exclusion criterion: Cannot return to screening location to perform the minimum of the baseline, 3-month and 6-month follow-up screenings", "Patient has no overlapping conditions/medications with exclusion criterion: Children or adolescents will be excluded from this project without a minimum of one accompanying parent or guardian"]}, {"trialId": "NCT05518227", "trialName": "Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous monovision patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).", "Patient has no overlapping conditions/medications with exclusion criterion: Previous ocular or refractive surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.", "Patient has no overlapping conditions/medications with exclusion criterion: Refractive lens exchange.", "Patient has no overlapping conditions/medications with exclusion criterion: Angle kappa measurement in a single eye over 0.6 mm.", "Patient has no overlapping conditions/medications with exclusion criterion: Irregular corneal astigmatism or ectasia.", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulties comprehending written or spoken English language.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).", "Patient has no overlapping conditions/medications with exclusion criterion: Severe/uncontrolled Ocular surface disease/Dry Eye Disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Intraoperative complications during procedure.", "Patient has no overlapping conditions/medications with exclusion criterion: Visual expectations exceed outcomes.", "Patient has no overlapping conditions/medications with exclusion criterion: Strabismus (with or without amblyopia).\n\nThe principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.\n\nPregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness."]}, {"trialId": "NCT06585527", "trialName": "Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating patients.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with encephalitis disease, multiple sclerosis, or other CNS (Central Nervous System) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of organ transplantation or waiting for organ transplantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled infectious diseases or other serious diseases, such as HIV positive.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with any unstable systemic illness (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris beginning within the last 3 months, congestive heart failure, myocardial infarction occurring within 12 months before enrollment, severe arrhythmia requiring medical treatment, liver or kidney failure, etc.)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with systemic autoimmune diseases or immunodeficiency diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with severe allergic constitution.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic diseases requiring long-term treatment with immune agents or glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with mental disorders."]}, {"trialId": "NCT05956327", "trialName": "Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Lack of reliability and sanity (examined by an independent psychiatrist)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive urine drug screen for illicit drugs (except benzodiazepines)", "Patient has no overlapping conditions/medications with exclusion criterion: Acute suicide risk", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant psychiatric axis-I disorders according to the diagnostic testing procedure (Mini International Neuropsychiatric Interview, MINI)", "Patient has no overlapping conditions/medications with exclusion criterion: Other relevant neurological or other disorders", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation"]}, {"trialId": "NCT05649176", "trialName": "Lifestyle Intervention for Improving Insulin Resistance and Concern for Health", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (50.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with a diagnosis of Type 2 diabetes received more than five years ago.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who have type 1 diabetes", "Patient has no overlapping conditions/medications with exclusion criterion: Participants being treated with prescription or over the counter medications that have a significant effect on insulin resistance, obesity, high density lipoprotein cholesterol, triglycerides, metabolic rate and those that significantly increase body weight.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants who are on concomitant therapy with glucocorticoids.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants with evidence and/or history (within the preceding 6 months) of significant gastrointestinal dysfunction.", "Patient has no overlapping conditions/medications with exclusion criterion: Participants that have had a fluctuation in body weight \\>5% in the preceding 2 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other conditions that may impede testing of the study hypothesis."]}, {"trialId": "NCT03916627", "trialName": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor", "Patient has no overlapping conditions/medications with exclusion criterion: Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with metastatic disease for whom the intent of surgery would not be curative", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 1 year", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent", "Patient has no overlapping conditions/medications with exclusion criterion: History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.", "Patient has no overlapping conditions/medications with exclusion criterion: NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply"]}, {"trialId": "NCT03712527", "trialName": "Intra-discal Injection of PRP for Low Back Pain", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 60.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: - Patient with Modic 1 discopathy in different vertebral levels", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a Modic I signal abnormality related to a static spinal disorder (such as previous vertebral fractures, or isthmic lysis, or spondyloarthritis)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with a history of lumbar spine surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with suspected spondylodiscitis or other infection", "Patient has no overlapping conditions/medications with exclusion criterion: Patient under anticoagulant or antiaggregant therapy, or with a coagulation disorder", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with allergy to iodine or to any of the components of Xylocaine", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to MRI: Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with anatomical difficulty of access to the injection area (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with an uncontrolled severe disease (i.e. heart, pulmonary, gastro-intestinal, neurologic, endocrine, auto-immune affections) limiting the patient's safety (judged by the investigator)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with previous malignancy less than 5 years (except for non-melanoma skin cancer)", "Patient has no overlapping conditions/medications with exclusion criterion: Prior to the screening visit:", "Patient has no overlapping conditions/medications with exclusion criterion: a current and recent use of morphine (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: a systemic or local corticosteroid therapy (\\< 1 month)", "Patient has no overlapping conditions/medications with exclusion criterion: Porphyria", "Patient has no overlapping conditions/medications with exclusion criterion: Patient with sphincter disorders indicating a cauda equina syndrome", "Patient has no overlapping conditions/medications with exclusion criterion: Psychotic state not controlled by a treatment", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy (βHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age", "Patient has no overlapping conditions/medications with exclusion criterion: Vulnerable persons protected by law", "Patient has no overlapping conditions/medications with exclusion criterion: Persons under guardianship", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who are in a dependency or employment with the sponsor or the investigator", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Subject unable to read or/and write"]}, {"trialId": "NCT03868527", "trialName": "The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (16.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who doesn't have hematological diseases"]}, {"trialId": "NCT04519476", "trialName": "Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n  1. Has received selinexor or another XPO1 inhibitor previously.\n  2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for \\>5 years previously and without evidence of recurrence will be allowed.\n  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome \\[polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes\\], primary amyloidosis, etc.) that is likely to interfere with study procedures.\n  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.\n  6. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and lenalidomide or steroids.\n  7. Concurrent use of other anti-cancer agents or treatments.\n  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\n  9. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin\n  10. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n  11. Pregnant or breastfeeding females.\n  12. BSA \\<1.4 m2 at baseline, calculated by the Dubois (58) or Mosteller (59) method.\n  13. Life expectancy of less than 3 months.\n  14. Major surgery within 4 weeks prior to C1D1.\n  15. Active, unstable cardiovascular function, as indicated by the presence of:\n\n  1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. CHF of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\< 40%, or 4. MI within 3 months prior to C1D1. 16. Known active HIV infection or HIV seropositivity. 17. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.\n\n  18. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.\n\n  19. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).\n\n  20. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n\n  21. Contraindication to any of the required concomitant drugs or supportive treatments.\n\n  22. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT06508827", "trialName": "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemoglobinopathies", "Patient has no overlapping conditions/medications with exclusion criterion: Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hemochromatosis", "Patient has no overlapping conditions/medications with exclusion criterion: Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible).", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating female adults", "Patient has no overlapping conditions/medications with exclusion criterion: Active infections which in research teams' opinion increases risk for toxicities", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures."]}, {"trialId": "NCT05900427", "trialName": "Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Ages: \\<18 and \\>90", "Patient has no overlapping conditions/medications with exclusion criterion: Weight \\< 60 kg", "Patient has no overlapping conditions/medications with exclusion criterion: Multiple surgeries during one hospital stay", "Patient has no overlapping conditions/medications with exclusion criterion: Emergency surgery", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy or any contraindication to local anesthetics used in trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindicated for use of liposomal bupivacaine", "Patient has no overlapping conditions/medications with exclusion criterion: Severe liver/kidney disease", "Patient has no overlapping conditions/medications with exclusion criterion: Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis", "Patient has no overlapping conditions/medications with exclusion criterion: Subject who received another local anesthetic block prior to the interscalene block.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to consent in English"]}, {"trialId": "NCT05422027", "trialName": "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who meet any of the following criteria will not be enrolled:\n\n  1. Plasma cell leukemia.\n  2. Documented active amyloidosis.\n  3. Involvement of the central nervous system(CNS) by Multiple myeloma.\n  4. Prior exposure to a SINE compound, including ATG-010.\n  5. Currently, whether or not the patient is on medication, \\> Grade 2 peripheral neuropathy or ≥ Grade ≥ 2 painful neuropathy at baseline.\n  6. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and Selinexor (ATG-010) .\n  7. Active, unstable cardiovascular function, as indicated by the presence of:\n\n     1. Symptomatic ischemia, or\n     2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or\n     3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \\<40%, or\n     4. Myocardial infarction within 6 months prior to C1D1.\n  8. Known positive serology for HIV or HIV seropositivity.\n  9. Known active hepatitis A, B, or C infection; eg. positive for HCV RNA or HBV-DNA.\n  10. Women who are pregnant or nursing.\n  11. Life expectancy of less than 6 months.\n  12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.\n  13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.\n  14. Contraindication to any of the required concomitant drugs or supportive treatments.\n  15. Has any concurrent diseases or complications that is likely to interfere with the study procedures.\n  16. Patients unwilling or unable to comply with the protocol."]}, {"trialId": "NCT05284227", "trialName": "Artificial Intelligence-augmented Perioperative Clinical Decision Support", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT05057676", "trialName": "Autoimmune Intervention Mastery Course Study", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT04772027", "trialName": "Motor Parameters in Patients With Limb Girdle Muscular Dystrophy", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: § For all:", "Patient has no overlapping conditions/medications with exclusion criterion: Without associated neuromuscular disorders such as respiratory or muscular-squeletic diseases, apart from the consequences of dystrophy;", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to the tests;", "Patient has no overlapping conditions/medications with exclusion criterion: Noncontrol cardiac rhythm disorders;", "Patient has no overlapping conditions/medications with exclusion criterion: Lying down position intolerance due to severe respiratory troubles;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or breastfeeding woman."]}, {"trialId": "NCT05525676", "trialName": "Relationship Checkups to Reduce Veteran Suicide Risk", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports severe intimate partner violence in the last year.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings)", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER reports experiencing suicidal intent requiring hospitalization.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER experiences past-month psychosis or mania.", "Patient has no overlapping conditions/medications with exclusion criterion: EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years."]}, {"trialId": "NCT05763576", "trialName": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Healthy volunteers:", "Patient has no overlapping conditions/medications with exclusion criterion: History of any clinically significant disease", "Patient has no overlapping conditions/medications with exclusion criterion: Concomitant disease that could interfere with treatment or conduct of study", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)\n\nCHB participants:", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of liver cirrhosis or decompensated liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: History or suspicion of hepatocellular carcinoma (HCC)", "Patient has no overlapping conditions/medications with exclusion criterion: History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease", "Patient has no overlapping conditions/medications with exclusion criterion: History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study."]}, {"trialId": "NCT05695027", "trialName": "Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (40.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05780476", "trialName": "A Novel VIRTUAL Reality Intervention for CAREgivers of People With Dementia (VirtualCare)", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Receiving daily assistance for more than 10 hours from formal CGs;", "Patient has no overlapping conditions/medications with exclusion criterion: Being formal CGs (i.e., nurse or another paid figure);", "Patient has no overlapping conditions/medications with exclusion criterion: Being informal CGs of i) persons with moderate-to-severe AD, or ii) persons with non-AD diseases;", "Patient has no overlapping conditions/medications with exclusion criterion: Not having or being able to use a device connected to internet (e.g., smartphones or PC).", "Patient has no overlapping conditions/medications with exclusion criterion: Having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs.", "Patient has no overlapping conditions/medications with exclusion criterion: Only a family member for person with dementia is accepted.\n\nExclusion Criteria for experimental group (Psychoeducation + VR):", "Patient has no overlapping conditions/medications with exclusion criterion: Medical history of epilepsy.\n\nExclusion Criteria for subsample of caregivers assess with MRI:", "Patient has no overlapping conditions/medications with exclusion criterion: Metal implants, artificial prostheses, pace-makers, prosthetic heart valves;", "Patient has no overlapping conditions/medications with exclusion criterion: Claustrophobia;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy."]}, {"trialId": "NCT03990727", "trialName": "Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (2.0, 90.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: 1) Not willing to visit every year."]}, {"trialId": "NCT05721027", "trialName": "Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 70.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Not available for follow-up", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis", "Patient has no overlapping conditions/medications with exclusion criterion: Allergic to or intolerant of investigational medications", "Patient has no overlapping conditions/medications with exclusion criterion: Chronic steroid use", "Patient has no overlapping conditions/medications with exclusion criterion: Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney disease (GFR \\<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x the upper limit of normal)"]}, {"trialId": "NCT06550427", "trialName": "Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: none"]}, {"trialId": "NCT04802876", "trialName": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior systemic anti-cancer therapy, including investigational agents within 2 weeks. Medical Monitor could consider shorter interval for kinase inhibitors or other short half-life drugs prior to allocation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants with ≤Grade 2 neuropathy may be eligible.\n\n   Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study treatment.\n\n   Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose of the previous investigational agent.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with thymoma are not eligible. Patients with active CNS metastases and/or carcinomatous meningitis are not eligible. Subjects with up to three cerebral metastases are eligible, if all lesions are stable and have been definitively treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any of its excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.", "Patient has no overlapping conditions/medications with exclusion criterion: Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior allogeneic stem cell transplantation or organ transplantation", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history of interstitial lung disease, (non-infectious) pneumonitis that required steroids or has current pneumonitis, uncontrolled lung including pulmonary fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary function, or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening.", "Patient has no overlapping conditions/medications with exclusion criterion: Has an active infection requiring systemic therapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Human Immunodeficiency Virus (HIV).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.", "Patient has no overlapping conditions/medications with exclusion criterion: Has a known history of active TBC (Bacillus Tuberculosis).", "Patient has no overlapping conditions/medications with exclusion criterion: Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of trial treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with spartalizumab or tislelizumab. Highly effective contraception methods include:\n\n    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.\n    4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.\n\n    Notes:\n    * Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.\n    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.", "Patient has no overlapping conditions/medications with exclusion criterion: Sexually active males, unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with spartalizumab or tislelizumab should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen."]}, {"trialId": "NCT04816227", "trialName": "Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusing to participate in the study", "Patient has no overlapping conditions/medications with exclusion criterion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research", "Patient has no overlapping conditions/medications with exclusion criterion: Being pregnant or breastfeeding"]}, {"trialId": "NCT06187727", "trialName": "Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Mechanical complications;", "Patient has no overlapping conditions/medications with exclusion criterion: Cardiogenic shock;", "Patient has no overlapping conditions/medications with exclusion criterion: Experienced myocardial infarction within 6 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Aortic dissection;", "Patient has no overlapping conditions/medications with exclusion criterion: Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included", "Patient has no overlapping conditions/medications with exclusion criterion: Urinary system infection"]}, {"trialId": "NCT04167527", "trialName": "Endovascular Therapy for Low NIHSS Ischemic Strokes", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: NIHSS ≥6", "Patient has no overlapping conditions/medications with exclusion criterion: Any sign of intracranial hemorrhage on baseline CT/MR (SDH/SAH/ICH)", "Patient has no overlapping conditions/medications with exclusion criterion: Any imaging findings suggestive of futile recanalization in the judgment of the local investigator", "Patient has no overlapping conditions/medications with exclusion criterion: High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD", "Patient has no overlapping conditions/medications with exclusion criterion: Premorbid disability (mRS ≥3)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to randomize within 8 hours of last known well", "Patient has no overlapping conditions/medications with exclusion criterion: Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS", "Patient has no overlapping conditions/medications with exclusion criterion: Baseline blood glucose of \\<50 mg/dL (2.78 mmol) or \\>400 mg/dL (22.20 mmol)", "Patient has no overlapping conditions/medications with exclusion criterion: Known coagulation disorders as defined as platelet count \\<100,000/uL", "Patient has no overlapping conditions/medications with exclusion criterion: Known renal failure as defined as serum creatinine levels \\> 3.0 mg/dL", "Patient has no overlapping conditions/medications with exclusion criterion: Presumed septic embolus or suspicion of bacterial endocarditis", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another investigational treatment study in the previous 30 days", "Patient has no overlapping conditions/medications with exclusion criterion: Intubation and mechanical ventilation prior to study enrollment is medically indicated", "Patient has no overlapping conditions/medications with exclusion criterion: History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Site investigator does not have equipoise towards the ideal treatment concept (thrombectomy vs. best medical management)", "Patient has no overlapping conditions/medications with exclusion criterion: Known pregnancy", "Patient has no overlapping conditions/medications with exclusion criterion: Prisoner or incarceration", "Patient has no overlapping conditions/medications with exclusion criterion: Known acute symptomatic COVID-19 infection"]}, {"trialId": "NCT02488876", "trialName": "Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: None."]}, {"trialId": "NCT04995627", "trialName": "Salt Supplementation in Gitelman Syndrome", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (16.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics", "Patient has no overlapping conditions/medications with exclusion criterion: pregnancy"]}, {"trialId": "NCT06218576", "trialName": "Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: age \\< 18 years"]}, {"trialId": "NCT03050476", "trialName": "Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (21.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Already on renal replacement therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with chronic kidney disease defined as estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m2 \\[ CKD stage \\> 3 \\]", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are pregnant or lactating", "Patient has no overlapping conditions/medications with exclusion criterion: Concurrent enrollment in another clinical trial", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reaction to bovine alkaline phosphatase or patient is vegetarian or vegan", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with ongoing infections or current use of steroids", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with high-risk emergency surgery or with follow-up procedures already planned at admission (like e.g. TEVAR)"]}, {"trialId": "NCT03131427", "trialName": "China Registry for Genetic / Metabolic Liver Diseases", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who are unable or unwilling to provide informed consent."]}, {"trialId": "NCT05500027", "trialName": "sCD8, as a Novel Biomarker for Pancreatic Cancer", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Refusal to participate", "Patient has no overlapping conditions/medications with exclusion criterion: Age less than 18-year old and over 85-year old"]}, {"trialId": "NCT05755776", "trialName": "The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Men and women of childbearing potential who are unwilling to use an \"effective\" method of contraception as defined in the protocol during the study period.", "Patient has no overlapping conditions/medications with exclusion criterion: Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have received a solid organ or bone marrow transplant", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.", "Patient has no overlapping conditions/medications with exclusion criterion: Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.", "Patient has no overlapping conditions/medications with exclusion criterion: Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior or existing clinical liver failure (Child-Pugh score ≥ grade B)."]}, {"trialId": "NCT05887076", "trialName": "Postoperative Delirium After Kidney Transplantation", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Incomplete data records of the parameters to be determined", "Patient has no overlapping conditions/medications with exclusion criterion: Underage Patients"]}, {"trialId": "NCT05272176", "trialName": "Veterans Coordinated Community Care (3C) Study", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Impaired decision-making capacity", "Patient has no overlapping conditions/medications with exclusion criterion: Limited or no English language proficiency", "Patient has no overlapping conditions/medications with exclusion criterion: Terminal illness"]}, {"trialId": "NCT05968976", "trialName": "Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Legally incompetent adults;", "Patient has no overlapping conditions/medications with exclusion criterion: Previous tremor-neurosurgery (e.g., DBS, thalamotomy);", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;", "Patient has no overlapping conditions/medications with exclusion criterion: Psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Current depression;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to provide written informed consent."]}, {"trialId": "NCT06182527", "trialName": "Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: diabetes mellitus", "Patient has no overlapping conditions/medications with exclusion criterion: use of medication interfering with glucose metabolism (steroid, antidiabetic medications)", "Patient has no overlapping conditions/medications with exclusion criterion: surgery of upper GI-tract", "Patient has no overlapping conditions/medications with exclusion criterion: known plaster allergies", "Patient has no overlapping conditions/medications with exclusion criterion: any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion"]}, {"trialId": "NCT06222827", "trialName": "Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, any major comorbidities (diabetes mellitus, cancer, severe autoimmune diseases, chronic renal failure, articular diseases that restricts exercise or participation in study assessments in the physician's opinion...), a history of relevant drug or food allergies; history of cardiovascular, respiratory, central nervous system disease; neuromuscular diseases except FSHD (e.g., myopathy, neuropathy, neuromuscular junction disorders)", "Patient has no overlapping conditions/medications with exclusion criterion: History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects who are on drug(s) or supplements that may affect muscle function, as determined by the treating physician must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Orthopedic conditions, such as unresolved fracture or arthrosis, interfering or precluding testing of muscle function", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to muscle MRI as per clinic standard practice", "Patient has no overlapping conditions/medications with exclusion criterion: Articular contracture limiting movements, scapular fixation or other surgeries, preceding or planned", "Patient has no overlapping conditions/medications with exclusion criterion: Any known hypersensitivity to satralizumab or any of its components and/or history of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)", "Patient has no overlapping conditions/medications with exclusion criterion: Evidence of latent or active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection for at least 4 weeks prior to enrollment), active opportunistic or life-threatening infections", "Patient has no overlapping conditions/medications with exclusion criterion: History of diverticulitis or concurrent severe GI disorders (such as symptomatic diverticulosis) that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation. Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit (Visit 1, week 0)", "Patient has no overlapping conditions/medications with exclusion criterion: Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody.", "Patient has no overlapping conditions/medications with exclusion criterion: Acute or chronic history of liver disease", "Patient has no overlapping conditions/medications with exclusion criterion: Abnormal laboratory results with: White blood cells (WBC) \\< 3.0x 10\\^9/L ; Absolute Neutrophils Counts (ANC)\\< 2.0x 10\\^9/L ; Platelet count \\< 10x10\\^4/µl ; Absolute lymphocyte count (ALC) \\< 0.8x 10\\^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 times the upper limit of normal (ULN)", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment (defined as a glomerular filtration rate of \\<30mL/min/1.73m²)", "Patient has no overlapping conditions/medications with exclusion criterion: Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy or lactation", "Patient has no overlapping conditions/medications with exclusion criterion: For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier \\[patient or partner\\] in conjunction with a spermicidal product, contraceptive pill, patch, injectable, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug.", "Patient has no overlapping conditions/medications with exclusion criterion: Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Use of another investigational product within 6 months or 5 half-lives (whichever is longer), or currently participating in a prospective study with an investigational product, whether it concerns an experimental drug or a medical device. Note: concurrent participation in natural history studies (non-drug, non-device studies) is not allowed during the course of the study.", "Patient has no overlapping conditions/medications with exclusion criterion: Any prior treatment with any agent targeting the IL-6 inhibition pathway (e.g. tocilizumab, sarilumab), alemtuzumab treatment, total body irradiation, or bone marrow transplantation; treatment in the past 24 weeks with an anti-B-lymphocyte antigen CD20 (e.g. rituximab, ocrelizumab), eculizumab, anti-B-lymphocyte stimulator, or any other multiple sclerosis disease-modifying treatment; treatment in the past 2 years with an anti-T-cell surface glycoprotein CD4, cladribine, cyclophosphamide, or mitoxantrone; or treatment with any other investigational drug within 3 months prior to baseline. See section 4.4.4 for details on the vaccination and immunization.", "Patient has no overlapping conditions/medications with exclusion criterion: Subject, or close relative of the subject, is the investigator or a coinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.", "Patient has no overlapping conditions/medications with exclusion criterion: Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code."]}, {"trialId": "NCT05505227", "trialName": "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: currently prescribing buprenorphine at full capacity"]}, {"trialId": "NCT05782127", "trialName": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.", "Patient has no overlapping conditions/medications with exclusion criterion: Previous diagnosis of:\n\n   * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)\n   * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.", "Patient has no overlapping conditions/medications with exclusion criterion: History of active malignancy within the past year prior to screening, with the exception of:\n\n   * Adequately treated carcinoma in situ of the uterine cervix\n   * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n   * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.\n\n   Patients with ongoing horomonotherapy could be included.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.", "Patient has no overlapping conditions/medications with exclusion criterion: Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.", "Patient has no overlapping conditions/medications with exclusion criterion: Received live attenuated vaccines prior to initiation of study treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions that could interfere with drug absorption including short gut syndrome, dysphagia, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mmHg or diastolic BP \\> 100 mmHg) or has not been stable for at least 1 month prior to treatment.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:\n\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Unstable angina or angina requiring surgical or medical intervention\n    * Significant cardiac arrhythmia\n    * And/or myocardial infarction", "Patient has no overlapping conditions/medications with exclusion criterion: Participant is a pregnant or lactating female.", "Patient has no overlapping conditions/medications with exclusion criterion: Participant has known or suspected to have hypersensitivity to any of the components of the assigned study treatments.", "Patient has no overlapping conditions/medications with exclusion criterion: Positive test result(s) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B surface \\[HBs\\] antibody positive and anti-hepatitis B core \\[HBc\\] antibody negative) may participate.", "Patient has no overlapping conditions/medications with exclusion criterion: Absence of social security affiliation."]}, {"trialId": "NCT03146676", "trialName": "The Ohio State University Dermatology Biorepository", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Inability to provide informed consent"]}, {"trialId": "NCT06524427", "trialName": "Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with the previous history of other malignancies;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with secondary primary cancer when enrolled;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as pure ground glass opacity (GGO) before surgery;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients diagnosed as mixed GGO whose solid part \\<= 50% and Maximum diameter of tumor \\<= 2cm;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with small cell lung cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with prior unilateral open thoracic surgical procedures;", "Patient has no overlapping conditions/medications with exclusion criterion: Woman who is pregnant or breastfeeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with an active bacterial or fungal infection that is difficult to control;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with serious psychosis;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months."]}, {"trialId": "NCT05537376", "trialName": "A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Veteran"]}, {"trialId": "NCT04643327", "trialName": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (Not Specified, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Contraindication to having MRI", "Patient has no overlapping conditions/medications with exclusion criterion: Bipolar disorder, Schizophrenia, Alcohol or substance abuse", "Patient has no overlapping conditions/medications with exclusion criterion: Major depression", "Patient has no overlapping conditions/medications with exclusion criterion: Suicidal Ideation", "Patient has no overlapping conditions/medications with exclusion criterion: Difficulty complying with protocol requirements", "Patient has no overlapping conditions/medications with exclusion criterion: Significant non-PD neurological disease", "Patient has no overlapping conditions/medications with exclusion criterion: Vascular dementia", "Patient has no overlapping conditions/medications with exclusion criterion: Sensitivity to levetiracetam", "Patient has no overlapping conditions/medications with exclusion criterion: Use of anticonvulsant medications", "Patient has no overlapping conditions/medications with exclusion criterion: Use of other excluded medications", "Patient has no overlapping conditions/medications with exclusion criterion: Severe renal impairment", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)", "Patient has no overlapping conditions/medications with exclusion criterion: Females of childbearing potential"]}, {"trialId": "NCT05189327", "trialName": "Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patient takes part in an interventional clinical trial;", "Patient has no overlapping conditions/medications with exclusion criterion: Patient is unable to follow the schedule of the visits;", "Patient has no overlapping conditions/medications with exclusion criterion: Any condition that the PI believes would prevent a study participant from participating in the study."]}, {"trialId": "NCT06447727", "trialName": "Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: After liver metastasis was diagnosed, the liver underwent external radiation therapy and transhepatic arterial chemoembolization", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with extrahepatic metastases", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant and lactating women", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe arrhythmia or heart failure", "Patient has no overlapping conditions/medications with exclusion criterion: Other researchers considered it inappropriate to participate in this study"]}, {"trialId": "NCT06176027", "trialName": "Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women"]}, {"trialId": "NCT04280627", "trialName": "Changes in the Microbiome Associated With Transplantation", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Outside of stated age range.", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to give informed consent"]}, {"trialId": "NCT03969927", "trialName": "User-friendliness of a Portable Driving Simulator", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (25.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Diagnosis of traumatic brain injury or any other neurological condition apart from stroke, PD, and MS."]}, {"trialId": "NCT06627127", "trialName": "A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects meeting any of the following criteria will be excluded from participation in this study:", "Patient has no overlapping conditions/medications with exclusion criterion: Major anatomical or functional abnormalities that would impair the ability of the electrode arrays to be positioned.", "Patient has no overlapping conditions/medications with exclusion criterion: Significant comorbidities that contraindicate surgery or general anesthesia/DISE", "Patient has no overlapping conditions/medications with exclusion criterion: Significant tongue weakness", "Patient has no overlapping conditions/medications with exclusion criterion: Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia/DISE in the judgment of the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Prior surgery or treatments that could compromise the placement and effectiveness of the electrode array systems:\n\n  * Airway cancer surgery or radiation,\n  * Mandible or maxilla surgery in the previous 3 years (not counting dental treatments),", "Patient has no overlapping conditions/medications with exclusion criterion: Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),", "Patient has no overlapping conditions/medications with exclusion criterion: Prior hypoglossal nerve stimulation device implantation.", "Patient has no overlapping conditions/medications with exclusion criterion: Currently pregnant, or breastfeeding during the study period"]}, {"trialId": "NCT05763927", "trialName": "Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 75.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients who have previously received immune checkpoint inhibitors;", "Patient has no overlapping conditions/medications with exclusion criterion: Known allergic reactions to PD-1 monoclonal antibody active ingredients, TKI inhibitor-related ingredients or any excipients;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with organ bleeding or bleeding tendency, except for rectal primary tumor bleeding (need investigator to assess the risk of bleeding;", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating women;", "Patient has no overlapping conditions/medications with exclusion criterion: years or at the same time have a history of other malignant tumors, but cured skin basal cell carcinoma and cervical carcinoma in situ and thyroid;", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with uncontrolled epilepsy, central nervous system disease or mental disorders, the investigator judged that their clinical severity may hinder the signing of informed consent or affect the patient 's compliance with oral drugs;", "Patient has no overlapping conditions/medications with exclusion criterion: Clinically serious (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalent daily) or other immunosuppressive agents (including organ transplant recipients) within 2 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Participated in other interventional drug clinical trials within 4 weeks before the first dose;", "Patient has no overlapping conditions/medications with exclusion criterion: Major surgery or severe trauma within 4 weeks before the first dose of study drug;", "Patient has no overlapping conditions/medications with exclusion criterion: Serious infection (CTCAE greater than grade 2) within 4 weeks before the first dose of study drug,Such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging suggests active pulmonary inflammation, symptoms and signs of infection within 2 weeks before the first dose of study drug, or the need for oral or intravenous antibiotics (excluding prophylactic antibiotics);", "Patient has no overlapping conditions/medications with exclusion criterion: Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes); autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone, using stable doses of insulin type 1 diabetes can be included; but excluding vitiligo or recovered childhood asthma/allergy, without any intervention in adults;", "Patient has no overlapping conditions/medications with exclusion criterion: History of immunodeficiency, including positive HIV test, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;", "Patient has no overlapping conditions/medications with exclusion criterion: Active pulmonary tuberculosis infection found by medical history or CT examination, Or patients with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or patients with a history of active pulmonary tuberculosis infection but without regular treatment 1 year before enrollment;", "Patient has no overlapping conditions/medications with exclusion criterion: Subjects with active hepatitis (HBV DNA ≥ 2000 IU/ml or 10000 copies/ml), hepatitis C (hepatitis C antibody positive,HCV-RNA was above the lower limit of detection of the assay);", "Patient has no overlapping conditions/medications with exclusion criterion: Had a known history of psychotropic drug abuse, alcoholism, or drug use;", "Patient has no overlapping conditions/medications with exclusion criterion: Had a history, illness, treatment, or laboratory abnormality that could interfere with the results of the trial, prevent the subject from participating throughout the study, or the investigator considered participation to be in the subject 's best interest."]}, {"trialId": "NCT05318976", "trialName": "A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (50.0, 85.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients will be excluded from the study if 1 or more of the following criteria are applicable:", "Patient has no overlapping conditions/medications with exclusion criterion: Have any contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in-skull and cardiac devices other than those approved as safe for use in MRI scanners);", "Patient has no overlapping conditions/medications with exclusion criterion: Receives considerable help to carry out basic ADL living either in the home or as a resident in a nursing home or similar facility;", "Patient has no overlapping conditions/medications with exclusion criterion: Lifetime history of a major psychiatric disorder including schizophrenia and bipolar disorder. Major depressive disorder that has resulted in 2 or more hospitalizations in a lifetime. Major depressive episode during the past 5 years that is judged by the clinical team unlikely to have been part of Alzheimer's prodrome. History of suicidality.", "Patient has no overlapping conditions/medications with exclusion criterion: History of substance abuse within 12 months; use of cannabis or cannabis products within 6 months of consent;", "Patient has no overlapping conditions/medications with exclusion criterion: Enrolled in another clinical trial where patients receive treatment with an investigational drug or treatment device or have had previous treatment with any investigational medicinal product within 60 days or 5 half-lives (whichever is longer) prior to study drug treatment;", "Patient has no overlapping conditions/medications with exclusion criterion: A prior organ or stem cell transplant;", "Patient has no overlapping conditions/medications with exclusion criterion: Seated blood pressure of ≥ 165/105 mmHg at Screening."]}, {"trialId": "NCT05264727", "trialName": "Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (25.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05555576", "trialName": "Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Opioid use 1 month prior to the ED visit;", "Patient has no overlapping conditions/medications with exclusion criterion: Already taking vitamin C supplement;", "Patient has no overlapping conditions/medications with exclusion criterion: Active cancer;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for chronic pain;", "Patient has no overlapping conditions/medications with exclusion criterion: Treated for opioid use disorder;", "Patient has no overlapping conditions/medications with exclusion criterion: Unable to fill out diary or unavailable for follow-up;", "Patient has no overlapping conditions/medications with exclusion criterion: Any allergy, intolerance or sensitivity to milk (lactose) or morphine", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with cyclosporin or coumadin", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)"]}, {"trialId": "NCT04557527", "trialName": "Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Hypersensitivity to hyaluronate or. HEALON5® PRO OVD", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.", "Patient has no overlapping conditions/medications with exclusion criterion: Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.\n\nStudy eye:", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of proliferative vitreoretinopathy (PVR) or any tractional RD", "Patient has no overlapping conditions/medications with exclusion criterion: Previous vitreoretinal surgery, open-globe injury or endophthalmitis", "Patient has no overlapping conditions/medications with exclusion criterion: Aphakia", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current congenital cataract", "Patient has no overlapping conditions/medications with exclusion criterion: Previous or current suprachoroidal haemorrhage", "Patient has no overlapping conditions/medications with exclusion criterion: Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment", "Patient has no overlapping conditions/medications with exclusion criterion: Current intraocular inflammation other than mild cellular activity thought to be secondary to RD", "Patient has no overlapping conditions/medications with exclusion criterion: Current ocular or periocular infection other than blepharitis"]}, {"trialId": "NCT05427227", "trialName": "Prospectively Predict the Efficacy and Explore the Mechanism of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Previous systemic therapy for metastatic GI cancer\n\n  * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.\n  * Allergic constitution or allergic history to protium biologic product or any investigating agents.\n  * Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.\n  * Pregnancy or lactation period\n  * Other previous malignancy within 5 year, except non-melanoma skin cancer\n  * Legal incapacity"]}, {"trialId": "NCT05628376", "trialName": "TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:", "Patient has no overlapping conditions/medications with exclusion criterion: Positive margins, incomplete resection or insufficient nodal sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).", "Patient has no overlapping conditions/medications with exclusion criterion: Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B/C:", "Patient has no overlapping conditions/medications with exclusion criterion: Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)"]}, {"trialId": "NCT04620876", "trialName": "Bimodal and Coaxial High Resolution Ophtalmic Imaging", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT00001727", "trialName": "Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (1.0, 100.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT05757076", "trialName": "Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 65.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of secondary hyperaldosteronism", "Patient has no overlapping conditions/medications with exclusion criterion: Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy status (verbal)"]}, {"trialId": "NCT04838327", "trialName": "Rare Subtypes of Gastrointestinal Cancers", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Conditions precluding translational blood sampling", "Patient has no overlapping conditions/medications with exclusion criterion: Another concomitant cancer"]}, {"trialId": "NCT03344276", "trialName": "Assessing Neurocognition After Cerebrovascular Intervention", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: patients \\<18 years of age", "Patient has no overlapping conditions/medications with exclusion criterion: patients with without compatibility for MRI", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring carotid stenting for reasons not related to long-standing stenosis", "Patient has no overlapping conditions/medications with exclusion criterion: patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.", "Patient has no overlapping conditions/medications with exclusion criterion: Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study."]}, {"trialId": "NCT06186427", "trialName": "A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, 80.0)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Those who cannot tolerate puncture biopsy or surgical contraindications;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who have undergone radiotherapy and chemotherapy in the past 3 months;", "Patient has no overlapping conditions/medications with exclusion criterion: Individuals who are allergic to multiple drugs or foods;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who refuse nuclear medicine examinations;", "Patient has no overlapping conditions/medications with exclusion criterion: Those who do not agree to sign an informed consent form and are unable or willing to follow up."]}, {"trialId": "NCT04695327", "trialName": "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg per day of prednisone/prednisolone.", "Patient has no overlapping conditions/medications with exclusion criterion: Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, etc) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of hormonal therapy or use of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.", "Patient has no overlapping conditions/medications with exclusion criterion: Uncontrolled cardiac or vascular diseases.", "Patient has no overlapping conditions/medications with exclusion criterion: History of myocardial infarction or cerebral stroke within the previous 12 months before screening or is not sufficiently recovered from an older infarction or cerebral stroke.", "Patient has no overlapping conditions/medications with exclusion criterion: History of severe hepatic dysfunction, hepatitis or HIV.", "Patient has no overlapping conditions/medications with exclusion criterion: History of coagulation disorder.", "Patient has no overlapping conditions/medications with exclusion criterion: Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.", "Patient has no overlapping conditions/medications with exclusion criterion: Female patients who are pregnant, breastfeeding or intend to become pregnant.", "Patient has no overlapping conditions/medications with exclusion criterion: Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.", "Patient has no overlapping conditions/medications with exclusion criterion: Previously treated (within 5 years) with any oncolytic or replication deficient adenovirus.", "Patient has no overlapping conditions/medications with exclusion criterion: Allergy to ingredients present in the investigational medicinal products (ingredients are listed in the protocol)."]}, {"trialId": "NCT06339827", "trialName": "ASk Questions in GYnecologic Oncology (ASQ-GYO)", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)", "Patient has no overlapping conditions/medications with exclusion criterion: History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis", "Patient has no overlapping conditions/medications with exclusion criterion: Previous treatment discussion with a Gynecologic Oncologist"]}, {"trialId": "NCT03921827", "trialName": "External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (21.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: Patients with atrial fibrillation/ arrhythmias.", "Patient has no overlapping conditions/medications with exclusion criterion: Within 2 weeks of cardiac catheterization or arterial puncture at femoral puncture site.", "Patient has no overlapping conditions/medications with exclusion criterion: Decompensated heart failure , usually class 3 or 4", "Patient has no overlapping conditions/medications with exclusion criterion: LV EF \\<30%", "Patient has no overlapping conditions/medications with exclusion criterion: Moderate or severe AR", "Patient has no overlapping conditions/medications with exclusion criterion: Persistent and uncontrolled hypertension (BP persistently \\>160/100 mmHg)", "Patient has no overlapping conditions/medications with exclusion criterion: Bleeding diathesis", "Patient has no overlapping conditions/medications with exclusion criterion: Active thrombophlebitis/ venous disease of lower limbs", "Patient has no overlapping conditions/medications with exclusion criterion: Severe lower extremity vaso-occlusive disease", "Patient has no overlapping conditions/medications with exclusion criterion: Presence of a documented aortic aneurysm/ dissection requiring surgical repair", "Patient has no overlapping conditions/medications with exclusion criterion: Pregnancy"]}, {"trialId": "NCT05312827", "trialName": "Training Intervention and Program of Support (TIPS): Fostering Family-centred Telehealth in Pediatric Rehabilitation", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)"]}, {"trialId": "NCT03529227", "trialName": "Gazyva Infusion Reaction Investigation", "eligibilityCriteriaMet": ["Patient Age (59) matches Expected Range (18.0, Not Specified)", "Patient Sex (F) matches Trial Sex Requirement (ALL)", "Patient Health Status (Not Healthy) matches Trial Requirement (Patients)", "Patient has no overlapping conditions/medications with exclusion criterion: The refusal of the patient to participate in the observational study and the withdrawal of informed consent that allow processing of personal data and data that refer to patient confidentiality."]}]}]